var title_f37_34_38432="X-ray of dactylitis and periosteal reaction in child with psJIA";
var content_f37_34_38432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F63642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F63642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Radiograph of dactylitis and periosteal reaction in child with psoriatic arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hand/wrist radiographs from a child with psJIA. Note dactylitic swelling of the digit (white arrowheads) and periosteal reaction of bone (black arrowheads) in comparison with the contralateral hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Nigrovic PA, Sundel RP, Petty RE. Juvenile psoriatic arthritis. In: Textbook of Pediatric Rheumatology, 6th ed, Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Eds), Saunders, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38432=[""].join("\n");
var outline_f37_34_38432=null;
var title_f37_34_38433="Calamine lotion: Pediatric drug information";
var content_f37_34_38433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calamine lotion: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?33/11/33969?source=see_link\">",
"    see \"Calamine lotion: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Topical Skin Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/11/33969?source=see_link\">",
"      see \"Calamine lotion: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Skin protectant:",
"     </b>",
"     Infants, Children, Adolescents, and Adults: Topical: Apply to affected area as often as needed;",
"     <b>",
"      Note:",
"     </b>",
"     For patients &lt;6 months, consult a physician prior to use.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12617674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, topical: 8% (118 mL, 177 mL, 240 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F12607330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Shake well before using. Apply to clean, dry skin; may apply using cotton or a soft cloth. Avoid contact with the eyes and mucous membranes; do not use on open wounds or burns.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F15513599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&ordm;C to 30&ordm;C (59&ordm;F to 86&ordm;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Employed primarily as an astringent, protectant, and soothing agent to relieve itching, pain, and discomfort for conditions such as poison ivy, poison oak, poison sumac, sunburn, insect bites, or minor skin irritations (FDA approved in ages &ge;6 months and adults)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15513598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to calamine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; avoid contact with eyes and mucous membranes. When using for self-medication (OTC use), discontinue use and contact healthcare provider if needed for &gt;7 days or if condition worsens.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12757380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1045666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active ingredients: Calamine, zinc oxide",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13105 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38433=[""].join("\n");
var outline_f37_34_38433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045661\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045659\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617674\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607330\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045664\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513599\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045663\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513598\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045658\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298924\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12757380\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045666\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13105\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13105|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/11/33969?source=related_link\">",
"      Calamine lotion: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_34_38434="PUPPP abdomen";
var content_f37_34_38434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PUPPP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and plaques with accentuation in abdominal striae and relative sparing of the umbilicus are present on this patient with PUPPP. Erythematous papules are also visible on the hands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38434=[""].join("\n");
var outline_f37_34_38434=null;
var title_f37_34_38435="Tinea pedis interdigital maceration";
var content_f37_34_38435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tinea pedis with interdigital maceration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF7AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDceRTGVGVAP3sDBrMkIbJdgoHQA/pV+eOPAy7+mP8APeq2yFVkZdxwMMCfXpiuRpn1Ue5BMFjZSyIGAyFJJLVSm85w3lRORuzuxV9SoXOxmUEkvjk+gqvPIdoOc8Akg0ht+RQZfILZ5kP5Y71WeRjkY2t1XAqa4wRjmPnOW64qB8fKqoFJOc929z7UkZyKszAxENyA2SSMEmuS8W4WEbTkFgPpXZShXjYH6/Q1xPjD5Qi7ixyN2e1XDdHDX+FnPw5GOa07Nyuc4NZEZ960bY8Z3D8a62eYjSiYnngVowj94F5OBWTFnNaFtIy7jkcisi0aEZwcqNtW4smVAT82eOKpRMPJDMfmJ6Vet13yBidoUdfSmWXFlSRkCZADcjpXTaOBvAHfnntXNWESPPGoYMd3Ud66jTEDysF4VjjJ7Cs56m1M3rQbvYdsdqsOxP8AvDgfSoYduSw+4nT3NIm4upH3ieM1DZstCwmXQgAbVOWJ7+1JABJISwwncih02hUUBVzkkdSatnylCohUxou5z6mlYognkBZVUKEHYUx2VJ8r8pPHB6UkCBgZS2FXr7mkgjElwS+FQnJzU6j0LCKq4bIXdwD6e9TfIJESPeQBu3d2FVXmEzsVXYDwMDtU8QLBlA28cknFNaCHyzI7bY0wnJxnvUCIuCDtD+nc094WjiXPDvyv09aTYiqcFyfU0nqUrbCOY1ZpPM+ZVwMdzU8CzeSMMRvOPc/hUEEZdvlVSEOTmrWXbfJKQpPQk4A/ChbXBj5AkbCNFJVByD3NEYLqHkcDIwF5BJ/wqIKCh27iOu4jGfYVNbFwGJBzjjHYVOjY+mhJceUiuiSo7DgHGME0yFRGrPksnRnbqfpQZljh2BUJJzxyWPpmnRmKJxLc/ORykQ5596q2otkTERypGjqRH2VRksfVqjkVRknB7YHUUyS4LkbgyjuicY/xpXZhFgRbT0Ge9Nu5NmRCFNhl8kv/ALfTFLBbzzjzclolG7aRwg7ZNKjEuWlZ2wMKrdKbLLdXDNErlIRhWOeDj2oTQWbGuruzGbJYLkKrEYp7BwFG9EB7L1FRxuQrhQ+3JJfPJNO8pSyeZGqADJYnJNJu/Q0SfUmtXIZViUSbegPIBp+95JMOAjDj5RkmoY9hdvKD7CBjirDziMfLlVx3IBo6Etaly2jTaq7GlY/dLNgA0TiNWYI0cCgAYGSSe+PWs5LwHcYwZHI+UDt+NTI0KqZLhy7kfdUfd9s1UZJkuNtbjjD5LDIEWecvgsfwqCSHoC/mA84JwKa88TPuSJnX07fiafMDMFMvHoqHCj/GnoKzKyr8rLGY8dwozU8UJY7RKTtH3Qo4qN2jE37uMCJeoyefyFSBC0RmeHIc/eYHK+gFCsMjlcrtDTbkHfHINQSXylf3CtI3TcSQK1UhkniPmCGKLH90bsepNVHjjyQN8gBwCE4I9qGn0BNN6lQ3D4VX8tWGTvxz9KetwbeXdHebm284Gfw5qX7L5iHEUWR0JO01HBbRLKfO3oPpmo940tGxE7u8m4KTkbvmbr+FNYE5G4rx0xyasK6xuux4jgYyRmmfaQEZHCNzkEHpRbzIu+xTCy8fMQAOpFNCsr58tnJHJzkVaLqW2LvOeBhhUMrSxsyOh4496lrqO7ZBPghiiHIHKqufzqB2iZV+RA4684qZ7qdW4AyvGfSq19dxmNWliVWHUgcGloxWYkjNtBQoPp0qltMrlExz1IqJJnuhtC7I84GO9adnbmHbgYz61Sh3KSFtbVY49oDB/Wr+0qiqT1pG2pgBst3FO3DBJB9Kps3UBhVYyMMKqzEDgH3Jp7HAycEdqrTEtkj7uMVlKR104IYyq7Z60UsJAGCOaKzub8rWxHI2AAqk7vlGapTbY1LLgYOSc1sXFi7uM4jxjAU/drPmto4WYrtdt3ygtk11tM5Y2MtWd2AQSNwcY7VG6vksWCED7qDNauGC7VyDjkj7o9fxqnLA2FdSx+TJJxxUtA3rYzJwoVcBsE8sTyKrSLx8+fU49KvyqFAKKSfvHNVG6MR6fxdvxqTOSRl3LfvPl3epI61xviwYijB5O/P0rs3ObhpArbc9M9q5LxpHugeTkLvGPeqp7nFiV7rOXjPHSrtu5A4rOhbJ6VcjYgiuxnlI1oH6ZAq/H2XoT3rMtz3rRt2LyL3IrMtGwpAyOBtXH41ZtiyxljwTms1CTk54q8MusSgEZPNMs19JhYeXldmMnNdVp/7u33Dhn9ea5yyy0r7nyVH6VvWhyFLHGBgCspaG8NjZtVZrcMVO3qcfyqzFH5ZIP+sPJ/2RTbUeUgkIyqLlQT198UkbOwLMCGbmosaJlqVd6IEJAUcn0psjMVEUeQGbJ9MepqWVtqpCp4+83HU+lPt1KRSBvvYy2ffpQ7FIY2dsSqNsI5z/AHj608QlM+cCVPUDqRUDuCw52ooAq9Hgo0jE7Ack9/YUlqwY0RkIGkwqE5C45AqBUVyJmY7VbIXsfrTw0lxLk/KCcZPpUjMhYE4CKMAY60mWtCVDFt3Mx4zkgZye2PaqckoZQFVievtVscbUCg5IIqtLGxnEajLHlvYUMEPs4ZXb92u4n5mHarbxuYkllXKlhn3PoPaoJZnRCkbbYyMOT/Eff2pGmMv7yUsyjhR2/KndJCs2F7KTIqBsqOKZMQUCruweBjvTkUSEAAsffilBWObClsn7zDsPasy79EOjDW5KAKCRgtjJWldZNodTt5xuOBmkhDTsfLwkKZO885xQ0O9PNMjmMHBJ/iPoPWrtpoJvXUjiHyblZ3cnGcf1NPxJGAZWAA5AJyakRpslo02qg43DAAqKKMT/ALyVvl5OFHJNQN3HSSebiKEMZHOM9MikwIp0hEgJ+8zAnCj/ABqUqjDyoI2GRnav9TVeMYkaMeVGMHcRzT1TBeROATMvlKxjU8bzjPvimzRb/mkJLjls8AUillRggJDDBY8mpY2YMs0i+Y5PRznNO/QLsGlfy9oeMemxCajggeVSz52A8s/QfhTo7ht+90VnPQE4UfhUc0s0yBZGIQdEVcAfWndBcv8A2eORV+z/ADHq5fCqKSa2jRW+0XKnGABH0qj5sycM22PHRQBkVPEhnjyEUD+FnIB/Kqi0+hDTRY2Mdq2kIMa8eb1yagjSNXLXJeRweBngn2xT/tWI/JExcA4KIvH/ANegSGEgIjic8glRgCm2hJPqWJCQqRpBMw6qpYD86Et5VbfPMQ2d2I1zTYpJmG1xMVPLYblqZNNKiALF5aAcEtg0cyFZsbcTxSEqAzEdyx/Wq77lZR5u3nPyk4pfMllz91yOBlO31oR5CQXUYU8KvGaXNfctKxHKCSroGf1Lcc0TP8m1hnJ9M4p80M2N2144z1qtKNq487LHOfWpbfQI7ksSxLGHaOQuT8y7eMeoPrUcsqbWwsY5zjbmpbdZMNjcuQB93NV3V3JCght2B8lK7sPdkAVWXAG0nqcVJsUMMspHqKDauowrAsecHiqN9dizgJkKMT0UDNSvMGF/JFbRlncOOq4H6VgyebezqzphB0UH9aMzXtxvkJK54HpW/DaCOFTjJPerjFD2K9rCsQ3SDaO2BVwsHXJyCBxTjb7QN74BGcVWuHEY2xkE05OxvThzFhJFLAOvGMZqNpEXIAJ5qvvDAeYD+FSsyHJU4x61m3dHVGnqNDK3UH6ZpEIkO08d8UnnAqfkx71CVBCndgj071m2dMYErJhic8UU1ZdrBduV9aKnR9TRaFq/idEKM43gZyCWz+IrIZipBbIA4AHrWo93O6MPMUeqjpWbscnewGT7V1zaex58U7ajQquhbgqPfGKo3JXdgEnJxtHerMhKkgkkL1C0kaLt3bSoXjcBkmpYrWMyUNJnep3A5Dk1SuGKjYWT1J6itW6Ug5YHcfVayLwMHP8AdHccYqFoKRTbCqQo2gHJOeTXN+KoC+k3EiD5QM4zyOetdMVLKCB7gntWT4pt2GjzFUcFlO044J74rSBxV1o0eZQNg8VdjbkZrOjPz1ehPy11nkRNW2bjjrWracjceuKyYD8o4rVtjthBqCkXrUM52gVquW3xqQVKAZ+tUdNwN7E44OMVoRfvbiRj1zTNDU09PmU5PzHBJHb1rrtNiSSQOR+6X7orlrAnYiD1wK7WwtgI40J+4MkjuahrU2joi0IS5D/wj27UhcSSblOFHHParDJ5ieVHlV6k1CIS4wpHlKeT3YZrOTNkiXBedAB8qDcQf4qUM1wT8wXccnnjFMlcE3D4woAUUyPKBjkBgNx+naosUGVLKAPlH4596twOUiJKBvM+7u6j3qvbxqmWnHAHy4x1qe4lHDDg46UfCtQvd2HBTKf3mWb+9nGBUmWAVmXgH5V7tUVswL8qWyMZ64qyTJJKGcKCPl2kY4oRVyWOJvLZ22o8hwvPPvg+1VLhljR1j3EnhmPerMplXBZkRAMgMeMVWjTOZZSQg5Vem/8A+tQ9rIa7kal4oWGAN555yfpToomlZVAYA9Bn9al4URk/efJJx/KpVVjG5gyIwMO7cZ9hRbQVxiELPsUnaCQ7Dq1PMYMSsQWycDPQj29ab5DkRQCPLsN+0dfxp1zKsTx4kEk5XHHCr7UJBfsQNK4cDaHKg8Hgc9qm2vhI48zOo6j7qj2phiaFjs4IGWbr+HNPtpSB5aAuT1jjHX6n0p7DauJcQOHYzqzqv3gDwT9alZ1jAZVYStwqLjAHvUq3LyqYsF2UblCYwP8AeNK7W8MbvdHzJGHEanGPcmpst0FyuPkZlaTdIfvCPOPpUG4MAFUKC2BgZzUlv5lyzbGEcSjqO49qkCtZnqkbHu3JFC94Nhs0TIi+ZI3JwFPBP4Uzy3iBI8tC3UZyVH+NSS3kMREodpbgj7xXPX2qsn3Tlcc5BY9fwp6X0GrkiJFuDM2UXr/tU95tvyQBUX0AJ/M1CjJ85bLsB8qxrhfxNOhkmmbbGcoPvbP8aFbYl+Y1xFvXdIXbP8MfFCMskp24VVODuBOfwFPZoRlWbcQMbUHH4nvUL3cm3ZEdi9top7Ai6diFC84GT8oC4NP3QsjLEqwxKOWclmb3qlbyvzIUO9uA7cGpw0shP7zJHQKuf1p3SQuupOPI3Awh2Cjr60KSHJWFCBjlu1JFHsOCA5HJ3tmnHaz5ZiQeixnaopFadC6ZC8KefPDsXnCgDHtWbPMhaQQJuUnqxwRSJGI1zFEjN137uBSkxtEGZYi/cb+ho5ugrK5Xd+cNJJjuqknNJs4JjhY5xhjVtUXDF3jUYzhWAzmod0JXhMt05Y0rdxXG3JG/MnmEY+8R/hVZysigJI5Uc4VMY/GpjmMFlkQA/wAKNzVa+uLW2iLDBdh8qscmmF0RXd5DaBnLuxA+VXGc1zO97653zfKgPAUEVO6m6bL7QeuMVdsoPLUyEDanbPWjdlxVx0FrFbwmRm5J6d6ma5d0CJ0HtSqhkYSvgIe1NcquSnC5yDRI2p0+4siMYvnzn3qJIkHLEcckU5nkfaG6GowqkEvzismzshGyJR5e7I6e9SOFADDoe2KhjYZ6D8akckjgcelK5soDWjLIcdKjKYXpTWZwDglVPanwMNuJOaTszSzSEYDGOlFOYCNic/IaKnlGpIid0OWOCRx0PNQYaQssaFnyMFQT+FXiSSFHtwFoLlYflY7e4XgmujTqeffsZN3bzl2jeMrt5OTTBGwiVscjjAyOT0qzct8wy+Sed3fPvUFw3mSErubncCWxn1qdCt1qVLoODu+bn1PXFZN4n7wlVAbv9K1CpYsFAyOBlu/Ws94ju+ZSv8LE9fpQkQxLaIkHAUEDv/CPWs/VI3eCSOTDgA7Sx6E9xWrHH8uU+Vc/Nnr9KbeRoYSGJBb5QD/D6mtI6HHVPCbiMxXUkZIyrHpVq36CneIYxFrE4UEKxzTbaupao8i1pNGlB1ArYgH7paxLUneK37fmIDHJqWVHc1Lb5YyF4z1q1atgqi4y7ckVUgH7vOcknitG0UpGr4Hygke5pFm9ocZnn8xRwCAtd5ZRZi2n8a5bQbZkjjjXC8BicV1sR2xiKMnzWxzjoKzbOiK0HzttZooyenzMKYWXavAQIO5pWQKD1ZjnHrTbtFjWCMjccb3GKzbb1NSosyruM3Qnew9/SmS3p2tFYwIZXOGl6kCoiDJ8m3Mjnr2FSQ7I49qKCW43elNTtoHKupZhAWBI0JLD5nY+tPVDI7PJkgdcdM+9JBE/lMciNCPmY1NHMgZUiH7oHn3PrUW7l7bFiOQosZVBHJtwMfzNSWyvKjttC/N88pPSq4Qvl3JWPsfX2FWkLR2axuAWKlkQHGz3J75qluJhc+VvEihmRT8u7q3vj0qKQPIfMdMF++ewpdxFuC2S2PlC8D86VlUYR3+8Bkgc1Ld9SkmkRyZmCNPIyxqDz6+wpYptw43IifdPZPp71PKqPgRRmMA5LOeFH0qGRV2oGyIx8xA/Q/WqE2MhlZ5G2BwDgHnt9aYGLTMUTIUY9akZDtYMTHH/AAooyzfWiJcR7TgRA4Pb8zSaewJ21Gbd52SbQoPY96uwKsNuT5ywLIMH5vmI/pUMZZH+0NGoUNtRAOp9cUzINwzzlRsGSB2/D1p2SHe5IE80stqAEQkF+xppjTcQxMp7noAaejDy1SIZUndhB9361DuVHy27I4AxilJIFcc8bIEcuBn7qD+H60jMWZFUHcowAoySPU09oSfL8w+TuOQvJJ9TipAqQAAcGQcovLE+/pRb7g0YxLdAglwpYfxN0zSSWqJjzZTK7AkRouMfX2ouJGbZkqGHQL0SoltmkiaV3YJkAux2g1Wi2QerJYHgjLRtF5zADaQflU0l1JKWTz2h2gcBMCmW1s0rFIgsYwSXYnB/ChIQGwRGWHByKbbsQx0EYmxhQw6bB059TS3EZUhPMVAeMBhgU66MpVVkyIiOEiXGajjtg8H3VXHVpT0+gpN9CknYVvs8ShY1eV84LnlRUizuqFUd2HcBf0zUcG9gExJKgJ5TAB96sRIgAEhCZP8AG+T+Qo16B6jFupGUHaMD1GKeGDqcqrZPRVxirETokn7uEy9gWqCfz9x3Exg9QBg1LutRxECKp/1KquP4j/SmfZ1kXesagk46Yz9KsxeSsXyo0kp79MfnSXE+XUOwATsTj9aNLBd32Io0KqfLjKoOSFXcTT5cKi7wwcc4P+FRLM4ZvLdVxwCik1T1S/8AskDSySnJ6Y4Jo06BbUfqlyltbmWfcoHQEAZrki0l1OZZc8ngDoBSlJb+68+Ysy4yFJ4FXRESoIG0DnmgqMCOC3LEBVHPc9qtJHyeflXripbNiUkPGOwpkwKIgPBc80N2RvFakUkjyADOEU8Yph+aaNc8VK2B8q/WonK/alXOVrJs6YoWU7JmCscY6VG773CimzEJM5XlelIWCurj0oubQWhIAMk54qYuwKgnAqoJA0Y2jkGn8uu/JxQbJdyWcGQ4QZpoXy32sDuoDPHEJB17VPFPhS8yZ3DFLS427KxUn6FecdqKJnw5JACn1oqWNFoshYjseAB1GKhd8LncRjpikih/vTEsTztHIqQrEkbKSSSeA1dDVzy3JXKEwD/NuBB/hCng1XkXYozCo4+8eeTV6Z90uA21ewNUnVyB5qkjdjryamxSd2VWYgAY384BxjHpiqtyjj5JPkJOS2cmrSxEdJSWXOQOi/WoePl2qDkYLk96pCY6KIsQuOWwo/2vei+iT7NIjlmU5UbTyKkVFB3ozNtGFPfPrRLb+ZAdiuxDZ44zitYK5xVjx/xxaiG+jZAuBlGx2PasSDoK7Hx7ahYiwGArZAHbJwa46DOBWsdjzasbTv3NSxGXyOa3osbEGSOckVi2CgoBjJJ7VvxDCoCAaTYol5FwijHGKvW2ZXROQCeg9qqgbRHz8x7Ve05czwgA7s5P50ylvY7vSTssV2gbmIAzW/ARboyqN8z8ZFYOmktMQq/N0Udh710EQSB4igyVG4kjqaxZ0xWhLcIYQu4Eu3JJqlMxO/HzSvxnP3RVu7dmMbuSzk7mFZl8+wsFOCRlse/aspPXQ1iiMyoiSsrYZRsU+pot42+zK54bg/SqjgBkXBKqN7c9/SrIlZ0diMIW5/woWpSLc9xucBBnPbt0qzAnk7BKCxIyVXiqsDIsizOucDCr6U9ixcoc56560rdRllXklwACWJ2hfSrQAHyOzFs4fHb2qtB8u2OPmQj5z/d9quwv5a/ukzzyx7D2ppMGhhJfCJGeP7xqSFDFLwAzr6DcKYD8/XheTn86IhIA0jHG7kYOKLDuRzy/O3mcA8v9KihlNxK27Cr1ZiPuj0FILd7i5EIbLsck9h9TU822IrBakuq/eJGAW/woTe7BpEUzqzeYo2/wqD1A9frSKg2qSG9mIwGNAVeWdwznqOyihpBJukYkbRtRfb1pktdiyzQiIFN7TH7xzwo9qrfK8rMQqIe7HJNM3MWKDEaDhiOSB6UnlmYOzMscCdcYy1N6jSsTSXBliEUC7E/iYfeapLNzGxihADMuHdhlvoPeobeIzKFVhHD/AHianEciw5jwiZ/1jd6iOuo20tCS4SW2OJA0LNx8zfPj3NQbWdA8SMV6luhP1NEcsUbeaxa4dDjdJyg/CpIpGvJFRpFiizgMRgfQCqFsMiSSJWb5Ej6Mx5Lewps5kZwxjYAcAy9/wqyzQWbmOEmSYHhjyPoB2qGSSe5uCZNilmwXIHH0ptW3JT1ISz42szEnjBPH5Crdu7MeXKhedsa8j8etR3P2WJ/v+cw6sg5J9zUcV24V0iQKG5JPH60Xtux25tjSkaEI0iWkkrnO15egqmGiJHnKzNjOBwBQUkUACYOx5wq5H5mpWESrvkc8j7rLn9TRdsLWGjyCMymUgDA5AFVkeIbo1QKTzksBRNGiMoBTcRu3H+VWIykQDpHC8g7s+aSlfQu1hiSOANgf6qCcVaSKeY7hGzMB1kfk/gOlMkuLuRN5aNUHoRUSO0jHa8jHGSY260tETqWZbTcQZiqr2FMBW3CnyVA9Rg5FVoV3ZLQuR1yTuzj8axvEetxQ4gtlZp/U8Bfwo32Atat4kisyY0h3zdVj7D3rnALnVrkTXPC54QdFFQWlrJK5llzljndmt+JY44wqke+O9WtEUkVPKMUwB6Djg1YIKR4J+TsTTnIEm5lGT2zUcrb4hk4APrUNm8YghIj+9gE064JdgpPReKgBJXOQBnpRcEjk8H+lQ2zVRVxWOOain4eNx0zil35i45Hc0ydg9q2OopGyIppV81wvU1ETuBGeRUMsjAKx5A54pFJMm4HqKlnRHRFhWwmM9alUkDZu96oltrYJ96fJPggrzQ9jS5ayXGGY4HarE8ym2UICSOvNZizAurD6GpHlBHHPtUgxJZmZfm6Ciqrt1GM0UrjujayFYkdQaS4ZHALMeeRUZXGMscEc46fWoJII8MpYk8Djriuo8i2oLKN/yEc9mHf61HJl8DheMc9SfaoW+8F2tnt3JqKUuAc4XPbryKm7NVHqErE8MAJCQDznioGEbPkYRewGcCpoyjHB3MCPmOOhp8beZLEhXknb5e3HHrVolixZbaQcYyfbPpT5nKxxNztIZs9z9PxojAk3+ZjgFsd1x7UxsSqiq4Qj5+OnTtWi0OWqjifFMEU9jcA58/Yd249COeBXnNsucdzXsF/bqsMpnbouCQASCfX8K8peExX0kWPuuR0689a0gzza61TNTSozuHHAGc1vQqNxc9hxWdpke1ASF/E1qqu9o4uMdyKHqQiaQFWQ98VraXGxmR8jJ6VlzENOQvP8Kmt7REDSqTwE6/WiWiLhudrpC+RAhcAyv1JrVQSTPgYUY5PpWNaDeyrklya3ox5MQUr8x71g/eOpKxXd1SKbB3dAQe9Zd2wd0UNuJ6n3q5NhlIboW5PtWdeONnyHbnOMdQKhIpFOWVi5QHjP5mru8KqQABsHcT15rNtiwJeRguMgE9a1Q6mPooJAAUDp7n3o32K6k8AKqOQxPAXsBV6PERKpy5+87dvpWYsgJIB4wAKvRqzKEC7s4Y5PelcZdQBULlxj7o49ac4AiRVDZbp71FDtaYecxMY52r0FW4WhCPIdwPb+gFNO4CSRlIz5mEGMkHqfamsFO1pGwTwFQdBUsbRSgSOzZ75GcUNNHGXZF3S4wueqj/Gm9NQTIWDI7iMZcjv2FMZo4Y8HMk2fwFSuPJiAKgyychc5JqHIjkMkzYmIO1FHQ+9TYb13COOS5kKgcfffjgAdqY0gmkdINkSIfmfGT+FNTf5WBuYk5KA8D3oyI0Xgsc4OBz9BTuS9CzCqCA/K0cGcs+fmf/CmqIhL5kkYVQP3cZ/maYiys5doh+7B+Rm+VT/U1GAJH/eMWYnoh/rVNaWETiZFjaXzFLg8KF4FQhGuSDI789N3J/LtU8htoJMPzPjCxoMhT9ajlUhP3zbAedgPJ9yf6UcoJ22HLLZw4TmdkG0Mc7VHrx1NQSTG4kCQr82cmUjGfp6UwuhOy3hPp06/hU8dmrjff3PlBRxEDliM9MUndqyK06kqpDHy04d93OwZ5/rSGVmYssbuc9X4H5Gn4jYstqq26LgeZIeT+FQKd0myEvcSE9SOKJOwLUtLHuG6e4QKQCQvHNV5hAHyHwg4HX+ZpGiIbLpGhHGSSaa3lquSQGP3eB+tTfQtEi3G10EMbHHAZqsTB5Ig7yRR7uMDr+tVILiRwAicA/MWBIP5Va/exkSzRRIh4DHH6VS21Ja1IYLeCNFd1klbn5WGAfxp00u5lRUhUEcKi1Gzf3njOTwAxzj8KUNGpJCkbjjCoTgfjSv0HfXUVoGRlPBB/wCejf0p32jyiQzwBVGdy8ioy1oqF7j7Rs5JJ4zXK6nqKX8xiskKQjqc8tSSd9AbRb1jXpJnaKzmbaOC44z9KyrO2Z33S5JIySx5NOsrYHbhSpbrmtmCCNI+c9eM1exSRLHGDFtAwqrnilVQFBwNo5NSkN8qgYAGSfaoFfl0H3TSk7GsIkD/AC7mwNx6DrUEuQGVRwDmnO7CQjH405yNu4H5iMc1nuboQAeUG6kHpT5pBtycfMMVHGcsVXqR3qvJKceW/Y9aASJNwIxjBqGXcgwMe/vUYZhLjrnp71OigsBklvQ0JXY72M1MlmI5HcHtTwhA3c8VI48qflT3zSpL8uCPwxTasaxn2K0gbep6ZFMOcn1q0yhueg7VC6McsBz61mbRkMjYhsY560hdi2Bx/WmlWx1xml4BAHIHejlHKdhyAqfmOSelFRM+enUUU+RGXOzYlYbl3MArDB4zgVUdtxwu7Kjk7qeCChGBweQaTgx+WEJI53DvWxyJWRS3Heu1tvbg+lPR8g7uRnJ9akWzZiXcqp/ugc/WpBCsRByWDKVJPTNJI0uVQJOV24JP4VZOGjlZuZiAdx7D2pIl+R4m4Odygjrz0p8kEnmFZpFUMArYP3atJszk11KkiGWd9h2Kn+sZOw9PrTJZFVVtioK9FYnGAe5q0rKq7VXaFyvX7x9/Wqjfv4xI8WIxwfb/AOtTSsYVNShqFuyWU+wFoyoyRx0Pb1rzzV4QNTLqSQ4znGOa9JlIbT7hUZjMclQeBjPP1ridbhAnjIBUKAAuexq4u1jz6quhLJQq7zg4GOav2zlN0jEEkcYrNjc/KoAx3+tW2Y54IK+lWc5aswXbJ5CjOa63w/aPIqsQVyeAawNBtjPKBtwvQ+9ei2FsYkTcBheeKmbNqSe5p6bCtsobgt396sTsx3OcgYwFptshO0lie+BTbydYlLvyTwFPas90boo3so3RpEDuxk57VkylZFaR+FTAX396sXMn7rfnAYnn2rOWQyFh91QPlHY1Je4+BNk28Esc5XPSrVsXw0mV+Ykc+vtTLeKTjGERhjJHWr8cSiRVcjYg79Cam1wuOs4n8oSvgID8vqTVgHMjFhmQjJx0xVdN0zFiTgcBR/CKtW4VFd2Y8ccVLRSLnktFDGxI3yA4ApyqsaFQBubq3pUcAMY3ygiQrwCenNTrIshVUTfg9/5k1SSBXQ/5nQYULEowCR1P9aR4ghXykAJHLsef/rVYaSCGISSOTcscKVHAHtURkWSTfMCqJyfVjTaQlLsRqI4IfMf5j7Hqaijj83zLm53LEOijuewqy86z7ZJlCxp91cfM2az7y4d1w7Hap+SIdqWiKvccmJTubckJ+9nv9Ks/6xkaMBIY89OD9faqrApGskgAdxxuHAFJOV2K8rFlIwFHBP8A9ahaqxDSJ57l7lgqZ+zp0J6e596iFwi5jCHbnOP4m/wFQ73m2xvlEHIRev8A9YU+d/Ij2ApFvGNq/MfzquYSRIWkRSieVGp5LnoPx7mox5fBYvM/ZVGAaiVgAAsfmN0+erR+0+VmRo4U6FeM0r9UUBNwV25S3RRyF+U/40+D59wVZDnk7FGT+Jqvm3j3SAtI5GMkZxUi3iAASyTCIH7owM1N+5ViS6txAysUwxHyo7bifc46U5PNcbprlIkXoFWq0twsrYtbUxR5zukblvrmiXz0IlnkVV/vccewFDVtQ1LKyKV3mYOWP3QCSPf0qKR1R8AxxFuST8zfkKrte27Shisz5+7x398VYSW+dM2lqsan+IqoP609xXIQ8ZyGluJD1O0Hbj6Usc8UZyIGcN0Mik5p4ju5HImuipA5A4/lUToWyJLp9q8c8ilbqiuYuR3kqMskFvbIR2IJNQz394kbmSZFjXJO04IrGutV021AWS8d36bYxk5rG1C9N/MBE0gg6Av1Jpq73Ba7Et7qE+pbkRm+zg4OTyasWNsiOWC9RwB2ptnbqV2Kvydc1pwwBMjOBQvI0jHuJjZMPl5x3qxECcByAPWhYyrKeuTg5olmBBwBkHaB7VRrGPQdM+QVB5HTntVTzST8vAFRTShW4B4qGSUDODWTZso2Q55f3vsOtCOJA6nn0NVLpv3iup+8MVLEnyHBFJDsSFtjBt3TjmqlxKC5LcVajw6YkGSDVG4G+QjHOetAkO3bovl5I6mpoJwNvciqMYMbcng04ZjfGcDOa0gTIfqchMoOdpYdqrrLjgng9TRqP7xAwJytZyyYGAeKU9yoOyNpJtyY9OlMdz9PrVOGUqwP6VbDrIuSAp71Fh3IZMBcg5PoKb5inoQaWTapyP1qNYjuHCqDzTK5gx1x1oq1HAAASx9Riiq5WHOjQUIGKFWz1JJ4akFwA4XHO35QfX1pJgZZPly5XjI4HNV5AHkYIemc57VTTMbp6C+ZLu3I3YliO/rUxglkRTlQcZyOtQBk3lNpVF4UA5x71ZSUqcMWACcjHNUvMG7LQeu2OMBFIIU/M3OaoHdIS25skEtjjkdKtO2CG2sWx8u7ofaq10QVYN8pwOB24pXF5lWYM05dyfMIBI6Ee1RrcBBmJv4twBHC8elK/CmPlXIB55LHpx7VUnjMe8SFSo+62f5e1PbUynroyZ3S4tsSsA64DMx6D0A964/Wvm80rnGchdvGBXWSQr9nmC7QwX5wRyPeub1IBbAnrkkZA6e1Xq0jgqdUjDgYqMkjJ6VfslM7hEXJNZFux78Z7V2XhuyAwZMc1TZyx1On8OWi28a5HIrq7chsAnrWLZIEHUYq+knHUqPWsrnXFaGss4VCxJAAwMVk3U5mlLHOP5VHPek7iB0HA6Y96zmnBDIAVj/iY96RQ+bE5faeQQAc8AUHy43Ubd4HGB+pqAo8zFs7EGAM9qsAB0RYhtGcE9yKGMniZjIZGOQgyAf0qzBGJHLOflzkk1XQKrjaNyr0z61fPytlgPMYDC4wAPWpeo7Csxd/KjG2MnOB1xVxdqRrjaAD8uev1IqBJAmHU5kYY9MCpQQsScDk5J6nNK42TyMjRthHd27k9aljcooaVECYwIwfvVC/mvEJZWYRA/TdSJg/Oy5PZR/DTBE0J8yQyyDCDoucU2RmkAGAiZ5YmnrglcIrOeijnB9T6U2dVjjYy4eUcBR2+lDV1oVdDDIcnYrbmGAvc/8A1qFi+zy4dl8xBk5P3SaSWOSDDF/3snQ+gqCSQMTtVti/mx9fwppW3EF/cNcOxmctjG49gOwqKAXN3KxjJVfuljxtHpSRpu/e32VhHKx92PrUtxM0zojt9ngPAReWanZbsm72QCdYWaKyCmXOGkPOPxpm2JTukYyuTyV6ZpYrV5JPLjQxxk42L1PufSrPlQwkB5FMo6HPH0xSd2NNIS2E7piKMRg/3RkkfWnM8VuCzOu5hyxOf0qGe8WNXXDEEdc4z9BVFXaVWKxomT9+U4/Spd0tBrzLRle4jbyIgu04MrcYNAmii25AuJe5A5H41Co80g3FyG28Kduf06U+OEYYMkjZ5+8FH5CjXqNtDmM0pBmaK3QdC7ZP5URxWzAO0VxNIBndnipo4YI9ubfLAcbWzk0ssbiTKr5ZPIGeMUK/Qm6FDHG2K1MaNyDxn+dPlfCgyI3l/eJEgxVG/ubOxiaS9dmk7KmOa47U7976QiLdFF2iySSPeqVxaHRal4psrEtHawLNKT1Y7gtctqOqX2ozEyyqsechIxtXFRx2QkJAUDjd83er1jaDep254qrJBFORWsLIbvNYdDwPWugjsttiGdcFnz07U62h2iIKmSDgrW7eorWkSYAYsM4oSubKPLZFG3h8rZu6eg71aibcpUDLk5HtQnyOSSQw+6DUcrMpIb8TUbHUo3Hu7KGVTyOazZSQTt6mp5m3LhcBRVa6bauQ3FRKRrBWIpASqrx+FVnDMOCMA4NWAPl3A81DswSfWouU2Rkbogc9OKfHkqM5JHSpIwoBB/KmyOQ+5MACnHczkyYthBL3IwR6VVK5PzZDdfrUkNwjhlfHNRO5xyen8qu2lyUyCRdz8cYpwj85TtbLCkeTLUkRMbnacqaE7BYq7t7MrZx0qi4CyEEY9K1biIqfNUAg9az72MnDJyMVpuJ3IlkIPDZ9qtJKCOVOO9ZvOQ2ORVm35Gc/hWQlI0IgGOCpINOkjkyUxwBnNFoW2sc444qxbQmaQ72wKaVy+a25HC37s+goplzG0LNt5TPJoqttGF76mrJKijEa7FUfcxjJ9aqgsCR8q5yWAqyVBwz3Oc8btvXNVpVVBEyks6/xE8EegrRvsYxAOuGKHOW5NWGIAKgt5h567iKgVPMUlXAboVI61LFGp3SCZkRs7icUldluwyRSu7cr78fMxPH5VBdqNpMgZJDglB396soIwN5RzFnnJ+8f8Kq3LtKd+SzNx9BRYhyuyKVS8w2hYiCAWJzgYqtOyyXBIjGAuPXaKmnDLgglXdsHjPSoiWTliCgyWC5waq3QybZUvA0C4WdQXXcSee/AzWJfKRYschnJ3H0b6Vt6pGHR3jUDcOEHTIrm72TajKGbaBwGH51V0ck1cyNKh3SlnU5zXd6SpEQdVAwcVyGmpnDKzdfzrrNPdowSyZX+VRzXM1Sa0OgilPTdS3N6yxBMgqB+dZb3yRpufgDt61XimLyiSXHHQUrXLT0NNWeYHEgQHopOPzqXzAxQRjcB1LdCazzcK7EvwSeFHf61o2hJ2jKjIp6D5iSCNnfDnkmr8UQRggK+m/0qKBRuJYfKepJqysiLHhRk54PpUaIrceiCKTk7mJyM8YqYhmBdoixPy7ietQsRksCCMZy3XNOjaSZkWLkDnrzUlInVg7xjaCejYOatMyK5VADIOg/hX3qLIhRkRgJB95gev0poWRQscA474Oc1Iyd5EeUCRi4HUg9T7elOYIIjw4Zzx9PrUcaTNMygYx1zgAU9sRcn97KO+elUrjsWg4jjEduNrHuDwPqaZG8aT7txKqOp+bnviq8QlKs7Hpz/ALNLkKCifeJzvP8ASmm7ktDL+4aMmaRiJCdqKRk49QKri3lESyOyrIxwsb8Z9zUiRNLIZxngEbm7AUirLM4ZN2Opkfrj2qo3EKiur/vGWR1AAPYVIy7Xd5CBIeWeQcgegHao2kBnZxMxKgBcDIU1WVibgSSIZBnnf3NPcVzRWRooTshZlP3QON39TWfIt27sSrRqDwQOcf0q7cXJiiBkKgDrggfrWPdawjgLaRmTHO5mwM/1oaXUFItxRFFVmKhm53MMnHrmpDNZwlXuPK65G7kt9ayElvJlZ7iTCt+R9hUY4YNvCkHAHc+9UrEuTN6XU7Xy8QxyNv5G1Rz7c9Ko3eoSE7IV6ngEnpVEMyoWW8UDPPQEk01LiJOTdqD935m/wodmCbLTT3u3eWSNc4Vgaz73Up4mVFuZGdR0B4qpfXSzBYoWaQqeWJ4/Co7WDL4JB9T7VGi2NIwb1ZGVkuZBLK5dzxlqmgtztLjnHNaFtbBnCKoGD371bjgUtsCjaAcmlqbWSKtvaeYRwOV7Cr9tZiKYxqvGM59KsWcTBpI4lGCuOe1SRJ8jFm27RwaeyHFXe5JAip+9J+UHGMdadvEsrk8HHApjPtCJICQSCM96Mfvmzg5HbtSbdtDeMF1FB+UHOSTx7GobtjnexGM8jvTXkEasqjJ9R2qjJKwbcckY5JrNyN1GxPI6ZPJUdsVTkkDMOSQOOaSXLDJJBqNDxtYZNZsrQlc524+77U4FGwMZpkLY4I4qaABSQwwc5FNIiTuRyJuQ4zkVWcMF5rQUEMdo5qrctzgjGKaJuZd1vhQSoudp6VrpB9qskmRD93JA7VTkIIK+vSrmiTNaybd25CCCD0ranZ6Mzm3uiqYOAeMH1o+zsBlDz6CrN+u1yR/q2ORio1bYAT0xQ4WGpCQgsxWQ5Wq8sYDsoT5e2RUrAKwbOFNOBaUEEj2oTtoDZhXcIiOGxgc/Wo41JYHgexrZu7UTJtwNw6ZrHZTG5BPI6+1NxIZp2cStk4xxjk1LLKFwAvA96zbdnkdEiy7uwVV9Selaz6cYtUWzmvrZHUjdLklFfrtJ+vHpR5IXOluylJPuiKnFFO1YTDUrn+0Bi7DkSYA5Prx26UUjRNNGpGzFQEXIUZXdxn8KiYl0A5CkAE7eh9qlVY3Yq5Dv6L0WpiMnKlgiHnb0IHoKtRuZOQyOJflZi+Dwq96keCEx5kCLu4Kg5ApiSYLOpbYOcsMHFRucneWHz9AOCCe9aENsZNdZfMYBONoOzGPpUEr/ADoZCS+DwBwKe8iifKx5Kjbk1BMEAUe/zH1x71Ldy15EV0WaIGRwFYZQL169arLkSSBSXDDbwcAU64JY7wAAo5APQUjqqxDIUb/nG2puJqxQ1Jz9mXAKFDtOPasLUciIuoypHQ1uXS7A0hbcjkrgj9aw7/BiCnIJHTsPem9jmmlfQh8Pgsw/rXY2VvkDGB+tcn4ciJ5bgd67m2i2xDjj1rNbHTyJleexDLgpnHOcZrOdP3mHJO37oXiugfhcrlieCf6VRuYAFVjgBT1HX/69HPYyqUbleCOBWAdTk9OetayxW6JjLCTrjpgVilR6HaeP8+lTRTtAwWQb4B2/iFUpJnM6bRtRQNtJRsnsT6UiRzZzHyo5OKpJOjkmzY56YPP4Yqwl0dvl4MbHJYq3GKmUUVGTJZJpThX+UZPAHr61ct7qQK2XVWPXjHFUI52VCVO5c5G7rVqKUNIDxJKTgoRxiodzZWaNVIxJGgV0UZ+bvj61JmMjapLKvXZx+tZ0ks87FRGFQDaVXjp/OpIUb5FkkRE4PynrV2Ei8gBidmBaQ8gDoB9aN6sNqIsaL95ic5PoPWmO8SkJHvmUD5h0FK93ISsaRxpx0UZIFS/MCz50sibC4WJRk59P60wSl0EedkB7lcsRUSKHAUhioPOTyTUlxvDjy1VFb5QDyQO9ONyXYbJcNKgViBCCPlxgtj+lV766klOWPlxseEXpxUsj7SUiTDdyOoqC5lhso2kmOXIyNw5PtWivYhtIJC8u2WbEMS9FBwKrTalvZ1tAj7OCxGFB9qzb+4+0APcuyRj7qdqrzXalEjhBSNMnp9760kxMlnfe265maefuF6AfyqGe+AbETIB06ZIqtvMxHl/L7npUsNrzk8t70OVhKLe5WlnuJXG6R9oOBk/0pFicn52J9s1oCEFh8xHqakWJAxJb8V5zUORsopFBLZmBPQepqs43yBI+VB5J71cuJhIxhgJC9GP9KW3gATAC4B4yapbXLirsLKBc8Dae2e9aMECllUcjruHf2pIlWRyrArkcADofariKD1yOemMUtzdRsWIFBboNwOM06DaZMN05pBJvOEHyAjPvU1wwEoMa/vMYb0o2RKWpJbPsV2Y4J496bK5EXk4+duQag3psVuevJHai5uyTnHI4DYpN6G0IajpxI+xSc4+UmkMpXjbghefeopZWkj+9huufWo/PQxFQdzE4NS31NkrrUS6yCGBIB6gVAzEltpyF6UrsykhwWB44qvOGij+XODUMvpYaXywUnA/U09ArRnkhx0x3pghbyw3Vj3qSIcA46GpsQ2tibf8AINw5HpUkaiQYLYPYUqKGB29aRQQxIwT0HtVpEXESRt2C2CKS5TzIi56ipZo1nTdGCJFHA9arGU7ACc+o96tIzbKMinBKjJHakSdgQCMVK5Ugt37Gq7jP3D165ppWFe5o29wGBRgMU6WLyjliGQ9PWsyN+ecAgVfgvkeNYpVwOgatI2ejIk7aohdkOB1B/SkEnkuFOD6Gq1ypgkyCWhPQ1G0okG3PB70ctgcjQWcSMc8YqtqunmSIOuFJHUd6z5pGtyd3TsadFfEhSWzjjFUnbczk77FKC5axuopcjzImDLnpkHiur/4l10zXraTrQaU+Y1ukWUJPJw3UAmsVUgmvbWQorlZkbaSADgjgmr+s2viNtWupINYgaF5GZCL9UwueBjPGOlDjbYxnPUy9V1Ge51W5uLmIwzSPloiMFPQfliisS/uJYb+5jvZRJcq+2SQSCQMfXd3+tFZ2Zqqisdyp2bnEQEajGM9PrTJ7sY2KDnA6HgVE0qIzKx3D+InvVKSULITgbOwBrSTsaWuXBJLImwEMRyBTWuTGDyoOMHjOaqpcoZMbCBz35pZ7lEXEO3aVxyM80JhbyJEmVyqvnJ5JJ+7+FVbiZRuUMGXOe+M1Vmf5w2VYn26Go9xJ5zt9cdaXMiuRp3LCSou5iCxYHip4yZUydoVEG4Y5qh6Y5PXPpWksRdGI4Zh1HapiZ1GUL8CQBouEBPFczqbYjZlVsAEA9s12MqABY5hwo5IHX61yeszkWkluqlVyXI7E9Biqa0uczld2LHhVSQCRnPY13MEfyDcO/SuR8Kx4RcjjpXax7URQ/DEcU4x90621eyI5YSDnH0+lVbyLaQB06g960FcTPhO3U1HMSfkZRz145NZSgOU2nZmDKpXK7c+9NXmMBiCMc46irN/FsIIzsNUI3KyFT1rPYzaT1RK0Tqm6M4Y9vWnQXBdgjAlhlenWrdiob5D1PU1JeaX5ubmNSuGAODW0VcwmtSGPzIhvMJPG3Ddqs2kpU7mZo9vfbgmoYd3+rBZ88/M3pUojbhIXyPRu350ONhxZfgn3uXlDSAfNgP3Perts8YcZzuxyyiqEeU25VWfGNpHFTwyooYeSDIOmOBUFGiJYFXAjcORxu7+lPG6NV2BWY9SB0qvHKPvAKpxzgZJqRrmaTksEVRywGOKF5gW1JX5IwqYyXc9RVSJ3+YxMAc/e68elQPhvmBIVeR3yfU1Wmuy7sIhhehGePxPeqIZYurtLaMQ2x8ycnlscZ96yJ5gJd0z+dMeueRUU1yF3xooMh9+M1WJfohOT1c9foKG22Qhb2XJUSNl8Zxjhf/r1HGjSZLDIPpU8NsgIZvmc+p61ehgLHaq8Y/Ck3bYuK7kMMeVwBU/knhgMZ5+lWFiAIHT3p5UAEDnPr2rJs1USrs2qCeCKo6hdED7PFgu3Uj+H2qfUZhbqFQ5lk+6D+tUrWHczOTz1PuaqCvuPRuyHWltsGFGXI656VoxRgKoyATzyP0pLYrCzHvjAIGeacqNuO7kdvStHsbRirk9upVQBxg4B9KsRZKO7klh97HOR61AOVVN+QRnAH3atRALnLjAHJx1pFMUrsH7skFvX+7UJ3BN5cbu9PkLIEwwbIypPHFRScq4DYKHIpS2CNtyy6iOEZO4uOMdjUDOBb+U+eeQ3bPpTVkfcjM2SAcD0pZNskG9yAwOcCpaNY6EMzs8UbLww4PvUDuCoKcMp5OKnlJXLKvyEYx7+tVpyo2uBs9SO9I2TuTmYMzHcWJxTwomUqM7sc1TglYEhmUgHPTmrEc5yWB+buPWgh6DbYGNyjthhx+FSsNsrbxxnjB4NJcxq0YdTlhywqS0dJowr/KcdfSqUbmU3bUElG4Hpih02uX3Z3dRUBVopWLgBDSR3AGc/TPtVJEXuWdygZVuR2qC4yymVQPcVC8mCoB+WkWXYxJPA4xTFoir56uCSMf0qJ2IX5fXnNOvAiv5kXQ9RUCSoxwWP+FFh3QElpcM2OOD604uQdrH7vQ9qbKUwB1oCo8RQ8j+VNRIlJEhfeOQMVQuB5XzK3B6g9qZcs8LAISU9abLKJECdyKvdWMZPqAuvNUq/zKagltmRS8RJTuO4qrMZIeIxuHU1AdVk4AxnuDRa25m5GxpWpWVsJBe6cL1mPys0xTaPTAq5LqOgSx/P4biI97lq5Oe7DAkYUmqMmoFSAxABYDcTwPehOxlJ3LWrwxvfTS2MYtoHbKQBtwQeme9FUNcuhp8uyG/s775irNbkkA/iBx70UrolSZ6BNOWA2oc1YttKmd0+0v5Abkbhzj1xWtpdk+A0Np8p/jLcn8e1akOhGRmluJHMrd1Y8D0q40W9WdU6/RGGdOhFz5cNwjRYG6RhjB9Kin8PyG3LrPEyg/wnJFdVH4ftwoLox5yck5+tNn0NYUBgZ0XOdykgE1q6PkYe3fRnLQeHnktZbq4mjjijbac5zj1xWZqUcKmIWqNtC/fzncPX2rpr7Sp1jdVupSG65Oc+3tWDeZt8o8W4MAEY9qynFRVkjSNWTfM2V7eEsy5GB3962kiIgBBCg8/h6VA0ccEcJ3xyyuMOF/hOO/vUw+dRuYjgdPSoUbOzM6lXm2KuogxRb/MXLAqMdR7GuG1k5VQBzkAD+ldlrMQ8xljcMpyQx7D2rhtXJFwi57/n705k09zr/C8YSJVwfUVr3cuw4IyT03elc/o14bWJD6dQOprXlma4lacryeNo7e1aPWKSPQowfNzPYlWSXAO4henHFWoJ8ziMlvu4GfX61SgLOenGenpUr5Vd38WcA1izaqkxmsqI4PlZT0PBzisWPPmDIIx1PrV5/lSZgoYMOpPTniqGeUKvljyRjpWNS17mEVZWNe1cp7561sQ3RPLKxRuCw7egI9KxbFo8bWyxPUetdcluH0lo44PL2sGOTuLVdK72M52W5kTxbo96PtkU7hxxg9aYcSbhEG55O4d/UVtx6afsyT5GCcDuT7fSovs2GMhZcY4TODXSlpqYu3QrWsbsNrMMc/j9KcY3i6EY9O9TOwR8xwhpOnAIzTXiuXAKkI46ACs5KKBNohZkQEs2PXbULXAUsxynA2gnOffFW/sCooDsWbPzE1G1uhIIUD2rN6DuZr3M7xtt3Hcec9/wqpL5jD945OOg7VqXChc9qouMg8D3zUjRUEQHIx070rELg4GBTJZPlJHGPWs6e8xkAVZBu28iHOcYPpzgVoQHcNu75cdK5azvFJUZyT+ldDZy7jnt0FZtmkUaixgEccAemaLxo7a2eWQcBeg6mpIWDL6DHaub1q9+1XYhjz5MXH+8c9aSjcp3sVZTLcXTTSclsA8dKuwDCZqvbl1U/NyQavxMiRbMAlsHceorS19i4aImAxEoC/fOT9KR5T5nA+Qd+1MaYHhRgLwPamyEj5mIw/p/WmzSL7l7ayxxsMBye3cVK6rGg3Nlc/oe1QxRF4wyuvGABnn8qDK2GB2/LwV9aGgu2wlYSGFOf3f8u1NP3Au4CRjz7VCZCshZflk24K/3qgMvzysW3AjnNSaouAEsxIAdT9zPOPUURyIfNi3EEHIGKqyN+7VnbvkEdfpSsd0qbeCBkN60ih0bsZAB/Dwc9hTb7bgBX4B6E1WnLpMZFOQ3DgdDSGZJARjHsKS7Mb3uhyjzCAnygjjPeljlwMEZweKrRSY+g+6KkUGTeUOHH8Jo5SXMtxTkSEE5PcDvUUskkUrDOFzkVVjkzIAxAbrzUs7CRXBO5l5BqkmZNpsuvOGjA25X+IGqFzIITxkoemKqi5O1uOaiecMMOTn3qnqQtC7Jcq4DH7w4wKhkn3MxPFUHlaPGeR0o84sgz60kriciyJGIODTZySu6IjPcetVWkwxy3Xp7U2WUIpAbJI6j1pxiZubG/bvmCsCrD1qRbznms24IdfmzkfxVSeSSNSwbcnr3q0u5Dl2N2W7UqQwGB0qpJLyNsijuATWHPe7hjJB61VadgC24k1V0tjO7ZrXN8ybsg8elZs0iSLl+D1FU2um55yo65qjd3Jk44A7UnK5Nrl+ziS81O0tPtDRieZItx/hyQM/rXTT2Ok6SmrajJo813Ct+umWNlcyNlyP9Y/HJPHHYZrz6GNrm8gtrYb7iaRUj5x8xOBz25r0DWZXgfTL658W6lPPp+oHT5rkQrst2KfM0YPLY6Fj1xSWpE3bQ5DxdYw6R4o1PT7Z2aC3lKoGOSoIBwT6jOKKo+ILG50zXL6yvpPOuYZSHlznzCed2T6g5oo0J1PrS3jSJVXAGKtNyuQmB2rNjvIZCAGHB9anMylcqTx7133SHyvqXGk2AL5YLY6nmql1MFX5jx71Umvo4F+diW9Kxb29a5cZPHoKiU0kaRotsn1C8VicfdPGKwLkCaQBsbMjr0JqxK5Iwegqs3Q4rmnK50qkkjOmi+zTZV/kJzx6+9aMTKYfl5IAxUbIJ/lkBLYxn2qtbTGMtHnO3p9azl3OZx1sVtUbaGYEkYwfauB1KYyaiiseB0Fdzqh8xMMcHqAOM1wM373WW2g8cYqd9C6MVzHVaXESqsPvY7jgiuit4iAARww5ArG0lWjiRmxg9e+PrWzBMSjAKRj7ua6EtD0OeysizGhiACkYzznrillUkHnPvnrUcEhwfNADGr0UbMrEAMoGT6ChwMpztuY7LthlIHGDn61QtoHKl9pI6bh0z6V0xtTNbuAPvDt7c06z0k7ceaI1PRT796ylRbehnCslqylaWixyA7tjbckn0NbdjLHH5arI5cqFdcFhj1qs9qY/lJLjIAOOtdDo+mrLAGxyMcetKMGti5yTV2NeKdnYCZQmMqq9AMU6OzUBTtJ5yCRW2trEsWGABPy/N0qVkjjwi42heDj2qZQfVnM566GGtjhtwQ5IqV7YBRuyOe4zVq4XjAJGD90nPUdaZ5gMakMQNtY9R62KskY28Y24Gc1QlgRt5QsJAD8o6e1avG3b19R2IrLuS0bboxn+voafMJIybtC7EgEv0H1rBnlVGZXZkfHyjHf3rq5BG8ZkYruXp65rEuraSV3LPhh9044+lWl1Ron0OeuJHdfusB16VkXQfJO1hx6V008d7skUSKQ3XKjI+mKbNpjfYVnixgkIyE5O4d8VfKyHGxx6NLFOhOQAwJx6V2umThwMkfge1Y0tgVHzqV3ZwDxUNg7W1zhmyp59hSlHQIys7HY32oeRYsFP7yT5R6j3rHtkVIh0JPPvUM0huboYIKr8o9KssNpAHYY4qNkaLVj1OFpsspDcE49adJbzNGrLG+317GqEjEDG45Jx92ldmsWi+kxVRuGY/UGmfaMsQrDAPFZjs8bYLgL61GXlKMQp2rg5xVXGmkdKbpVbMZ+bGTinGRZY924Ed8dT9a5iC6G9QG5JxiriXA3kIcrnk0XKSXQ1WOV3g/jT1LAHcuOMg9mHvVSKUvFhcbSeakMmDuB+XoAT0qkg5yZGUja0ZKEZGDUckjB8KQQB8o9qiJ2oyEAK44OehqG3nUxukuD646g1LK5i4ssmVAjAUj8M1Vu1Ay8AKD+IEdDUZLAou4qByAx4NL9oTbuYMQRhl96dl1J57BFI2OSHC90FSByGyhYn1H9ajeESbhbMQ23JXsapyz+ScbTnAyc4qrWRm53Llw2WMg2hx+tMEqyYPXsQOuaqR3m6UIcbe3HWi6crlouh70lZk8xIxKSrwQD3NNlYMMtgMPSq8Uu8cguD09jTZyYyC/PH40Ily1JROCNrrnv0qtcJIPmiJ919qY7+YNyEj696RZsjaflPcGtFqQ5WKxmLZWQFWB4zUe9trjJx3pLl1H32znvVGdwCPLkz6g0iHInmlcfdc4qhc3bICO3tVa6viny45rNnuGYlmIAqWxItSXQw3y/jVWa52glmAH1qhPdnJCHPvVOYs+STQotvUylVUdjQe+YriMce9V2dmHJNRRjCipQtDsgheWpJYSXEV/ayWYY3SSq0IUZJcHgAd+a9PkRbqycX3gTxAZnvPt8kMXEDTYwe2QhPOK850swxanZzXYZraOZHlCnkqGBOK9DvNO8Q3XiSTWLLxHanTDP5sd2L4LHHFnIBjzngcbcc0KQ3TOF8VLq0ut3N7rljPZ3V45l2yRFBj0XPYDAorsPFF3DfeHtVkW6E1rd6r5umQs+540UESPjqik9BRUuaXU1jSbR6dlt4OTUwlkA4ZvzpACcYFP2ius6LoiyzHkk/Wo2JAI/Gps4zxUM3PtSsUn0K8zEA8VXZuCKS5l64qIZY5ycVhKWps4+7cbJJsMbdwcVXnbbOx/vHJxRdZI2jqOlP1GSF7a0aAtv2HzcjgHNK90cE9JXMbVJQLd92cckVw2nyiS9dgep4NdXrs+yxlYH+AgD+tcjo4IYZ4xSSHTtc7/THItgynoRkHpWpGzSFmZizdT71ytg7tgckGulsiydTyOldMZXN5PkV7l2GIuu5jkKc8Dp9atRyq8YRXySdvlqeuO59qoSeaWKKxVmx0PFaWmwxRRkuDuP3SfWtErswnPS7Ni3iA28kLxkitFYBGu4AFD6+tUrKQSABsY9RxWiZwU2hgAB68V0xSscqu2Q+SrlmMZA9K6rTLDbaI0UZJOCaxrJmLL5YyD2xnNd5pkY+zpv4PGQPSpaS1HVqOKsY82nyvyVkKnsRUcunFYgvz7z0AFdcqjcAp5qKZfvAoTjnINc8qakYqu0cS1hOQS0bNEPU4qstv5RG9GKgYORXazQrggr9c1TeBGiK7hgdBjpUfV0X7dnNR2UD4xKQvoDg1Wu7CKSUQW+95vXtXQzafHIfu/MScHFNFmIUXyuSOpz0NDw6GqpzH9kNHbySTKsYx8uf4jWbNbBYxkEOR07CuxurYnDSneMY68CsO9RVBGM+9Cp8prTlzHOSWi42dSfzNUZrON5EWGPDMfvGukWDerYUOBxmlFokUbtw7gdTxik1oaNpHJa5aL9qJiBXaB17kVzN5aZLNECCpJyOh9q7vUbfcikg98NjriuU1dfJhkfHIBP1rNLuTe60KNoxLgIM47etblkYobd2mjRnbkMx5H4Vl6HbqYDNMMYGRzzVwIsrlgPl7VlZoqMuf3SZ5nn2hiWVegPQfhTvJaTAYcDpSoBjCjFTrGT161pGPU6VFJajNy5UvDHlDnIHWqt9cSFcIVzjbygA2+lXpAAc4BAHIqpKO2OvStlZozdNPUxn063mJYkQSEcKp+U1nstxaSNHMm3A6nvXV2kC3JMZAB680stnGkbw3EYmibgbuSvuDUyo32IdV09DnLaUyEKCQw7VqK/yK4Kkj7wx0NZWqwy2cUSwss1mpJDKPmT602yvIyoJJJPBXuayUeXQ0U+ZXNKZmf5s89SOwqI7fPzkrgcMoqWCbzf3e0be31pskOdq5JbpgnFHL1HzBJKCiqsm4g5wvSmBlWRgMBjyrDufQ1HLhVEbDao43L60xUW3IeRcoT8rseM0raiciWOV0lJUDe3Le1WJUE0ZZcYIw1UPOBuS0YZmHB96nj+5mLcuD8wx1qlqZuVypPbpG+2BiQfWnRMkbKkgUbh9cVfY/aIC0sQXb91h1FUSBJIwJ2EDPSq5UtUK4wqfM+Q5Ht0pruASrAChi8Chl+YP27k03BnJZzscDkUrCchhA8wYHy+lQXD/KwYLsPSmPcIuMbwx6nHFVZ7p8MTjBqtEQ7kV9G4iDxyb/AG71z93OwOMMD0q9eXjsRsJBxjAqmYmlcFucfpWUproVTpuTKLs3Vjknt6VUk3Oec10EenFyeKkfRWZeFP1xWakbug7HKOmKjK1t3emSRdVOPpWWYz5u09fStFK5xzotD7eIuBjNa9npcsrcKSO3FdD4W8NPOsbyrwcHkV6Lp/h+GCMDYM+tYyk2dsIRitTzjSPC5utQs4ZlKxSyojnpgE4NehPpGg28V3KfClj5dnfLbOrFt5jOcPn+9x+taiacHmjiiADswVfqTXQRJHBfyyvrDS3RxHLm1DK23gdeDjHWqgrk1r9DzLWfC0cXiK+QRRRgy8JCm1QuBgAduKK7+WxX7XPN5xuGkct5rLgt74orT2UQTdhTFjp1HWmMMHgirhUEfhk1WlU1u3YiMrleRtp+tU7iQ7eo5q1KOKoSHcAM81HMdMLFSRSSc80+JRjPapRH82W6elLkFcsMD2rO1x1KvQzrqPbMMHuDWc0xWzkBHyxykZz61Z1OY/aVUHHcVQ1KaCHTo1tyuWB80t1Y56inBbnn1JXlocp4pvCIliVgvmH9BVfSoDKVCgbuv1rH1m5FxqBHUR/KCK0dIuSg3M3HYVUNNxc1ndHZ6bZyxFA+F3dMHJroYoPs6sNjbgvGema53SdVWDbtXLtxuI6VsHXBKwRmJ7H0zXRHkQpVZssxDYDvLO556VObtyQqqSAPSp7GaylADkkt6mh9Pd5yI5kYdQScfhitVHS6FCqpP3i7ZSFsKRyRxtrfsNKe4QPIThjWJpUYgnAYDeO4ORXX6ddMVC79qA8hRWl0lqXKdleJq6fpxhTMfzY6Yrati+3h+BwaybfUTFGCMYyTgdquQzrJh0bDMcn86Tkmc0+Z/EazXSxleQzdwO1Qy3bJuJyV9qgiljJYDb69OtCvuzlR071nZEIa2rEqcxnp0IpYp94BA564qtcMCAy43Dg89at2tugG5yeecZ4BoVypKKRI8JYA7iCR6dagmhKAGIlmbjB7VfEyjAHc45qIvGX53bu5B7VRipamPMjCaOKTbtYH5iane1t/KU7OCOpHWn3UyYBYKzDofSqklwpR1LEN1WpbRquZrQrXFnHEhdT7YrCvThvlwOP1rYludykA+5FYd+29s4IOOKzm1Y3gn1Me9fLHceOtcvri7reQHOCK6SdgAC+GAPK1gaovmI4B3Kelc3Mb8rsY1pdMJfs8Y+UjBz6VqjKKADXN2ExF8wbhhxXTRqJAGz1FOT1IoSs9SWA5OPWryINvWqsSFQMVaU/Lg00dUp3I5R8pFVJMBcHr2qeeTggVQlmwRkZHfFVF2KT0J7aXZLnsf0rRnAeMHGeKwWk+bgGtCyuDIoVjyBWsZdDGrC/vFS78y3RzCqlH+8h71yl959leefErIj/dIHSu4m2gHIHP6VzusxOYWK5MZGGXP8qVSCaMIuzKVrfK0ODuMpPUVfhvMpl0I5wMmuXSVoH2kcA5BHFWVvnE2QS8ZPKnmsEzS7eqN+YCQbmChRyMVX+0IXKEblPBBqit9ufLAgdFx1qAzfvhIwbHTKjrQ/IE+5oEzMHTcqqDwoHUVJbSMCoilKg8YPaq0criB2KLt/h5+anq6OUeNVV9uQxP6GhIHLoXZLg27MJFwccN1DUiTw3CBbj5WI4Ydqyjfuvyzxo65+61U5b1YixikAXOQrdRT5rEbm1PDJHEZFkV1HCnuPwrLmudrEDcGA+Y1n3GtyycmQKB0AHNVpdRlujyASeMgc1MpopKTLFzdkdGzg9DWZcTyTOxx8voKuW1lLMQXBNb1h4cecg+W4z6jFc0619EdtLC31nocmlvK2CFP4da3NK0G7uCNqMFzyTXa6V4UhjZTOz+2RxXY29hDFEiQuoK8Yx1q6cObWRcrQ0hqcZpXhq1WPM8siPnunArXh8OR7cRzRO3p0NdHPp/zKcEyY3HPQVBKCjDKBlHy4rpXJHdGTUpK6ZyOqeH/lxJCTjuBXDar4ZEd3DPEP3XmANn3Ne2+a8Uezy1ZP4lzn8qzrvTbK/tXezfJA+dO4NRKMd4syba0mUdDtRHboEHAGOa3Fj/AHe1Rk/Sq+kwkQKCOnFayoNuG5BrkudcdDLEQNzAHkMa71BYdV5610MzwC4nLaUu7cQWZ2Bf/a44561VisftD+Z9phhZGBXzDgnjqK3UN1HtM2rQYK9C2P6VrS1Mq7V1/wAH9DAZFeVmji2LnIRedvtmirt1qey4lSNUmO7mUchj6iitbxXUFTk1sZMbgLUEjA8CmJJlRlqZLKOMGtZHnxlYjmHOKrNGAafK2Sc1G0g2gg1FrmvtrDG4GSKpXD7Fc5wTzU80oC5Oa53Wr/CmMEAscY7inymcqtypcXG+WaUnKoOtct4j1MRxYXJfbtXA9aua1qEdrbJEjYbq2eo+tcPqN7JeXG98bf4QO1CiYSmNjJJJY89TWlYHDKe1ZERJIrRtSc8HBpMqMjprSUJliVHpU4n/AHfyE5PU5rHtBI5Ga2ba3ZiBjj6UuU1jqXodVnUJmNSFGOM5rTttQvpflRimegHaoLPTgzDINdFZWCKo4waLyRryRNDw3DKkY81yxblsn+VdRaytFHJ5aNgnIrBtYTGw2kjPWtWFnCkK5K5yOeav2uliuRvUvRXLnkq/Jzj0q7FqAViM7fTNZocDHJ9MZ5Bp+QX5GQByKh1WivZJm0moSsNy/vGA45qzFqO5ATkAjkHrXPAqoIAJz0wSMU1XJfGX46c55oVZoh0LnSLfQjI6896V9X2rtGDzXN+YMkZ9utM3/MMHn1JrT2zIeHTOl/tRinJyuex6UsmpMzHadoPHXkVzKs6qCxJ9gf1oaZlk+U8+maPbA8Okbdxf7RnIznp61Rlu92Tn8jVCWcscEjJ7EVEzfeGfrWU6rLhRsXftfUMuc1EziRgOeKqNk/e49DQ5yuPmz7dKhVGa+yIbs7yp2qCB2HWsW8hQ5U7d2eWHT8K2yo27sEfTtUctsJBkBW9waXNdl8iR5hqyNYaowYAbsMMdMVvaddb4hkggjitDxLo4u7J2RMTRKWQ+vtXGaXfNHKsb5HPcdK1Wup59WPs5eR2schBwD1qXftHvWVDcblFSmbj61RpGVyeeQFjiqbtknk4olmwOcGqMs/NNM6Y7E7vg8n86jFy0bAgiqpuBnkbh6VXln54qkxtm6t+sg2s2DVa6lUqxzkelYMlzjoSKqS3jjI3nApuWhzSguhpXmkzTRtJGoO3khfQ1mC0nhKPIjKhYgHoD+NTWmu3mlBbizcNKylNrDII+lSt4iSPT1tNRDSqx8xjGRlST+lLlizm55R0ICCHeTaSgOMgjNSyzZjCIduDwPWseK5SaQrFudd3yqeuKibUlRdvKc8luaQ+Y1zLtOV5JXn2qs9yFjIViM8EdjWPJrW3/AFaAnOTnkGqct49w25U2t+lS2kUm2bU96A6bSDtHJqncXSTyMYg5kPp0qC1sXuGG/P4Diur0bQGcIWTy0JxnH86wlU6I6qdBvVmFZ6XLchfNJJz0HWul0zw1M+zZFgHp2Ndlo+iQxMCULMvLxng/UV0FhZIqMzKXjXoe6mo9m5PU6IyjD4TF0fwtFAqGVfNY9c8Mprq7XTgjJhQo4+Vh+lWIk8y3OVBZeQ68GtWNFSJDct5kZG4MnUH3rohBLREOTk7siNnbSKc4Ysp+Q8FT2rNk0t4gG2jdnAA6/StWXbcEbZfkXnzDVaWVmVyr7gMFmolFGkG0ZxSVVO4t19elVJcspwG3ZzWm8m+QE4UdfmqDC+XuJyxJAIHNZNs1jZbmcSy9cZrCvjPZatFc2Tff4ZF6H610s8aqm5j19+TWShVrrkDjkVnKp0KtzG1Y/c3P1bBxV9owp4ySao2X3RWkrcDI/wDrVMdUTazII7aaeUtFE7gHkqucVPc6fcXDKzW82QMD5DToUk81VikdC7AcEgE1sKkIVib27wsnlE54z/hWkF0JqScWrGD9jMYKPGy4OCCOlFaN1EEllBLlgx5bk/iaKpD52zzmG9HJ3DpxSvert5cZrzi31zaVWObOR34xVo6vOXHyjH55rpb7ngqdzt57xdudwziqst8qLgtkDv0rjJNUuWPJIqhfao2dryj3IOTRGLb0Q5VIpas6TU9a2KwjbJzxXJ6lrYtlYud07HIz/D71m3mqSGN0g+Unqx6muZnkd2YyEsfU1t7Ce8jB109ETX2oSXUpLEnJySf4j61XDnNQ9aUU3GxHM2y7EwNX7QNu2qMluntWZAORiui0iAswIJJHYVi9DaDN7RbISAb/ALx4APWultrNRGpAJx6dQaz9MjKAFmKjsowSf8K6K1vRbztIUV4z8pVun/66pKNjohJ3LGnQ9ACK3rVEwCeW7VQRrRriMqywo6bwD61dxskRI2Viwz8pzUuNjoU0zRiVdpPc8VPCACAMZPAOKoRM6IJJ22BWywbvTxeLkMTwDuwBWTSW5tB32NLblRtAJA4Hr61IkEhc7D82M49aowXQIBzjucVft79FK+YR5Y4yBzj0qeWLLbaHRwO0xU5RgM461BIu18iQ5B/hNT3d6k8jEMflyFIGMj0NQMApwAWYDp6U+VbIab6jOx2hmzjvTeMKF6nkg0rj5d24g4H86RUYklsDGeaVjRNEZYrjBxipbUg3A87aUHUk1GX2j5mGBz9aeVCMFbA3DeuelK1mOSTVhbyZJLmRrbJTpkjr74qBFCkoRhhzmnSsNoOCB1B9aRSWK+h6E96ynuCjoJjOW5yeMU/ZkfNx9KQHB+UZ4NJvwMDGWFSOzFYbcjOB1qNiqj5lwSe1NeXPBOCOOlQPJngYHqfWncXLcJCPmIJ9K4HxTpPlzNd2a8NyyDt712srEjPQD0NZd225Dnnt9aqM2jOpRU1ZnFWOplW2PkEVrfalZR8wrP1jS0d3lthsl6lezVzttqbxEhvmA6mumLurnmyTpOzOukl688VVkkyM5rLi1aJh8xwfeh72JukgA+tTY2hXLDz4PX6VUmucdOtVpbyIkjzBxVO4vIgpOc0Mt1ky1LcFuozUUCyXc6wWys8jHAUVkNcvMPl+UdzV/T9SNhGRasEkI5kPLU0r7mM6jexsS2tvY7kvJhLMoICJyqt7nvWLdr5pJHU9ccUvnzSHMatIX5zTfsl5Ou6McdMDvT5r7GXJLqUZJGix5ZK47g81Td8nJJJPrW3deH762hWS4j2bjgAnnNZz2Uu/BTGO9KV1uXCPMUlJJArodG0xp2UsMA1lrZSLyEDY5rsNBfZGqnr6elZ6S0NUuTY6HQ9Kt4Yj5oBxg47n1NdDbxLEdqrkZwy/3h6isyzkxsK8/wBa1oZAdhH31+6R1pPayOuCua9oQoRyTtHCSjqPY1dyFK7yY2PPmJzmsWOc/M0YGcfOnZhViC7BAEZ2lf8Almw4qeY3VM3kmLhZHUPjgSxnn2yKntnKy5t7lZH67HGM1hRXAV9wJt3yOP4amM+QfOUMMffTiqUkHszYuLxW2I0Rhlzjr8p9zTGlJOMcg8yJzn61k/aj5exJgwHaQc0guGUEYZCf7rYBodQpU7bF9pzlwJFcnjLCmNMQCDKCDxhBVJ3UqN0TE+pOagaUAfcYH2NZuTLUUWblzsyFwOnzGqNkgaaRjhTnAzTbi4AjOcgf7XNR6VcM7EEYBNZKzepMrpaHQWYKqM9KvockY571nQODxn6EVbicBSOQK0WhKepcidjtbkEHKgHvWtn/AEl4ZYE3SYdo9+Bu9c+tYlu+yZJQPmQ7sZ61ckFpNK04vCiMdzIUO/PtVJ6E1FdjLy6eS4kaRdjliGHp7UVFcXAuLmSUAgMc47gUUilokrHzVIFkJ3KDn1FQPHGoyEx9CatBccnj2qvO3FfYyhF7o+FTaKkv449+aqyc1cdGc8Dio2tmxk1n7O2yDmbM+QcHNULqHd8y8Gth4wB0qrMOwrOdPmVmVGTRhHjqKNw9auzxgk5xVYxA8L1rhnSZ1xncktnw45ro9LuACpJUc/T9a5cAofpWjZXRjHBxXM6bRtGZ6FZX4EahAqkf3B/MmtFL5AqIFXCnJDHOT61wcOoYVVBPqeepq4mocghuTUtM2jM7Z7zeS7gnnlqkh1B4mPlOQ5HBB6Vx8WoYb5mAbvzmrkN6DjDYI/WsZRsdMaq6nXf2s8jRmWQuccEmrCahuz83IwcE1yQuc5cMPpnpUovV53cnI59qzlFnTCqraHaw3jpI5DemPStJL4Egtxjv71wkN7hl+Y+laUOoggZIKZ456VCia+1TOxiu8gHcNpGalFz8wILHjr0Fcsl6FfkqV67etalrcx+S7gssK53En9AK0hBsUqqSNSO9LkqrZwMew9KtLdowDYJXOSMVz0l3ETm3wWJAAXvUkV0CqnkjOD9DQ7xZUZKUTdaSNyo3bTjG3HSo5ZFj2Ddlsc57VlvccdyCc8deKfHIOxyTzg9/Socrmke5rG43r5UhVdpyrAdqicBHIjBwoycnrVJ5lkhUDiQZHHcUjT7lUZ5A65qZMcdNi2shzgD5vbmniN2VnQFlH3vas9JwuccEd/Sr8F8qxCBvmU8scYb8KiMU3uVNtaohZ8KQrFc+1QNIxbAKt/WpXK+Z+7dmyOQ4wR/SqsxICsCuCOo61Fi009RsrZJBAzjgCs27G0kHr1NW5TsA6gZ69zVS5XKnaeO3uapEsxbzq3061594mszBeNPECqPwccc16LdpkHPfrXO6pbebEykZUj9a2hKzOWtBTRwQupk43ZH+0KkS4nfIWIOfYVbmsykhR/wOOtT6dZtHcBlJ6YIA6+1bK5wcvQy3kmJIxtPfAojgklP8Tk9Aa6yY+ZDFCoVGi+QADnGc5q5ZacjFScE0SjqaQS3aMm3022NuBnbNjJPJA96u2WleTdLKqhkAz83X61sPaxh8RgAdsdKuQIsW3bgnryKLmih2LOhQ6bvBuIgI/vkouNx9CewrVeGwurwyiNI7ZAGbbwF9PxrPMUU6DnockjgfTFU72+RTsgXEStjb0z7n3ro9qox1Rz+xcnoSeIZoZgsXlk5J4HJUdhWT9iRcDeSMZAZc49qdbklpJGwZG5HNWFzgl9ynvg1zTqczuzojT5FYotZRMM7Iy3p0NQTE20ilYfLUHkjnNaTsgySQxxwGGP1rPvVXZuUAsfQ0r3Je5tWE4ZEK4/CteKfqCAAea43T7vyyobIz3rdguty5HTpms5I6aU7m8soK85Leo5IqUT9CxDr0z3rHinPOGJ9h3qzHMCMEH3I61kdsZXNiKcYysnH91hn9aVZ1H3W2H07VmLIQcKT9e9OW4OcZUkdiMUrmhpNL8wLxjHqp60nnjoGH+6wrLM4Gedp9jmhpywx8rD9aVy0avnjHIfHscVG10Vz87r7nmsr7RjkAr7ZqJ7vqd5PtUiui5eXIVepPsehpuh3geUjIBDcntWNe3Y2ks3PYVU8PX+28mRjkHnJpJWZlJ3PTrZy/fGRx6Grgl2rjILeh4Irn7K7DIq5BzWo0hKqcggfwmtkrma0NeC5YkRo+0M6t8w7joa23a7S5ER1KzEh/hKc5/KuTt7po2RlLb4mDc8jjmtgJaXDG+8i/MZO8xiLgn2b0qloRUSv/AMAfqSSxSNNLJBLl9jsnG1vQjtRVG71WOWCYEEzXEvmOARtVR0A9aKT3LpxdvePnzy2YZNNMSqRnk1PI7M2BwKREIySK+2asfCXIcDBwMVBKDg1bc4B9Kp3DBRUS0GUZgRnNUpannm61RllzkCueTGiCbvVKb7xqeV6rSmueb0N4jBOytzhvrUguELjAIP6VVf71M69a5JSaN0kaiTHna2R7VYtpmZ1Uybc8ZNYWTnqamhuGjbIJPp7Gp5ovcPeOmjDeY0ZkAdRuODkY/wAaWO8OQRu2Zxk96wJtSuJWLSMCxyTxjNMW9Y4U7tvpSaiy1KR1sV+N+FY+1X4LsPkyNg44FcUl2mRgkVfjvMAYfOTkc1DpJ6otVWjs4pd74ibfhRkVaSYqV3bgoOK5O1vmjw0cnluP88Vpw3e4Ltlz65HT8aydI3jWOmtr2MnEhbcD2A5+tdIs2/TJoXQsWwU2/wAPfg964eAO0yl1I79MAj1roLzVY/7Pt44mw5yrEHjI7VdOFk7jdW7RNBcFAqncjAcr0z3rQgugRjf0OMd+a5AajkhU4APTOcDvzV23vBnL9D0Irmceh0xq3Os+0kHBb2yPWpI7gFwa5sXR4xnJ6VajnIU7ie/FZ2sbxqm4s52E5AI7D1pftRU46E8nuM1mfaHUJ8xDH7uOn404zB1ZgcE9PrUuJqqiNOKXc/PU9RUokAzzggd/WsreYySDgLjvgtTkufmBKjPoOfzosi+c2FfJwSw+vvUZYncO2eg6mqqXEYbLsxk9e2KcJcr8hGTwefu/jQ0CmSSYYjJGeg9FqvJHzjPJ9f50LIQeADjgf40r7ZeD1PAOe1Kw3IzblAD+g/Gsm7i4YD1/pW5OpYE445rOuEHzHHemlYzbOS1G23g59sEDpWZFO8Emx+Ce/r/hXUXUZweM4INYWoWu8Hjnt+BrSLaOWauSxzKcE4z0rSt5+u2uQWSSGQhmyB2q9b6ieuCPXHart1M4ztudcs27pinLJngEVzsGoA8lhzVlLwMeoHH61EtzdTRsXV5kBV4RcgCqDyMwHJJPUYyKgabPJI4HIFIkm4jHT1qHdlxlFGgrADC5zjHWnjjpyaqiUHg8Hpmp0uEA+dTjviqUWQ5okI3nOWUEZODVPyzcThFbLFgoUdzWtbWouJY13O+44VenHvXS2PhsQ32nln/cyOFIHUAc4FdVPDt6nJUrpbGN8QNOtNC0/SsbvOcBTkcZ7mudtLvPAY4z0q/8bNVW91EpE4EdplFyPvN3rz3RNXIYRTNnH3TVYmmk9DOhXtoz0WKfAG0nmriTZxz0rmbS8VsHk1fS6KDCkVwOB6cKxveeGxjnHrSrMSw+9n2OaxVuuMhunpStecHcwqOU3VU1pLnqM/mtRyXCAjgf8BNY/wBrOfmchfrUEl2Ac5GaLFqqa73XJwSOe5qrPesD97ismW8yx64qvLdICu5xz6+vpQoClXSNG5lkmXk4Q9+1ZlrctBrFukbgg8MPrUF/q0YQ25cqvUlKwLbVVtb7cyCQNxlhz9a6I0lexwVcS1qezaVdgqASCP0rVW9yQu87QOma820DU/NtwxJDDg10EN8SACDms3HldmdlOopq6O0s79FuYTKcxK6l+M8Z55robhNak1N7i2nLwM+6OcSjy1TPH0AHavNVujgYqzDcjcFZnKkgYzx+VBo1fVHSa1eQyavdtaFTE0hKkLwfUj2zmisrxE8Vtr1/DAoSKOTaqKOFGBRUtXZUJe6rM87VaVzhKUVHJyeTivuGfBWK8z4BxWXeSEt1NXrlsd/rWTcHJ4rnmyirKeKqS+1WZDxUEnSsGXEqPUEnSp3FQP1NZTNkV39e9RnrUr1Ca4po3WwZozSGgHNZ2sMWikpRSAVSefSt7RdHe5ayWQBY7yXy1b0rBz712HhPXFkUaRqzwrYTNxKwwYW7EHtWlK3NqTO9tDN8T2U+h63PZMu0Rn5M85X1zVa11FlGCG3DnIOK7jxT4dnv7G0h3Rtq1rmFXkcA3kR5R1z19M1xcWlXdhdRte2NwFWQBty4B5xirnF82mwKSsbenaq06pG0jSORxg9B3zXQwwh7ZZLgbUH3QTjJ+lcVe6lHa6tMYrYIqOQFHBqbUvE013FE8RMb8Ky9RxS9zqNOSNy3ujHdlZI1XPOAM1rrPbDCuCj4zuzgGuGPiKQwxfuQsqE5cc5/OtCw1iG4gmhkdYmUAgkZ3+tR7OL0RoqrW51f2uNQqs5OTkMhzirdvcgkEbivfjpXJGaFHX7NcxtnqoOakS9AIQNtYdBu6isJ0mjaFY7SK6G0hZVI54PWp1ulJBJ+Qdq4+G/zhT69a0IbsZx5mSBkjpWLizojVOla43ALuI469aQOzDufbpkCsSG4Lsdh3E/pVoyjAO7nAwTUchsqprwzhlO4EnOSeh/CpvOIJCnk9D0yKxi5JxuHTjB4pzzHhWJLDjHt9aHDQpVXc2fPAbjj+Gka5GcLyD3zWZ5paISRPuUdjxUQugQF4HsanlaLU7my8mEOSeeBVSdshjkjkVWFwyA5ycEEd6c8yt6Bj1IPamkDkmQTpvBOTjkYrNuU37j0z+ua0nywbb2/XvUMkQYgfhgfnVIzkzldRtiQSFPesWR7iBXETFATgnrxXZXkJG4EYI5FYmp2alVKEtxg/XrVRutjCepzr30hOX6+o4p0WrMh5JGKbc2xGcrVCSPBOOlUrPcwk5R2N+LXV/i+97Vbj12OJmYbZYhyCeO3euO+6QRVi2nkibIYDJ53dKtQRHtZHdW2szzyQJaQmeQnGxEJNdLZ+HNXnHmy2c0IK71Vhg57j2q/8M73SobuOa+EFtJwSScKx9a9guvEdi9qEspIcFSc7htx65rrp4eO7M5VpHn2g2CaerCTY8y8gdcVZvry6W8t7sskdvCCQG4J96nXU7aG8kebDKRnIHWuO+I3iCC506dLaTbkY9Me1dDtFGTk2eb+Pbr7dr1zdSTpKjt+7VDnj3rlSzF9xJ/CnudzHGQM8ZNEcRI/+vXBKXM7miVtjSsNYeFxuyAOh9BXRRaiQEdiVVhkN2Nca6ccdasPf3b2sdu0xMMR+VcdKy5U9zaNWUTslv1JwG4NSNc7dw3g5FcMt/IhAYfjVhNUBI3Gs3SNliDqzeLgkNk1XmvwONwrm31JORux9Kga+B6NUqmX9YOglvuOG/Kqdxfbmzvx3rEe9JPFQPcO2R2q40zJ4nsaFzdAAsG+Y/rWcZGZ9zHPOaZnPUk/Whu1aqFjnlNy3Os8JXsSXDJMxRJOC/XaccfnXWRXDA7WJz0GP515ZaytDMrIeh5A7iuxsb1poVdQ20dR1xU1KfNqjpw9dwVmz0DRvEeoaVC8djOqLI25gyK2T+Na8fjXWdoP2yPJP/PFP8K5Xwxo1xrouGt720hMA3skzEMV7sAAcgd63x4X8mJXfXdHG7nmc/4VioSOt1oPVlS9v5Lq7mubl988rbncADJorNvmWyvJLczQXHlNjzIjlG9we4oqHE1VbTQqHABqrM2Rip2PBrOu5Vj4HPNfZzdj5BFa5kwOetZ8pz0GRUz75Gx2oWLb1rmldjKe01DMpHar7J1qu6c81DRSZlygjg9agYVoyp1qrImBWUkaxkUZQRVc1clWqrgYrkqRsbRZHSDig0GsWaBRSUVIC1IM+9RijNAHVaR4zv8AT7BLSSOO7hjOYfPG4xewPYV2XhTxdaa6psNfeC2lLgQSsv3j2B+leR0+NyjqykhlOQfQ9q1jWkt9iXFHT/ECxn03xBNb3dqkExPmAg/fU9D+Ncxmreqape6rcm51K5kuZyAu+Q5OB0H0FUiaiTuykrIfzszxjOOtOjkMbqy9VORTB93HryKQmpGSu+ZC+ACfTgU+G6lhI2ORVcGjdTuKyNi21Zlb98OOxFbVrqablaNlLHjg5FcbuNORypyGIJov3Gm1sd9HdsRksB654rStbhpjwU2n+InA49DXnaX8wRVY7gPXrWzDrMbrFGGdTwWyOpo5IstVWdmtw0bfKQVHUHsKuyzxyW6NFKrk9f8AZNc2NTjWNWs3WdVO0o4ww9frUE93IGQNGypweGztqXSsWqtzoGumDhS20/dINOeQoDuwRjofWsT+0y2Isq5H8YHP4mpPPjeESGVy55IOTz/SsHTaNlVNmO52g5YY+tXI7tAgWRyig7sY5rmVnhI5k2YOASKsrMZW2ody9ucE0lFle0TNf7TgZQkZ6j196RZgu3a+MD06msmVpI227sLj1z9akjlcqCFJz61NncrnuXWmDowZB13cHGfwqpNEr9Ac45z29KQvuJZgRj0qN5CuN4YZ45PX0q0xN3M26s1bPqCeBWNcWmM5HHaumcqwyOeOMdhVGSIkD5VOOR680zM5qS3PFReSwdeO9dDLbKAOoz0GM1Xlt8cED6EUEOCep1/w/sbeexlGqOWjWQEK3oOfyNXfG+o24WG3syNgG4BOAvsKwNMluLGCJgzLERnaB972z6VT1i4eecEYQBf4RjB9K7o1EoWRzyi3I6V/EEX9gQZDSzLxgttOa4zXr2W9ByQik5EYpJmYwjJAB7D+dUm2rkYzkYrKpVurDjDqykiZ7H8qsEBRjGMVF5mOO9I0mRXPctWFZcnqfypCoI/+tSK3vzUnTOfTNNAVZUGKqsCDWg/1AHWqUhBI45qkSyHOeTSN0pW60wnmmIdRTM0ZoAkBqeGEStEAcB+pbjBqp171KkzRjCcDO7HvTT7kkix/PhCCM4Jz0GetdV4ZWKW7khdgYAmC3TB9a5ETsrblADZzuFX7fUNiyud2+QbW28A1pBpC1Pa/DFsmlTQXGnzCS6HEZC7sZ/z0qx4l0OYQ+a0TNITuwE4X2xXnXgL4h6h4b1GMPI50yUeXNHFjcOwdM9HH612zfFrW5Yysrz7WbYrgbSfc8YrVOMk1YpTcdbnF387wtJ5q+WykhQeD+VFUPHOqpq16buSRmupWLSSZ+8feiuaVFXNliGka91d5JVKqLA0hy/8AOtOKy2KM8mrAtxjnpX0fI5O7PGuZYgCgYpjx4rTlRV/pVWQVLjYZnuhPaoJEFX5Bx71TlUkkVnJAUJlqnMABV+VcZqjMMk5rKRcSjJjHSqkoz0q+y4qtKnFctSJ0RdikaSnSDBptcjRsFFFFKwBRRRRYAFLmkooswFzRmgUYppAHcGiigUNAFAoPSkpALRmkopAOBpVYjocUyigCwJnjA2sc9RVhNRmLZckn3NZ5PrRnFCk0Fjdj1UEfvVU46HpVmPVQ/wB/GDwSOMD+tc1nilUgdSc1fMGqOtN7CUzHIwfnduGRikhukJbMoUDoB3/GuXEzgYBpy3DdwcfWlaI1OSOwi1CMsY3Yqo45OTmrsd9BjCzPuHA3DA/GuJW8K4JGfr1q6t9bybRHA+4DJy2QTRyIpVDr7N2MhadWKPlVYnIzUF150U4DKfVSMnIrnLXWZ4HXyW8sgkcVoQay4YEyMwfqG56dgaPZJqw1UaL5uGXcrIAc9ehp3museHT5skg46mqf9vSSsUYrHGOcHGfoM0+LW2aQYl3gfwydce1T7Jdx+0JDKCeTk8ED3p4iluJMKrNICCe+BUVxqWxx8sBXHXgn9KefEgFssSKdo+8c7T9KPZruHtDYwsNumHO9OETquP8AGsO6lSZt43E55B9afNqYnit44mEQjU5Q5Y7j/FnvWPNIVLAsnzDPDdactVoKLV7kssw5BAI9fSs6aTr6Usknyndy3bFVJmBHBzWXKxuSY1396aHxUb9abmnYi5ajmAJzUwnAXpx35qiMEgMeParGbdEyRIW9M8U1EXMPeYYG1QpH45qCRyxycU0uOgAB9c5pjsN3Bz9adguISCTUZ604kk+1JtppANopaSiwgpabk56UZpALTlbB56d6ZR1p3A774fpdJoWs3WgWsN54jhkiEaPGJXigIO+SNDwWzgE4OK9D8NXfjeZrVL2Ga5M3+siubIeWBno2VGB78V5b4I0izks7zX9XvL22sbCWOJBYgedJI2TgE9AAOTXe+ObmS48PWt9p2tX19o91KtuxMpDwOSPklUHg46Hoa0gt2xNnDeNptLsvF+sw6SsUltHcsISDuTH8QB9Ac4orH8aaVb6H4s1TTLNpGtrWYxoZCCxGAecfWip5w5T1BIT/ABVBO+GwtX5AzH2qtJEMg4yScV9O0eWjMdWJ5qMocdK0mj71C8YJ5rKUS0zNkX2qq8fvWq6KBxwarMgHPFZyiMx5k61SlirZnVcEmqM+0E56VjKI4sypIvaqssWO1Xp5RnANVJHz3rGSVjaJQmQZzVcjmrj8mq7YBNcdSJumR4pMUrGjNZuyLExS0ZpKVwFzRmkNJmi4Ds0hNJmjrSuAuaTJoopAGTRQKUigBKKKKQBRRRQAtFJmjNAC0UUUAFFFFMBc8Cr2naibJZF8tXVxgk9R9KoUU02tUD1Lc90srFhEqemKjjmIBVs4PoehqHNFPmYkrErSsj/eJ+vNO+0naQc1XopXCxahkVjgDa2OOetK0+Hw+cjsRVM+/T0oyehNHMFi+l46jKSkHGKcbppRtkKfUCs6kIzRzBYvO7RuVOBjnB5pjSO3XaR6gVVNANIZM2epB/E03NR0mTSAl7c4zSlsdTmoaOpoAmEgH1prSEnOKjozRqA/ee9NYk96SkoAXNFJRQAtFJRQAtFJS0AdB4b8R/2RYX9jdWcV/Y3gDNBIxTZIoOyRWHQjPTvUfhrxJd6DeTSpHFdW1yuy6tZxmOdc5GR2IPII5FWfB2hRakJLq8imuIRKltb2sL7Gup2BITd/CoALM3YfWtOxh0zVhqEd1oljaW1icS3OnXDtNCu7b5u1mIlQHGcY4PWlfoM53xTqw17xFqGqCEwC7k8zyy27ZwBjPfpRVXWNPm0nVbqwudpmt5DGxXo2OhHsRg/jRTEe3SMoHFVpZOOKSYnHXvVV+9fVN2PKQSS9c1UklpZ+hqg5PrWEpFokkkHOTVaWf0psnSoJO1ZNjIbiU4H1rNuJGOauz1RlrGTuVHcpvnvUTVLJUZ61kzZEL9DVZxyatN3qFuhrnqGkSvjNIQacaK52jUYKKKSkAvWlpFpWoAKPpRSigBuDS4paDTsAlBpDRUgFFFFABRQKU9KAEooooAUUUCigAoo7UUwCiilHShAAoPSig9KYCHoKSlPQUlSwCkoNJSAU0lFFAC0UlFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB2vgLUlW3NiHt1vIbn7XbJcSeXHc7ozHLAX/AISyH5T6jFa9voFvpiXzR6dqelw3ETW815q8iLFbQt9/ywvMrkcDHr0rzM/dNKzM2AzMwXoCc4pWGafibUY9W1++voIzHDK/7pD1CKAq598AUVl0UxH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema and white, macerated skin are present between the toes in this patient with tinea pedis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38435=[""].join("\n");
var outline_f37_34_38435=null;
var title_f37_34_38436="Doxapram: Pediatric drug information";
var content_f37_34_38436=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxapram: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?14/37/14933?source=see_link\">",
"    see \"Doxapram: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dopram&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Central Nervous System Stimulant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Respiratory Stimulant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Apnea of prematurity: Initial loading dose: 2.5-3 mg/kg followed by a continuous I.V. infusion of 1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; titrate to the lowest rate at which apnea is controlled (maximum dose: 2.5 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     );",
"     <b>",
"      Note:",
"     </b>",
"     Typically considered third-line agent.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/37/14933?source=see_link\">",
"      see \"Doxapram: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory depression following anesthesia: Adults: Titrate to sustain the desired level of respiratory stimulation with a minimum of side effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 0.5-1 mg/kg; may repeat at 5-minute intervals; maximum total dose: 2 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: Initial: 5 mg/minute until adequate response or adverse effects seen; decrease to 1-3 mg/minute; usual total infusion dose: 0.5-4 mg/kg or 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Drug-induced CNS depression: Adults: Mild to moderate depression: Initial: 1-2 mg/kg; may repeat in 5 minutes; may repeat at 1-2 hour intervals (until sustained consciousness); maximum dose: 3 g/day; if depression recurs, may repeat in 24 hours. As an alternative, after the initial doses, a continuous infusion of 1-3 mg/minute may be used. Discontinue if patient begins to waken; do not infuse for more than 2 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypercapnia associated with COPD: Adults: Continuous infusion of 1-2 mg/minute for 2 hours; may increase to 3 mg/minute if needed. Do not infuse for more than 2 hours. Monitor arterial blood gases closely (in a minimum of 30-minute intervals)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F162814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 20 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dopram&reg;: 20 mg/mL (20 mL) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F162799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V. use only: Dilute loading dose to a maximum concentration of 2 mg/mL and infuse over 15-30 minutes; for infusion, dilute in NS or dextrose (D",
"     <sub>",
"      5",
"     </sub>",
"     W or D",
"     <sub>",
"      10",
"     </sub>",
"     W) to 1 mg/mL (maximum concentration: 2 mg/mL); irritating to tissues; avoid extravasation",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F162862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Caffeine citrate, erythromycin lactobionate, gentamicin, metoclopramide, ranitidine, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Clindamycin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ampicillin, calcium chloride, calcium gluconate, cefazolin, ceftazidime, fentanyl, heparin, insulin (regular), metronidazole, oxacillin, phenobarbital.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable at room temperature; incompatible with aminophylline, sodium bicarbonate, thiopental sodium, and other alkaline solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and CNS stimulant for treatment of respiratory depression secondary to anesthesia, drug-induced CNS depression, and acute hypercapnia secondary to COPD (FDA approved in ages &ge;12 years and adults); has also been used for idiopathic apnea of prematurity refractory to xanthines",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F162864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxapram may be confused with doxazosin, doxepin, DOXOrubicin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dopram&reg; may be confused with DOPamine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxapram may be confused with Doxinate brand name for doxylamine and pyridoxine [Italy]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F162861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, blood pressure increased, chest pain, chest tightness, flushing, heart rate changes, T waves lowered, ventricular tachycardia, ventricular fibrillation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Apprehension, Babinski turns positive, disorientation, dizziness, hallucinations, headache, hyperactivity, pyrexia, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Burning sensation, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Defecation urge, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Spontaneous voiding, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hematocrit decreased, hemoglobin decreased, hemolysis, red blood cell count decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Clonus, deep tendon reflexes increase, fasciculations, involuntary muscle movement, muscle spasm, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Pupillary dilatation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Albuminuria, BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, cough, dyspnea, hiccups, hyperventilation, laryngospasm, rebound hypoventilation, tachypnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Emergence agitation, second-degree AV block (premature neonates), QT-interval prolonged (premature neonates)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxapram or any component; epilepsy, cerebral edema, head injury, suspected or proven pulmonary embolism, pheochromocytoma, cardiovascular or coronary artery disease, severe hypertension, hyperthyroidism, cardiac arrhythmias; concomitant use with mechanical ventilation in COPD patients; patients with mechanical disorders of ventilation such as bronchial obstruction, muscle paresis (including NM blockade), flail chest, pneumothorax, pulmonary fibrosis, asthma, or other conditions resulting in restriction of chest wall muscles of respiration or alveolar expansion",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in premature neonates and infants; hypertension (dose-related), irritability, seizures, excessive crying, sleep disturbances, abdominal distention, vomiting, NEC, increased gastric residuals, bloody stools, hyperglycemia, and glycosuria have been reported. Oxygen, resuscitative equipment, and anticonvulsants should be readily available to manage excessive CNS stimulation. Frequent arterial blood gas measurements are recommended to identify and prevent the development of CO",
"     <sub>",
"      2",
"     </sub>",
"     retention and acidosis in COPD patients with acute hypercapnia; infusion of doxapram in premature neonates has been associated with a statistically significant but moderate lengthening of QT",
"     <sub>",
"      c",
"     </sub>",
"     interval; cardiac monitoring during treatment is suggested (Maillard, 2001); use caution in patients with impaired hepatic or renal function or receiving MAOIs or sympathomimetic drugs",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in conjunction with mechanical ventilation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Doxapram contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse. Recommended doses of doxapram for treatment of neonatal apnea will deliver 5.4-27 mg/kg/day of benzyl alcohol; the use of doxapram should be reserved for neonates who are unresponsive to the treatment of apnea with therapeutic serum concentrations of theophylline or caffeine.",
"     <i>",
"      In vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein-binding sites.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Doxapram is not an antagonist to muscle relaxant drugs nor a specific narcotic antagonist; doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed; use as an adjunct to establish supportive measures; since respiratory depression may recur after stimulation with doxapram, monitor closely until the patient has been fully alert for 30-60 minutes; to reduce the potential for arrhythmias, including VT and VF, in patients who have received general anesthesia with a volatile agent known to sensitize the myocardium to catecholamines, administration of doxapram should be delayed until the complete excretion of anesthetic has occurred.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F162808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Doxapram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F162810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F162821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse fetal effects have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pulse oximetry, blood pressure, heart rate, arterial blood gases, deep tendon reflexes; for apnea: number, duration, and severity of apneic episodes",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1058202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial studies suggest a therapeutic serum level of at least 1.5 mg/L; toxicity becomes frequent at serum levels &gt;5 mg/L",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates respiration through action on respiratory center in medulla or through reflex stimulation of carotid, aortic, or other peripheral chemoreceptors; antagonizes opiate-induced respiratory depression, but does not affect analgesia",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following a single I.V. injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of respiratory stimulation: Within 20-40 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 1-2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 5-12 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver to active metabolite (keto-doxapram)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Neonates: 4-7.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates, premature: 6.6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Mean: 3.4 hours (range: 2.4-4.1 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Clearance: Neonates, premature: 0.44-0.7 L/hour/kg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barrington KJ, Finer NN, Torok-Both G, et al, &ldquo;Dose-Response Relationship of Doxapram in the Therapy for Refractory Idiopathic Apnea of Prematurity,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1987, 80(1):22-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/34/38436/abstract-text/3110729/pubmed\" id=\"3110729\" target=\"_blank\">",
"        3110729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt-Mehta V and Schumacher RE, &ldquo;Treatment of Apnea of Prematurity,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2003, 5(3):195-210.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/34/38436/abstract-text/12608884 /pubmed\" id=\"12608884 \" target=\"_blank\">",
"        12608884",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maillard C, Boutroy MJ, Fresson J, et al, &ldquo;QT Interval Lengthening in Premature Infants Treated With Doxapram,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2001, 70(6):540-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/34/38436/abstract-text/11753270/pubmed\" id=\"11753270\" target=\"_blank\">",
"        11753270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13252 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-BF10BB01C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38436=[""].join("\n");
var outline_f37_34_38436=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162830\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058200\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442336\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058193\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162814\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162799\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058204\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162862\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058196\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058203\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162864\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162861\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058208\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058192\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058191\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299230\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162808\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162810\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162821\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058199\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058202\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058190\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058206\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058207\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13252\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13252|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/37/14933?source=related_link\">",
"      Doxapram: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_34_38437="Complications of peripheral nerve irradiation";
var content_f37_34_38437=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of peripheral nerve irradiation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38437/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38437/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38437/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38437/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38437/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38437/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/34/38437/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy can cause toxicity to either the central or peripheral nervous system when these structures are included in the treatment field. Nervous system toxicity is usually subdivided into acute (during the course of radiation), early delayed (weeks to three months after radiation), and delayed reaction (more than three months).",
"   </p>",
"   <p>",
"    Damage to peripheral nerves secondary to radiation is a rare but significant complication of treatment. Plexopathies are most often described in the brachial or lumbosacral plexus, and include three distinct clinical syndromes: a reversible or transient plexopathy, a classic delayed, progressive radiation",
"    <span class=\"nowrap\">",
"     injury/fibrosis,",
"    </span>",
"    and an acute ischemic plexopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, radiation-induced cranial nerve injury has been reported, generally at doses exceeding 60 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The complications that can occur following irradiation of peripheral nerves will be reviewed here. Other relevant topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complications of cranial irradiation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"       \"Complications of cranial irradiation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Complications of cranial stereotactic radiosurgery (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/32/2566?source=see_link\">",
"       \"Complications of cranial stereotactic radiosurgery\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Complications of spinal cord irradiation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7190?source=see_link\">",
"       \"Complications of spinal cord irradiation\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BRACHIAL PLEXOPATHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transient brachial plexopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute brachial plexopathy can occur during radiation or more often within a few weeks or months after finishing treatment when an external beam radiation therapy field includes the brachial plexus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/3\">",
"     3",
"    </a>",
"    ]. Symptoms include numbness in the thumb and first finger of the affected side, and weakness in the shoulder and biceps muscle, clinically similar to acute idiopathic brachial neuritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2906?source=see_link\">",
"     \"Brachial plexus syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis is not known, but an autoimmune mechanism has been postulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/4\">",
"     4",
"    </a>",
"    ]. Treatment is generally not required, and symptoms resolve spontaneously within weeks or months; corticosteroids may hasten resolution of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8906?source=see_link&amp;anchor=H41#H41\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Brachial plexopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Late-delayed brachial plexopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late-delayed brachial plexopathy has a widely variable latency, occurring months to many years following axillary or supraclavicular radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/6\">",
"     6",
"    </a>",
"    ]. The natural history of delayed plexopathy suggests that damage stems primarily from vasculitis, with sclerotic occlusion of small supplying vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/7\">",
"     7",
"    </a>",
"    ]. Demyelination and fibrosis within and surrounding nerves also play a role in pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms may include paresthesias, hypesthesias, weakness, and impaired reflexes. In one study, 80 percent of women with radiation-induced brachial plexopathy had focal signs but no pain, and resolution within 12 months was typical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/9\">",
"     9",
"    </a>",
"    ]. However, in the remainder, symptoms progressed to pain and progressive arm paralysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Radiation injury versus tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of radiation-induced brachial plexopathy can be made only after recurrent or metastatic tumor has been ruled out. Features suggesting the diagnosis of recurrent tumor rather than radiation-induced brachial plexopathy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe pain",
"     </li>",
"     <li>",
"      Horner's syndrome",
"     </li>",
"     <li>",
"      Involvement of the lower brachial plexus (C7, C8, T1)",
"     </li>",
"     <li>",
"      Radiation dose &lt;60 Gy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI is the best modality to differentiate radiation-induced brachial plexopathy from malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/10\">",
"     10",
"    </a>",
"    ]. Characteristic MRI findings of radiation-induced plexopathy include thickening and diffuse enhancement of the brachial plexus without a focal mass, and soft-tissue changes with low signal intensity on both T1- and T2-weighted images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/11\">",
"     11",
"    </a>",
"    ]. However, tissue plane loss and high signal intensity on T2-weighted images may be seen with both radiation-induced brachial plexopathy and tumor infiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. None of the MRI findings are unique to radiation-induced plexopathy, and the primary role of MRI is in the exclusion of tumor relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electromyography (EMG) can also be helpful, as myokymic discharge is very suggestive of radiation-induced plexopathy. This finding is present in at least one affected muscle in 50 to 75 percent of patients with radiation injury but is rare when the plexopathy is due to malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/14\">",
"     14",
"    </a>",
"    ]. However, EMG cannot rule out malignancy since patients with brachial plexus tumors may also have some radiation fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical neurophysiology\", section on 'Electromyography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biopsy may ultimately be required to establish a diagnosis. However a negative biopsy cannot definitively rule out tumor because of sampling issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachial plexopathy is most frequently seen in women with early stage breast cancer, who have been treated with conservative surgery and radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/9,15,16\">",
"     9,15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=see_link\">",
"     \"Breast conserving therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link\">",
"     \"Role of radiation therapy in breast conservation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link\">",
"     \"Postmastectomy chest wall irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The features of brachial plexopathy in this setting are illustrated by an analysis of 1624 women, in which the following findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of brachial plexopathy was 1.3 percent among women who received less than 50 Gy to the axilla, and 1.8 percent in those receiving radiation to the supraclavicular fossa.",
"     </li>",
"     <li>",
"      The incidence was higher in women who also received chemotherapy (4.5 percent) and in those treated with axillary doses greater than 50 Gy (5.6 percent).",
"     </li>",
"     <li>",
"      The median time to development of symptoms after therapy was about 10 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of larger radiation fractions may increase the risk of developing radiation-induced brachial plexus damage. In a series of 449 women, the incidence of plexopathy was 6 percent in patients receiving 45 Gy in 15 fractions versus 1 percent for those receiving 54 Gy in 30 fractions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no established treatments for late-delayed brachial plexopathy. Anticoagulants have been reported to be beneficial in a few patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Physical therapy and pain control are useful, and transcutaneous electrical nerve stimulation (TENS) and dorsal column stimulator therapy have also been employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute ischemic brachial plexopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation for breast cancer has been reported to cause a delayed occlusion of the subclavian artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/19\">",
"     19",
"    </a>",
"    ]. This can result in a painless, acute neurologic deficit, which is not progressive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LUMBOSACRAL PLEXOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of radiation-induced lumbosacral plexopathy are similar to those associated with metastatic involvement of the lumbosacral plexus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients with radiation-induced lumbosacral plexopathy typically present with unilateral or bilateral leg weakness, often accompanied by sensory loss. Pain is usually absent or mild. Symptoms typically progress slowly for years after radiation therapy; rarely, spontaneous resolution or stabilization for several years can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with brachial plexopathies, the differential diagnosis focuses on separating radiation-induced damage from recurrent tumor. The slow, painless progression of bilateral leg weakness is more compatible with a diagnosis of radiation-induced plexopathy, while unilateral weakness or the presence of pain suggests tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Imaging studies may be helpful in determining whether or not tumor is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Incidence and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbosacral plexopathies can be seen in patients receiving pelvic irradiation, but are uncommon with standard external beam radiation doses and conventional fractionation schedules. However, specialized RT techniques that provide an increased dose of radiation to the pelvis may increase the risk of lumbosacral plexopathy. These include intracavitary RT and intraoperative RT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intracavitary RT - Intracavitary irradiation is used in women with cervical and endometrial cancer to achieve higher radiation doses and better local control. Although intracavitary RT initially was thought to increase the likelihood of a treatment-related lumbosacral plexopathy, improvements in technique and equipment have decreased the incidence of this complication. This was illustrated in a series of 2410 women with cervical or endometrial cancer receiving external and intracavitary pelvic radiation; there were only four patients (0.17 percent) who developed radiation-induced lumbosacral plexopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18810?source=see_link\">",
"       \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7976?source=see_link\">",
"       \"Management of locally advanced cervical cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intraoperative RT - Intraoperative RT permits the administration of a single large dose of radiation during an operation, theoretically allowing critical organs to be shifted away from the radiation field and allowing the radiation dose to be precisely administered. However, unlike many other organs, peripheral nerves are not easily moved out of the radiation field.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increased risk of lumbosacral plexopathy in association with intraoperative RT is supported by both animal models and clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In a study of patients with pelvic malignancies, the incidence of grade 1 to 3 neuropathy following 50.4 Gy of external radiation with an IORT boost of 10 to 25 Gy was 32 percent, with 6 percent having severe (grade 3) toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/27\">",
"     27",
"    </a>",
"    ]. Neurotoxicity was more common with intraoperative radiation doses &gt;15 Gy compared to 10 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38437/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=see_link\">",
"     \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/37/11866?source=see_link\">",
"     \"Treatment of locally advanced unresectable or recurrent rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CRANIAL NERVE DAMAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy to the head and neck region can result in damage to cranial nerves. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation therapy that includes the brachial plexus in the treatment field can result in a transient, acute brachial plexopathy that is self limited. Symptoms include numbness in the thumb and first finger of the affected side, and weakness in the shoulder and biceps muscle. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transient brachial plexopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brachial plexus irradiation can also cause a more serious late-delayed brachial plexopathy, manifested by paresthesias, hypesthesias, weakness, and impaired reflexes, with symptoms progressing to chronic pain and progressive arm paralysis. This entity occurs after a variable latent period that can span many years and is generally irreversible. The primary diagnostic difficulty is distinguishing radiation-induced late-delayed brachial plexopathy from recurrent tumor. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Late-delayed brachial plexopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiation to the pelvis can cause a lumbosacral plexopathy that is similar to that associated with metastatic involvement of the lumbosacral plexus. Radiation-induced lumbosacral plexopathy typically presents with unilateral or bilateral leg weakness, often accompanied by sensory loss; symptoms usually progress slowly for years after radiation. Lumbosacral plexopathy has been seen most commonly after intracavitary or intraoperative radiation therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Lumbosacral plexopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/1\">",
"      Bowen BC, Verma A, Brandon AH, Fiedler JA. Radiation-induced brachial plexopathy: MR and clinical findings. AJNR Am J Neuroradiol 1996; 17:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/2\">",
"      Gillette EL, Mahler PA, Powers BE, et al. Late radiation injury to muscle and peripheral nerves. Int J Radiat Oncol Biol Phys 1995; 31:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/3\">",
"      Churn M, Clough V, Slater A. Early onset of bilateral brachial plexopathy during mantle radiotherapy for Hodgkin's disease. Clin Oncol (R Coll Radiol) 2000; 12:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/4\">",
"      Malow BA, Dawson DM. Neuralgic amyotrophy in association with radiation therapy for Hodgkin's disease. Neurology 1991; 41:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/5\">",
"      Lachance DH, O'Neill BP, Harper CM Jr, et al. Paraneoplastic brachial plexopathy in a patient with Hodgkin's disease. Mayo Clin Proc 1991; 66:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/6\">",
"      Schierle C, Winograd JM. Radiation-induced brachial plexopathy: review. Complication without a cure. J Reconstr Microsurg 2004; 20:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/7\">",
"      Pritchard J, Anand P, Broome J, et al. Double-blind randomized phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy. Radiother Oncol 2001; 58:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/8\">",
"      Johansson S, Svensson H, Denekamp J. Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. Int J Radiat Oncol Biol Phys 2002; 52:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/9\">",
"      Pierce SM, Recht A, Lingos TI, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 1992; 23:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/10\">",
"      Thyagarajan D, Cascino T, Harms G. Magnetic resonance imaging in brachial plexopathy of cancer. Neurology 1995; 45:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/11\">",
"      Wittenberg KH, Adkins MC. MR imaging of nontraumatic brachial plexopathies: frequency and spectrum of findings. Radiographics 2000; 20:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/12\">",
"      Wouter van Es H, Engelen AM, Witkamp TD, et al. Radiation-induced brachial plexopathy: MR imaging. Skeletal Radiol 1997; 26:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/13\">",
"      Hoeller U, Bonacker M, Bajrovic A, et al. Radiation-induced plexopathy and fibrosis. Is magnetic resonance imaging the adequate diagnostic tool? Strahlenther Onkol 2004; 180:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/14\">",
"      Cross NE, Glantz MJ. Neurologic complications of radiation therapy. Neurol Clin 2003; 21:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/15\">",
"      Powell S, Cooke J, Parsons C. Radiation-induced brachial plexus injury: follow-up of two different fractionation schedules. Radiother Oncol 1990; 18:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/16\">",
"      Olsen NK, Pfeiffer P, Johannsen L, et al. Radiation-induced brachial plexopathy: neurological follow-up in 161 recurrence-free breast cancer patients. Int J Radiat Oncol Biol Phys 1993; 26:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/17\">",
"      Glantz MJ, Burger PC, Friedman AH, et al. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 1994; 44:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/18\">",
"      Soto O. Radiation-induced conduction block: resolution following anticoagulant therapy. Muscle Nerve 2005; 31:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/19\">",
"      Gerard JM, Franck N, Moussa Z, Hildebrand J. Acute ischemic brachial plexus neuropathy following radiation therapy. Neurology 1989; 39:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/20\">",
"      Ducray F, Guillevin R, Psimaras D, et al. Postradiation lumbosacral radiculopathy with spinal root cavernomas mimicking carcinomatous meningitis. Neuro Oncol 2008; 10:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/21\">",
"      Enevoldson TP, Scadding JW, Rustin GJ, Senanayake LF. Spontaneous resolution of a postirradiation lumbosacral plexopathy. Neurology 1992; 42:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/22\">",
"      Thomas JE, Cascino TL, Earle JD. Differential diagnosis between radiation and tumor plexopathy of the pelvis. Neurology 1985; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/23\">",
"      Jaeckle KA. Neurological manifestations of neoplastic and radiation-induced plexopathies. Semin Neurol 2004; 24:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/24\">",
"      Pettigrew LC, Glass JP, Maor M, Zornoza J. Diagnosis and treatment of lumbosacral plexopathies in patients with cancer. Arch Neurol 1984; 41:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/25\">",
"      Georgiou A, Grigsby PW, Perez CA. Radiation induced lumbosacral plexopathy in gynecologic tumors: clinical findings and dosimetric analysis. Int J Radiat Oncol Biol Phys 1993; 26:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/26\">",
"      Kinsella TJ, Sindelar WF, DeLuca AM, et al. Tolerance of peripheral nerve to intraoperative radiotherapy (IORT): clinical and experimental studies. Int J Radiat Oncol Biol Phys 1985; 11:1579.",
"     </a>",
"    </li>",
"    <li>",
"     Gunderson, L, Willett, C, Harrison, L. In: American Society of Therapeutic Radiology, Phoenix, AZ 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38437/abstract/28\">",
"      Shaw EG, Gunderson LL, Martin JK, et al. Peripheral nerve and ureteral tolerance to intraoperative radiation therapy: clinical and dose-response analysis. Radiother Oncol 1990; 18:247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7061 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-DEDEA7E9BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38437=[""].join("\n");
var outline_f37_34_38437=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BRACHIAL PLEXOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transient brachial plexopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Late-delayed brachial plexopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Radiation injury versus tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute ischemic brachial plexopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LUMBOSACRAL PLEXOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CRANIAL NERVE DAMAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=related_link\">",
"      Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/32/2566?source=related_link\">",
"      Complications of cranial stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7190?source=related_link\">",
"      Complications of spinal cord irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7976?source=related_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/37/11866?source=related_link\">",
"      Treatment of locally advanced unresectable or recurrent rectal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_34_38438="Trimethoprim-sulfamethoxazole: An overview";
var content_f37_34_38438=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Trimethoprim-sulfamethoxazole: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38438/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38438/contributors\">",
"     D Byron May, PharmD, BCPS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38438/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38438/contributors\">",
"     David C Hooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38438/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38438/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/34/38438/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX), also known as co-trimoxazole, is a combination of two antimicrobial agents that act synergistically against a wide variety of bacteria. Although other combinations of sulfonamides are available with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    , TMP-SMX is by far the most widely used.",
"   </p>",
"   <p>",
"    This topic will review basic issues related to the clinical use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    . The multiple clinical settings in which this combination may be used are discussed separately on the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two components, TMP and SMX, work sequentially to inhibit enzyme systems involved in the bacterial synthesis of tetrahydrofolic acid (THF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SMX is a structural analog of para-aminobenzoic acid (PABA) and competes with PABA to inhibit the synthesis of dihydrofolic acid, an intermediate step in the formation of THF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/1,3\">",
"       1,3",
"      </a>",
"      ]. SMX binds to dihydropteroate synthetase which catalyses this reaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TMP binds to bacterial dihydrofolate reductase (in preference to human dihydrofolate reductase), also preventing the formation of THF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reduced availability of THF inhibits thymidine synthesis and subsequently DNA synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Thus, small amounts of thymidine (present in vivo or in vitro) can reverse the activity of TMP-SMX.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the widespread use of TMP-SMX, resistance has developed in most bacterial species worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/1,2,5-8\">",
"     1,2,5-8",
"    </a>",
"    ]. A variety of mechanisms have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some bacteria have a decreased permeability for TMP-SMX or have a target enzyme with decreased affinity for the drugs. As examples, resistance of Pneumocystis jirovecii to SMX after the administration of TMP-SMX has been correlated with dihydropteroate synthase gene mutations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/9\">",
"       9",
"      </a>",
"      ], while dihydrofolate reductase gene mutations can account for high level resistance in other organisms such as Enterococcus faecalis and Campylobacter jejuni [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/4,10,11\">",
"       4,10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some bacteria (eg, Pseudomonas aeruginosa) have an active efflux mechanism to eliminate the drug from the cell [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Naturally resistant bacteria to SMX (eg, E. faecalis) are typically auxotrophic for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maximal synergistic action occurs when microorganisms are susceptible to both drugs. Thus, bacteria naturally resistant to TMP at low levels and susceptible to SMX can be inhibited by the combination and vice-versa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SPECTRUM OF ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;TMP-SMX is effective against a wide variety of aerobic gram-positive and gram-negative bacteria, P. jirovecii, and some protozoa (",
"    <a class=\"graphic graphic_table graphicRef54746 \" href=\"mobipreview.htm?39/7/40059\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/1,2,5,6,8,13-15\">",
"     1,2,5,6,8,13-15",
"    </a>",
"    ]. Some nosocomial pathogens are frequently inhibited by TMP-SMX. These include Burkholderia cepacia (formerly Pseudomonas cepacia), Stenotrophomonas maltophilia (formerly Xanthomonas maltophilia) and Serratia marcescens.",
"   </p>",
"   <p>",
"    Many pathogens are typically resistant to TMP-SMX. These include P. aeruginosa, Bacteroides fragilis (and most other anaerobes), Mycobacterium tuberculosis, Treponema pallidum, Campylobacter, penicillin-resistant pneumococci, and rickettsiae. Methicillin-resistant Staphylococcus aureus is variably susceptible.",
"   </p>",
"   <p>",
"    Over time, resistance develops among previously susceptible bacteria, using the mechanisms described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACODYNAMICS AND PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although TMP and SMX are weak bactericidal agents when given alone, the combination is highly bactericidal against many bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/1,2,5,13,16\">",
"     1,2,5,13,16",
"    </a>",
"    ]. Maximum synergistic inhibition of most susceptible bacteria occurs when the TMP-SMX concentration ratio is 1:20. The drug combination is prepared in a higher fixed ratio of 1:5; however, peak serum concentrations of 1:20 are still achieved by both oral and intravenous therapy because of the wider volume of distribution of TMP.",
"   </p>",
"   <p>",
"    Bioavailability of TMP-SMX is approximately 85 percent for both compounds. Absorption of TMP-SMX is not affected by food or other medications.",
"   </p>",
"   <p>",
"    Peak serum levels of TMP-SMX after administration of a double-strength tablet are 1 to 2",
"    <span class=\"nowrap\">",
"     microgram/mL",
"    </span>",
"    and 25 to 60",
"    <span class=\"nowrap\">",
"     microgram/mL,",
"    </span>",
"    respectively. Peak concentrations are reached at two to four hours; peak concentrations are reached more quickly (one to two hours) with parenteral therapy. The concentrations achieved after intravenous administration of TMP-SMX equivalent to two DS tablets are 3.5",
"    <span class=\"nowrap\">",
"     microgram/mL",
"    </span>",
"    and 47.3",
"    <span class=\"nowrap\">",
"     microgram/mL",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    TMP-SMX is widely distributed in the body but tissue concentrations are generally less than serum concentrations. TMP is more lipophilic than SMX (apparent volume of distribution 100 to 120 L and 12 to 18 L respectively), resulting in ratios of 1:2 to 1:10 in tissues compared with 1:20 in the extracellular fluid. CSF penetration of TMP-SMX is generally good, with TMP concentrations ranging from 20 to 60 percent of serum values and SMX concentrations ranging from 12 to 50 percent of serum values. The approximate ratio of TMP-SMX in the CSF is 1:15.",
"   </p>",
"   <p>",
"    Overall, the kinetics of TMP-SMX are first-order. The half-life for both compounds is 10 to 12 hours.",
"   </p>",
"   <p>",
"    Therapeutic drug monitoring of TMP-SMX is not routinely done [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Metabolism and excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;TMP-SMX is excreted in the urine with 50 percent of the drug eliminated in the first 24 hours. SMX is approximately 70 percent protein bound; it is acetylated (61 percent) and glucuronide-conjugated (15 percent) in the liver. In comparison, TMP is excreted in the urine unchanged. There are four major TMP metabolites with little antibacterial activity.",
"   </p>",
"   <p>",
"    Compromised renal function results in prolongation of the half-lives of each drug. Accumulation of TMP-SMX and metabolites occurs when creatinine clearance is less than 30",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    necessitating dose adjustment. Uremic and hypoalbuminemic patients may have reduced protein binding and an increased volume of distribution of SMX component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1787243\">",
"     'Renal dose adjustment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DOSAGE AND ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple formulations of TMP-SMX are available for use:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral single strength (SS) tablet &ndash; 80 mg",
"      <span class=\"nowrap\">",
"       TMP/400",
"      </span>",
"      mg SMX",
"     </li>",
"     <li>",
"      Oral double-strength tablet &ndash; 160 mg",
"      <span class=\"nowrap\">",
"       TMP/800",
"      </span>",
"      mg SMX",
"     </li>",
"     <li>",
"      Oral suspension &ndash; 40 mg",
"      <span class=\"nowrap\">",
"       TMP/200",
"      </span>",
"      mg SMX per 5 mL",
"     </li>",
"     <li>",
"      Intravenous &ndash; 80 mg",
"      <span class=\"nowrap\">",
"       TMP/400",
"      </span>",
"      mg SMX per 5 mL (16",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      TMP; 80",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      SMX).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dosing of TMP-SMX is based on the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    component and expressed as a",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of TMP. Oral doses of TMP-SMX are usually given as a SS or more commonly a DS tablet once to four times daily depending upon the indication and renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/1,5,14,15,19,20\">",
"     1,5,14,15,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous TMP-SMX must be mixed with dextrose in water at a",
"    <strong>",
"     maximum",
"    </strong>",
"    concentration of 5 mL TMP-SMX (equivalent to 80 mg TMP component) per 75 mL. At this concentration, the product is only stable for two hours. A more standard concentration is 5 mL (equivalent to 80 mg TMP component) per 125 mL of 5 percent dextrose in water which retains stability for up to six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/21\">",
"     21",
"    </a>",
"    ]. All dilutions should be inspected for cloudiness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    particulate formation prior to and during administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1787243\">",
"    <span class=\"h2\">",
"     Renal dose adjustment",
"    </span>",
"    &nbsp;&mdash;&nbsp;TMP-SMX dosing should be altered for patients with renal insufficiency whose creatinine clearance is less than or equal to 30 mL per minute. US Food and Drug Administration (FDA) prescribing information recommends against use of TMP-SMX in patients with a creatinine clearance less than 15 mL per minute due to risk of drug accumulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/21\">",
"     21",
"    </a>",
"    ]. However, dose adjustment guidelines are available for patients with a creatinine clearance less than 15 mL per minute and for those receiving renal replacement therapy; these guidelines are useful when acceptable alternatives are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/18,22-24\">",
"     18,22-24",
"    </a>",
"    ]. For specific dose adjustment recommendations, (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information\"",
"    </a>",
"    .) A calculator is available to estimate a patient&rsquo;s creatinine clearance (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/57/30609?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TMP-SMX is generally well tolerated in non-HIV-infected patients in whom adverse reactions occur in approximately 6 to 8 percent of individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/5,14,25\">",
"     5,14,25",
"    </a>",
"    ]. In comparison, the adverse reaction rate is as high as 25 to 50 percent in HIV-infected patients, with many of the reactions being severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/5,26-29\">",
"     5,26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The more common adverse reactions to TMP-SMX involve the gastrointestinal tract (nausea, vomiting) and skin (rash and pruritus) (",
"    <a class=\"graphic graphic_table graphicRef81921 \" href=\"mobipreview.htm?11/52/12108\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Life-threatening effects, which are more likely to occur in HIV-infected patients and older adults, include neutropenia and uncommon severe dermatologic reactions such as Steven-Johnson syndrome (involving the mucosal surfaces), exfoliative dermatitis (a severe skin disorder with generalized erythema and scaling) and toxic epidermal necrolysis (an acute severe reaction with widespread erythema and detachment of the epidermis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/25,26,29\">",
"     25,26,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    .) Cutaneous complications occur in up to 15 percent of HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24538?source=see_link\">",
"     \"Fever and rash in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few data support an elevated risk of hypersensitivity to nonantibiotic sulfonamides (eg, loop and thiazide diuretics and sulfonylureas) in patients with known sulfonamide antimicrobial allergy. A predisposition of drug hypersensitivity reactions, in general, appears to be a better predictor for sulfonamide allergy, than a past reaction to a different type of sulfonamide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23594?source=see_link&amp;anchor=H20#H20\">",
"     \"Sulfonamide allergy in non HIV-infected patients\", section on 'Cross-reactivity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TMP-SMX should",
"    <strong>",
"     not",
"    </strong>",
"    be given to patients who have",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency or who are pregnant because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    may interfere with folic acid metabolism; it should only be used during pregnancy if the potential benefit to the mother outweighs the possible risk to the fetus. As noted above, trimethoprim is a weak inhibitor of dihydrofolate reductase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/4\">",
"     4",
"    </a>",
"    ]; in high doses, it has been implicated in megaloblastic pancytopenia. Coadministration of folinic acid can prevent or reduce the antifolate activity of TMP-SMX without affecting its antimicrobial activity.",
"   </p>",
"   <p>",
"    TMP-SMX should also not be given to patients with glucose-6-phosphate dehydrogenase deficiency (in whom it can precipitate a hemolytic episode) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4505?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\", section on 'Drugs and chemicals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other side effects that can occur include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anaphylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/26,32\">",
"       26,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hepatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hyperkalemia due to blockade of the collecting tubule sodium channel by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      (an action similar to that induced by the potassium-sparing diuretic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      ); this is most common in HIV-infected patients who are treated with high doses and may be associated with distal renal tubular acidosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/33,34\">",
"       33,34",
"      </a>",
"      ], but normal doses can produce a modest elevation in the plasma potassium concentration in non-HIV-infected subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypoglycemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nephrotoxicity associated with TMP-SMX is uncommon; however, TMP is known to decrease the tubular secretion of creatinine. This has led to increases in serum creatinine through interference with certain assays that is not reflective of a true reduction in glomerular filtration rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adequate hydration should be maintained, as feasible, in order to decrease the risk of urinary tract crystal formation. Patients with low urine output and low urinary pH may be at increased risk of crystalluria due to the SMX component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects from TMP-SMX can usually be managed by stopping the drug. There is no specific treatment except for folinic acid for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency. For conditions in which TMP-SMX is the primary therapy (eg, Pneumocystis jirovecii pneumonia in HIV-infected patients), continued treatment with TMP-SMX is important despite the development of certain adverse reactions (eg, rash) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients in whom TMP-SMX was previously discontinued because of skin reactions can be desensitized if repeat therapy with TMP-SMX is necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TMP-SMX can interact with a variety of drugs that may require adjustment of therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more frequent monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38438/abstract/1,5,6,15\">",
"     1,5,6,15",
"    </a>",
"    ]. Interacting drugs include oral anticoagulants (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , oral hypoglycemics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/57/3989?source=see_link\">",
"     methenamine",
"    </a>",
"    (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information\"",
"    </a>",
"    .). Specific interactions of TMP-SMX with other medications may be determined using the drug interactions tool (Lexi-Interact online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6246789\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX), also known as co-trimoxazole, is a combination of two antimicrobial agents that act synergistically against a wide variety of bacteria. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two components, TMP and SMX, work sequentially to inhibit enzyme systems involved in the bacterial synthesis of tetrahydrofolic acid (THF). Reduced availability of THF inhibits thymidine synthesis, which in turn inhibits DNA synthesis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maximal synergistic action occurs when microorganisms are susceptible to both component drugs. However, bacteria that are resistant to one drug component, but remain fully susceptible to the other drug, can still be inhibited by the combination. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TMP-SMX is effective against a wide variety of aerobic gram-positive and gram-negative bacteria, Pneumocystis, and some protozoa. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Spectrum of activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bioavailability of TMP-SMX is approximately 85 percent for both compounds; absorption of TMP-SMX is not affected by food or other medications. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacodynamics and pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dosing of TMP-SMX is based on the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      component. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Dosage and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The more common adverse reactions to TMP-SMX involve the gastrointestinal tract (nausea, vomiting) and skin (rash and pruritus). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Adverse effects and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Life-threatening effects, which are more likely to occur in HIV-infected patients and older adults, include neutropenia and uncommon severe dermatologic reactions such as Steven-Johnson syndrome and toxic epidermal necrolysis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Adverse effects and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TMP-SMX can interact with a variety of drugs that may require adjustment of therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      more frequent monitoring. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/1\">",
"      Kalkut G. Sulfonamides and trimethoprim. Cancer Invest 1998; 16:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/2\">",
"      Gleckman R, Blagg N, Joubert DW. Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacotherapy 1981; 1:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/3\">",
"      Hong YL, Hossler PA, Calhoun DH, Meshnick SR. Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother 1995; 39:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/4\">",
"      Pattishall KH, Acar J, Burchall JJ, et al. Two distinct types of trimethoprim-resistant dihydrofolate reductase specified by R-plasmids of different compatibility groups. J Biol Chem 1977; 252:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/5\">",
"      Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc 1999; 74:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/6\">",
"      Lundstrom TS, Sobel JD. Vancomycin, trimethoprim-sulfamethoxazole, and rifampin. Infect Dis Clin North Am 1995; 9:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/7\">",
"      Huovinen P. Increases in rates of resistance to trimethoprim. Clin Infect Dis 1997; 24 Suppl 1:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/8\">",
"      Zhanel GG, Karlowsky JA, Harding GK, et al. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother 2000; 44:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/9\">",
"      Ma L, Borio L, Masur H, Kovacs JA. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis 1999; 180:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/10\">",
"      Coque TM, Singh KV, Weinstock GM, Murray BE. Characterization of dihydrofolate reductase genes from trimethoprim-susceptible and trimethoprim-resistant strains of Enterococcus faecalis. Antimicrob Agents Chemother 1999; 43:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/11\">",
"      Gibreel A, Sk&ouml;ld O. High-level resistance to trimethoprim in clinical isolates of Campylobacter jejuni by acquisition of foreign genes (dfr1 and dfr9) expressing drug-insensitive dihydrofolate reductases. Antimicrob Agents Chemother 1998; 42:3059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/12\">",
"      Ziha-Zarifi I, Llanes C, K&ouml;hler T, et al. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/13\">",
"      Gleckman R, Gantz NM, Joubert DW. Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions. Pharmacotherapy 1981; 1:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/14\">",
"      Howe RA, Spencer RC. Cotrimoxazole. Rationale for re-examining its indications for use. Drug Saf 1996; 14:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/15\">",
"      Cunha BA. New uses for older antibiotics. The 'rediscovery' of four beneficial and cost-effective antimicrobials. Postgrad Med 1997; 101:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/16\">",
"      Svedhem A, Iwarson S. Cerebrospinal fluid concentrations of trimethoprim during oral and parenteral treatment. J Antimicrob Chemother 1979; 5:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/17\">",
"      Chin TW, Vandenbroucke A, Fong IW. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother 1995; 39:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/18\">",
"      Paap CM, Nahata MC. Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction. DICP 1989; 23:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/19\">",
"      Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/20\">",
"      Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342:1416.",
"     </a>",
"    </li>",
"    <li>",
"     Sulfamethoxazole and trimethoprim injection. FDA approved product information. US National Library of Medicine. file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=15491 (Accessed on August 09, 2010).",
"    </li>",
"    <li>",
"     Aronoff, GR, Bennett, WM, Berns, JS, et al. Drug prescribing in renal failure, 5th, American College of Physicians, Philadelphia 2007. p.154.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/23\">",
"      Nahata MC. Dosage regimens of trimethoprim/sulfamethoxazole (TPM/SMX) in patients with renal dysfunction. Ann Pharmacother 1995; 29:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/24\">",
"      Mofenson LM, Oleske J, Serchuck L, et al. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/25\">",
"      Jick H, Derby LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy 1995; 15:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/26\">",
"      Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/27\">",
"      van der Ven AJ, Vree TB, Koopmans PP, van der Meer JW. Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis. J Antimicrob Chemother 1996; 37 Suppl B:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/28\">",
"      Jung AC, Paauw DS. Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. Arch Intern Med 1994; 154:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/29\">",
"      Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/30\">",
"      Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/31\">",
"      Markowitz N, Saravolatz LD. Use of trimethoprim-sulfamethoxazole in a glucose-6-phosphate dehydrogenase-deficient population. Rev Infect Dis 1987; 9 Suppl 2:S218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/32\">",
"      Johnson MP, Goodwin SD, Shands JW Jr. Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review. Pharmacotherapy 1990; 10:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/33\">",
"      Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993; 119:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/34\">",
"      Hemstreet BA. Antimicrobial-associated renal tubular acidosis. Ann Pharmacother 2004; 38:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/35\">",
"      Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996; 124:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/36\">",
"      Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clin Nephrol 1996; 46:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/37\">",
"      Mathews WA, Manint JE, Kleiss J. Trimethoprim-sulfamethoxazole-induced hypoglycemia as a cause of altered mental status in an elderly patient. J Am Board Fam Pract 2000; 13:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/38\">",
"      Masters PA, O'Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003; 163:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/39\">",
"      Gompels MM, Simpson N, Snow M, et al. Desensitization to co-trimoxazole (trimethoprim-sulphamethoxazole) in HIV-infected patients: is patch testing a useful predictor of reaction? J Infect 1999; 38:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38438/abstract/40\">",
"      Cortese LM, Soucy DM, Endy TP. Trimethoprim/sulfamethoxazole desensitization. Ann Pharmacother 1996; 30:184.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 493 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.102.30.19-F80A67E9C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38438=[""].join("\n");
var outline_f37_34_38438=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6246789\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SPECTRUM OF ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACODYNAMICS AND PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Metabolism and excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DOSAGE AND ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1787243\">",
"      Renal dose adjustment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ADVERSE EFFECTS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6246789\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/493\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/493|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/7/40059\" title=\"table 1\">",
"      Susceptibility to TMP SMX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/52/12108\" title=\"table 2\">",
"      TMP SMX adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/57/30609?source=related_link\" title=\"calculator 1\">",
"      Calculator: Creatinine clearance estimate by Cockcroft-Gault equation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24538?source=related_link\">",
"      Fever and rash in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23594?source=related_link\">",
"      Sulfonamide allergy in non HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=related_link\">",
"      Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_34_38439="Overview of pulmonary disease in injection drug users";
var content_f37_34_38439=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of pulmonary disease in injection drug users",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38439/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38439/contributors\">",
"     Jill P Karpel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38439/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38439/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38439/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38439/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/34/38439/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection drug abuse may result in acute or chronic pulmonary complications. These sequelae may be due to pharmacodynamic properties of the drugs, effects of intravenous contaminants, or complications of the intravenous route of administration.",
"   </p>",
"   <p>",
"    The general pulmonary complications and drug-specific pulmonary diseases that may result from injection drug use will be reviewed here. Other complications of injection drug use, such as infective endocarditis, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=see_link\">",
"     \"Foreign body granulomatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40215?source=see_link\">",
"     \"Infective endocarditis in injection drug users\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary complications associated with intravenous injection of illicit drugs include pulmonary infection, septic embolization, foreign body granulomatosis, emphysema, interstitial pneumonia, organizing pneumonia, pulmonary vascular disease, pneumothorax, and an increased incidence of fatal asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pulmonary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection drug users (IDUs) have a",
"    <strong>",
"     ten-fold",
"    </strong>",
"    increased risk of community-acquired pneumonia compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/1\">",
"     1",
"    </a>",
"    ]. This may be due to a number of factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Concurrent smoking of cigarettes or illicit drugs may impair local lung defenses, macrophage activity, and mucociliary clearance.",
"     </li>",
"     <li>",
"      The stupor induced by some injected drugs favors development of aspiration pneumonia or lung abscess. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"       \"Aspiration pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24729?source=see_link\">",
"       \"Lung abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacteremia may follow injection and may hematogenously infect the lung.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The organisms that most commonly cause community-acquired pneumonia in this population include Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, and Klebsiella pneumoniae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/2\">",
"     2",
"    </a>",
"    ]. Antimicrobial therapy should be selected, which has good activity against these pathogens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    .) Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    are commonly used in this setting, although serious consideration of Staphylococcus should prompt the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Tuberculosis (particularly multidrug-resistant tuberculosis) is more prevalent among IDUs than it is in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The excess risk largely relates to covariates which are more frequent among IDUs, such as poverty, homelessness, malnutrition, HIV infection, and poor medical care. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18649?source=see_link\">",
"     \"Epidemiology of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of injection drugs is a strong risk factor for the acquisition of HIV infection. A variety of opportunistic pulmonary infections in addition to tuberculosis may occur in drug users who are HIV-positive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/43/20154?source=see_link\">",
"     \"Approach to the HIV-infected patient with pulmonary symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Septic emboli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic pulmonary emboli can originate in the peripheral veins at sites of thrombophlebitis or they can arise from heart valves that have been damaged and infected due to injection drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17718?source=see_link\">",
"     \"Pathogenesis of vegetation formation in infective endocarditis\"",
"    </a>",
"    .) Septic emboli may result in pulmonary infiltrates, cavities, abscesses, infarction, and pulmonary gangrene (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59037 \" href=\"mobipreview.htm?11/37/11861\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87979163\">",
"    <span class=\"h2\">",
"     Noncardiogenic pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncardiogenic pulmonary edema (NPE) refers to the radiographic evidence of alveolar fluid accumulation without hemodynamic evidence to suggest a cardiogenic etiology and is caused by increased pulmonary capillary permeability. Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are more severe forms of noncardiogenic pulmonary edema. NPE is a potential adverse effect of intravenous injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , heroin, and other opiates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Patients with NPE due to opiate intoxication typically present with respiratory depression requiring",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    reversal. Co-intoxication with alcohol or cocaine is present in approximately 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/7\">",
"     7",
"    </a>",
"    ]. The majority of these patients are hypoxemic on arrival in the emergency department [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In a series of 27 patients with opiate-related NPE, 74 percent had bilateral, ground glass opacities suggestive of pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/6\">",
"     6",
"    </a>",
"    ]. Symptoms and signs typically resolved in 24 hours with supportive care (eg, supplemental oxygen), although 33 percent required mechanical ventilation for 24 to 48 hours. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3897?source=see_link\">",
"     \"Opioid intoxication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1944?source=see_link\">",
"     \"Noncardiogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Foreign body granulomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug users sometimes pulverize tablets intended for oral use, dissolve them in water, and inject them intravenously. Talc, starch, cotton, and cellulose are used as filler agents in these tablets and may be carried by the bloodstream until they lodge in the pulmonary capillary bed; chronic inflammation and multiple foreign body granulomata in the lungs may ensue. Pulmonary hypertension, emphysema, and interstitial fibrosis can occur if the process is severe. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=see_link\">",
"     \"Foreign body granulomatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bullous lung disease and emphysema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emphysema and bullous lung disease have been described in association with HIV infection, but HIV-negative IDUs may also develop these complications, particularly when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    , or talc-containing drugs are injected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37575?source=see_link\">",
"     \"Emphysema-like disease in HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=see_link\">",
"     \"Foreign body granulomatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of bullous lung damage and emphysema among intravenous drug users (as assessed by chest radiographs) is 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/11\">",
"     11",
"    </a>",
"    ]. The bullous cysts occur predominantly in the upper lobes and in the lung periphery, with sparing of the central portions of the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Patients present with cough and dyspnea, and usually have combined obstructive and restrictive defects on pulmonary function testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Interstitial lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial lung disease in IDUs is generally associated with foreign body granulomatosis, but may also be a nonspecific finding due to previous episodes of infection or infarction. Lymphocytic interstitial pneumonia, a rare interstitial lung disease in the general population, is seen with increased frequency in HIV-infected individuals, particularly children. In addition, organizing pneumonia, sarcoidosis, drug hypersensitivity, and immune reconstitution syndrome can develop in HIV-infected patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=see_link\">",
"     \"Foreign body granulomatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/43/20154?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the HIV-infected patient with pulmonary symptoms\", section on 'Pulmonary diseases and HIV'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension may be induced by obstruction or obliteration of the pulmonary vascular bed from multiple causes, including foreign body granulomatosis, emphysema, or interstitial disease. Patients who are HIV-positive may develop pulmonary arterial hypertension with plexiform lesions and medial hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drugs with sympathomimetic properties (eg, cocaine, methamphetamine) may produce transient pulmonary vasoconstriction. It also appears that chronic use of these drugs can lead to irreversible injury and production of a syndrome indistinguishable from primary pulmonary hypertension. In one retrospective study, patients with idiopathic pulmonary arterial hypertension (IPAH) were ten times more likely to use stimulants (ie, amphetamines, methamphetamines, or cocaine) than patients with pulmonary arterial hypertension (PAH) and known risk factors, such as collagen vascular disease, congenital heart disease, or anorexigen use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax may result from unsuccessful attempts to inject drugs into the central circulation via the subclavian and jugular veins (\"pocket shots\"). It has also been reported as a complication of septic pulmonary emboli and drug-related bullous disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Illicit use of drugs by asthmatics appears to be associated with an increased risk of fatal asthma: (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13735?source=see_link&amp;anchor=H8#H8\">",
"     \"Identifying patients at risk for fatal asthma\", section on 'Minor risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One toxicologic study of 92 cases of fatal asthma in Chicago found evidence of substance abuse, most commonly cocaine or opiates, in 32 percent of individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/16\">",
"       16",
"      </a>",
"      ]. It is unclear whether the drugs themselves or other unidentified factors are responsible for the increased asthma fatalities. Optimal use of asthma medicines is less frequent among drug users [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/17\">",
"       17",
"      </a>",
"      ], and antiinflammatory medications were being utilized by just two patients in the Chicago series.",
"     </li>",
"     <li>",
"      A retrospective review of 152 inner city asthma patients found that intubation and mechanical ventilation were required more often among patients presenting with an acute exacerbation if they use cocaine (31 versus 11.5 percent) or heroin (17 versus 2.3 percent), compared to non users [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral pulmonary nodules containing amyloid (AA) protein have been reported in patients with HIV disease and a history of IDU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DRUG-SPECIFIC COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of abnormal chest radiographs among cocaine users admitted to the hospital with pulmonary complaints ranges from 12 to 55 percent; abnormalities include focal infiltrates, atelectasis, pneumothorax, pneumomediastinum, and pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34649?source=see_link\">",
"     \"Pulmonary complications of cocaine abuse\"",
"    </a>",
"    .) There is a higher incidence of clinically apparent pulmonary complications when cocaine is smoked versus used intravenously or intranasally. However, one autopsy series which examined lung histopathology among 52 cocaine users found that lung histopathology was similar regardless of the route of cocaine use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/21\">",
"     21",
"    </a>",
"    ]. Histopathologic changes included congestion (88 percent), intraalveolar edema (77 percent), acute hemorrhage (58 percent), chronic hemorrhage (40 percent), and interstitial",
"    <span class=\"nowrap\">",
"     fibrosis/pneumonia",
"    </span>",
"    (38 percent).",
"   </p>",
"   <p>",
"    The pulmonary complications associated with the use of cocaine are multiple and can be divided into acute and chronic pulmonary disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Acute pulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute pulmonary complications primarily associated with inhaling cocaine include pulmonary edema, pulmonary hemorrhage, bronchiolitis obliterans with organizing pneumonia, and acute bronchospasm. \"Crack lung\" is a syndrome characterized by the acute onset of wheezing, dyspnea, fever, pulmonary infiltrates, and pulmonary or peripheral eosinophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. It is probably a hypersensitivity-type reaction, as these patients usually have elevated serum immunoglobulin E concentrations and develop the syndrome upon repeat exposure. Corticosteroids are the treatment of choice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34649?source=see_link\">",
"     \"Pulmonary complications of cocaine abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The acute complications of injection cocaine use overlap with those of inhaled crack cocaine and most commonly include acute pulmonary edema and pulmonary hemorrhage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute noncardiogenic pulmonary edema presents with the rapid onset of dyspnea, hypoxemia, and diffuse infiltrates on chest radiograph; altered mental status is frequently also present. Treatment is supportive and includes supplemental oxygen and ventilator support if necessary. Clinical improvement generally occurs within 24 to 48 hours. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1944?source=see_link\">",
"       \"Noncardiogenic pulmonary edema\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiogenic edema may result from cocaine-induced coronary artery spasm, myocardial ischemia, and left ventricular dysfunction (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58394 \" href=\"mobipreview.htm?5/36/5701\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/24\">",
"       24",
"      </a>",
"      ]. Treatment includes coronary vasodilators and diuretics. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=see_link\">",
"       \"Treatment of acute decompensated heart failure: General considerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary hemorrhage can occur with or without frank hemoptysis and is commonly found on autopsy in asymptomatic cocaine users [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/21\">",
"       21",
"      </a>",
"      ]. The causes of hemorrhage are probably multifactorial and may include pulmonary infarction, infection, inflammation, and pulmonary hypertension. Treatment is supportive. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34649?source=see_link\">",
"       \"Pulmonary complications of cocaine abuse\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chronic pulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic pulmonary complications of cocaine use are more common when the drug is inhaled and include chronic bronchitis, interstitial fibrosis, and an isolated decrease in the diffusing capacity for carbon monoxide (DLCO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The last two complications may also occur with intravenous use of cocaine and may be sequelae of foreign-body granulomata, pulmonary infections, pulmonary infarction, or pulmonary hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/27\">",
"     27",
"    </a>",
"    ]. Pulmonary infiltrates and hilar adenopathy may also occur and mimic sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Opiates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of heroin (diacetyl",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) is rising in the United States, and increasingly pure formulations of the drug are available at a decreased price. Most of the direct morbidity and mortality related to opiate use occur after acute intoxication and are due to anaphylaxis, acute lung injury, acute respiratory acidosis, and aspiration pneumonitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3897?source=see_link\">",
"     \"Opioid intoxication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Massive release of histamine may follow narcotic injection due to an anaphylactoid reaction to the narcotics themselves or to adulterants or contaminants. Shock, bronchospasm, and upper airway edema may ensue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heroin-induced noncardiogenic pulmonary edema usually develops rapidly within the first few hours following injection, but rarely occurs as late as 24 hours. This complication can also occur with other opiates such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      . Oxygen therapy and noninvasive positive pressure ventilation or intubation with mechanical ventilation may be required. Improvement can occur rapidly, but full resolution generally requires two to three days. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1944?source=see_link\">",
"       \"Noncardiogenic pulmonary edema\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Narcotics powerfully suppress central respiratory drive. Acute administration may produce hypercapnia, acute respiratory acidosis, and if severe, cardiopulmonary arrest and death.",
"     </li>",
"     <li>",
"      Narcotics also diminish the level of consciousness and depress the cough reflex. These actions render narcotic users less able to protect the airway and more likely to develop aspiration pneumonitis (due to infection or aspirated gastric contents) and lung abscess. Lower lobe bronchiectasis has been reported among heroin users and may result from prior episodes of aspiration or pulmonary infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"       \"Aspiration pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24729?source=see_link\">",
"       \"Lung abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a case report, an intravenous heroin user developed respiratory failure due to organizing pneumonia; scattered, nonnecrotizing granulomata and multinucleated giant cells with foreign body particles were also noted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Methylphenidate and methamphetamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     Methylphenidate",
"    </a>",
"    and methamphetamine are sympathomimetic stimulants that may be used intravenously. General signs and symptoms of toxicity include restlessness, tachycardia, hypertension, diaphoresis, and confusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Methylphenidate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    has been associated with the development of hemoptysis, chest pain, and wheezing. One series of 22 patients hospitalized following methylphenidate use reported that 80 percent had one or more of these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/32\">",
"     32",
"    </a>",
"    ]. Excess adrenergic activity and vasospasm may underlie these complications.",
"   </p>",
"   <p>",
"    Habitual intravenous use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    has been associated with the development of panlobar emphysema after one to six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Emphysema primarily involves the lower lobes of the lungs and has a similar radiographic appearance to alpha-1 antitrypsin deficiency. The relative contribution of methylphenidate, foreign body granulomatosis, and concomitant smoking in the genesis of emphysema among these patients is unclear, but one study compared the findings on chest CT of patients with foreign body granulomatosis who abused intravenous methylphenidate with others who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38439/abstract/35\">",
"     35",
"    </a>",
"    ]. A significantly increased prevalence of lower lobe panacinar emphysema was demonstrated in patients abusing methylphenidate, and was frequently associated with a fine micronodular pattern and ground glass attenuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Methamphetamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methamphetamine (\"speed\" or \"crank\") is a stimulant drug that has similar effects to cocaine. It can be smoked or administered intravenously or intranasally. There are case reports of acute pulmonary edema and pulmonary hypertension following the inhalation of methamphetamine, but complications of intravenous use are not well documented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97240033\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary complications associated with intravenous injection of illicit drugs include pulmonary infection, septic embolization, foreign body granulomatosis, emphysema, interstitial lung disease, organizing pneumonia, pulmonary vascular disease, pneumothorax, and an increased incidence of fatal asthma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injection drug users (IDUs) have a",
"      <strong>",
"       ten-fold",
"      </strong>",
"      increased risk of community-acquired pneumonia compared with the general population; common causative organisms include Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, and Klebsiella pneumoniae. In addition, those who develop AIDS are at risk for opportunistic pulmonary infections (eg, tuberculosis, atypical mycobacteria, Pneumocystis jirovecii, cytomegalovirus). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pulmonary infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When tablets intended for oral use are pulverized and injected intravenously, the insoluble agents in the tablets (eg, talc, cotton, and cellulose) can be trapped in the pulmonary vasculature, migrate through the vessel walls, and initiate a granulomatous inflammatory response in the perivascular interstitium. This disease process, known as foreign body granulomatosis, can lead to development of progressive interstitial lung disease, emphysema, and pulmonary hypertension. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Foreign body granulomatosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=see_link\">",
"       \"Foreign body granulomatosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Emphysema and bullous lung disease may result from concomitant cigarette smoking, but are also associated with HIV infection and intravenous injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      , and talc-containing drugs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumothorax may result from unsuccessful attempts to inject drugs into the central circulation via the subclavian and jugular veins (\"pocket shots\"). It has also been reported as a complication of septic pulmonary emboli and drug-related bullous disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pneumothorax'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of intravenous injection of crack cocaine include noncardiogenic and cardiogenic pulmonary edema, acute and recurrent alveolar hemorrhage, and interstitial lung disease due to foreign body granulomatosis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cocaine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary complications related to opiate use typically occur in the setting of acute intoxication and are due to anaphylaxis, noncardiogenic pulmonary edema, hypoventilation with acute respiratory acidosis, and aspiration pneumonitis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Opiates'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3897?source=see_link\">",
"       \"Opioid intoxication in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/21/22874?source=see_link\">",
"       \"Opioid intoxication in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      has been associated with hemoptysis, chest pain, and wheezing; excess adrenergic activity and vasospasm may underlie these complications. Foreign body granulomatosis and emphysema are complications associated with long term use. Methamphetamine (\"speed\" or \"crank\") is a stimulant drug that has similar effects to cocaine and is associated with noncardiogenic pulmonary edema and pulmonary hypertension. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Methylphenidate and methamphetamine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/1\">",
"      Hind CR. Pulmonary complications of intravenous drug misuse. 1. Epidemiology and non-infective complications. Thorax 1990; 45:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/2\">",
"      Caiaffa WT, Vlahov D, Graham NM, et al. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. Am J Respir Crit Care Med 1994; 150:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/3\">",
"      Reichman LB, Felton CP, Edsall JR. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med 1979; 139:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/4\">",
"      Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/5\">",
"      Perlman DC, Salomon N, Perkins MP, et al. Tuberculosis in drug users. Clin Infect Dis 1995; 21:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/6\">",
"      Sporer KA, Dorn E. Heroin-related noncardiogenic pulmonary edema : a case series. Chest 2001; 120:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/7\">",
"      Sterrett C, Brownfield J, Korn CS, et al. Patterns of presentation in heroin overdose resulting in pulmonary edema. Am J Emerg Med 2003; 21:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/8\">",
"      O'Donnell AE, Pappas LS. Pulmonary complications of intravenous drug abuse. Experience at an inner-city hospital. Chest 1988; 94:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/9\">",
"      Par&eacute; JP, Cote G, Fraser RS. Long-term follow-up of drug abusers with intravenous talcosis. Am Rev Respir Dis 1989; 139:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/10\">",
"      Stern EJ, Frank MS, Schmutz JF, et al. Panlobular pulmonary emphysema caused by i.v. injection of methylphenidate (Ritalin): findings on chest radiographs and CT scans. AJR Am J Roentgenol 1994; 162:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/11\">",
"      Goldstein DS, Karpel JP, Appel D, Williams MH Jr. Bullous pulmonary damage in users of intravenous drugs. Chest 1986; 89:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/12\">",
"      Gurney JW, Bates FT. Pulmonary cystic disease: comparison of Pneumocystis carinii pneumatoceles and bullous emphysema due to intravenous drug abuse. Radiology 1989; 173:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/13\">",
"      Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. Chest 1991; 100:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/14\">",
"      Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006; 130:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/15\">",
"      Aguado JM, Arjona R, Ugarte P. Septic pulmonary emboli. A rare cause of bilateral pneumothorax in drug abusers. Chest 1990; 98:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/16\">",
"      Levenson T, Greenberger PA, Donoghue ER, Lifschultz BD. Asthma deaths confounded by substance abuse. An assessment of fatal asthma. Chest 1996; 110:604.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on February 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/18\">",
"      Levine M, Iliescu ME, Margellos-Anast H, et al. The effects of cocaine and heroin use on intubation rates and hospital utilization in patients with acute asthma exacerbations. Chest 2005; 128:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/19\">",
"      Shah SP, Khine M, Anigbogu J, Miller A. Nodular amyloidosis of the lung from intravenous drug abuse: an uncommon cause of multiple pulmonary nodules. South Med J 1998; 91:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/20\">",
"      McCarroll KA, Roszler MH. Lung disorders due to drug abuse. J Thorac Imaging 1991; 6:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/21\">",
"      Bailey ME, Fraire AE, Greenberg SD, et al. Pulmonary histopathology in cocaine abusers. Hum Pathol 1994; 25:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/22\">",
"      Kissner DG, Lawrence WD, Selis JE, Flint A. Crack lung: pulmonary disease caused by cocaine abuse. Am Rev Respir Dis 1987; 136:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/23\">",
"      Oh PI, Balter MS. Cocaine induced eosinophilic lung disease. Thorax 1992; 47:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/24\">",
"      Amin M, Gabelman G, Karpel J, Buttrick P. Acute myocardial infarction and chest pain syndromes after cocaine use. Am J Cardiol 1990; 66:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/25\">",
"      Tashkin DP, Khalsa ME, Gorelick D, et al. Pulmonary status of habitual cocaine smokers. Am Rev Respir Dis 1992; 145:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/26\">",
"      O'Donnell AE, Mappin FG, Sebo TJ, Tazelaar H. Interstitial pneumonitis associated with \"crack\" cocaine abuse. Chest 1991; 100:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/27\">",
"      Yakel DL Jr, Eisenberg MJ. Pulmonary artery hypertension in chronic intravenous cocaine users. Am Heart J 1995; 130:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/28\">",
"      Dicpinigaitis PV, Jones JG, Frymus MM, Folkert VW. \"Crack\" cocaine-induced syndrome mimicking sarcoidosis. Am J Med Sci 1999; 317:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/29\">",
"      Edston E, van Hage-Hamsten M. Anaphylactoid shock--a common cause of death in heroin addicts? Allergy 1997; 52:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/30\">",
"      Banner AS, Rodriguez J, Sunderrajan EV, et al. Bronchiectasis: a cause of pulmonary symptoms in heroin addicts. Respiration 1979; 37:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/31\">",
"      Bishay A, Amchentsev A, Saleh A, et al. A hitherto unreported pulmonary complication in an IV heroin user. Chest 2008; 133:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/32\">",
"      Parran TV Jr, Jasinski DR. Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch Intern Med 1991; 151:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/33\">",
"      Sherman CB, Hudson LD, Pierson DJ. Severe precocious emphysema in intravenous methylphenidate (Ritalin) abusers. Chest 1987; 92:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/34\">",
"      Shlomi D, Shitrit D, Bendayan D, et al. Successful lung transplantation for talcosis secondary to intravenous abuse of oral drug. Int J Chron Obstruct Pulmon Dis 2008; 3:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38439/abstract/35\">",
"      Ward S, Heyneman LE, Reittner P, et al. Talcosis associated with IV abuse of oral medications: CT findings. AJR Am J Roentgenol 2000; 174:789.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4337 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38439=[""].join("\n");
var outline_f37_34_38439=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H97240033\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pulmonary infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Septic emboli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87979163\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Foreign body granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bullous lung disease and emphysema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DRUG-SPECIFIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cocaine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Acute pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chronic pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Opiates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Methylphenidate and methamphetamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Methylphenidate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Methamphetamine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97240033\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4337\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4337|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/37/11861\" title=\"diagnostic image 1\">",
"      Septic embolization PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/36/5701\" title=\"diagnostic image 2\">",
"      Pulmonary edema PA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/43/20154?source=related_link\">",
"      Approach to the HIV-infected patient with pulmonary symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37575?source=related_link\">",
"      Emphysema-like disease in HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=related_link\">",
"      Foreign body granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13735?source=related_link\">",
"      Identifying patients at risk for fatal asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40215?source=related_link\">",
"      Infective endocarditis in injection drug users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24729?source=related_link\">",
"      Lung abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/21/22874?source=related_link\">",
"      Opioid intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17718?source=related_link\">",
"      Pathogenesis of vegetation formation in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34649?source=related_link\">",
"      Pulmonary complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_34_38440="Surgical instruments for gynecologic surgery";
var content_f37_34_38440=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical instruments for gynecologic surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38440/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38440/contributors\">",
"     John C Jennings, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38440/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38440/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38440/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38440/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/34/38440/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been said that \"a good carpenter knows his tools.\" Similarly, skilled surgeons must know the applications and limitations of the instruments they regularly use. Novice surgeons usually select instruments according to the advice and habits of their surgical mentors. Personal experience modifies, and often limits, the selection of instruments eventually used by the advanced surgeon. The economic forces at work to standardize operative costs may further limit the choice of instrumentation.",
"   </p>",
"   <p>",
"    Surgical instruments are, in many ways, simply extensions of the human hand. There is inevitably a \"feel\" for different instruments designed to accomplish the same purpose. This topic review is an effort to familiarize the reader with basic instrumentation for gynecologic surgery and advantages of individual instruments. The author has put forth some of his preferences for instrumentation based upon his experience, but is cognizant that satisfactory alternatives exist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CUTTING INSTRUMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exposure and conduct of a surgical procedure depends upon use of cutting instruments that are properly chosen to accomplish a specific task.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Scalpel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional surgical scalpel, available in a variety of sizes and shapes, is adequate for most gynecologic procedures. Disposable blades can be firmly attached to the scalpel handle using a needle holder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Handle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Bard-Parker handle has general utility, and all blades that are commonly used during gynecologic surgeries will fit this handle. The length of the knife handle to be used depends upon the surgical task. Shorter handles are easier to control and are best used for making skin incisions and for working in shallow incisions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30265?source=see_link\">",
"     \"Principles of abdominal wall incisions\"",
"    </a>",
"    .) Longer handles are particularly useful in a deep pelvis. An angled scalpel handle, which has a spear-pointed design, attached to a #11 blade (see below) is frequently used for cold knife cervical conization (",
"    <a class=\"graphic graphic_figure graphicRef62851 \" href=\"mobipreview.htm?38/39/39538\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33048?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Procedures for cervical conization\"",
"    </a>",
"    .) Resting the operating hand on the abdominal wall or against a self-retaining retractor can improve the surgeon's control of the knife.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Blade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scalpel blades have been designed in various sizes and shapes to accommodate special purposes (",
"    <a class=\"graphic graphic_figure graphicRef71823 \" href=\"mobipreview.htm?31/7/31858\">",
"     figure 2",
"    </a>",
"    ). Abdominal incisions are best made with either a #20 or a #22 Bard-Parker blade. The #22 is the most versatile; this blade can be used through the fascial incision and to open the peritoneum. There is no evidence to show that it is necessary to have a separate \"skin knife\" and \"deep knife\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/2\">",
"     2",
"    </a>",
"    ]. The #15 blade has a small cutting area, which increases safety when a scalpel is used in a tight operative field. This #15 blade is also useful for making small skin incisions that are necessary for laparoscopic procedures, postpartum sterilizations, and drain incisions. The #11 blade is ideally suited for incision and drainage procedures. Its sharply pointed design both defines and limits its use.",
"   </p>",
"   <p>",
"    Disposable surgical knife blades are very sharp, but will dull when incising rigid abdominal scar tissue or if inadvertently scraped against a metal surface, such as previously placed wire suture material. A dull blade can be hazardous because the surgeon may sacrifice control by increasing the pressure applied to the knife to accomplish the desired cut.",
"   </p>",
"   <p>",
"    It is possible to carefully use the knife handle for blunt dissection, but the cutting edge of the blade must be directed away from hands in the operative field. If unintentional injury to the patient or to the surgical assistants is to be avoided, the sharpness of the surgical knife must be constantly respected. After use, the knife should be given handle-first to the scrub assistant. A knife should never be in the surgical field unless it is in the control of the surgeon's hand, and should never be laid on the drapes of the operative field.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Scissors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specialized design and construction of surgical scissors make their use efficient and safe. Scissors are not meant to replace the scalpel. They are designed to be used when the scalpel is impractical or even hazardous.",
"   </p>",
"   <p>",
"    Scissors are designed with either straight or curved blades. They may have sharp-sharp points, blunt-blunt points, or blunt-sharp points. The Mayo dissecting scissors (",
"    <a class=\"graphic graphic_figure graphicRef66226 \" href=\"mobipreview.htm?35/53/36702\">",
"     figure 3",
"    </a>",
"    ) have rounded tips that reduce inadvertent puncture of tissue and can have either beveled or rounded cutting blades. In varying lengths, the Mayo scissors can be useful for surgery in the pelvis and abdomen. Metzenbaum scissors (",
"    <a class=\"graphic graphic_figure graphicRef58110 \" href=\"mobipreview.htm?34/5/34910\">",
"     figure 4",
"    </a>",
"    ) have shorter blades proportionate to the shafts than Mayo scissors and are more suitable for delicate tissue dissection. The versatility of these two types of scissors has resulted in their widespread popularity among gynecologists.",
"   </p>",
"   <p>",
"    Other specially modified scissors have useful functions in gynecologic surgery. Jorgenson scissors (",
"    <a class=\"graphic graphic_figure graphicRef73949 \" href=\"mobipreview.htm?6/26/6565\">",
"     figure 5",
"    </a>",
"    ) have very sharply curved blades that can be placed into the opened vagina and can circumferentially cut the vagina at the level of the vaginal fornices. Excision of the cervix in this manner preserves vaginal length and provides a smoothly cut edge for easy suturing of the vaginal cuff. Iris scissors (",
"    <a class=\"graphic graphic_figure graphicRef62803 \" href=\"mobipreview.htm?39/37/40529\">",
"     figure 6",
"    </a>",
"    ) with sharp-sharp points are frequently used by plastic surgeons because of their delicate blades and resultant precision cuts. These scissors can be useful in vaginal repair work when tissue is scarred, as might be found with a repeat anterior colporrhaphy. The points of these scissors have a delicate cut that can be precisely controlled, but can penetrate the urinary bladder if used carelessly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Instruments that use an energy source",
"    </span>",
"    &nbsp;&mdash;&nbsp;For some surgical tasks, it is useful to cut with instruments that use electrosurgery or another energy source (eg, ultrasound, laser). Instruments that use an energy source are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37737?source=see_link\">",
"     \"Overview of electrosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NEEDLE-HOLDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The needle-holder's purpose is to firmly hold a curved surgical needle as it is passed through tissue, to easily release the needle, and then to easily regrasp the needle. Much effort has been directed to the design of needle-holders because the accurate placement and recovery of the needle can be critical in preventing unnecessary bleeding and tissue damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/3\">",
"     3",
"    </a>",
"    ]. Ideally, the needle-holder should be designed to grasp the needle firmly without flattening or bending it or damaging the suture material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/4\">",
"     4",
"    </a>",
"    ]. The jaws of most needle-holders are flat and thus have the potential to bend needles with a small radius or caliber [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/5\">",
"     5",
"    </a>",
"    ]. Much of the critical placement of sutures in gynecologic procedures requires only one or two passes through tissue. Consequently, the ability of the needle-holder to accurately drive the needle through tissue is more important than any damage to a needle that will soon be discarded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not unusual for a surgeon to use a large caliber needle during pelvic surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10633?source=see_link&amp;anchor=H8#H8\">",
"     \"Principles of abdominal wall closure\", section on 'Needles'",
"    </a>",
"    .) The needle-holder should have jaw strength that is sufficient to hold these needles without springing. Smaller radius needles can be protected from bending with the use of a needle-holder with a narrower jaw; however, this will sacrifice some of the holder's firmness of grasp and decrease the needle's potential to roll, depending upon the tissue resistance.",
"   </p>",
"   <p>",
"    The quality of needle sharpness is important to the performance of the needle-holder. A sharp needle causes less tissue trauma and requires less force to pass through tissue. In addition, there is reduced tendency for needles to bend or break if the needle is optimally sharp. Surgical needles are manufactured to resist breakage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/7\">",
"     7",
"    </a>",
"    ], but the improper use of the needle-holder and a poor choice of needle can lead to an unpleasant and sometimes futile search for a broken needle. Although it is theoretically possible to reduce needle bending and breakage by calculating and matching strengths of needle-holders and needles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/8\">",
"     8",
"    </a>",
"    ], the same needle-holder is usually used for multiple needle types during a procedure.",
"   </p>",
"   <p>",
"    The use of blunt needles, particularly for closure of fascia, has been advocated as a measure for reducing needle stick injuries.",
"   </p>",
"   <p>",
"    Needle-holders are available in short, medium, and long lengths. In some cases, only long instruments can be used for safe suture placement. However, for most gynecologic cases, the eight inch needle-holder is adequate. Needle-holders may be straight or curved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Straight &mdash; The straight-jawed needle-holder (",
"      <a class=\"graphic graphic_figure graphicRef59271 \" href=\"mobipreview.htm?2/29/2513\">",
"       figure 7",
"      </a>",
"      ) has the most utility in pelvic surgery. The exit of the needle from the tissue is predictable, and there is less tendency for the needle to roll in firm tissue. The straight needle-holder is also more forgiving when regrasping needles because the functional length of the jaws is longer than that of curved needle-holders.",
"     </li>",
"     <li>",
"      Curved &mdash; A curved needle-holder, such as the Heaney design (",
"      <a class=\"graphic graphic_figure graphicRef57317 \" href=\"mobipreview.htm?24/51/25407\">",
"       figure 8",
"      </a>",
"      ), has some advantages in vaginal surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/9\">",
"       9",
"      </a>",
"      ]. This type of needle-holder allows easier visualization of needle placement, although possibly at the expense of more difficult visualization of needle exit. A double-curved Stratte needle-holder (",
"      <a class=\"graphic graphic_figure graphicRef50169 \" href=\"mobipreview.htm?26/56/27535\">",
"       figure 9",
"      </a>",
"      ) works well in the tight confines of the retropubic space during urethral or paravaginal suspension procedures: its unique curvature allows the operator to effectively place sutures without the hand obscuring visualization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Needle-holders are generally designed with a locking mechanism that requires an opposite action for locking and unlocking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/1\">",
"     1",
"    </a>",
"    ]. For a right-handed surgeon, this motion becomes very natural and is easy to master because the thumb of the right hand can easily produce the motion to lock or unlock the needle-holder. Left-handed surgeons may have less difficulty with an offset locking mechanism that requires only a push-push or squeezing motion to lock and unlock the needle holder (",
"    <a class=\"graphic graphic_figure graphicRef52828 \" href=\"mobipreview.htm?10/7/10355\">",
"     figure 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/10\">",
"     10",
"    </a>",
"    ]. Regardless of the type of locking mechanism, the surgeon's personal experience is the most important factor in preventing poorly timed needle release.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FORCEPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical forceps serve as an extension of the surgeon's thumb and index finger and enable grasping of small structures in limited spaces. However, they do not provide the tactile information obtained by the surgeon's fingertips. The design of all forceps is very similar, with differences limited to length, width, and type of surface that grips the tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/1\">",
"     1",
"    </a>",
"    ]. Variations in the widths and textures of the grasping surfaces and the lengths of the shafts have increased their utility. The colloquial term \"pickup\" that is used interchangeably with \"forceps\" implies a limited function that is inaccurate.",
"   </p>",
"   <p>",
"    Knowledge of how to handle forceps is important because transmission of disease by body fluids can be reduced by minimizing direct handling of tissue and needles and by keeping hands out of surgical fields when sharp instruments are being passed through tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/11\">",
"     11",
"    </a>",
"    ]. As an example, most novice surgeons tend to use their hands, instead of an instrument, to reload needles on holders when a surgical assistant is not present. Proper use of forceps facilitates visualization of the operative field and can reduce the amount of tissue handling. Although the tensile strength of most forceps is such that considerable trauma is required to damage them, it is possible to \"spring\" the forceps or change the alignment of the grasping surface with improper use.",
"   </p>",
"   <p>",
"    Retrieving needles with forceps is sometimes necessary and expeditious. Ideally, the forceps should be used to grasp the tissue through which the needle is to be passed and to hold the tissue until the needle has completed its arc and has been regrasped by the needle-holder. Repositioning of the needle on the needle-holder is sometimes necessary with this technique; it is possible to perform this maneuver with minimal stress on the forceps and little risk of damage to the instrument.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Types",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most experienced surgeons, the selection of forceps for a particular surgical maneuver is almost a reflex based upon the thickness of the tissue to be grasped and the countertraction that is required.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin &mdash; Adson forceps and the Brown-Adson modification are commonly used for handling the skin. Brown-Adson forceps appear superior because the design of the jaws allows easy manipulation of skin (",
"      <a class=\"graphic graphic_figure graphicRef56348 \" href=\"mobipreview.htm?40/51/41778\">",
"       figure 11",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Fascia &mdash; There is no clear advantage of one type of forceps over another for handling fascial tissue. The texture of fascial tissue requires the grasping design of instruments such as Martin forceps (",
"      <a class=\"graphic graphic_figure graphicRef73124 \" href=\"mobipreview.htm?14/54/15215\">",
"       figure 12",
"      </a>",
"      ), Bonney forceps (",
"      <a class=\"graphic graphic_figure graphicRef66577 \" href=\"mobipreview.htm?0/16/271\">",
"       figure 13",
"      </a>",
"      ), Russian forceps (",
"      <a class=\"graphic graphic_figure graphicRef65901 \" href=\"mobipreview.htm?2/0/2063\">",
"       figure 14",
"      </a>",
"      ), or the Potts-Smith forceps with teeth (",
"      <a class=\"graphic graphic_figure graphicRef68606 \" href=\"mobipreview.htm?26/43/27326\">",
"       figure 15",
"      </a>",
"      ). Many obstetricians and gynecologists learn to use the Russian forceps when doing cesarean deliveries. These forceps have a large grasping surface and are particularly suitable for use in closure of the uterus at cesarean. Martin forceps have two teeth and a serrated grasping surface that will firmly hold tissue. Bonney forceps have multiple smaller teeth and may be less traumatic without sacrificing grasping efficiency. The Potts-Smith forceps with teeth have a smaller grasping surface, but the teeth are large enough to effectively grasp tissue and hold tension.",
"     </li>",
"     <li>",
"      Peritoneum &mdash; The tissue within the peritoneal cavity should be handled with the least traumatic forceps that will effectively grasp the tissue. Because of the delicate nature of visceral tissue, it is not desirable to apply firm tension. The forceps that have already been mentioned can be useful in the peritoneal cavity. A general thumb forceps with a cross-serrated grasping surface without teeth can be used for minimally traumatic handling of tissue. Evans pelvic tissue forceps in the 10 inch length or longer can also be useful in the deep pelvis. Adson bayonet forceps have a design that can displace the hand from potential obstruction of the field of view (",
"      <a class=\"graphic graphic_figure graphicRef76315 \" href=\"mobipreview.htm?20/1/20497\">",
"       figure 16",
"      </a>",
"      ). The selection of forceps with grasping teeth for use in the pelvis is acceptable, but with the recognition that the teeth can be traumatic to vasculature. An atraumatic grasping instrument, such as the Babcock clamp, is useful for grasping rounded structures such as the fallopian tubes (",
"      <a class=\"graphic graphic_figure graphicRef79728 \" href=\"mobipreview.htm?24/31/25072\">",
"       figure 17",
"      </a>",
"      ). Debakey forceps may also be used on peritoneal surfaces.",
"     </li>",
"     <li>",
"      Lymphatics &mdash; Nontoothed ring forceps are generally used to dissect lymph nodes to minimize tissue shredding. Large smooth forceps may also be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HEMOSTATIC CLAMPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a surgical catalog, the instruments that surgeons commonly refer to as \"hemostats\" are labeled \"forceps\". The colloquial term \"clamp\" is almost universally used to refer to the group of ratchet-design hemostatic forceps. In a single instrument catalog, there are as many as 100 different types of hemostatic forceps. This discussion is limited to five different clamps that incorporate the basic design that is common to all hemostats.",
"   </p>",
"   <p>",
"    The Halsted mosquito forceps come in curved and straight patterns with horizontal serrations (",
"    <a class=\"graphic graphic_figure graphicRef73787 \" href=\"mobipreview.htm?0/38/610\">",
"     figure 18",
"    </a>",
"    ). These are delicate hemostats designed to specifically grasp the vessel below the point of severance. Applying the hemostat to a large wad of tissue surrounding the bleeding point leads to excessive tissue necrosis either from ligature constriction or cauterization of a larger than necessary amount of tissue.",
"   </p>",
"   <p>",
"    Kelly clamps (",
"    <a class=\"graphic graphic_figure graphicRef64793 \" href=\"mobipreview.htm?15/10/15521\">",
"     figure 19",
"    </a>",
"    ) are large curved instruments frequently used by gynecologic surgeons. Tonsil forceps (",
"    <a class=\"graphic graphic_figure graphicRef71094 \" href=\"mobipreview.htm?5/48/5903\">",
"     figure 20",
"    </a>",
"    ) have a longer-shaft and a fine grasping surface that is particularly useful to the pelvic surgeon. Kocher or Rochester-Ochsner clamps (",
"    <a class=\"graphic graphic_figure graphicRef63386 \" href=\"mobipreview.htm?7/57/8095\">",
"     figure 21",
"    </a>",
"    ) are often used on the vagina because of their tooth design, which can grasp the opened vaginal cuff firmly. However, the tooth may puncture vessels when used in the broad ligament. The Mixter forceps (",
"    <a class=\"graphic graphic_figure graphicRef53617 \" href=\"mobipreview.htm?0/39/627\">",
"     figure 22",
"    </a>",
"    ), commonly called a right-angle forceps, and its modifications can be used for passing a ligature around a clamped pedicle as well as for hemostasis. The narrow tip of these forceps and the right-angle curve can simplify the clamping of smaller, difficult-to-isolate vessels. Ballentine clamps, straight or curved, are heavy tissue clamps with serrations that prevent tissue slippage. Unlike the Kocher clamp, they do not have a tooth.",
"   </p>",
"   <p>",
"    Hemostats are multiuse instruments, thus they have been subjected to a variety of abuses that can ruin their clamping surfaces. It is quite frustrating to isolate a vessel with difficulty, clamp it, loosen the grasp of the hemostat, and then find that the clamping tips are bent or worn from improper usage. Hemostats can satisfactorily substitute for almost any tissue-grasping instrument.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HYSTERECTOMY CLAMPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether hysterectomy is performed via the abdominal or vaginal route, it is necessary to control the rich vascular supply of the uterus. A variety of specialized clamps have been designed to accomplish this purpose.",
"   </p>",
"   <p>",
"    The ideal hysterectomy clamp should maintain a secure purchase on tissue without excessive crushing force [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/12\">",
"     12",
"    </a>",
"    ]. The vascular supply to the uterus is extensive and well collateralized, and in the paracolpos and parametria, the vessels are surrounded by dense supporting structures. The hysterectomy clamp must be able to firmly grasp and hold these structures until the pedicles are severed and secured by suture. If tissue slips from the clamp, bleeding will occur that may be difficult to control. Subsequent attempts at hemostasis potentially increase the risk of damage to the urinary tract or larger vessels. The relative safety of this operation is largely based upon the design and efficiency of use of the hysterectomy clamp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hysterectomy clamps are typically 8 to 9 inches long and may have either a curved or straight tip with oblique, longitudinal, or horizontal serrations on the grasping surface. The curve of the clamp should be gentle enough to avoid forcing the bite of tissue laterally. The Heaney clamp (",
"    <a class=\"graphic graphic_figure graphicRef77289 \" href=\"mobipreview.htm?39/5/40019\">",
"     figure 23",
"    </a>",
"    ) and its curved Ballentine modification (",
"    <a class=\"graphic graphic_figure graphicRef51477 \" href=\"mobipreview.htm?24/37/25170\">",
"     figure 24",
"    </a>",
"    ) have radii that make them useful throughout the hysterectomy procedure, particularly when performed vaginally. The straight Ballentine clamp (",
"    <a class=\"graphic graphic_figure graphicRef68388 \" href=\"mobipreview.htm?39/11/40127\">",
"     figure 25",
"    </a>",
"    ) is most suited for use in clamping the cardinal ligament complex in the abdominal approach because without detachment of the uterosacral ligament, a curved clamp is awkward to apply. The serrations on the Heaney clamp are oblique, and the grasping tip may have either a single or double tooth. The coarseness of the serration pattern on the Heaney clamp can also be varied to increase the strength of the tissue grip. The Heaney-Ballentine or curved Ballentine has longitudinal serrations that may be preferable because this design will minimize the risk of lateral slippage of tissue from the clamp. The Garland hysterectomy forceps (",
"    <a class=\"graphic graphic_figure graphicRef77046 \" href=\"mobipreview.htm?43/38/44655\">",
"     figure 26",
"    </a>",
"    ) are angled, not curved, and have longitudinal serrations similar to the Ballentine clamp.",
"   </p>",
"   <p>",
"    Hysterectomy clamps are crushing clamps that inflict a relatively large area of tissue trauma. Therefore, large-bite hysterectomy clamps should not be placed across tissue where the surgeon desires to maintain viability. The vascular supply to the uterus must be ligated during hysterectomy, and any tissue that is distal to a hemostatic ligature will be nonviable. A hysterectomy performed with atraumatic small bites is likely to have just as much nonviable tissue distal to the ligatures as a procedure performed with a larger clamp. It is for this reason that gynecologists are likely to continue using these same hysterectomy clamps or a similar variation for both vaginal and abdominal cases (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/46/32490?source=see_link\">",
"     \"Abdominal hysterectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/36/35401?source=see_link\">",
"     \"Vaginal hysterectomy\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RETRACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All retractors have the same basic function of providing exposure of the surgical field. Knowledge and appropriate selection of retractors can simplify a procedure. Conversely, inadequate exposure can create difficulties in an otherwise easy operation. When complications arise and a surgeon calls for help from a surgical consultant, a frequent first step is the improvement of exposure by either repositioning or changing retractors. This is obvious testimony to the need for wisely choosing and positioning retractors.",
"   </p>",
"   <p>",
"    Handheld retractors have been designed for almost every conceivable need; by necessity this discussion must be limited to those instruments most frequently used by the gynecologist. It is not unusual to use several different handheld retractors during the course of an operation. The surgeon should direct the positioning of the retractors by the assistants and choose the most appropriate retractor for the particular surgical step. Self-retaining retractors are almost universally used in gynecologic laparotomies and have been adapted for maximizing pelvic exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hand held",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Heaney retractor is a right-angled vaginal retractor that is found on almost every vaginal surgery setup (",
"    <a class=\"graphic graphic_figure graphicRef70162 \" href=\"mobipreview.htm?33/44/34498\">",
"     figure 27",
"    </a>",
"    ). This retractor will easily extend to the depth of the cervix in most patients and can be useful for exposure of the cervix, vaginal fornices, and the vaginal approach to the peritoneal cavity. The long blade on the large Heaney retractor has the disadvantage of sometimes pushing the operative site away from the surgeon, particularly when the vaginal epithelium is intact. A smaller version of the Heaney retractor has been manufactured for situations in which a shorter blade is desirable. The abrupt bend of the retractor can occasionally interfere with visualization at the introitus; other retractors with a rounded curvature are more appropriate when this happens.",
"   </p>",
"   <p>",
"    The Breisky-Navratil retractors are widely used for vaginal exposure among European gynecologic surgeons, but are less popular in the United States (",
"    <a class=\"graphic graphic_figure graphicRef53830 \" href=\"mobipreview.htm?25/62/26607\">",
"     figure 28",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/9\">",
"     9",
"    </a>",
"    ]. These retractors have the advantage of a curve that will allow a lateral, superior, or inferior tow on vaginal tissue without the assistant's hand drifting into the operator's field of view. They come in a variety of lengths and widths that expand the usefulness of the basic design. The Harrington or \"sweetheart\" retractor has a similar curved shank, but a wider heart-shaped tip. It is useful for retracting the bladder, or when wider areas of tissue need to be held.",
"   </p>",
"   <p>",
"    The design of the Deaver retractor (",
"    <a class=\"graphic graphic_figure graphicRef64339 \" href=\"mobipreview.htm?14/14/14560\">",
"     figure 29",
"    </a>",
"    ) has also been modified in varying lengths and widths to make it useful in both vaginal and abdominal surgeries. If the Deaver retractor is placed too deeply, the assistant's hand and the bulge of the retractor's curve may limit the operator's vision.",
"   </p>",
"   <p>",
"    The Richardson retractor (",
"    <a class=\"graphic graphic_figure graphicRef54817 \" href=\"mobipreview.htm?17/29/17872\">",
"     figure 30",
"    </a>",
"    ) and its Eastman modification (",
"    <a class=\"graphic graphic_figure graphicRef75741 \" href=\"mobipreview.htm?43/29/44496\">",
"     figure 31",
"    </a>",
"    ) are favorites of gynecologic surgeons. These designs are useful in both abdominal and vaginal operations. They are particularly effective while opening and closing incisions when it is desirable to directly visualize the fascial surface. They can also be useful for lifting the abdominal wall or enhancing exposure in the pelvis. The curved tip of the blade favors the traction on tissue, but is capable of damage by digging into tissue if too much force is applied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Self retaining",
"    </span>",
"    &nbsp;&mdash;&nbsp;Self-retaining retractors facilitate continued operative exposure with fewer hands in the operative field, but can be disadvantageous if improperly used. The variations in blade size bespeak the fact that one size does not \"fit all\". Improper size of blades and poor retractor placement not only do not give the expected exposure, but can lead to serious injury to vasculature, nerves, intestines, and muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3129?source=see_link\">",
"     \"Nerve injury associated with pelvic surgery\"",
"    </a>",
"    .) Self-retaining retractors should be intermittently released during prolonged surgical procedures to avoid sustained pressure from the blades. Upper abdominal blades combined with firm packing can compress the vena cava and contribute to postoperative adynamic ileus. Bruising of the rectus muscles from self-retaining retractors can significantly contribute to postoperative discomfort. Careful selection and proper placement of the self-retaining retractor can avoid the potential problems with its use and can provide the necessary operative exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Types",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Balfour retractor can be modified with either solid or fenestrated side blades of varying sizes and with different designs of center blades (",
"    <a class=\"graphic graphic_figure graphicRef59227 \" href=\"mobipreview.htm?3/61/4055\">",
"     figure 32",
"    </a>",
"    ). The retractor bar can be either smooth or ratcheted. An extension can be added to accommodate an upper abdominal blade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The O'Sullivan-O'Connor retractor has two smaller side blades and upper and lower center blades providing a four quadrant retraction configuration (",
"    <a class=\"graphic graphic_figure graphicRef61098 \" href=\"mobipreview.htm?9/32/9729\">",
"     figure 33",
"    </a>",
"    ). This retractor has less versatility than the Balfour because the side blades are not detachable. Because it is easily placed and the upper abdominal blade can aid in keeping the bowel out of the pelvic operative site, the O'Sullivan-O'Connor is the preference of many gynecologists.",
"   </p>",
"   <p>",
"    The Franz retractor (",
"    <a class=\"graphic graphic_figure graphicRef51009 \" href=\"mobipreview.htm?13/43/14004\">",
"     figure 34",
"    </a>",
"    ) is frequently used for tubal infertility surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/16\">",
"     16",
"    </a>",
"    ]. This retractor has the advantage of easy placement in smaller incisions while providing retraction in four directions. It also has interchangeable blades of various sizes that make it useful even in overweight patients.",
"   </p>",
"   <p>",
"    The Bookwalter retractor is a favorite of gynecologic oncologists because of the versatility of the blade application (",
"    <a class=\"graphic graphic_figure graphicRef79154 \" href=\"mobipreview.htm?21/10/21670\">",
"     figure 35",
"    </a>",
"    ). The Rigby vaginal retractor (",
"    <a class=\"graphic graphic_figure graphicRef67616 \" href=\"mobipreview.htm?11/38/11872\">",
"     figure 36",
"    </a>",
"    ) and the Gelpi perineal retractor (",
"    <a class=\"graphic graphic_figure graphicRef65767 \" href=\"mobipreview.htm?11/39/11903\">",
"     figure 37",
"    </a>",
"    ) are useful for vaginal procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Specula",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Auvard weighted speculum and its modifications (",
"    <a class=\"graphic graphic_figure graphicRef58171 \" href=\"mobipreview.htm?31/4/31808\">",
"     figure 38",
"    </a>",
"    ) are essential for many types of vaginal surgery. Some models are manufactured with suction channels that may be connected to standard operating room suction equipment. The blades have also been modified to accommodate variations in vaginal size and curvature of the sacrum. The shorter-blade weighted speculum is multipurpose, but is ideal for uterine dilation and curettage, cervical conization, and other vaginal procedures. The longer-blade weighted specula, including the duck-billed variation, are most useful when a posterior colpotomy is being performed (",
"    <a class=\"graphic graphic_figure graphicRef80690 \" href=\"mobipreview.htm?1/55/1905\">",
"     figure 39",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUCTION DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many specialized suction devices have been designed for specific surgical procedures. Variations of the Yankauer tonsil suction are most commonly used by gynecologic surgeons (",
"    <a class=\"graphic graphic_figure graphicRef56478 \" href=\"mobipreview.htm?27/14/27887\">",
"     figure 40",
"    </a>",
"    ). The tips of this suction tube are rounded and therefore reasonably atraumatic. The device may be equipped with a shutoff valve or with a finger hole to control suction use. Disposable variations have been designed with irrigation capability and light attachments. The tonsil-type suction with controlled suction can be used as a retracting device and for gentle blunt dissection. The original Yankauer suction has a major disadvantage: the screw-on tip sometimes loosens and falls into the surgical would. The relatively small holes in the suction tip are capable of concentrating significant suction force that may catch and firmly hold tissue even after the negative pressure is released.",
"   </p>",
"   <p>",
"    A double lumen Poole suction (",
"    <a class=\"graphic graphic_figure graphicRef57036 \" href=\"mobipreview.htm?13/42/13984\">",
"     figure 41",
"    </a>",
"    ) is useful for evacuating blood from the deep pelvis or abdominal \"gutters\" but is not as effective as other devices for tissue retraction. The proliferation of disposable suction-irrigation devices has made the selection of these instruments one of individual preference and operating room supply.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CERVICAL DILATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three commonly used types of cervical dilators, none of which has distinct advantages over the others beyond the surgeon's personal preference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/17\">",
"     17",
"    </a>",
"    ]. The Hanks uterine dilator (",
"    <a class=\"graphic graphic_figure graphicRef50262 \" href=\"mobipreview.htm?3/36/3650\">",
"     figure 42",
"    </a>",
"    ) has a collar that theoretically will gauge and control the depth of penetration into the uterine cavity (",
"    <a class=\"graphic graphic_figure graphicRef63035 \" href=\"mobipreview.htm?0/3/60\">",
"     figure 43",
"    </a>",
"    ). Hegar dilators (",
"    <a class=\"graphic graphic_figure graphicRef74741 \" href=\"mobipreview.htm?23/30/24038\">",
"     figure 44",
"    </a>",
"    ) may come as single or double ended instruments and have a smaller curvature than the Hanks dilator. The Pratt dilator is double ended with a long midshaft (",
"    <a class=\"graphic graphic_figure graphicRef82709 \" href=\"mobipreview.htm?27/6/27746\">",
"     figure 45",
"    </a>",
"    ). Some gynecologists prefer a Wylie or Goodell type dilator (",
"    <a class=\"graphic graphic_figure graphicRef50152 \" href=\"mobipreview.htm?42/41/43666\">",
"     figure 46",
"    </a>",
"    ), but these instruments are prone to tear the cervix because their dilating force is concentrated in two directions rather than circumferentially. Safe cervical dilation is always preceded by evaluation of the direction and depth of the uterine cavity by sounding with a malleable, calibrated sound (in the nongravid, nonpuerperal uterus) (",
"    <a class=\"graphic graphic_figure graphicRef82457 \" href=\"mobipreview.htm?26/61/27605\">",
"     figure 47",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LIGATURE CARRIERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of vaginal vault prolapse by sacrospinous ligament suspension has prompted the design and modification of ligature carriers for the specific purpose of safely penetrating and retrieving a suture in this location. This procedure was originally performed using a Deschamp aneurysm needle (",
"    <a class=\"graphic graphic_figure graphicRef53873 \" href=\"mobipreview.htm?14/15/14590\">",
"     figure 48",
"    </a>",
"    ), but there can be considerable difficulty in ligature retrieval with this instrument (",
"    <a class=\"graphic graphic_figure graphicRef75298 \" href=\"mobipreview.htm?5/30/5605\">",
"     figure 49",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/9\">",
"     9",
"    </a>",
"    ]. The Miya hook and its accompanying grooved retractor further simplified the procedure. A modification of the Shutt suture punch, originally an orthopedic instrument, has been used successfully for sacrospinous ligament suspension (",
"    <a class=\"graphic graphic_figure graphicRef55346 \" href=\"mobipreview.htm?29/36/30280\">",
"     figure 50",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/18\">",
"     18",
"    </a>",
"    ]. Exposure of the sacrospinous ligament surface is critical to the successful, uncomplicated completion of this procedure. Any of the above mentioned instruments are capable of safe passage of the ligature throughout the sacrospinous ligament and use is a matter of personal preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     STAPLING DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is very little argument among gynecologists that skin closure staples are a satisfactory alternative to suturing techniques (",
"    <a class=\"graphic graphic_figure graphicRef56572 \" href=\"mobipreview.htm?0/31/503\">",
"     figure 51",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/19\">",
"     19",
"    </a>",
"    ]. The controversy continues to center around the intra-abdominal or intravaginal uses of stapling devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/20\">",
"     20",
"    </a>",
"    ]. The widespread acceptance of staples in gastrointestinal surgery has occurred because of significant time saving along with technical equality to suture techniques. Gynecologic surgeons have generally been a \"hard sell\" for most stapling devices because the time reduction is not as great and the cost-effectiveness is either marginal or unacceptable.",
"   </p>",
"   <p>",
"    The development of lactomer copolymer absorbable staples has made their use acceptable for vaginal closure because nonabsorbable sutures can cause dyspareunia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/21\">",
"     21",
"    </a>",
"    ]. Staples offer the advantage of a reduction in blood loss at the time of vaginal cuff closure and the possibility of a decrease in granulation tissue formation. However, the tight closure of the vaginal cuff resulting from stapling has the disadvantage of potentially restricting spontaneous, dependent drainage from the hysterectomy site. This same phenomenon can occur with suture closure. Placement of the staple line at the vaginal cuff requires vaginal dissection beyond the cervix to create enough surface to allow adequate tissue approximation. This can be limited by a large or abnormally configured cervix and therefore will negate the use of the stapler in many cases. Lactomer polymer staples have also been used successfully for closure of the uterine incision at the time of cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stapling devices for other aspects of hysterectomy have been used more in European countries than in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/20\">",
"     20",
"    </a>",
"    ]. Several manufacturers now produce devices that are quite satisfactory for ligation of the attachment structures of the uterus (",
"    <a class=\"graphic graphic_figure graphicRef56572 \" href=\"mobipreview.htm?0/31/503\">",
"     figure 51",
"    </a>",
"    ). These devices are technically easy to use, particularly if the pelvic anatomy is not distorted. A potentially life saving use of a stapling device in pelvic surgery has been the control of bleeding from the presacral veins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/23\">",
"     23",
"    </a>",
"    ]. The most common indications for hysterectomy in the United States are uterine leiomyoma and endometriosis, both of which are likely to be accompanied by considerable alteration in pelvic anatomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38440/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major problem with using stapling devices in the pelvis is the need to insure that the instrument can be safely positioned without encroaching on adjacent structures, such as the ureter. This may require more dissection than usual. Continued improvement in staple technology and reduction in cost are likely to increase the use of these devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SURGICAL CLIPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Titanium surgical clips may be used for hemostasis or lymph node dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LAPAROSCOPIC INSTRUMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecologic surgeons were the pioneers of minimally invasive surgery. The instrumentation, surgical technique, and complications of laparoscopic surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17334?source=see_link\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1836881\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgeons must know the applications and limitations of the instruments they regularly use. Novice surgeons usually select instruments according to the advice and habits of their surgical mentors. Personal experience modifies, and often limits, the selection of instruments eventually used by the advanced surgeon. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutting instruments for gynecologic surgery include scalpels, scissors, and instruments that use electrosurgery or other energy sources (eg, ultrasound, laser). For scalpels, the size of blade and handle chosen depend upon the task. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cutting instruments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The needle-holder's purpose is to firmly hold a curved surgical needle as it is passed through tissue, to easily release the needle, and then to easily regrasp the needle. Ideally, the needle-holder should be designed to grasp the needle firmly without flattening or bending it or damaging the suture material. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Needle-holders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical forceps serve as an extension of the surgeon's thumb and index finger and enable grasping of small structures in limited spaces. The design of all forceps is very similar, with differences limited to length, width, and type of surface that grips the tissue. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Forceps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whether hysterectomy is performed via the abdominal or vaginal route, it is necessary to control the rich vascular supply of the uterus. A variety of specialized clamps has been designed to accomplish this purpose. The ideal hysterectomy clamp should maintain a secure purchase on tissue without excessive crushing force. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hysterectomy clamps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All retractors have the same basic function of providing exposure of the surgical field. Knowledge and appropriate selection of retractors can simplify a procedure. Conversely, inadequate exposure can create difficulties in an otherwise easy operation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Retractors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three commonly used types of cervical dilators, none of which has distinct advantages over the others beyond the surgeon's personal preference. The Hanks uterine dilator (",
"      <a class=\"graphic graphic_figure graphicRef50262 \" href=\"mobipreview.htm?3/36/3650\">",
"       figure 42",
"      </a>",
"      ) has a collar that theoretically will gauge and control the depth of penetration into the uterine cavity (",
"      <a class=\"graphic graphic_figure graphicRef63035 \" href=\"mobipreview.htm?0/3/60\">",
"       figure 43",
"      </a>",
"      ). Hegar dilators (",
"      <a class=\"graphic graphic_figure graphicRef74741 \" href=\"mobipreview.htm?23/30/24038\">",
"       figure 44",
"      </a>",
"      ) may come as single or double ended instruments and have a smaller curvature than the Hanks dilator. The Pratt dilator is double ended with a long midshaft (",
"      <a class=\"graphic graphic_figure graphicRef82709 \" href=\"mobipreview.htm?27/6/27746\">",
"       figure 45",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Malt, RA. The Practice of Surgery. WB Saunders, Philadelphia, 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/2\">",
"      Hasselgren PO, Hagberg E, Malmer H, et al. One instead of two knives for surgical incision. Does it increase the risk of postoperative wound infection? Arch Surg 1984; 119:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/3\">",
"      Chen NC, Towler MA, Moody FP, et al. Mechanical performance of surgical needle holders. J Emerg Med 1991; 9 Suppl 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/4\">",
"      Stamp CV, McGregor W, Rodeheaver GT, et al. Surgical needle holder damage to sutures. Am Surg 1988; 54:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/5\">",
"      Towler MA, Chen NC, Moody FP, et al. Biomechanics of a new atraumatic surgical needle holder. J Emerg Med 1991; 9:477.",
"     </a>",
"    </li>",
"    <li>",
"     Corson, SL, Sedlacek, TV, Hoffman, JJ. Greenhill's Surgical Gynecology. 5th Ed. Year Book Medical, Chicago, 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/7\">",
"      Abidin MR, Thacker JG, Lombardi SA, et al. Needle holder damage to surgical needles. Am Surg 1989; 55:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/8\">",
"      Edlich RF, Towler MA, Rodeheaver GT, et al. Scientific basis for selecting surgical needles and needle holders for wound closure. Clin Plast Surg 1990; 17:583.",
"     </a>",
"    </li>",
"    <li>",
"     Nichols, DH. Instruments and sutures. p. 120. In Nichols DH (ed): Gynecologic and Obstetric Surgery. Mosby-Yearbook, St. Louis, 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/10\">",
"      Bernstein G. Needle holders--an instrument especially for the left-handed surgeon. J Dermatol Surg Oncol 1988; 14:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/11\">",
"      Bennett NT, Howard RJ. Quantity of blood inoculated in a needlestick injury from suture needles. J Am Coll Surg 1994; 178:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/12\">",
"      Masterson BJ, Sullivan TG, Townsend PR. Development of a noncrushing vascular clamp for pelvic surgery. Am J Obstet Gynecol 1978; 132:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/13\">",
"      Masterson, BJ. Selecting instruments for gynecologic surgery. Contemp Ob/Gyn 1978; 12:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/14\">",
"      Applegate WV. Abdominal cutaneous nerve entrapment syndrome. Surgery 1972; 71:118.",
"     </a>",
"    </li>",
"    <li>",
"     Gershenson, DM, DeCherney, AH, Curry, SL. Operative Gynecology. WB Saunders, Philadelphia, 1993.",
"    </li>",
"    <li>",
"     Hunt, RB. Atlas of Female Infertility Surgery. 2nd Ed. Mosby-Year Book, St. Louis, 1992.",
"    </li>",
"    <li>",
"     Smith, MF, Stehn, JL. Basic Surgical Instrumentation. WB Saunders, Philadelphia, 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/18\">",
"      Sharp TR. Sacrospinous suspension made easy. Obstet Gynecol 1993; 82:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/19\">",
"      Barnhill, DR, Park, RC. Latest on stapling. Contemp Ob/Gyn 1994; 39:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/20\">",
"      Beresford JM. Automatic stapling techniques in abdominal hysterectomy. Surg Clin North Am 1984; 64:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/21\">",
"      Stovall TG, Summitt RL Jr, Lipscomb GH, Ling FW. Vaginal cuff closure at abdominal hysterectomy: comparing sutures with absorbable staples. Obstet Gynecol 1991; 78:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/22\">",
"      Villeneuve MG, Khalif&eacute; S, Marcoux S, Blanchet P. Surgical staples in cesarean section: a randomized controlled trial. Am J Obstet Gynecol 1990; 163:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/23\">",
"      Hill AD, Menzies-Gow N, Darzi A. Methods of controlling presacral bleeding. J Am Coll Surg 1994; 178:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38440/abstract/24\">",
"      Wilcox LS, Koonin LM, Pokras R, et al. Hysterectomy in the United States, 1988-1990. Obstet Gynecol 1994; 83:549.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3275 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38440=[""].join("\n");
var outline_f37_34_38440=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1836881\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CUTTING INSTRUMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Scalpel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Handle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Blade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Scissors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Instruments that use an energy source",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NEEDLE-HOLDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FORCEPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Types",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HEMOSTATIC CLAMPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HYSTERECTOMY CLAMPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RETRACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hand held",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Self retaining",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Specula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUCTION DEVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CERVICAL DILATORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LIGATURE CARRIERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      STAPLING DEVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SURGICAL CLIPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LAPAROSCOPIC INSTRUMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1836881\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3275\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3275|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/39/39538\" title=\"figure 1\">",
"      Knife handles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/7/31858\" title=\"figure 2\">",
"      Scalpels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/53/36702\" title=\"figure 3\">",
"      Mayo dissecting scissors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/5/34910\" title=\"figure 4\">",
"      Metzenbaum dissecting scissors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/26/6565\" title=\"figure 5\">",
"      Jorgenson scissors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/37/40529\" title=\"figure 6\">",
"      Iris scissors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/29/2513\" title=\"figure 7\">",
"      Straight needle holder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/51/25407\" title=\"figure 8\">",
"      Heaney needle holder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/56/27535\" title=\"figure 9\">",
"      Stratte needle holder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/7/10355\" title=\"figure 10\">",
"      Locking handle needle holder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/51/41778\" title=\"figure 11\">",
"      Adson forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/54/15215\" title=\"figure 12\">",
"      Martin forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/16/271\" title=\"figure 13\">",
"      Bonney forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/0/2063\" title=\"figure 14\">",
"      Russian forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/43/27326\" title=\"figure 15\">",
"      Potts Smith forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/1/20497\" title=\"figure 16\">",
"      Adson bayonet forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/31/25072\" title=\"figure 17\">",
"      Babcock clamp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/38/610\" title=\"figure 18\">",
"      Curved and Straight Halstead mosquito forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/10/15521\" title=\"figure 19\">",
"      Kelley clamps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/48/5903\" title=\"figure 20\">",
"      Tonsil forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/57/8095\" title=\"figure 21\">",
"      Rochester Ochsner forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/39/627\" title=\"figure 22\">",
"      Mixter forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/5/40019\" title=\"figure 23\">",
"      Heaney clamp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/37/25170\" title=\"figure 24\">",
"      Modified Heaney clamp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/11/40127\" title=\"figure 25\">",
"      Ballantine clamp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/38/44655\" title=\"figure 26\">",
"      Garland hysterectomy clamp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/44/34498\" title=\"figure 27\">",
"      Heaney retractor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/62/26607\" title=\"figure 28\">",
"      Breisky Navratil retractors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/14/14560\" title=\"figure 29\">",
"      Narrow Deaver retractor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/29/17872\" title=\"figure 30\">",
"      Richardson retractor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/29/44496\" title=\"figure 31\">",
"      Eastman retractor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/61/4055\" title=\"figure 32\">",
"      Balfour retractor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/32/9729\" title=\"figure 33\">",
"      OSullivan OConnor retractor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/43/14004\" title=\"figure 34\">",
"      Franz abdominal retractor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/10/21670\" title=\"figure 35\">",
"      Bookwalter retractor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/38/11872\" title=\"figure 36\">",
"      Rigby vaginal retractor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/39/11903\" title=\"figure 37\">",
"      Gelpi retractor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/4/31808\" title=\"figure 38\">",
"      Auvard weighted speculum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/55/1905\" title=\"figure 39\">",
"      Duck bill weighted retractor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/14/27887\" title=\"figure 40\">",
"      Yankauer suction device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/42/13984\" title=\"figure 41\">",
"      Poole tip suction device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/36/3650\" title=\"figure 42\">",
"      Hanks dilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/3/60\" title=\"figure 43\">",
"      Hanks dilator in cervix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/30/24038\" title=\"figure 44\">",
"      Hegar dilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/6/27746\" title=\"figure 45\">",
"      Pratt cervical dilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/41/43666\" title=\"figure 46\">",
"      Wyliet Goodell dilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/61/27605\" title=\"figure 47\">",
"      Simpson uterine sound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/15/14590\" title=\"figure 48\">",
"      Deschamp ligature carrier",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/30/5605\" title=\"figure 49\">",
"      Deschamp carrier in use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/36/30280\" title=\"figure 50\">",
"      Shutt suture punch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/31/503\" title=\"figure 51\">",
"      Stapling devices",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/46/32490?source=related_link\">",
"      Abdominal hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33048?source=related_link\">",
"      Cervical intraepithelial neoplasia: Procedures for cervical conization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17334?source=related_link\">",
"      Overview of conventional gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37737?source=related_link\">",
"      Overview of electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10633?source=related_link\">",
"      Principles of abdominal wall closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30265?source=related_link\">",
"      Principles of abdominal wall incisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/36/35401?source=related_link\">",
"      Vaginal hysterectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_34_38441="MR normal placenta";
var content_f37_34_38441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81005%7EOBGYN%2F61154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81005%7EOBGYN%2F61154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance image of normal placental attachment (no accreta)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note homogeneity of the placental mass, no \"bulging\" of the placenta toward the bladder, and the well delineated uterine wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Resnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance image suggestive of placenta accreta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 355px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFjAcoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5atbea7uYbe2ieaeZxHHGi7mdicAADqSe1dr/AMKk8eYz/wAIxfnnHAXr+dY/w3GfiJ4WH/UVtf8A0ctffttpk7SpLNEF2jChF+VcdhxWM3PmtD8r/qh6Janw6Pg94/PTwvffjsH9af8A8Ka+IJOP+EYvP++4/wD4qvutoAowS27ruIpY4i0ihjk46Z7jNL973X3f8EOaPb8f+AfCv/Cl/iF/0LN1/wB/I/8A4qk/4U18QB18N3A+s0Q/9mr7quLZiGZCXX68DFclrkKTKyyn2GeopP2vdfc/8w5o9v6+4+QT8HPHoHPh6X/v/D/8XSj4NePicDw9JnOP+PmH/wCLr6N1S3toLGae4lCIpwAw6ds471R0ZraSdGsbhpSRlmDZH45qOatfdfc/8yXUiun4/wDAPAh8F/iAenh5ycZx9pg/+LprfBrx4pIbQgCvUG9t8j/yJX1zfXUHhnQLi51Aj7VKuI0A5xXy7c3Et9qzhTJIzSFvmOe+eSfzqm63dfc/8xucV0/H/gGVH8GPH0hIj0AuR2W8gJ/9DqVPgf8AER22p4cct6C7g/8Ai6+hvhTpd7Z+Hbm6ZF3yH92CAMe5H9a7vRRD4fje4v7kG6lBJy3C8njrTTq9Wvu/4IKcX0/r7j5CHwI+JOCf+EZlwP8Ap6g/+Lpf+FEfEndj/hGZM/8AX3b/APxyvsyDxppcMCwpNvl5L7iMDPvVqPxvoc7eW1z97j+dWnLuvu/4I+aJ8Tj4F/EY4x4bbn/p8t//AI5T/wDhQ/xKxkeGZD/292//AMcr7ks77SsNPFcxEHgc5xV62khuBv8ANEh6Yzxmmufuvu/4IXifBf8Awon4j7c/8I2QPX7bb/8AxynH4DfEkHB8MuP+3y3/APjlfe88ObXYduBz9KSOFkUMBlgOrHOKdp9193/BDQ+CB8CPiQenhtj/ANvlv/8AHKgb4KeP0Yq2hxKw4KnULUEfh5lfc97OlneqTKFLgYTGRmsDxjYJHAdRQFkAzLgZOKhuoluvu/4IXXY+Nm+Cvj1SA2iwgnpnUbXn/wAiUjfBjx2pw2jwA/8AYStf/jtfQ+pa1Fcabi1Qo0eSH2dOP8/41h6XYSXllNGqhSxbJZyWJz061DnU6Nfd/wAEz9pHsfNXivwvq/hPUIbLX7VbW5mhE6Ks0coZCzKDuRiOqsOvasSvV/2h08vXvDSndkaIn3jz/wAfNx1ryitaUnKKb3NH5BRRRWggooooAKKKKACiiigAooooAK7af4Y+J7YlbqHSrdwAWSbWrKNlyARkNMCOCOvrXE17j8UolTxff3W55FdIDt243L5EfPoRWFSclNRj1T/C3+YPRXOEPwx8Thd3l6Pt27s/25Y9PX/XdKYfht4jDFSNFDDPB12x/wDj1dHPfma3iS0tyqoQ5JI3t/h/n8aMkS3E7QQK88S5bdGDkMefTt0p3n3X3f8ABI5/IzYvhh4nmYrFHo7kLvIXXLE4X1/13T3qtL8P9biYrLNoCMOobX7AH/0dWo1xJp8DLIhinyfnDFWYEdx6Vz99ctcS7ixP1PWmnU7r7v8Aglx95lj/AIQbVv8An78O/wDhQ6f/APH6P+EH1Y/8vfh3/wAKHT//AI9Wdmiq97v/AF95pyI2bT4ceIbzP2M6JcYO0+Vrti/J6DiatSP4LePJRmLR7dx/s6naH/2rXVfDDw5afZYr+8lZbi4YxwoF3bR3Y+nfntivo3QEt9ItFtZJEEZ/jZdzH6n61nzTvuvu/wCCY86vY+SW+C3jxULnRoAgGSf7StcY/wC/tUT8LPFYjeQ22mBEzub+2LPAx1z+9r2P4seN3iL6VpkqmeTiQRj5V/GvHFiCXKRFVnRTmTrjd3/wpc1R9V93/BHzIfF8KPF0yB4bPT5EIyGTV7NgR7Yl5o/4VP4v2B/sVhtIzn+1rPH/AKNq3qM5jkjWABAygGNTwOMYOO9Nhs7hLQ3hgzbr8o2/MMHg/lzzQ/a9Gvuf+Yc67EDfCTxkoUtp9kA3TOq2nP8A5Fpo+E/jAttFhYlvQaraZ/8ARtXVsp5p0QFpYlw0HG4gf5/lUlx4cv4XV5oz05brtHqcc9+KTdb+Zfc/8w54lL/hUHjb/oF23/gytf8A45S/8Kf8b9tJtz9NRtT/AO1KtWMs+mOybjEOQVP9fSp7a8+1XrrAGW3kADxlQQSP/wBVF63dfc/8w549vx/4BnH4PeON23+yId3oNQtv/jlH/Cn/ABxux/ZEOeuP7Qtv/jldbca3CZLbyGWJFzGyCLJYHoMH8q6D+zrG+tPPktH3xssiPHkh+Pu+v+RScqyV7r7n/mL2ke34/wDAPNP+FN+O9m4aIpX1F9bn/wBqU1fg945Y4GioSO3223/+OV71oM11HbGHKKACJfmXIB+79cDFeL2j2mneLbmN2xI07ZkbGADn14780c1Z9V9z/wAxqcWtn/XyOP8AFngzX/CSWjeILD7It2XEJ86OTfs27vuMcY3L19a52vXPjPfQX/hbwy9vIsgjvb+Nio4DCO0JAPfrXkdbUnJxvLcd09jpPhrx8RvCv/YVtf8A0ctfo+JTtIyd54C4xj8a/OH4acfEbwr/ANhW0/8ARy19x+B/HqeILXy5WxOCVbgBww6gj8KOZKdgvZHamUhyJPXqTT9iOVLAq+OUHXPSqMd5cBP3fKjrlcHNTRm5MbGUkZHUAcVYrkOovJaQPJ0POAK8Y8Qa9uv55GLIIyd4IJya6T4j68NPxaws245UEN65rwLV77UI38pZ5CzH5ww3D8MnP/6zWM23ojOT6Gx4k16+vz5YV/LDbRgYI6Zrvfhraado2nHWNSaOOOJNxJ6bq8u0eYpIryOokBy4cAA9unX1ra17XNSvdOMcBjFonCRiMNyMfnUvQhPUz/iL4suPFerPJHKI4EOECsMIB64zn/61M+H/AIfm1bWUgiRHQMDLNn7o/L0Bqjo+gXOoXqxSx/f5IVdob1Pp0r0+G503wjpD2ttGounBMjbs84+vp6U7j33NPx54iTQbm3t9KdDFAAJFLYDHjp/ntXm+p+NtT1GYxrPhHUkhRgrn88jr6dqZqFxFeyM7xyhn4Jds5x/9b+XSqF1fW1mxaKGOEkY3E5JPA/KnuK9xG1JgWNxJJjrIQxzimxNNHGrKbgEDMZAzx3yfUc1Tk1V9h8ryhGckErv3cf8A6qqPf3MpLT3ZMZ7JwT+HbpQKxtDWNSHlGOW4/djGN3P/ANf/AOtXV6R8S9S0sRwXBYKc87un415nNNNHl4pZERWJJC5J9yadDdiVMBm39CzdvX8KLW1GfQOj/EyfUYFtiVdvv5DdcdR/n1r03S/FEc9h5rRnO3AA/r6V8ZR30lrKjWk22Uc7lPAPtXp3gbxJrGs3MenbwiqCplHBP/6/8aabRak0ejjWhea+7S3EaFW5j3Dn6ZrY1DXLePTbiK7uI0gZCGLPxjHvXF638L0uybq1vbmC5Y5L72bP4E+vpiqumfCdrh92t6nd3kSHPktK2w/hmjXYLs42z1ezi+2S2V3J9lilbyy4ySefuk9en86f4V8UyaZdTTX1g0VlMNy3XlYGfT/PpXqp8B6PGsPmQRxwRjIBJwfrW1JoWk3enfZjDby2nACAZXP+OaSiLlZ8oftF3kWoeIvDl3bnMU2io6n1BuLjBryavZv2prO20/xtodpYqFtotGjVFHOB589eM1VFWgrm7CiiitRBRRRQAUUUUAFFFFABRRRQAV7R8SdSa0+JOsojqMeRww3A/uIxjmvF69M+MzZ+JOsEdf3HT/rhHXLU1rwXlL84mijzQa9P1KqmSecbchpTzGDwCO9X5MGWQW7AIVwSoPU+vuefaua07VDFtE5ZtnTHXHpXTxOs1mdRhdFErFBByGfp8wA/Lt2rVqxzSi09TnfFEmb5UV3YKig7zk8AViZqzqM/2i8kkwRk4warVaVkdMFZBTl6jNNFSRRvK4WNSzHsKCmeyeAPEy6Xp7N9nhMaKnCAKQe5J5/pU/jL4nSJBJDYW/lzugUZbdt9SfevKZJry10xoGcCCRgduRy3r61SRS7BpX3NngE9ajk1OWMepp2cF9qE5b95LJJkl8ZI9a24NJm0zTmkv5FSJ+m05Y5Hp/n+VXbK8bw5pqSIVS4lO5W+8dvQ/hWFqOqS38cks85nkfHXjHtgUO70FdyOt8AeGzq2ptd3CiaGMfKFAA/GvRx4at7WLzY4JI2QsdpclGyOQR0I6Vh/s/H7V9phl5HqDtKj8Otez3unG0VcYa2K4XjrSauK1zyay8MQIiSxWsaMAcAryuSeSc1ftPD0q2tzFO5eEnhScMPq3XH+ea9IjtYvLJiThs4X+6fc+lOOlpKirsUIVz94/MfyqeUfKeJ3vhdYr9LZ4Va2Zuc5PA9+n4mua8UaOdPeU2IVYjgBdg3DvjNe8eJNMjFoXKtGpGMk53Y64rzfxB/o1pLMx2QHOcjcSuO/HXP6VLbQrWPLYWmgKTo6mWQbgrfdwPX368VoW3jy40i4nMcMdyrgAxS52q3qB2rMl3w3UggbFuzbkUndnpyPes642M7eeQX3YA74rTcaS6mg3jnWPKYQrFEzEkOic81zMsNwsu58mRuSc561rQRxxA7ypf8AhXg4q3eecJcXBTeANpXGB+IqtFsWpKOyM7xErp8PNCEmd39r6j19PIsf/r1xtd741ZG8BeHtg/5ieobiOhPk2X/1q4KnTd4/f+ZW50nw1OPiN4VOcf8AE1tef+2y16T4W1u70jUY57Ob5WbLer+/tXm3w1GfiL4VHrqtr/6OWuvtxHLDG8GI0OTjGD7Cs5/xPkKfwn1l4C8Z6br+niPzI1mQAkMeT9fyNdss0QtxITGIACchutfGGi39xpVyl3EyLISDu3/eGen0x/KvoD4deLtP8QRusmFvEh+5tIjHHUetUp9CIyPPPG3iOLV/EFzFC+1fN8tDgg9TnqP85riteEcc8cbZlbYcM/06n6cener1hp41Txc9tfy+ajXLvMIzyvJ6E/Sqfilsa9cooSGKNhHFuOSccVmu5m9x2iW4nXISRgx2KjEkYz9OetemWfhS4NrBGwK8/wAZA+U9geBXIfDbTru5vZtRjgja3sBul81sKT16H6D9K1b34m/aNVF07mSYLsihHESD1PHJ6UOw15nU669h4Q04hVE11KOFbkLwP/rV49NfSXl4z4bzJDzuGCasatqsur3xmYv5qkEnaQp9f6d6iltgUdrkeau3LEMAAT6fh2z6fSjYTdzO1m9ZAYZgSW4yRkEZ9aoRJGCDHsfC4Yk/MKZegxO0eQ0bnITAO32I71nwTPHMxG0qQd2efertYaWhplHVG5xz8vPT8/w5+tMgLxTgxuEkX+NTz9KtOYwkcrldxHBOSPy96rXjow2MVU59sr7+mOaAJJLrzZAJJCj46AcY684qjKwZw5Z/u/Kobp+XepFtsoWldSn99uc/4U5wLeBi/wAkmMhQ3yn3B65oQEsFynIG4MRjJUmug8Jak9lq42yu8Z7MACOew/HtXJpIA8bDBycfMN1aujMpvYhgjP3U4IH9aHsJn1NoGorfacu8lVAA3Dv+NYvjrxrF4Qs2KOk1/cKVhTsPf1x0qXwDNJdWsCuyvAEyHXvivnn4m6tcy+Or9rlyYo5WjiAHCjPp60XvsaXui/Lr/iidbtGLSxXGXcKPujrwPx7f41Z8H+MNW8KuHtoA0W8maJiRuB68E9eldb8PVtr2wzbToJkAzF1BznnntXR+LPA8fiHSYxbrFa6gjcSqOPofrSRCu9TxD9pvUYtX8W+H9QtwwiudEikUMMHBmn7V49Xq/wC0Pp02ka74Y0+7YNPb6FEjkdz58/NeUVVH4Fc6GFFFFaiCiiigAooooAKKKKACiiigAr0741Ef8LM1jA4Ig/8AREdeY16b8aufiZrPT/lh0/64R1y1P94h6S/OJtT+F/L9Thx1rpvC2r/Z5ZItiC9nKol5IxJgQckKOmT0/TvXNUZwcjiuhilFSVia8dpLuZnbcxc5bGM81CwwcUpDfeOeeh9aCPXrjNA0Fa5XUNEt13w+R9sjDpIfvFc9vT/9VZtoP9Ij+TecjC+vtVzVbq51C8Xz3MkijYqjoo9BSIk7uzGCWIxSSyySSXbHg9sVY0PSbzWL0Q2Me6ReWJOAB6nNMsNIubu4MaISV+/jqPw6n8K928HwWljotpHYRmFyhMsgBznHVu+f85pSlymU5qOkTndI+GQe2e61a/eScKCoh5x+hz+lQ6p4CtrW3uZrOWSTyV3HzSN0hHUdABXoumyXNrfSowE0O0/NkLkdsYPPOewqxqet6dpcCw3Fs8s90PKgjU53M5/Tk96y5mzO55P8NfEsPhbxXHPcSNDBMBDK2c4B6H/69fXukyJqdmhsnhaAp94cnn19DXy78RfA9zo0kBjs2aaUbvk5CY7D0/GtT4WeP9T8GI1tqMJnsjzv3bnQdxj0q1JDTs9T3y7tYreRoyu0jJYb+tVo5Ukgb7OOF6bic/Ue1S6N4p0XxTEJ7SWPzNhO0nHPv+VVr65RNjMGRTyCPWjTdFszG/eZF6yEjJjRv4a818ZOt1eyQzohgft6genbP5V3GuXNwyb9KkTnhy4JwPYetcW+nZZ7Fklmjc7pOQWGT06cColroRLY871rSpAsVwQUt4iVhi4LlR047D61xmrwCC7M0gBBwccH+VfQ114UkmmF4rkkJhcA7SPQ4NeM+M7SK11edplAKDAh24HHGePzqo6MSOULxyvnGzHIzxn2qbUJEtrJQCPNfpg9BVRpmkcKseATT9XHmRq/GV+U1oaJaq4uu8/DrQ2JJJ1jUf8A0RY1yFdfrv8AyTjQv+wxqP8A6Isa5CnDY0ludL8Mv+SkeFP+wtaf+jkrttNgSeJUjXaVzhguCMdiOorivhj/AMlJ8J/9ha0/9HJXdWEP75IQ5WH7+5OWAPT8Kyn8fyM6nwlR0MU4imUpJyjNjKj0PH41oaVqk+i3sc9tKI51+X5QfmQ4H+ePX3qK4SKWczOBtHypjOSPXP5frUbxw+TKkZcSMuBuHAHtnt+lBieg6ZatpPiC3uxuZLmNpflGAG6nJ9/p/wDW468uWn1Ke5dDHJNI2xhhlx0J5+p7V0dprMf9g27zqJWt41jQ52hc8df89q4DXNUlhmubWL5ZZPlk45UZ6CktWCVy82p6hq9uND0dpPsTS42wgqZmPHze314q/ceHU0mX7HdS+ZqG0NIg5VfQEkd/w7V12lzDwD4QtPLhKarfLuLP/wAs8jqR1AGR+tchaBXummllZ5mLOxIxknvn1o06DbILwsrvbp5aE4YjDYHpxj6e9WNHlCXP2aPk4LbVUbCe+VPXiopM3Eksu0fM3y/Lgn8up961AJLWwtokRY3kG5iSevv6daGSZmswLyUhRbjdksDgjv0+mPzrMjtt4YzbfqoB/WtzxBHdJBG6oBP90pxkjOAeegrGuojJh0JEQ4Yd859M8009BopTH7MwG8uvQqTjv2p8LKAjeauBk7ivI9j+tU3jVrlg4baDwDwKsHYRs+6+Tt2g8fjVDJZbph+8UcntyBj/ADxVe4fznwQFGDySTmrM8u6FCGUkcc4PP5024Mi2C+Y2ZpOw/hX/ADzSTAqK75VshcdccAjNa1hdyBwlvtBJAyTjJ7AZ+nrUNlEsdt877hgnGMK3T+VX7OYIylIwsg4yeD9PQ9xQwPfvhlZumnq8jsuAepztFcL8YfCIu743n2fZKx++g++ScY/z/wDrb4W8fro8Yt2tpLiRQWeeQ8Dp0zXrXhLUm8R6cl5cIY43XzPmHQYzSXYa2seG6B4V1fS4bSSNTaI0gIlc5JHHb9Pxr33Q5vPgjhhmDPGo3vtz+VeDfFTxVf8AiHWW0zSWK6Tp8hDjdgyEZHPcgYP866D4JJqeueImupbmRdLgTAQLjLZFC8g2Z57+1x/yUbSwcgjSIuvX/XTV4hXun7YOf+Fl6ZkYP9kRcf8AbaavC6ul8P3/AJm7CiiitBBRRRQAUUUUAFFFFABRRRQAV6b8aTn4l6ycf88Mf9+I68yr0741KR8TNZBBz+56/wDXCOuWp/vEPSX5xNqfwv5fqcPQKMGjtXQMl8+RoEgZiYkYsq+hOM/yFNJ3uSB1NJtPp2zQOlArdjo/Aen/AG/xFHwvlwI0pLHAGBwfzxWhcS2elz3VrpRF5fXI+e6cD90M5Ozjg+ppng3T55NOurjZKYHby9sbEGQjkjjtjn0/lTJ7OG1sY9Ruf3plP7oBvvH1wBwB+tQ3qc0neTPTvgr4b026g/tASKdRR9vzOG2992CePT869CvNKjeK6uAZbTLf65SAPqOeleNeDNBu9UQ3OlXc9jK5G9Ldvlyfxx07V6KfDfiWDT45b3UZdSkUfu4ZMeWig/xDPJ9zUO5noasS29tKdw3XBwCIVLMwHfpjHtWjr+gWGs2VtczvNYS27B0kTG8kexBx61X02wv7VXbU/nckEFduACB2HQdab4tne30iYum1HGCzfwZHDYHviktEV0Oz8KRp4j0u6SWVLlsBYpG5GB3461wHxA+GEunWUr6ajyQMcugJwTn9O/0ql8Inu/D2vXc1tdNPbXRXzEZTt4zux6da9tj8c+GLnVG0mPV7abUgButowzsp9wOnb/Jq9GrMqKUkfJtz/aPhu7Se3U2XmEssTMFY46g4xn/PQ11dl47nmsRDfSCYxgAyRIcrz9OvSvoDWn8MNetHerGLjgDMDFVJ6HIGK5q08LeHLuVZreWN0ic5C25wB37UnEXK0cTpFxPqN2iMJWtlUNG20AknqPWuy0DQA+pXV/8AZ3ZBgNwN0mB6+grtdB0vRgRLYmKUoCuE7fhW4lrEsLRKq7G6gcZz/n9KqMOpSh3PNNTvra1tpIYY48MMvIBnBrwH4rafDJJZSwuxkmQkBgQWAx6/XvzX0B43NvoyPLcxyfZbcFkjRQd2B1xXzf4ovoNVjmu4YJjdO+0bzkoOuR2xz/Koe4nucTbLYwRzG7u3MwH7uGFc5PozHp36Zo1Iwyx7oNwfoIeT+NUL6I2VwU8tlcYOX61JF5gRpZN5kzkk1rbqVa2qJNeUr8OtDDDB/tjUeP8AthY1x9dx4si8v4feHWAx5up6g/X/AKZWY/pXD04bDvfU6b4Yf8lK8J/9he0/9HJXpV8j2/hnS9XgkWQu/kugA+Xg8ZrzX4Y8fErwn/2F7T/0cleueFo4b34XFd0aMrnDtHkA/wCOPxFY1PjJnsjHtvJnSRvMiUqCRvBJz3wRUUnkPdQo0m4k5YxAk/TnA/wrGnM2myxmZl2H5sc/Nz3HbpV2zlEn70MxYDCIG4/KnbQxsdLqtukKBbZGSPlgFYYPJPTOT0P5msb4beGJfFHjk/bV/wBGt28+4DdMDkLz2r0b4MeHW1/XbyQsy21uhIODlZT9RnirnxM0m8+HnhhYLCdP7S1m6K3F4gCyMmM8fhx/nNJXKitDgfHGorqnia9kjkDwxnyYvRdpxx685/ziqcczNbJHDChzwHj+979evQZ7/pVVIogY4Yj5jD5QEzknnnPepPtcNu0iyfuRGvzDfuZumBjpnr1o6EstWkEDHy5RKpRSWUZyuM9QPpU8sjFzKpKgjLB23ZGB1GAfWqWjwJJaG4vWuBNJkIoc/KOmSP5VoopN4PKgLRHkkFsR+vHrSJe5DJKohke6EsjEYSFOo5GDj0rk72drVdk+A7tkhsg//Xrs9XubWygZZAioThmbIJ9O3PT16/rRhS3uWju5Vw/RJOCQOxAI9Mdaa0Vxp2MO3sLg2/nSRqEyApx2/wA4qUWkm5iLaUJg7SpwPzJ966K5jEc3Dbt3QttOe/4f561GbUGSRpRFmNTk7jgn0HP6CmmFzmLkSwxgSROsfXOMk/jUU1wJHBXB2jAyc4FdFcwQ3EKxyBpOOBHn5uMcZ7HHB/xqtNp9sYyn2baoGNofPP1Ofb8uKNBpmOstuyAHzBg/cU9eDWpeSRRW6xxu3I+VVXIBrBuY2tyXKzAHoWyCKtW0pa0kBkZTnO/knt/n8adh2NvSLe3eS1tfnubmZv3iHgAZH+NfTOoX0Wg+FGaC3JZYcJEnAzjufauJ+CXgPS10yHVrlpLnUZAeZGx5Y6YFd3qi2+rTHSobfz7c/JO5faFU8HHr+lHQqK6ngXhrSL7xfrk9vbywmEPuuJY4x/e+7k+/evonQLCx8LaLcSyKEtbdN0zNwDjsPzq1oehWHh/TxZ6PCkSNwNo5J9Se9eWfGDVpNaLeH7K/jt9IsQHvZSOJX6hMnr2P4UW5UCSWrPFP2k9UfW/FOganIrIbrRklCt1VTcT7QffGK8jr0747FzqHhLzEMbf2DECh6r+/n4rzGnQ/hq5tLcKKKK1EFFFFABRRRQAUUUUAFFFFABXqHxrXHxI1Y7s58noOOII68vr1L42kn4k6rliRiHAPb9xHXNP+PH0l+cTWHwv5fqcHS0UVuULUqwSGZYlRjI2AFA5ya0vCektrevWtim752ydoycDk/wD669H8J6Jp6+N5tV1+9gtdPt2P+tyNzY+VeOOn9KTlYynU5XYwLjV4LbS7XRNOhV5ITunvowCS3OVX/wDXXU+E9L0/XLhtU8Q3lraadYItvFayusYkxjLN2HOOnX8KwdR0z7LqUMdvZySWN7cCcW8IUHYT0GeRnp6Vf/4Re71bxeif2Qtrpn8SRFT5cQOSGPQnA6jNZXW5z6HaWPjvw1pV0bTw5Z3N7cKxxHYW3mYA7qWIDfUV2dneanqs9rdXl09isoOLCfAkA55YKSFznvVOw0PT7G+iXw7p7Rae0ax3Cqo49yTySe9aEuoQ2e+yh0+SdYm3y3Oz93/us3UnA96WgbbF3VZtK0p7e6vruTKDmNBkH06dfrWPc6vpWszM0vmPYSLuZUQs3ToVPeuT8S6dL4lvo765l+1Q5MlusSHyol6ADnk8Zyc/SprPw9dPpz2xkkhmmTy7eZ84XIIzweMe/NJsL6hrWrWWhQzppc4llvl8uGJZN8oz32D7uPr1rvvBWlJoGnnUrqBIJbpRJI8iAOR2APc/jXnXwi8PxaTaz/aJYLieaaTdNG2CI1ODjIyQSMn8K9F1NE1gGMulxbptBDjjI5GPfIqttRpE1iy373GrTHz7tj5aQkthV6A89z9K04L3ypY7RbeOMOedrcHuc1nWsL+SftEqjYpIwDjj1OOtR/2is062zkKVbdvBznjpgdPxppjK3i+DU0aJdDkfT5AczXsZXcVHQc9fxrptE8TX8FhBvI1CHaQZ3wkrHjDEdP7w98jpisaSZpLhYQ0jjGSUjJGMdCQcVq28G51SCHMBUZTPAH+fWhb6Du7k3iHVNM8T6LNGrpFPtI2swyw9jXzD4ikXS5mRkvLWPeWMIQDfg8fhgmvafGOk22k2rXWm26iVTvwDgsc84AOCcZH414v8TbmzvblruK5ERu0y1qQS8Tr1BPY+3ele7E9Xqef6vqD6pdmb7OsY+6AnP/6609Es0mmitJRLukzu2ruI/CnaJcxShLWG0RoSQXbA3Fvr2Feo3V5oXg2xgbSmtZtfuFPmSBhIbc47L0HXv+vSrbsrIJP7KPPPizHDb+FPDlrbhRHb3t7Hx1z5NmTn0PNeW13/AI7eSbwhpE80jSyzaxqMjyMoG9jDZZPHHX0rgKdL4fv/ADNFsdP8Ls/8LL8JY6/2vaf+jkr1v4cor+FIrMRsfPjLDDEA9OnpXknww/5KV4SyCR/a9pwP+uyV754N04WVhbFyEKIAjBc/hnvyetZ1H71iKmyOI8b6Dqb26BIC/wBmTLuOOPxPWsTwRDJcLdBVJaJeobBzn/PSvZdWPnWsqSRDyyp3b2xk49cde1cx+z/pA1LX9atXRSu4fKR15NCbasQtrHvfwq0yPw74ahadiHuF8yRivfrXhvxd8SyeJfiFcwIpFpYLtibnuBknjj/61fU01kiaRJFFGm8RYXjHOMV8T6u10nifV4rzJdblt6kj5lzxjv6VUtLItrljZDLVT5rNv8tSuFRcgk+vGD39q1bWERQtH5R4GSQVbJ+vX/8AVWNp9s9v5wuWy0hwgxkIK2gka7GCpIUyODnb/wDX71LMWWF3PMM8KxIHlnGe559+D/nidX8ogEgkHAwN+AM+9RA7lLMTuQH7nO7pjnt1P609mK7JQ8jAMcKQTjjt+Hr/AIVJJBcfZ79UjmjjSHeWKdW69fb/AD2p8m6LHlZG9RsVk6YJHU8D8+9TTbUXbbxqF+9ubByRjv36Y/CoJQzS5YuRImCV6L1x1/pQ2MS6UZCEBXKhTtBIPPp6cimGNJElLSIj9TjJYdOx+nf2qcBoowRgYYqSCvHr1HGMe9QgERADeQeCGlyxI9f1/X609xFWfESE5CFjg7hgkY7c1XK+e6FFwB1IIBP4/n71dkU5JEZJx9wgYHVh+oziqrBxLty8jqfmzlQc/p/+uheZRXlj+0jy3hIVgcbkx6nH8/0pnhnSryeRrOyiy10/lLJKw2xju2O9SGKRpI8tll4AzjP9en411Xwn8Kyat4xtpLSWZ7eBy88hJ2rweB+VNbWGj3bwZpVnpOgLoumXjXMkKgXE5XaAcc4rcttKtrZkMQPmJyZOzdqu2/khnFkkaQxHDddxPqag1G/jgtHkhDO3bJ4J/wAK12WptaxynxK8WRaBpjWFl5l3rV8DHFb2w3OexIPYcjk14VD4fil122svEc95aLuLtZwZeQscjLtggE5r1PX7+HRYpb57i3Gt3W7bkDCr6An6/j7VneEYLRJZdb1jbJcvySzZwMdv896zu2zOTvoeIftKWUem+KPDtnCrrHDokSqHbcwHnz4ya8ir1/8AaYvI9Q8W6FeQDEU+jRyICMcGefFeQVVH4FY3YUUUVqIKKKKACiiigAooooAKKKKACvUvjUD/AMLM1lS2FBh756wR15bXrHxhXHxK1oqGUHyP4un7iOuaf8ePpL84mkXaD+X6nCJAzRlx26io1XJx0q9bYZzE74B9Fzk+9M0yFbi8ETOAGBGemePetyVN6nXfD0T6Rb3ermNgsyG1hDKQHyRuYNjjGMZpnirW3v8ATZrG43K0VwrxdNuACPz5rqPDGnxr4UMLSyTwMrTSo65WNgSAB3B4Pt+dcx4wjtpdC065jMn2mR23K6qPlHHY59PzrK95GCfNO5qeFr6aDw/earNm61AKtnaBz84J5+TuTjPvXtPw0jvrLwdaS6xZGC5uGKqs3+sbnqVxxWPY6ZpPhDwxa6hOd89vbBgxXdhyMcD1JrZ1nXpdE0q21bU7YskioFt1ALK7f1yTSb1uJW3Ga3rM+ny3mlJl5eC3JXap6HPf0+oqroUUt9Aqo7tG4yu3lcd8kcevFVtL1ePWLo3kdjcQ3F5/rC44O3gAc+g/WuxsQJ40lhURInUY547e9JbhvqFxp6pYxpCQzhgApAyXrkPGemPcMLW6vJnuJ5FYJHuIULjpjoB0962L3WBaiS7uAoEAJUKCenXgcVW8MXFz4hht9aNuVaXLR7jnauePzx70aMb7GnpmlrLNbS5KyR2xRkjBxjjk9u3atyGwawCRD9+hBZc8BWx3PrUNrBPBqpZmRgE5CnOfbnpWjc/vuI5WVoyGO1c8+lUkkNIqBzNaKZ5Y1EK4znAGOuf8ayJJraO5WHgB33qob75x0HtWrcSW9refY57iOOecM8Sbhukx97ap64yOlUtNtY7jUZL4AARZVQ38PHpQwLunuYLYF4uZXJJX0zwMVd1G6eK2QQbllbGducj6isqC6S7luIYM7opQrNgdfb60+8nCNI53Nv4GTgr+HagDL127tBDJJeTxQ2oUnd0VR/eOfevlnxVdpfa3MYLjzoC52vgqD74PSvoXX9O/tSzltLpiUkTHykjkc9P6/SvAPEukW9hr7WFjKZQmCzE5x7Z9cUQet2VFq5tWOqyDQk0fTtLh3LlpLw/MzjOTtGOPrk1nz2ybTKH2sFA+c5LZ9h/Wpbi9EDRWlv5qPtwXi+UD29+Kc8aRaeqSMygNwpH+sP17AdaZBm+NAB4H0EAj/kJ3+QBjB8myrg67nxexPgPQuc41XUOfU+TZVw1XT+H7/wAzVHT/AAv4+JfhLHX+17T/ANHJX1JYRCKRUbcQn909B2H5V8t/DD/kpfhL/sL2n/o5K+krbUUc+fDcIxkO0YHygex/rWVX4yZ7I1dW0sXEbiLLSFcgCuN+DKXWj/EuW33KGlYrIMjnHP8An616RpTGdPL2qyAZLDuTXFsq6J8ULO4ChdzhThepNJaambPpDVCzQrEmSznqO1fInxEs30/x/qwlxK8uJFz0HAHrzX1rrYl/sq+a3ZRN5DbGb+E4/wDrV8k65qtnbXU1rqF1bSsdzTXFuGMrSZ+73K496uo9UXU2MS0Ty1y7MznnzQMAjnp7f4Vo20qhhtDeY/GwnDA9+fw+nauXt50lvFuCHIHChW+T24weevrW9aaragnbcqCclvMJ6/j9MZqGtDFo1RLFJHv3bMfMC4yWHsAOeq/QmkmlG/yoD5pYdCOB+PU/596prqEYwwkg3Zx13BhjsBwCOadbSv8AbGDTRSYBICupYD8/rSQglkW3nRJ3dYlbIKp83XAwMZxirklr5sIlSV8N8w+UbiAO6n+nNVZ1ilZYZESQ7sqQT17+3p3p6zJC7QxBYiVy2GICk+w68k0adAJU2lGQXEqjbuyEwwJ74OTUM0sqwyeZIChO1CowSPftj/P1sOySQbArXD45HIPT3H0HTv8AhWRNcxwwHayRgA9VbqM84xj1poCWedQxt2MRYg7n3E9+o9uaGjzlvL80Ywdqg459TyOn61WmuVS1iN3LmIDeCDtb9B6EVj3Wr+cfLeMMh4BJwf8AJppajSOt8MaLd+KNWj0vQlWW4JBuJsHbbpnufXjp+tfVfgrwzYeFdHXTtPjwy/NI+D87dckmuO+AV7bXXgWBbDSrexG8hxBn94QSCxPXsOppfEXi9pPiMmjWV45t7GHzZ4kj+QMeAGbv9KtWjqbRtFXO/v44hbskjx5Y7ti8ZH+e9cnrs+yzdklxGqlVjH8Z/wDrVbhnt7uZb1Vj+0SHaJM4OB25rj/HmpRaVIxYs0gUsqIM45/z+tEmDZ5X8QL+JpjbPKrXLnDDyyTg9vT0/KuX1TV57i3TT7UOIEB3DzMBjnrx05qvrN1Le6hPLLEcu5567fTNXNG0S51uSIRQ5t4xuZj8hDdffjgiosZHL/GsfvfBf3cf8I7Bjb0/109ebV6r+0LGkWueGYoyCqaHEnBz0nnFeVVdD+GjpYUUUVqIKKKKACiiigAooooAKKKKACvXPjAiL8S9W6kEQHHYfuI68jr1P41EL8TdZxknMPBPT9xHXNP+PH0l+cTRK8H8v1OWePIOz75PyhRVK3Zo5kZfvA8VetrtUURvFGTjAfGD+dU5wnnv5ZJTPBNboiHVM9Jiu7ie2tIxGFvpSdiQgoN2OOvXg9jn86u678PtYn0PT7qwCXN7NJ5cttHwU6kOCeg4Gc9zUPh+GVrTw3NHMskbXAQLEvzKcD5S/c9sH0r6A8NfCaO9kOp+JdW1i4aWARJZmQQhI+PlfZy3T16HmsUm3oYRTvoeZeOvFulWmgmxtPKubuCRY2kTlY5Bzu69iPzrjfFHjiLxJa2iyrLbLaAMig7/ADpenPoADmvrWT4eeE2sWsxoGnJbMcsiQqu4+p457V574y+AWjXsHmeF55tJuY28xYwdyMfx5X6iq5Wty+QzvCNklx4ftoWAjvWtxKCeqMR06Y796zrqw1/SdHGoJqkLqZGyGxtAGVZTjuCD6YPFW9N0vx34eiOm6r4fn1iBG+S+tZFdnHbcCQePX2qHxjrfiHVtI+xaf4S1yRAhiEj2L7RngHkc/WoaJUdLM8Z8YeONQ8RSR2L+XFEpKHavPXsfyr6A0C4GleELZoJCVgtk8wFNpYqvYdzXy/NpGr6DfJNfaXeW3lMHBuLZ0HB/2gK7+D4rXs2qwQvDb/YTtXAQ7s8DPXH6VTXYpq2x6d4P8RX13cmfVdHvIhLgw7l4YZ4GfWu+1G3SG9to9hhnmXfGh5AAx1x6VzGna1extH9nigCKMsjnPJ79RXNfEfx3Y2UMQkaRLjJKeWrYLD+EnpipTEj0HUkSa6lY28bXCoY1k2cgHGQD1wcAnp0HpTbSEPaysJBuVfmUHABH9a5eDxhp194Ytbp9Qs1cw8gTLgSHAI9c9qp3Xi3QLRNMs49XiuNVk27V37Y2Y9N7/dH0yM9s072Dcl0KQr4r1a0MpbcqzgJx2wSe3px7Gr2oTJFbeZczqE6/MQMe3tXAWXhH4leJfFlzqtjbxafbzOV+1GQLA6qcAqpJLA4645r0rTPgRp0wSXxbrOpazNg+ZCsnkQE5PRV+Ydf73P6VSi2gUWeM+M/iDHdWw03w4JJLyY7fOGNqqew9T79q4KHThZGVnkMtwCVkKDdg555/rXufxh+GmjeFbPSm8Lp9ijv7r7JNHLKzjBUkNliTkY9cda8b1j7ZpOjjbbx7I5vLFyxBy3XK889OopLTRDaadkV4LO8ub2OCwikleZ9gUJ/F+VP8R6bNZTXMFwM3Frhbh2OBk9FUVtWeuQ6f4Pk/s8TjXrtsSXWDgKc5YH+92GK57WbNIYYgss8yohaZnP3n7k/iaa3JRl+KCx8BaGWI/wCQrf4HoPIsq4uu08TsW8A6GSc/8TbUOnT/AFFjXF1dPb7zU6f4X/8AJS/CXX/kL2nT/rslezsskcdtKE3rwcqdoHHce9eM/C44+JnhIntq9p/6OSvpq/02za1j+4rRjh0XBHHNY1fi+RFRaCeGdVX7SoSSMMw53d8c4469c/jU/jGxS+vLa7j8svCyybtxycEHFefxRl9etra3eTbITuIY8jP1689a6+T7TCHsfPaa3Vd25uXGeg44/wD1D61PQyT6Hp/xU8SXOj/DZ7yxbE80QTKttxkAHH518aySFizBw5ySXPBbP86+mZy/if4c3GlyNmWNf3axsScDkbs/TkV813du9tcy20gIZGKc9RjitL3Zo3cFXdCd3GwDjPUnvx+P5VErlSCu3PXK9RTlkIjIw3Ptk0yMFRgrweuehpiJCQAGJxzjGe/0oeQM5P3j7D/PpUjYTPC7yMnHJFIBvYcncRz7Gi4iaHVLyJVUOWjX+FuQO/Sp4dbuI2Y4UtnPzc59OPSs6VMMOCCRximgAHCj5j1JPGTRYLI2X1u8lhdHlBixnAGAP881ktezyMWeZsjGMGmqwEbeYMovQ7u9NkcFs7mOe2aYJEskm6bLlgvbB6Hr61G+eqqWOMc8GmOpIHoD616V8GvAb+MfEMb3O9NOtSHlkj4yRyF5oGfQ3wZ06XQPhxZLOrGRl3bOScknrn3Nef8Ai3WLHTNX1eORl+3zpvnl43DrhR+eK9vnmtdPS2t1QkfcgiUZ6dz/AJ/nXyl4x0e7vPi1q9jNHIqyfOW7sMdiO3b8PxpT6IqSsjvvhfqieKtJkXzTDfWznJVj0zkdef8AP4Vx/j26nv72aN5hMIywDHOfp9PetbwhYN4L0e+khDtNKDkPjYMcdcZH61w+q3f2mRIt4EYyx3Mdzk5OOefXn2qHq9DNvSxTstOuL9ZorNckY3LjJ54xnI96+h/BPhf+zfC6qwUzzRHHTIOPQVx/wF0i2mt9QvJo3YFuXKfKoAJzk/WtjxJ8XbOxv207Q7A3MsLiMOzDY3TP3TnvVaLccV1Pnn9oK3mtNa8MW1zt8+HRI0faCBkXFx6815XXtH7VcvnePNHl8sRmTRomKjPUzTE9a8XqqKtBI3luFFFFaiCiiigAooooAKKKKACiiigAr1L42HPxN1k4H/LHOP8ArhHXltey/FPTG1H4r6xF5iqT5AXd3PkR8fWuaf8AHi/KX5xNIyUYNvy/U8+sIxPdIjlEUnlmBx+lT6lZiGdjGjJHngN1/lXrUHw606y0Nr67cPNCAWCNiMtjgYPOTx3FcZ4h/wCJkbyUKiyQ4RlA2hce2c5/xrTn1Mfaa3R6f8BvB2i+IBpdw0Er3tnMLiRmlYKuGJHy9D619XDoM18t/sq6rFZajeWs5IEwXYScjPP+Ir6kPBxzk+lVEIdRG/X86OjdCCfalH1oz096o0EOM5AyRQBleP8A64pD0AwfbFKvPB4+tAEdxHFPC0VxGkkLDDK6hgfqO9eU+M/gT4X1+6a90kSaDf53BrRQYS3GCYjxx/slevevWckDJ4x2NAGFwc0NJgfOOrfDH4rJcvHp2v6RNaNhVbOxgB3IaJiPwY1f0/8AZ/udXMdx488U3N1cbceTp0aosZ9ndfm/74U19AAjAxjA9KGz2zmkopCSS2PMNL+BfgHTzEW0V7yaPnzbq5lbd/vIGCH/AL5rp7b4e+D7SdJ7bwtokU0bbkdbCIFT2IO3r710447E/wBKD0zjH1FOwxFAUBQAFA4CincnGcg4pCBnkf41BqF1BYWM91dSxw28SF3eQ4VQOpJNDdtQPC/2j7y3v/EHhvQpbmONY0lvpsscphSqcDnkk49cGvDPiRZW2naXotlDJKGVGklEhwTnG0lOx61peL/Fl7rF1deKpyi3V/KqQQ7AfJhQ/InOSMnJOD9K47xndzT3ca3YIuyBJMTkEsQOufSsYpt3I3mULDUSlyipChBAQKx/X610J8SzQaZdWWpWkc7yLhZJCC0fp+Ht71xO4q4ZTgjoRV/Ur1biKLaBvKjeff8AzitHFMqUNVYm8RHPw+0T31fUD/5Asa46uw14/wDFu9CHGf7X1D/0RY1x9OGwS3Oo+F3/ACU3wjjr/bFn/wCjkr6S1O7UWrjeANvDK+WHXtXzb8Lf+Sm+Ef8AsMWf/o5K9km02CwsxJfXImLDIbso/PocD+dY1fjM6myGaPqsU+pMIkdupZh65x8x9fr+HSuwaX/RJm35/wBnHXuPSue0nSmsPDc17NbpF9offlhgKoPBAqkPE0msSfZNOtAZI8J5gPGO/X8eP/1VL8jE6jwf4hj0fUPOltImtpjtPlptJPTk9/Y1zvxW0G1uZv7Z0YKI5P8AWxf3T68f54qTUjCxhit/LHl/6wq2OnsevOT2rd8MahavHNY6jHujc7A5/LoenahMadtDwvb94k4YenenKoU7WXLH1YZrtPiD4Pn8P3/nwgtYzNmNuMjIBwe3r6VxbjaCcgZPAzjFaJ6FCOc/KVIwvcYH5igEeZ2GOfmwc03B+6ACfbpUqgCPc5JOSM9h9KbAbtAiY4yeOhAqI8n1HPFSjJQsQQOgyM5pNqtwygMR1HNIBpDE5IC8Y560Fj5TcYI79eKVAxbg4HqDXUaV4UuPsB1PUd0FgoGC3WQnpgdfxouBB4L8J3/izWbfTNOAFwwEm6QHYid2Y/yHevpjRdR0XwJo8Xh/S7hTLDj7TeSLlS5BJC4xubrwOgrxnw54xksbKbSrTTrfSsHc9xCC00ufU/TiqV9Nd3nzxSsW8zcqmU8c9frUuTQlKx9O+H9W0zXGDW93KkgOCm4Av9f8K8/8R6PbwfFn7ZgEm2ULnBwT9fqa818K+IZ/D+pw3MS741mHniV8Yz1I+hPTvXr/AIgvLS/8Y6ReW7K5mj2nBo5rotS5kZHxadNP0y2sYeJJU3t8o+U/lXiFvukm8wZK7WZwSTk/j2/zzXrPx6mlTxFFCHI2wgqABxXlEwMVncSY3KgA3c8+nTvmk92RLc67TfGcfh74fXGkaXBcG+vgfMmEi7Ys5H179hisXwRo0us6vYxwLHKI/nkRtuSM9cnr/wDrqDWfD+oaRBYTR2zvDew5DKp+XoTn8x+VdT8N9FvonTUpLeUShSIYyNrAd8cd6fqLeyOC/av2f8J9o4i+4NHiUcY6TTDpXilez/tUEt440UlmY/2NFknrnz58/rXjFaUfgOmQUUUVoIKKKKACiiigAooooAKKKKACvovUVt5vjVrJufLWKJIWYyNt48iME9etfOles/F2+uLL4p6xNaytG4MPKnr+5TrXLV1rxXlL84l8vNTa9P1LnjvxNfPqqQR+fBYCTzRFvyCRwOnB6Z79a5yQ3F3czO4iiSQlnkKkLkjJ4HSsnV9YvNVujcXDEE8ALwo9gKsW0zR2O1pxjOV9c1oo2Ri4tI0PDWsyaHqsb20jJiRf3odhjBGTj8PSvuX4f+ILTxB4as7q0ufP+TDM33sgkHNfnxI53k55J65zmu18BfErXvB97HLYXBltxgPbSE7GXPT2Pv8Azq7W1L5WtUffGMetJjGScfnXO+AvF2n+NPD1vqumllWTIeJvvRsOCD+NdFjHfj61Q73E6fT1pe59T+lKe/Gf60hHrQMQ5wP6UuAOi/SjpRnryOlACfnS89R+eaCfm7nHfNJyc88cigBeffpSHO3rx3oHA5z179qDxyTgDrQAHOT9OK+avj342/4SLVpvDGlTKNI09g+pXAfAkkH/ACy464J5HPzD2NW/jL8bIPtqeHvCOphLdjtvdWtWDbFP8MLYIyByXGeuAc5I8A1/XLdbT+x9DUrpcbbjO6YmuGxyWPYZJAHoOfQZyvLRbA77IW61Ce4v/tMUcKSKSyLI42RDryxwM9cCuevizymR5fNZurc8/nV6DVl+yx2s8C/Z4yHVUJA3erAkhiferni5yY7PdtKyr50bAKPkPAHH06VSViY3jK1jnURpHCIpZj0A6mmdOtXtLi3tNIR/q03A5AGfxqiTzzTNU7uxra6c/DzQv+wtqH/oiyrkK67Xv+SeaF/2FtQ/9E2VcjSht9/5kS3Oo+F3/JTfCP8A2F7P/wBHJX0X4Q8Bw6nDDK+otdyQ4xAWzlgMENyemK+dPhbj/hZvhHPT+17P/wBHJX0xqV8+j6XaBI/s7TjczEDrjjBHvis6nx/Iyna2pveLdDk1qzgs2uIlRV2lE5EePWsT/hDBpFqIbZ1uWHBdCVUH3x3xmuds/F15ZxuQxnlYsW3YPPXBx06ntTrnxR9oJkthLZyrkKwBCj3xuP61D1M7oo6xbC1crMuBlljx8u4nk8+v+fWqto8gdWlly24ABcA46ck//WqxNrl1eJ+/CqzNt8xTu3DAPTt2/wA9abzR3Df6LuiRhypX5hweARzxk/lSIPVPC1vaeLvBt1a6z+8kgDIkuACpGcEA/hXgvi/wzdaBqTxzpJsc5jcrw34+uK9C8KyajBP5NvDOsTDB+dlXn8SPw+ld1ptvpWrxnSddkTYvG/bu+bHc9fxq0y07o+ZhbvkFRz1xjp+FPRWLN0PTAGQDXser/Bu7e6lHh/ULG7jIJ2LMu76da57W/hxq/hyyF5q9uikYACyfT3IPX9Kd9Ljd0efSxlmTCs2TnHU+v9Ks2enTXMjMqt5S/ebb0+tdTpulQ3UkKmUxK2cgrk/QHpmu20Pw1bF2mltX2HGNrHB7g4/Sk5E3vsY/hHwUkqrd+QY41wd06hix9QO3NdVr76fpMIa/L3MoXesZwXPpheg6Z4qzqutRabBFZadEj3LDZBAQeBxzgdK5nUdKutNRb+7mme8PzSSuQDGMfdUelS/INjnf7Mu5Yr7XL4tZLL8kEMYDBs8YJ6joO3eltZpYQpwynGFBk3EY7546VdujqU9qZjKZbZiFy7LwTxnjjJJ9PT1qpZNDIhLuuCQpbPzKfft3z/hSuIc9hI7n7RLGJWG4b8qeM9CCe38q7r4Yw2V1r1nHfmee8gI2vHuZAfc9sYrkBNsnLkrJIBhSTzn0wPxrpPCPiRfDuuRXFzbmK0LKsrjlQScAnGD+lNPXUFuXPjyv/FZxAkndbjAzx747dq80myuk3EBzskCghCCcqRxnOAPp6HnmvVvj/GJPEmh3KuPIniKbicd/5V5TeDyji2BYHgbyMAD/AD1603uVP4j6h8OrA3gjTp9QWD7NFACGcZKjHavOPE/xK/syeW38P2cIkC/LNOgwPfGfTP6U3x3e2l/8KtCFtqLwTQFcW1tkI5HBDY5wOo/yK8xXT7+8t7meIO1oCQ85IPYccnnH0xTcr6FOXKlY5v8AaU1GTV/E/hzUJ4kiludDhkdEOQrGafOPxryGvUPj0CNT8KAkEjQIeR0/109eX1VB3ppm0twooorYQUUUUAFFFFABRRRQAUUUUAFeqfGoR/8ACyta7H9z09fIjryuvWPjLaTD4laq6xMUYxbSO4EKc+1c0/48PSX5xNI/A/l+pwxldbZY8YG4tn1qNpGYYJJq9fK8pjWWZWkUbcbsgfjTLiOC2gEZRjd5+Zi4KgewA/XNbijJFcyAxKoXBByT60gOKWIJglj0pCQRgYplLyO6+GfxB1PwTq0c9rKz2nPmW5Y7XBxnj14619p+AfGel+NdEXUdKl9pIm4eJvRhX55qcV6R4H8dz+E57S8guXe8CqhKNlGiB/1cin0HRgCR781D01RElbY+6eCOvXikAxnJ7/jXM+BPG2k+NNOFxpk2y4VVaa0kYebDnpkDsexHBrpunXqKtO+wkIQcEYzn1o6nC46fnQOfp15FKeSMcY7UDE+pyPag4znAJxwaB254PevLPjP8WLPwLZmzsGjutfmU+VDwywjs8noM9B1P5kJyUQSueg67rmmaBYPfa3fW9lbIOXmlCg57DPU8YA6ntXyZ8XvjdqfiqSbTvD7TaZof3WKttmufUsw+6vbaOo6nnA808Sa/qvifWJL/AMQX01zdv3fogwMBV6KOB0+vJpYIdNitS93I6SD+EENvHtxxUO7+Ibko6IwXcsTk5qM1JcMjSM0Y2pnhT1xUVaFoM08sWgxzw1RUDkgZxmgGjW02zM2kalcZIEKqR8udxJAx7dc1kV3+maeI/h5rNzanzAmFklGcHLL09uR1rgKlO7ZFN3uzW13P/CvNC9P7W1D/ANEWVcjXXa6B/wAK80I8Z/tbUB7/AOosq5GnDb7xS3Oo+F3/ACU3wj/2F7Pp/wBdkr6Rv/Eia/4aaxnsAbm2kxC6DJCj1P8A9evm74Wf8lO8If8AYYs//RyV7z4Vs38QajbWOm2rqkqjzXhx5Z7nOKxqO0zKd7aGRdaYk9yP7MdTLLz5YAGcY5H5j9Kamk6vdTLDDYyzyHOBvVOcepIz+tew3Hwikhjjl0y88uSMZWP+EHHb864i98KahFcSPq+gK9zG/wC6nDFkI4wSp6HP8ql3W5lyNHK3vh/xJBdpFLpOcgb2EqER9uoP+c1nzWGuBisVmvB/1obOO3XPrXbpbXNvtS8sXg80Ay7YsHv/AJ/xqS6mhhESo0qLt2/u0PHseOOoqeZILPsc1ZNrUKGG4u5pFDZbDkjHp+Xauh8M+I7awuVN3FEiuTucup2L6kdv8fzrPube/dSba2uZ/JUD91blVI9ie3sKxLvTJ7onzUeFyDtE3yEjjqDg9h/X2OZbis7nump+KvBH2WNxexrPj5ZY2Gc+5HvmvK9e8a3N0LzTGvI9QtX4RgxcYOeMk9PWuF1PwrfqAR5j5z2OOnBqhFpmrW7kC0lljQD5kXp364+tVzRfU0d2ju/D97Dd6hBb28e2NBnYqYB6c13mq30Gm6c8pbbAibju4BNeJ6Tc3+n30d3FZyxqg2HfCSe3fqK2bbU9V1TW7RLiJ0t45AwjZCASeMnPUVPNHuSk10Nq11OUTNqRhmNxcgeXLIpVUX/ZOPTFa9v5F1pLvc3AurlPmCSszn8zVzXdA1SO3iN9q5kgmGY1MRZUXHA64H1rnhDNY824luI848xSSMe360OSW7FytdCBLvyWP9lOqFs/uWJCEd16df8AGtHxDpFreaNHr+gw+ZEP+Py2PzMhGQSB/T2rElgl8x5XZiCMhVT06nPPPetHQbu70jVGmt1do5PlnhJyHXkcD16+/FCkg5WY6Tq0wIdHeQZEgT5Tj19+n5/hU2oyNIqoxOyVMONucsO/t61qa9ptpxc6EpgtnbL2Z42HPJXHQdTWddqJY0XEijG9WJJHv17fT2/Fc8e4crOj8SajJr/wq029ZmmvtOkAO4c8NtPXB6HPauD8QypBarcCSMgIduxuRu64rsPATP8AaNS0OYObO6QujMDgE5yPbjHHHSvO/FdvLbaRcpKjoYJjA5IODjkdvrV80b7lcrdjT8PXmmaj4WuYLrUUs9VR/wBybhyFkX6gf5zWlo9nr9lElystp/Z5ced/pKiMr0J6+9ZXwi8LQ67JcfbYXfYB5a4+8CM8V3OufCeGWJ5LKBhLGciLsfr+FN26CcdbHCfGa00a5+Ing+21bURZ6I2kQ+fdwIZNkfnTk7AAc+g4PXvVO+8EeC7L4aaT40mfxEbK/wBRNl5CzweYiBpR5n3ME4iJ25HJxu71S/aDs5NP1vwxZzIEkg0GFCozgYmm9a6DXmtLn9mLw7pEGraM2q2l82oTWf8Aalv5qxHzyPk35LYkT5B82TjGcislzcsGnbX/ADOtW1MXw98MdF1yx8f6jZeInltvDX2t4YYoQxuY0SUwSGXO3DGPJCqcgHlcgjyWvdPgPPZ2Pw6+IsF/quj2c+sad9msYrnUYInlkEdwuNrOCvLrywA5zXhdb0nLmlFu9rfkS0rJhRRRW5IUUUUAFFFFAHsPwk+HnhTx7fWWkjVdUXVf7Pkvr14lRYoWEyosShlyxKsGJzge+SBgWmieAbv+zbufxFqWl2TtOt3bzQLcXAaNotip5eMB1kYhmAAMbD5sYPV/soalp+i+OtU1HWNS07TrMac0AkvLuOHLtLGwCh2BbiNs4BA4zjIzyPgbwRY6t45l03xJ4h0TTNKs2El1dHUoCs69QkDhirMw7jITnPICnjbanJOTsl/XQ0VrLQf8ZfAlh4H1jTl0XV11PS9TtBe2ztjzFjYnbnHDAjBDYGeRjitb40XUsXxI1yJHwjGEMFPB/cpR+0BBYnWbC/i8X2fibUbrzBILAIttZW67BDDGqu+0D97xuyeCeSWZnxxiZPiVq0jZCSGLaxBAOIYwR74PFRB3nTcnfSX5xLSVmrdv1OFjfYGG1ST0J7U0kknJzmg4HUgfjSZX+8v512XCwtLSPhGw5Cn0JxSb0z/rE/76FNMB4NTRhmQbVzg9QOarqyMwAkT/AL6FdNea/pi+FrfS9O063huA++5vXYPJI3oD/CvHShsiTeyPT/gDqWl3f2rTNR1b+xdYgIl07Uk2o4H8UZY8Onco2Rg+3H0PaeM7/TIlXxbpM0MO4LHqulhry0nH94hAZIun8SkD+8a+D9PkLXcItmElwWGxEO5s9sAV7FoPiXxL4OW3vFmurq1lxlNzEqxJyBn5c4z161lKXK9zN+6z6Hv/AIweArO1a4fxLaTAY+SBXlc/8BUE1xeoftJeGYZ3Sz0/UrlAcLIEChh64JBFeU/EbxJ4A8WeGpb+zSLTvE0eNwjXYJTnkMM4PfkdK8ZM8X/PWP8A76FUm3uWrSR9C+Nv2gtYvrMw6Daf2SJP45SGkI45HYcfzrxC6luL24lvryUzXEz7mZjlmPqaqWUSybXbJjJ+8CAPz6U+4njgiOXjIf7h3Y49aFa/mS7rREd7tRyMESH34FUySTzyaaZoy2TIhJ9WpDLH/wA9Ix/wIVaNIqwtJSebH/z0T/voUnmR95E/76FBVx1JSeZH/wA9E/76FJ5kf/PRP++hQB2Ohz6le+EdVtIL6MWkEe6SGZ2zt3A/IOn1rkK1/C95AmoPbT3EaQ3cbQsS3y5I+Un2zisbzI/+eif99CktzOKs2jZ10/8AFu9CH/UW1D/0RZVyFddrjK3w70Lacj+1tQ5ByP8AUWVcjRDb7/zFLc6T4bwJdfETwtbymQRy6raoxjkaN8GZQdrKQyn0III6g19teKPBlrp1oJLO41d2LBcS67qJHv8A8vAr4q+FX/JUPB//AGGLP/0elffPjjUrezWzjfb58rEKpzkge9TUgpbiu0tDhbzRdPtrd5JH1b5FyxOv6iB/6PryfXvGD2mrzW9pDcrbLgpJPreqMcfhcj+VavxV8X288y6TZuC4x5qt0RgRjnof/wBVeaxo8wxNAxJb5twGVHt7cYrL2cTJ1JdzqT4z1ARB1gmII+WT+2dUAJz1x9r+lUJfiBfrJ5bQyI5PzE6vqm0nOM/8fdUJ408mRi6x7zjejBWX5uynr07etYMgEKqgimkH3VZh1/Kl7OPUFUl3PSbLxZPPcJC8VxuK5AGt6mu71xm6+nr39KV/E13JO6RQ3WTnYH1nU2PTJ5F0K4rS2Nsibop0m4xIpJY+wAxnr0/ydpLCRoGumKrLgsqE7TkE9gcc8Gl7OJLqyXU338RzwW6SXkNyWJIAGs6mp+uDdHj3obxPPHEZHtrhiqhtq69qS7hznDfaSM/nWJNasLdZ/sqtIxHPQpxj5Rnpx0/pWPqiNIu6dkcqATsG3acjqe/X+fryvZRD2su56ppWr6Nq88KWN7qLBhueKTV9URo/YsZ8f5zWy1gl3KItKlvWmQ/vIZta1QEgHkq/n4OPSvD7bUL1UjurJzFN0KcfMp9PU13fhLxsFtpF1G5lifdgTIuSPY5z7dqfs4j9rJHevpKROguG1SMfxltY1JcdehNzUWiWVjqGoSxS3N/FCh+UrrWplsfT7RWnp+sDULNMtGI3zskLiTf7kY4p/hO3S51a4jn1GxeOE5DJmPb7EZ5p+zi2V7SRfu/Cekx26tBday0jYwG1rURx648+szWNAtbNAYf7XZtvVtb1Fsn8LgcVsapqryEwWAhljHytKRyfoTTJZC0UUPllsfxkH8eBQ6cR877mVFotiLRftJ1drgrxs13UAq/UfaCfWsnXbBdOsmntFv5pBkLnXtRwPX/l4BP4HtXZbQqhpPmz252j3xXPa2Y9RS5sYmVxENxWNim3PTOOaHTVg9pLueV3nibVImOyGdYxyWk1XVAPw/0zPp2Fbmi6pJfW8cjpdgNxhNZ1MZ+gNz/n+XIeINF/flIrqNbgNlkV+Rjgc45+prr/AA3p62W1fMlJVcrv549se1TyRI9rLuJ4x1b+wtNaeKO9Mu4BfM1nUivPP/P0D0rjJPHt82zZEoY9pNX1XP1yLutX4jyNHp32fy5Q1wcqzOWLY9j07Z/znzfyo1ZI/N3S9pC2QPpj/P8ASo0421Gqku50Oo6ppuuakkmpaDpd/cmMJ51xd6hM3AyF3vdjAyT/AJ5rNuotMhlKDwd4cbaSGIlvyPzF1iltI4HuyLy4+YD5SqAnPpjFUJVMJKbmSFicBevp8wq1G2gudlxJNFKtu8F6CSDjcJr8Djrx9qqxFJ4ZV18/wfoxXncFnvs/Qf6T9azfJCZkjbMWSCy5/UdqdBBFFAZpA8qsSOOAD1/Hr29aLeb+9j52Xbibw67MbXwPpEcSnAea5vm3H8LkcVE82gkkw+ENAZQMHMmoZz/4FdM1FLqMt9p0duESMwPmNo0xkeh5+lU1c4yzqD/eB6Hmjlt1f3sOZm7rPhnQ9QX4dG30yHSjrmozWl79ikmIKCaJAV855MEB29s9qzptK8HjVr2xTRNeLW0rx7xrcXzbWIzj7JxXT53H4OK2QRrc4PGMf6Tb1yt0zW3iPxA+1ci6mjOecZdulYU5Sk1Fv+b/ANKsdErKDa8vyJ9J0nwRevOJ9K8QwJCMs66vE6g/7R+yjb+tNn0nwSG22ul+IZyThT/a8Kg+ucWpxXPKzr5wVnQyEBgDwR7113hewUpLLcAZXPl7c5OB1AroatrcwlNopHQ/Ce1iNE8QZHZtahHr3+ye1Fxo/gqBFL6dr24n7o1mE8f+An9Kv+ItUEG6CFlLlcsRzx2z7964e8uJJX+ctuHfPWiMW+o4OUjoJbXwJFnfpfiQn+Hbq8OD+P2Wt9PEek2kMMOm6j468mMBI0TxKI1jUYAAH2bjAA4HArzoyMwIYk0jbl4BOBTdNPc0Sa6np6+I7WSWRINQ+IEqquSy+KAB+ttWxpsz3CLNNqPj+C2Y480eKg3P0+zf/q5rx+0uJ43HlOwGcnBrXh8SXcBKCWbGMbjIcj8qh0V0Jk57Jnftq9uj3EcuueOBJERtC+Kyd3P/AF68f5+lZUvjARzOn2/x9he//CXf/ctc0byK/YSBds453BuD9RVm0xFasz20cpk+Xe5JwR70ezS6E+0ktzupNYs2gsxZeI/iBNcygNMj+KNiQD/e+zkt+C9qq6r4hs7fU0s9P174gXyBd80v/CUbFjH0+zHNcckdwix3MauskeSI9pAI9cY5FS6IsCXlzc3Txb3GBub5WJ7c0lTiHtJI73QNQtNTtLi4uvEfxDtYo+YwPEokaQfTyBt/WqsmtWq2clxHrnxGYAgJnxLgN9T9n459jXLpCtzZG1jcJDJLuLIDhAMkqeP1/wAa0L5Y7IIohYRRAE/xLKPTGf1qeRXF7WXc6qSeOK2SSTxB8RFlYZ8seJ8n8/s9ZOveI4dKvo7dde+Ic7YBkx4pwYzxxj7Pz+dZtlqMt7PaR+aAASse/LYXOdvJxxk8mua1O6a41iZ7kmQBuSuPmxxxQqd3qCqS6nrvhl9G1+Panjn4iQXeceRJ4gySMdiIsdv0rmfFfiP+wr4w2+ufEK9g6ecPFmwZ7j/j2P8AOuLt55tOkW5t2dZVXCqpILZ7mr1+pGibbiS3kYp5kjZBZc8hRg8Hnn61XIkx+0d9SyPiG2cDUfiH/wCFj/8ActSx+PyxGdU+Iisev/FX54/8Bq862MzblQgE8Y7Urs0cxO7kdxWvs4m3od//AMLDfP8AyEviFx/1OJ/+Rac3xDIVSNU+IhbPI/4TDp+P2WvOM1ZtrOa5AMYyM46E0vZx7Ddlud6fiIQwxqfxEI9f+EwPH/krTh8Q13OP7W+I2MfKR4u6nHf/AEbj9a5dPDozmW6CoOrben4Eise+higuGS3nE0Y6NjFL2cWKMoy0R6QfHcH2CGb+2/iOZ3Zg0I8VcLjoQ32fnOfTiqjfEVgx26n8RCB0J8Yf/ctcZp7xG3j+1Kxt4pSWCnBbI6A/hWacFsD1oVKILVs6j4jagda8PaHqp1DxFc7rq7tPK1jVft/l7Etn3Rny02583BGDnaK8/rr9fXb8PtEU9Rq+oj/yBZVyFaU1aJEtzqfhV/yU/wAH/wDYYs//AEelfV37R/iX+ybnTI4pdskQaQgYz0/xr5R+FX/JUPB//YYs/wD0ele6ftbyTnxdp0bN+5a2+QehB5/pSlvYlq6scfofg/Urzw2fEUm0yXErPsckHZ6jHqe3oRWbGJJJ3jBDyAnlm2j2H86+nfDulb/A9vbmMRAwKFRWAA49Pxrw7xJ4a/0+4NvKHkt32yRHHyc5H1PPes5Mxfc5W7Nw04tWKymIZDlNwT6k/wCeahZpMyxsoQlQPMJJwR6Vc08Lcag9u0KtlSQI2Cbj16k/qf8A61Q3d19iuFt7Pe6DKyI53H8Ox4xzQuwiK1mkERRRLKqnHnvk7R+H0ratZLf+2IUaWaU43qH7Hr1z+lULSG3uJiH2BJCcKH4B9OmB+R696ilM+n6pGjO0Sn5SVQPhc+3T/wDX6UNC3Oo1OeNopWYxxMVAdmHC/wAu38q49bpI2e2MBkcnIllOF246YHWtUyLexkQM21Rz5sXLnkY7AfjWLdxebE6NEsYjJw7sMhvfH4dM9RSiCLENqt5IHRMFPvMOF47c98fyq1bACXzI0xhsEg5Vu5yCOfTvWDGZXsw4LieM8KzZDfQVtaU63Vk5njm+0EfKVQEH/wCtTeg2dx4QvtONkttqdrNbF3P73zGVSeoIPGPpXf6D4ai1IXDW0k95EvI8xicHsM9Tj3rwm83PfKmJS3Lc/IV9MAnr+X4V6Z8G/FKWLXEV7/pADBFlccDqP8PzosgWm5313pOr/YY7bT0h01ScPdSqrHb6IvrV6LT4rGNYElkaZhl5ZiSze4/wrcvEiubGNwDg/MuCRx/SseWMkY3TNGfu7xyD7Zp2saMivT5OnyeY+5l5DtKDz6betZdo1naxmV4BGki4Z5SxXP4Dinawk8dg1s4Yl2HzE8n8uadYSW8ts1sJoPNRQTF96Q/gD9OaVxX1OeOk210JvNVbqAscOfuqp7Doccn161HdWirMI4yUWLDLIGHT0x3/AM96PENu0TWyS3EkUrODtDYVee6jg/X/AOvTNS8wz3PlxeZIy4B52sPoe2RUWJbOC+KIudtmqAKoPUPkH6/nXnc0t0ZAShkCkfvBgn/Gu/8AH6+TJaLIyjKklihC/Uk1w6SzQWpSSyyzkgSq4JP061cb2BCOlwclLaUs/IJBJPv1qKdbwjdcxFDnqxGf508zSlUDw3DbeMtjIJ9u9RzypOgTEqhOhK96oYjq6267VIO0gkP19zinjP8AZqfMWPXBJGPXH5VCoX7J88fzdMk5z+FXjaPHp01yS/kouPMRSevA7gDr+tDAy7adi/znKEYwDUrblRSqkR9iOQ1Vol3Rrs+91L5HAqxAG+UeWpYD5ck/nTY2dqkEcdx8HZtifaG1iVGlwC5QXUJVSepALOQOxZveuX8RE22ta4UYBjfzbgVyPvtjrXWjOPgyWGM61Nz6/wClQVw3ixzJ4o1yJm4F9Mcg9cSNXJRu5r/t7/0o6ZK8Pu/IpTA/KU+Zxg7jxmu70xAfDxldN/lEhkWTn5sDr6ev0615zLJIsahjyTkEd637LV3g0eS14EcpBO7np7V1yTsc8ouyMy7vCNUaQnI3DgdBXQ3+gRXOnfbdPYONgdwP4OOc/wCFcbPjz2wcgnIrq/BOsW9gZra9DmOddq4HAPPWm1pdFTjZJo5+1gR5Sh+ebdjHY/41aubCWG4jQHl1Dhcda0fECR2eqJNbBFKBTtDbgDjqcV1Onmw1XS4WiU+YjhpiyAKOPUc/lUuXUmU3ucTbaf583lxARjryeT/Ss2/spbSQ7wdpPBxjIr0J7O3t5CYkaN41AK43Zb1/zimmKHUYpI7mMKzIVVzGRg9emcf5/NKfUI1LM82jkZGyvatCHUCpHmE4xgY7VXv7KexmMc67Tk4PqKq1pozdxUtTrU1XexNuWWPb8o3bjnvjPQ1PPZnUtPjDyLDLEmQjKFJHbkdyT19xXKWcoRxuY4PGAK2bOa4Dh1LBQC3JxuqWrGEo8rG2l/d6RNCZI9jEZDMDyOcZ9RWpZ+KLQ6ZJbzW0n2yRixn3gjPbHGQPbNaAudI1XT/J1BcSsv7oAkLCf97HfPpWN4bXTINSiXUbRbyBXw43EHGeNuDzSunuL3WtVqTxaraokgs2mWRk6Hp7/wBasabZJIkN9Mn7rqWZeD2xnoDXuvg/Vvh9emcR2cFpPDGdzSr5e0EdP5f5xXk93Gulpd2TkGGJ28tYwSNuTtIGTxz/ADqL22E9tDD1e5i02GSSCGORp0xb7gGaMEnOR0zjI/zmvS/FngqOb4e+H9WgjiW5WBDcqPl+UqMjjg4rzeW1F1C0r5GSFDlcHf26H+ldVp3xCurLwddaNJLGt6hCxtISe+GyD3x6Yp20BM4C50qWwiYTpIYhJwyL94eo9utczOwaZ2AwCSQK9Um8Q27aPqpdrRbqKP8AcgggSBuCBkZyP8K8ozznvVwbe5tR1uwpQcY5P0FPnZDt2JtwOec5NRCrNt0WFLtEf3zemzcelQsAM89P1pMfLnPOcUu4bc8lvcdKBJWFMn7tUXp1OR1NPtAHuY1fO3PaltYPtG9VdRJjKqf4vYe9NiZY9rHk8/hQJ9kbni8g+B9EPBLatqDEgdf3Fl/hXD12Gv5Pw80In/oL6j/6Isa4+lT0X3mdrHU/Cv8A5Kf4P/7DFn/6PSvoL9rSxRvFPh+VFJllhkjIByGwVxx2618+/Cr/AJKh4P8A+wxZ/wDo9K+nf2o7Ij+yNTMOUt7gIzdeGH+IFEtxPY9O8Jym68L2rbY4coA2zgV478Q7PTrbxMLmcr5E/wAkoMmQwOMNx06DrxXonwc1ASacunmQNFGo2sT+hz17Vl/GzQkNpNdTRrsUcPgDPtntWb1jcyteJ5N4o8N29jIdQ0i4Zbby8gq3frxXm16s95cq0Ts+SACXxz9cV2ml6nM4a3lWGOMH7hkwGHPJB+lWdSuLURFY57VU6blRcDsfqOn1pKWpCdjD0nTro2vmXhdFXkfLuUnOOo6GoL29WKWFpYgxAXO0bB71PcanEU2LKdvIbYpUMPai4tIrjTy4m2xLnEbt91u59+9Hmw9TSuJ/tEBnlRZY5lxGAT8hz06D0/WufvUWKJlZf3rchScAf45606zmVwwlmdolG0nJIXjA/l6VFt81Gjy7ocfMDswPUU0hrQoXRkgZWkUAPxgsCGP1/Gt/TbqL7MjkywMnDGCQjcMjAxn6/wD6qypY/tMgVmYhPkVicgj/AD/Krmm/ZYoWBO7aedz556ZxTeoPY1PEJRdFguhKjsSSGUYfHAwfbg/n3qHwXMlyJFQFW35EXJyecEc/WnX8Md7JDDeSKtiV+WcOSvHt+X51gW3m6ZcSy2STPCjlFm8oqT2yDzg/jU2urAtrH0DaeOZdI8PKdTgeeNQCFt1yce47n8f51Xb4m2dzcW8Ok6RPfzOMeRbsiOh6YYNj9K8wtr5720lE1vKfNAUMylAG9vftxWRDPeWTJLazypLC/HlHD8e55PGaFcEz3K2v9Wu5nXUtDl0nyjuXznjkDD04PHb/AOvXTpKhsc+S7sVzvj4OfevEdN8c3yXML6rdTqhGx5dxYDpyQeTXq2j+IdN/s9ZLbUUuI2HDAZJ98du9F7FJ3MK404zpHfDzYpZJNzuQ2SASME04KDJeSkIyjg5wMce5/wAKsar4i0+00f8As9NSjhk3/ud0fmvyegUc96Zb6euoRF45GZWXe0ykYPHr36VIrHCeMYnF3bkPAjKhH70Myj/9Yz09frXAENCZFhaLCkboWZiAR3X07V6J8Q4EXT5Y5PLDxndESygt6457V5zNcpNkuS8m0b2Xufr+X5U4iRas5A+3e73DA48pX25+hxxzmqeqGWZXMkESbGxgoQYz6e546mpdNvliQB1YoOGyc5/A9KrXqI88wt3dYl+YdyPqaoa3Kk2fsgCREt3b/wCtWx80Hh6WR7qJ2KhGtycsVPH4f/WqnCovIZI/NzIR97PB9P5+lVngaC2kjZ8A8896e4yFbeIJvh2sjDBBJyn4VPbKE5bBQcGRASB+VU7KUJlTkAfxA9BVyMBOFBTIyNn3WpsbO02bB8G1xj/idz9T/wBPUFcJ4rTZ4z1tEGALyf2wN5rvI38xvgu3If8AtqbPH/T3BXHfEy2W28a6qUAXzLiRyFJwDuPrXLQXvL/t7/0o6+lvT8jDvFSMRqVcSDk5FbGmvapZSfabVbiQcqzEkKP7vB4+pqnZhp4WuWhWdUADgnBHbIpsEktos8SszxOfnjBwSK63rocz2sUrhVefzEjCRsfug8D863dIFssZa8HmxMmxVH3lb1/z61mpBFdTuFLRxAfImckmtuXTPK0m3kBbKEjayfKOfXrSk+gSd7Ip3+n3MFkkh3Ojj6lB/h0qv4e1ufTJ18skxMw84HoVB9K6S0vjPeBJ7pWdozEWmDcDHQDHHp0rjdYszYalLbsrIFPFEXfRhD3rxZ22oXMkyrc2WEt52zHI5y2e4z0HP860vD0aQLeT6jJMsjDeBt6kDOMEYPXr2rhNK1EwARPMFjRGA+XOCe+M9a7jStS8vSLSR5RJGPllQDIyOhIIwOM1Mk1sZyVtCp4r0+21Gziu4ICJV+Xy0YgEdQ3PPQ9uK8/htjLceSPkfPBNejavqLXavODFFMckbBlBn2x1579sVxGn6iLS/neSFZDJwXAwy/QdKcL2LptpOxVNkY45i7rvibB2MD/+urum3VvaOj3a/aok5MWcfnVJ8i42xSFV3fKrDHHvXXaD4Z0jVIGl1nXLbT53OEwdy5/2jVN23Kk/5jJufEj388US2lpbQKRt8qMAjHvWhptrbDXYIrO4W8k4YiNT8p/H0qPTbfTtI8W2MbXNnc6es4WaZ03KUzyR17c16la6/wDDbw7NP/Zlpvl2kb0VmZsnPDN0H4/SobS2JlZ7I4dLpdV12e61N4E+QwyMhA80jAyykg9u3p+FQa/a6zoMSmZRf6UcPHJ1IHOB0yP5V0eoeIPhxf8A+kNp9zFcq2SioSrD14I5rD1DxBa6eDNoGvmc8D7Nc2z5K55DEgqanXsTZ32OTn1GXUrresxiklcIByQo9f8A9Ver+HvhFHq2nRH7Q8t1uOZ1JOPTg4x+v4Vy15eeDPEFm5urX/hHNSj+5c2ytLFKQc/cGMZ/w5rr/hV8TU8NudN8QXbPbTuBb6gsRKr2yx4OOn05zVehT8jh/iF4fm8GNcaTOjS296qzWk7YYrg/Oucevb3968+jHzgsMqvJr60+N2mR+IvAUlxDLFez2hSeCVdmGBIyVPbg9K+XbmEIg+zsknnDkdxz9KqL6GkZW0IdYvU1G9E8cEduCipsQYAwAM/pVEYU5YZH6VYe0mMLutvKBFxIdpIH+H/1qrFmOATnHTParWhpGzVkObCfdIbvmmZFHUE56U2gpI6ZIdNmGkzaZLJZ37KI5UlGY/MHBcOex67ccetYtzZXEN1NDIh8yPOffHcetJHck2ogkbCo2+M4+6T1qxfz2rXsbWnniJUAcy/MS2Pmx7ZpGaTTJ9c/5J1oX/YX1H/0RY1yFdr4oMR8A6H9nz5Z1bUDjGMHyLGuKohsJ6s6n4Vf8lQ8H/8AYYs//R6V9s/Hfw++ueBdQjgR5bhEEsaJxypyPzx+tfE/wp/5Kj4P/wCwzZ/+j0r9GdShe4tniAUqy/MSabV7iex8xfB/xRGI7VGmkLnAbDYVWHYj8q+hNTgj8ReFp43VS7oVyvJ+tfIni62u/A/iq/ghTawl+0QMowrIScgew6fhXvHwr8cx6xpsEp2RpImyVM7sPjkf/rqEZL3dD551Jl0/UbnS7+3zcCQqlxtDZAP90g/pzVNomtbjyZZGKqOMHa2D68A4rrvi9ZxnxLdIJBMeXG5uUyTwO34+wrgrC/NkDFNGj7iCGz82PTIqVqibGgk6218kbNuU4K705GeeOtXri4hktpt4wJ2AMWTg+/A/r3qpL5F2FKQRWvmDOUBbd15yaktIFj8t45I7gpkBlAjIz7ZOe1AmYq3NvBdOqRearjaUzng+hFaU+Y4llBQL0wGyU9iDVudWjl/fi3gyc7l+bePw/Ef41LYGzkQoirtlO0hF5U4HzZyehov2BvqZAdCivLKJGH3Yl+Ujp1OatxyLJIEljJfGPk5BHbPv/hVq+tJbWURyt9oQ8+f03cDgc/5xVNVjkikeSB9sYCbc5bJ68r3oA17KWGWAETWKbSVKuoGD2wCeay9W8z7SscSmRQDyBtVcnnOOv1pby1tzFuWFEkC4wx+YYPXvz/KsOKGRiVEblRlt/wB4+w7U7CSNnS9ZEYFtLJ8i91+X/P8A9aq15qQe7L25RztALOqgAgYqmqYTzt+3ttKEn070k1ugh/ekbmAK+v45pWRWhKJ/MiyxhZzyFjBP86veHdUvNFuXktpxET98DJ3n0I7ViKJCuTHhRyo3c1J5hjCSu+Q3DAnPOTxTt0HY+nPg7rmn65pn+l2+7UeUnEYX5eeOfpimXc0ekR6iLXyfLgJZR5gzjv8ATvXiHhjxDN4a1i11m2EotmJW5hyGBHt+h5r2bUrq21XSJ5rCcvb3g+7Gu4KPcf04qXcL6HnHiTWY9RgTyShWUE7mYHrnjd+XavOr2OJZ5N6kZOSeeDn6VoRSi0nubSU/v4pC2JMoR64H9PpUscli9z5mrW0twj8gp99TzzgnkdfyoSsJaGOv2csqLGJcZwAf8mtnRbTzWuI5CtsTGSCx4PbHFbllDaRSBY0b+z5Bt3wxn5CeOe4P41sXmhypDcR2V3IwaMuAYyFYY7tnGe340cwmzk9JhiTT9SlYeZbQDIEZwWPuc8f/AFqsQeLdM1JIrPVdEEKfdE8MhkZBjqAB1rJ0XTdSvRdAIyIisMbgAxz0APX/AOtU/h/wheXN0TeGKAhS6o8yBvqQCTinp3Hprcxr23ja7f7BMk9rnCnIQ/ipqvOjQkRSIUYHPPf6dq6LU9KZ5CGuAbhTtKwx5xxnkcdvas+e3ms7chyQjAEnhlfHqvbr/nihMaZ00ByfgySfmOtzEnr/AMvUFVPi3HHe3FxeQHmK6lV9zDj5uw71cgxj4LlVK/8AE7n+n/H3B0rY8UWENxe6vb3CwJMZZG2qudyEnBA3cEnvXNT0kv8At7/0o6KkrJP0/I8g0ZwXkt2aNRIMBn7H69qv6lZRRFHtZ5Hkx+8Qj7p/3uhrIeN7HUSjA7on/iGK3JrdrY+Y8f8Ao9wcRvnCev8AkV2Pczno7rqY8q5XeMpKnYHk+9XNMvEfbHKu6RT8oPI96ku4jIPLO3yx91lVQ2fcd6y5gY5RwVnU447+9C1DSSsbeoW4gvIiCWhbGGHQe26s7WWaSYJIBuXhSO4p1pfh0a3uABuO4ueoP5cVox2Nve2zh5NoiGQ45/8Ar+lLbcXwvU5pDtfDHBBrYsNVmtJswS7EkwJFHTH0/CktdCub2+e1hGZhuKkjG8AZqjLaTWcrJPG6SjqrDBU+9Voy24yOo1HWbrydpnYrIvytG/6EA1x8zFpWY9c80+OZ48DrtORu6CmSsXcuRjdQo2HCPKywlxiM7WKkDgVNc3Nq8EfkxFJiv7zB4LZ9Kz0++MirD25MhWH94Qu47fSmDjFMbHHwrsQVJ6A811nhWwut3yaabi2Y4ZmX8cD9K6/4c/Cw6tpUOsak0kaL85t2TAkTtg5GPWvZLHT9P05re1tm3WbKSFZN23PXntUSkZTk5aI5jwp4b+w6WwW3WAO28tGoBPHf0+lS3vhjTbmCSV0hkJwu2Rd20DHb6V113YSadKS8m62kIK9gPQ+vX61JYf2bctJA0bLdxHDArgE4BrPqTyni/iLwhZPbzvZabJY3C8LNbElJBjunb8M1xaSDQ9Qha/t4ryyV9skTjCn2I/hNfS7Rw2shszPnzPnUH7q89j+Vct4y8EQa1HPczrEyBQX2Kd+MdyD9D+lHqFmedXPim98PaXdJ4enln8K3hKy2z9bNz/d7gcgjtXB6pJdwyWsskjurcxS/wt7g1pT2q6Fqd7o9y/mQuoaOZT/rYTyOO/r9Qao29rJLcJpDuHtZWY2kjcAPtyB7E8DHqRVJLcoy9cnDXIli3K0i4cf569Kx62NVhbyFUkGWJirrjkEcVkVotjenawrY/hJ/GnP+8XcFAI67RUY61Zka3+XyUb0YOc5/KmU9CrzSjk/WtKxtLW7jKee0V2W+RWUFNvqWz/SnXujXlldQwPHHO80fmIIHDgr+HIPGcGjyFzoseI0KfDvQAWDEatqA47fuLHiuMrsvEUZi+HehKcZ/tjUe/T9xY1xtKG33kM6n4VHHxQ8Hn/qMWfv/AMt0r9JCM5BH4V+bnwq5+KHg/wD7DNn/AOj0r9IxjaQB7Cq6geAftL+FfP0+HWrcCOW1BDEZw6kjNeAeCPE2oeG75Jomd9MjmDTxgLxnjdzzX3pq9hBqdhNa3SK8cqlSDz+NfGnjPwbJ4c+Ir2l3ARY3UmIzjcpB/HtUNJGctNzZ+KcomvNO1iEI5uF2BcAhvfOPevPb6yVY5JkVgwOSDg/rWh410PVfDFpFaGWWfSWcPBKvRT/dPp1/zzViztY5ooDK00qzjBUHPOOM859KhaIzempS01C8Ckg+UwIbJ4z9OlSWdpvCwrJEHYlQrDGOoySM9/WpYLSVL82oQxxxEsgIOF68/r+tVWWaa+kmkuAFwMuXDAemPyo3ETm2BjEUsgm8ttu7oB/j2/KmQCOJ3il3DyuyH15yfp/WpJFLjbGqyRIpIfOSffGKwED3GoLJA24KRvAO0n6DrQgSvub0t5LlbxyZrYrgEvtKdOPc/h60joqMskkbRlsY2sTuHqR+Bpkn2mEqscMksedxZ027Tz69v/rVHJJG1vsuCoJYEMrAt/nj/CkIsanbGSNntp03qvMZA3HP4YA5/SsyGVbiEmdwrIOFzj/6xrOv4kkuC0knzdmJ6imoohIjhnV2JzgD/GqS0KsadxEJLfFwyKc55OOfYCqEG85QBGCHI3ntTpEuWlCP8pfjGRuz9OtSJakxtE8oGOSCeTQMhe4XMjbD9Mkg/nVC8uTIuHAyDngAfy61pTrCQI8bAufmzkN7VTukwiyJH8o6g96aGi/YlJLWFJGzu6gjGea7f4Y61MuorpM4Jic+v3RjsB1rgDKI9MV8kOW4VTxj1qzJPPLb291blVe3xjnJyMHJNJrQR2PxX0JdMnt7tXcRyHHzAZ9ufpXE+dKZyikksBtyMn/61e0+D9dtvFmhiG9SKV4l8uTODzjrg84rh9a8IW39sPaySfYdzExyA79+fbjaOfepTXUV7HLaPrVzptwSrEgnGCevvivSLTxWkth5MVpK0rxkYj2MFbHow6815/r/AIYv9EuPKnUTQt80Vwgz5n071rfD64lEt5aqI1kePh5XwF+n5+opyV9UJ23RS8wi3ky7LMZfmTbgjvxg1nTa1qEigW85tynHmIArN7EgZrfvUXS9PkvWm33DOUaNeink84/D865qwA2rvA8xjvIVhnGD+tCGu5d003ctlcag7NIsLKsjbgMA9OnPXvVrxZfH7JaxOghmKq4VH3BlI4J/z+lT+EkFzBLbxqGmaYEqYwWA9fT86wvEcss/iC5+0OxdW2n5vugcY4/lRa7Bas7Bdufgt82VOtTHP/b3Bmuo1i1a41+4jlAVpJZQp2Z3Ddg9Pw4/+vXLR7S/wX2klP7amwTxkfa4e1dbqMijU7yATbrgTSSJIx27eTgVywtdf9vf+lG1b4V8vyPJviHoyWGpm4t7hLiGTA3A8ggYwffin6CLvxJp0elpt8y2GYjt5OT0J/xrvtf8Prq2gqJZykyK2EY8lj/PoPzryrQr2bw94gikmRlMT7ZUzgkdDXXFpoiL5426o7SfQf7OhQqGa4K4fcOSemOpA5P6dO9c/q+mt5rpOpSRVDDOeAelepPYW+vmO4tJ5FspgrE5/jHAHTj+tYHiDTAdRNsY2VwMSztGF8z0AzzjtURkzNOzPJbsMrKG5IHDetS2eoTWzKAd0Y6oehrQ1bTpoN6zRGMj15H51hmttzqhaSszpJ/EhdIzHaQpcRsSsh+bg9sH0rHv7y41G5aWULvbqEXAP4VDBOYmyQGBOSD3rUXVri2IEKiOTHB7gdcUJJbE25HojJcsCA69OOlIrbSdveuvhS/u9ND3OnTT20gZmkClhx3yOmK56eKB1/dZXBxu65oUgU09GU9qsvyZx39qt6JFNLqVssAO8yKuc+pqSG2SKMOXUnvj096msba+E63Glw3BETD94kZOD7+1NsTlo0fSFrHrGn2KRGZY0MQJixx/n61c06K7i023LEuzH5HxjJz7d6j8CavNrvhKOOYAXsOVYMNpODzgH09a19H8NTyQ/ZYXlkBJZVJ+UEnPr+Nc6RjY0dPn+3xtb30JkEf8ZwcH0qlrelraSC7iEjq33lUYLL9a19Pt57O5Hm3EKSouHU4x16nmsfWpkS6Igkch1wuWOxT64qnsWh8MHnWkkJ2oyMHiJH3Rx+dWdcWFLa1kaYoOI5j0EhI4OK52OLWJI3aOPzLYE43LnH0/SprL7VG7Wl5I8aEAkupY4z0UfjSv5Cuec/Fvw6J47e6tWIkshw7DJMbHp+BPH1rgtRe6is7m2vQ8Oo6eI57Z0cDgMPmHqf8AD2rtPi/runXmsQWWnRt59ttEpdTHkA5wQeCOferHxM0L+zJ9E1uK2jGQfNjC5DxkDk9uMn86cXbcNmcTbXkGrCPUbiy84uohvTnA8w/dYHoM/wA6xdS8LyiFLnT2E0buEMJ4eMkkAH8q3tfsF8NXkF7aOsul6iAZoE6KvGOh6jn8a0NEsYtSub/S9UuYoLX7P5sE8v3IycFdzehzwemeKadtUHM4u8TzTULG6028ktL+3lt7mM4eKVSrD8DVccGuo1CfUGSDT/EJmkiAxbzz/M8aDjCsf4fbOKx7vS5rSYxyjOQHiYcrIvqCK0TudCqLqDCFbMGIbnLDcrevtXWeNpLDT7YacYTdamVRo7xZCohXPK7f4j1HtXKXca/ZYShAbuD1BqkxknYsxZ29TScbsiKT1Zqa7n/hXGhE/wDQZ1Hn/thYVx9dhrv/ACTjQv8AsMaj/wCiLCuPqobDludV8Kv+SoeD/wDsMWf/AKPSv0kIOB1r82vhVn/haHg/HX+2LP8A9HpX6SLxk9z7YzT6gLjAGc/SuF+KHhFNfsBdQKft0GDGVUE8HNd0PTpimOiPHtP3SPz/ABoaurCavoec6f4bsPEXhmTS9UhjEyrzwR9CcGvD/GPhmfwnerp97GiQu7CKZjgkdBgg+n+eK+l/7OXRZ47m1LMm7EgZjyPfrzWZ8R9F0/xHo6LMI8n/AFcwXLIahxuZuOh8n3DlyAFKQ7zyr9R2OcH0/wA5qlc6ktspW8tnmdSDHLvCjGPYc/lXXeJfDmoaBqSQXRxG4zHOYwEYAjPbrz69TXN3NrbzxHzQWkzkS+WefaoVkZepz+oaib66jSFmRiOcEfzxT4YLm1LSRBWYEDfwQM+xwaivYp7CcGFAF3ZHy5Kn6kfyqzpc05uBJIz+eW+6Byf85quhZ0Vj4mubaxa1vrSKe3YBVIHzg9M5HpWe8LDeymGR3GdpJV8dsHGOvFUJ2xcSSKd0gYHbK2aS31a/Fwrh1aNMkqF28d6m3Ymxl3ik38iMgj25+/hj+lWbcRCNHZNpA7nBPXv2rT1awS8t0vopYlkcfMpYbnP+QayjGYVUy5VuD32n6VQ90OdwlwWRhljnIPI9gahxE2SWlxyc980LPChDGZACeAE5H6VMl0jgpGxMgwQ7cZNIZTCkgFQGjH8RPWllDmAoAAWb5gOPzp20FDnJlU5IzxToUnlfzQu6QnguRgfiaYFS5kCxCEgMygEd6s2kQhkiy4dpOkaZ/XNRyWssNyY5AzzYyVj+YD2yPrU4lVYCibQXOCWGSv8An29qBmvpGov4c1iO7tQfKODMq4HB6ivVNRtbfxAba70+6g82UDYfLYlfbcDj8D614/bys9u0bt5iNxu3YYfhXoXwwutGMN9oHiTUIbGydfNgu5hhUbrjPGORnmodyWrm1q2j/a9J/s2Y3LXlr8y7oseZ264x0P8A+rtz/hJIVvJbVomDsDxlcl+pJx+VVNA8Z6hp+uXNlNqEeqabBJ5UV9E2zcMnBCnrn9PXvUvjOGTTb+DXNKjlj83552VPlB9SPxOam2thNW0OJ1K4ludQuraUtxKQNuBjB757e/41ektBD5SRujKCGLrzjviqmueda69HfZTyL0B1mA3YPGcjtz2qwzySOEdVBKfN2LcematbDZpeFIHTVLqGO5+zpJGWGUJ3dv1rmtQg+w6hMs3luHc/MNxz+YzV7UVP2fdMwAyASpO5D6Ajg1hyvOJAZQ+5eRvPJppa3GkeizAi5+C65yv9sy7T6j7XD69q7TXNMea8mmnVFxK21yQFcluBz3z9K4gytPP8F5JM7m1mXLYxn/S4R/Su31hdup+ZfCaSBLovDFEwAU54OeoHT865YdL+f/pRrW+FfL8isIfPlbdAELyBUkfkoQR83vnH6CvN/if4ca0vZtRhdGiJAYfxc9z2r0OSSFI5hL5i/bHELKobEYycAf3hz1A/+tJe2C65bvZ3rRwxxbiueZJhjAP05BJAraLtqjCMuV3OP+B3iOCwu59Lvj+7vHQJnpnkYx+I/KvQPGNqLac3CbpLUnPmHPLY7DB44rwubTBb3clrbOkl1HMfLVcj5QepJ/nX0X4E8TWniLRbZbkbvJxFNGeQpB6tj6Z/Grkr6oqVmzwvUXj1R5IbVS90xIfA6nPJ/SuJurdreTaTkZxuxwa+oPE3gyws2v38KJH59wufNjbG8d1BJwD1/KvEbjQorrTwQzW7qrMFmjbfJg4O04x1OMU4yS0KhLkZykVuZbdWIG0HAPQ0FXuHEeMlBncBnC1pJompjbCsUhjbmNscEn/Ire1jw3BpGhRS319BDetkNCuWZuOmR0Oe1VzIblqe1/AHxJ4fvtKXRrkouoINgzxlR/F7n1rjfjX8O9H8P3suqWOr2lsLlyyWb5y5z8238/SvNfC1nqela3a3UJa3uYxvjxycEED161L4/uPEj6nbnxc0k0+zfB5hG3YcdMfQflSe+gRir2RStLQ3V24ihMIRT5gOSoGOpr1nw1r8N34ae00yGP8AtEWJiuNsWcbM7XP6V5NZ3N9qM1xcRWZkVI8SCCP7q9OcVp6Hq95oV/8AatLmMUAykjBBulib7w5z0x2pSV9CWmmej/C+3u476G91CR3NqJN8eMYd8EHjqCK9mN/NbWEMFup80kYK8sWP9O9cV4Mn0y/01L21lP2YIFUntjjHXiuq0oLI8l3I5APES5wXA9j9DUrsKNzI1i4hsb7y9UmVbe4GHbOcEcj/AD7Vsac2kTadGk7m7lDfuyQQMdRVfUdI0/et1fSh4icwq4yrHpzUOlz3E2reS32dCn+riySMd+f6UtmUX7KQCe5jg/jcKBuwQOfwNUNXtUOoQB94uIASCTjBB6EemKsavI2nv5u1o0IYHaDuQ/4e9cd4s8SR2Fn9jSD7drl2P3MSNl+nBODnA9qfkDOQ8T6d/wAJV8W7VbK13CMpLdHYAABgBW9c4A/GvaPGGn6Re+D49L1dk3KpVSOvTnHvxWd8M/Cz6V4cTVdTU/bLkmWY7SrFj9T0HQU/UL1UaSV42lAzGwI+6T39TT2VmJX3Z863Yh0zUTomsSSz6QHKW9yVwyI2CeOuAcH8Kn0LULjTZpdIeVxe2nz2F3Go3OnOODkMCD0OccjtU/irQDrGq3ZtbqMTKxkVXIVcdlzkknP88VycUEhMkLCWLVbbDQYcZBHJA9QQaFaSDRo1EuYdet73Tryf7LexO0tmnl/KWPJjHcZPQdvSm38L3HhmyVgwktyYz+J6Y6jnNUb9U1yxn1eVo7e8QrGVTgM4B5PoTirHhzU5NW1nzNWmklukUBSABuA45wOoHfrVW7A1ZXXQ5q+cSBWThk4YCorcbHV2BCN3rX8RafDpPiCeJg81m43xuDtLIw4Pfv8AyrMmiktyYLvepXlO6keo9RVrY2W2hf8AEoA+H2h8Ef8AE41Hg9v3FjXF12XiJi3w70Iscn+19R5Hf9xY1xtKGwM6r4Uf8lS8Hf8AYZs//R6V+ka845561+bnwp/5Kj4O/wCwzZ/+j0r9JFwQO/8AKq6gLwOB27U0EYyc8HNL0HAxjtijGMdaYFfUXijtJWuZFjixyxOME9P1ryvxPqj6HcLgyNA5y4KnCgnG7nnFesYwCHzIRzjA/wA9q89+Lfh+a/sH1KzkmeSGPY0CFRlfUZ71E72JktNCmRp2uaMFnK3llKpJ2jJGQOnp61534g+Hktnun0BxeW6jLW7N+9QcHpjnv/8AXrF8I+J7nwzdxW0iNLZzAJ8x4Q9+2K9dt9YLFJIFyZcY4HP41nuZaS3PnfVmhs7h0wG253wklWU9x7duayJLUwKskMjqzg4U85H+TX0Hr/hzTvFBmW8sJopMf8fMJAZT9COf1rzDxf4MuvD2nGee9iaykISFzneW/wBofw9+mfwovYXLbY89ntuAzuQCflUjB/HrVyG2tzbSSX1z56YwqR8Y59KTyiVjFxuaPOSQQefw/wA8Uhs9xUwqV65BIPP1piILS1WJdxhAj3HADE7B6mrPno0ZWVTleQduQ4zn1x+Q4zxS+XIyN++dcDOAOuOvT6UziaBYy0nYkkEM38/5UgIrmztZQ0kMYif+IMcD3x+fSqVxp8QmjVHIHcAZ5rSa7d22l12LhFIH6kmkMKSupDR8BR8vQH8fr9KLtDRUSM4eRSFwSArnlvpiopsKhGCvzZYtnB+n6VfvoHWQPKu04yCGBB/rVVIgxDMpz1VfX65pgTQW0k0ALylT6A7SB6//AFqhlWJ9xwjIMgNtPP6UTSM0i4QgsNjZHP0xTItkROAzoDk4XkD/ADmjUERjfuWSFlGfuseaiuLc3ECBmw464Hy/ianuVUyADgbeAB8y/X/61RxwsY97lwoPzELkEf160DKGs3VgdPgtoLSWO9U5lkaQFT9ABXb/AAV8YDSr290u/sor201BFQySdYMBhkDuDkD8BXPppUevXBjjlSFI14k2YJ44yP8A69d18I9E0OwF3dXOqwS6jkLHFgptHPc9Sfb2p3ViuZctupi6zZjTr+40m7edtNlk8yC4KKVwecYxkY/x45rPvopNJvBbO0SlfmSWMnO30yMYPHeu7+IVuvk71MbnO/IUnbxnP/665O4lsL6wt7i6jDNtMJ+b5m96zRmcvqzIJSR9/GFy2Qf/AK9Z8DSHlGCkdeeT9KbL5dqZom3OVY7S+CCPwqGK6CMuE3sTwBzmtEuxokelI3mT/BXOeNYlX/ybhrptXuxLqd3BbzXEkaTOJLRY8ldp4IbPHfI9MVytskkbfBRZOHOsStgjnm8ixXV6xMTrM0qxJp1xFM6YhUlLnJ4LHnnrmuSG6v8A3v8A0o0rfD935DNPvftFiYzC24OAEZgAfdW656d/8aN8llf299dQtKi5MbN92Q4+6xPPTvjHFQxwRi8ltbiEGQL5jRgkBTkcnPcflVGW7uLOC4gvN81rgCGRTvMYHY/T1rVeRyljxxbW9zE9xbWypdzDcJVUZQqOOnLfyrhrDVbjTUkl0e+a11WbMV7C6/67J4IyPlP5da7vStchvS1vFLFPPCoCZ+85JPDDGfyHc1w3jrQLjR71r6TUN2oO+ZUC7SGIzxg8jFXHszSOrsz034X6+tuCLK6huYUILWY+UwnuRnryck11XizwzY+MLWK5hu4rO8iVhH5Dc8kZUg9QSOtfO/h3UHmu4hbzraapnEcuMJLk/db6+td/pupzSXUU1tb3Fhf2kgWa03BnkyckpnGV9scZ+lNqwneOhN4h8G+LNG0eK3uoAbJSGjuYDh2JIO3HG38Ki+w+HmkhuNWsZtXCr5TXCzMqo3XoD82Oa9Y0rxemv2cWl61F+7cERO4AVeOST1B9j7+1dbeaBpR8MKmlWCX+Sf3KAKz7urY9c80rN6oaSexx/wANvAugyaqNYhZLyzlUKnUrGR+PWrvxT8G6BrVsIr2N22FvJuFkw8bdwPVe3P8AhXlOtXPjT4dwS6apMNvqiPbpv+bA7Mo/hYA9fb246rwZBJpugWVjdXUl2sILmYk5O47uASfXGPai6sNPlOj8K+GdP8O2Elro0cRkwDvAz5uB1JPWuU+LWmaY2hwzau8WmStu8uOBAWmOOenTgD9K7lr21gl+0wOyxxqS0UnG0EdSM1zviSxttYtWW+2ybhiKVedm8YOOmP60MEeCeFLPxHKXn0GGfyYSJBg4VtpznB4bp05r0nT/AB7L5sV94ystTtY0+RXiXEZ44x0P9K3fCujXOhaf/Zly3m+WWiWaEEh0OSuRjjH41ZF3Z31+lnOkU9op2eYwDASjqu09+vHfmhu7E2ZY+IvhHUrpBeavqtqq/d3RMwX2IGfzFdTP458JRWKyaXr1nabM8Ku5jx785x7VneLdD0jVLfF1ZwTu4xuVShHpgDGMV47P4BuP7RsoLaYGC7bgsvzR+zdumKFylXR3Y8b6/r9zJH4et3kt1GJrxwAc56gHPGMcc12ng/wQ1pdPqd9d+ZqkxLvcXOGLsfQj7oHTAqvpmm2nhfQYLCxYsI/neYgZkNb0GoNJaJMzFiF+ZNuQBQTu9St9o8W2utwXs1/aavoasYrnTobZYyMdGyTnr79unOaq6/q1vNHLO2k3T3EaNJGsTMMrjocHkiltbovqNxeBZI4G2pjBAz/e569asaohVJL6G8+VV+ZS3yyL/d/l/wDqpNu2hR5J4iZJpob+wguIDyZkWAhihHIU4IDDnnpWJoHha91qbUZ7UztHZw7087AaVc8Lj19/au1XV4/tT2luFDv8mDgqMjIPPUfSpdDuBDqrRQoWtLmIKflYgOAQeRwM88URdjO55H4qtoYpJJbFrgM4H2qJ1wPY8fh1rmoJpIJklicpIh3Ky8EGvbPFnhs3d5NfRFCDZssyuCNyK3BwB1xg/hXneveDrnRrjT5LmaH+z79N9vcodyH/AGSex6f5zjSElazN4TVrM67R/wCyvF/hibQ72BoPEChp9OuVYeXJ/EY2OeO/8+ted6VHb3JNhcqtvO7YiuHJHlv2Vhg8E8e2a3xFPptmJB5kN5YuCY3j5696yvEsSxa1LJFsEV2FuY2ToobnH4HIoW5MHpYi8TZ/4QDRVddrrrOoqw9xBYg1xdekfEe5tb7wdod3YxeTHPql+7Rk5Kv9nsQ35kZ/GvN6qn8P3/mWdT8K/wDkp/hD/sMWf/o9K+4PhZ46g17w7ZNcHy5XQcHqK+H/AIV/8lP8If8AYYs//R6V6d8NtRvbO4RLdjGh6+axwfp+FTJ2kTN8tmfa4O4Zxx25oJGMk4xXmPhPxl9mhaHUWUkHGFPf6mr/AIo+KPh3RbMtd3ToWGMohbaT9M1ammNSR0eveI7PSkRXlQyOcDY44PSsSw8Wx6vDcxREYQhGbHA/DvXj1v4e8Q/EHWvtUC3EOiuFkhncj94hAIIzz9PrXo3hfwBJ4Q3PDcPcRy4Em5snPqf/AK1RzSZN2zJ8eeC7TW7JrqEiK92/OIU2pIAD+RH+etct4F8TRR3Y0jVhAbgHbBNGuc9eGxgV66yNho4BvQdv7v0zXD+Mfhw2qyNf6PIq3jAGSEnZ5mPRh0NJrsS11OwQbLcRgRlmG5mXow61j+JLRL/RL63e2aZXQ52qCw/MYrz3wj47Hhy/k0fxNcxwTxERAyTAlOOj88V6fbatY3jwz2epWsi53bIZ0IbP169qTsxo+Y7iOFDm1hkSPcQ24YZT7jjp6VRU+WrRTPGPMICuBgrj8eetep/FnQtTi1ibWrw2Evh66XaGtIfnifGAWxx1HX36d680u1WEpE4AcEnzWXLfiw+gxQZtWdivbuRN5bbpUjxgSOCv1x+NUzKd7ooHOSqgkgdOn5jr6CppHkFykYaJVVfvAq2e3fvUTSIHVpSEcYAJOBx7DOO9PcBptbtlEsiYjUj5yykgdeTnjpTmuYQ6bvmYc44+U/h9KfK5jULbLy3Ejg5z7A01IMOsySGRM4dgDhP0pdNRiOiSFpGeVYD91DHkM3Trnio4/lkjQxgryMv8uP8A61TSQRrMztMWKZcL5eQR+fHaoZoo5oy7MRGcY2nJz/OhMCKdrZXYuWRt2AAo2/Xk/wCNSYaJQYiD+J5+vOKdcWsMgUxwOJFwGz/PH4/qKY9wbYu0sYjlIwwzkD/69MA3qkSHPluT80i/KCCcY96pXchLYZ1ESnow4PuO9QXV4Nzrbqu1sZkkUFifXvj8KzH3uf3jMT+dNIpRNiXUYQYo4VkjQD5trjr7DH86twwC8tppoHSRUG90AAYfUVzSoXP3efXoakgleB90TbXU5zT5RuJ3Xh7WCbG6sboPNbSofLGNxRjxu56dSeazrdSZ5raQ+YwGV6nJ+uePyo0rWUmdbos8Goq2N8bEKR6lR/SrE1vdTTi9igh8qL+OFiyv9cf54qNtzPZmZO/mpiaNWydrAkZX2GO3FVLS1ijlfPyD+E4ziuut49PvoVldHhl4VgqcfUsefTp/hjJubWK2eQQ+dIrN8smwqCv9P5UJjTOnlXbffBduPm1mU8MSP+PyLvXW3+y+v9TSKKOK4QuGiYEox3nkkeorkGUJf/BZUWNVGryYCMSM/bIvXvVyPXLS51e8W3WRZ4JpMhFLLtDnJyOx+v8A9bmhq0vX/wBKN6qfLf0/IsWr/Zb64e7JijhXETrH/q4/9pc8+vGetLZq9+xW4uBawXIMqvbITJMp+pwucDkj/CrpRdWg82YOkZ5MRO9pRxwPRfUd6qWkkszyw3ccroJQquz4eNR0AcchR09/xzWyOUytV0S0eWFbWNoBGDsCrggdyzZ5P1q54cml/s2XToVle3UkkImDIpJJBJ5PX65ragtIy8csjuzsCSqZCnHIycn25qF9PFtcLJYs4djvII++eeD6D3Aov0Hdnn3i3wTMkkt9pMavC7Em3Q5K/T1+nvWV4P16HTb2FL9XEAJy8aguCeOSew9PrXslrKlxC8UMRjYZ89HBDIOhJzz0OM+9ef8AjvwnJdn+0dKtEQqpM0cR4bvlR+eauMvss1jPm92R6L9sjEGdNnj8i8j8vb5ZxOQMjJ6Lj6elasV7PamGKJzGwYIpDY28Z69q8D8J+Jp9EmEc4keEHhST8h78V7Xp2rpfWyMsqz27LukkQAnB7Nz2559/rUuNiGnB6mp4s1+TV/C2qaXdT+ak8JVXnbCpKvKnIHXIB+oFZ3hTV7hPBNjqOrP58VvAC7gnLbSRz9Mc+vNFqssVxOjb57dhtVnXmMc7uOh64rX8K6VaRWMmm2lxJLZljIhbhlD5JBA7Zzz/AIUldjvc2dQeOS1tr4SB4ZiEYrhhhhxj3Fc1o3h68tLu4tru685FZ1t2yc7CehPIJ6V0P9i3NjZLbHyXQD92vUDnjjv2qCQIhi2q+1jtck8Kw6inYe5R0HdcWLR3TPE3zQMhJxhTwc46ng8VFqGlrqPlqT5UkUoct3RgPl5PXrUg8kXFyRwlwdyJvONw9D6/SrGl3/nJJPG4laVcoVxliPqPr0oF5EFhFNcW5iuX23UTZby2znnOcY4zxVZB5ev28EzZZZdpweUO3IqZ7qR9Tmxbqk9wgy+c5K8Zx+IqnKLj7fABtMqNmQt8u/jHQjk4pAauop9suhCVP394J7c96fMWhR3jABGBkDHTg5qtFer5zTRFWBJymckc46YrSskWRohdKFMh5ikJ3EeuF6UDGortZLJcAx2z5ZkI4BrHvElg842ID2qgNIgfcWH+zXYSrMisLSO2eKNgiImWyMe+Kx7hRKsqq6pMGOUHXr7U7A0eUeINV0258WaXDfYgPlOsvyYyT93cfz703RtbtbLUWMRMkIdsbASMZ6kYznvT/iZ4ZaXxDpjTRbUe6WGTY+5mRyDnHbvXodvoOkaZp4kMUVnbWw+RnwFVQP7zctnJ5oS0JaDUrS1isJJp5mjhKtKx3Y8sEHI4/Lp+deVabq1xPaLoGr6Yt7ZXzf6I4lCjZnJ2t0yMAjJrpL+61nxZNe23hzT5dW0Vo0jluZcQQ7s5IR269Me1TN4Y1Dw/4buLe+8GzalZTOWZoNRE01qeMGNUAYj6fjTt1KseZ6/4cvtDXzrZ11HRSR5d1GQQp6FWAOVI6en8hzl1KcLFHIRbnLpu7HHIrsF09tQ0i+u9H82304FQInkMgLY+beexz6jvXP3VlC8MUSsELx+cJJV8tf8AaQeuOx71cX3KUlcq+JEK/DzQSejatqLD/vxYj+lcZXceLYfs/gPRYt4dF1jUdrL0I8ix5FcPVQ2+/wDM0Z1Pwr/5Kf4Q/wCwxZ/+j0rrdJXUUktb9HLbAM542g88/wCFcj8LQD8TvCIYZB1izyP+2yV12nyuuHlZ3Owfuiueo7AgL+P5VMvi+RnPY9e0vVBq0f2lYASMIrAErnAzk/jUGqaDZawsUd3vEckokdSSwO3qAfem+C5LiTRLdJ1AwSqAvyB6/nnpWi2y3kVBgbSWUZIYnvjP41n1Mj1z4WeN7DxjocrWls2nz2Mv2Wezk4MTL2HqMf5611molTZzBmG0Dn2PvXyf4P8AEtj4Wl1WeIXMmq3kon+xWas7NGGILdQOue9df4F8aeNvGWrXkdgdK0iyOVaa9je4lXg42RqygnIGdxA574rVTdjZSuj19/KlYeZGGULnevGDXG3/AMSvD+j3f2FNQXVrl1Yx2ekqbmclOSu2PO0+zEdD+EreCI9RtBD4t1jVtfBRQ6S3H2aAkf8ATCDYpyf7+/6+utBoVnpkBh0bT7awtydxW2t1hTPqQoA/SlqGh5V4u0G28XWs+oTeGNF8IWHmC4m1nVpkS4cScktFF/GWPR3BJPTPFeQDwJejyNSuI7oeHZ3DQXhhWCS6iz99I2J2hgMqW6gg4PSvqTU9C0zXrqzbW7CK6azcyQI5JjDEY3NHna5wTgsDjnGM10cqRX1kLa7Vbi2OQYplyGB9+3Wmg5nbQ43wifDOveDF8PaMsENiibFhTOYsknJB5LZ5JOSTyea8t8Y+C9V8OXMcPnJLbt/qp1GGYZzgjNdh4t+G1zpN5LrHg4XJki+byYmy6DB4HXcDxwfT82aJ4us9dsn0vxzAluqN+7vSuwA4/i/uHPHOOal66MzZ4vcWL28z+fJHlsjDsckeh59qoSGNVImnhgdSR5aZJPr37cd+9dt8TfhrrOlzz6npryatpTjcs0ZLsq++O1eSzEo+MZPfJppAonVebamBZILyBhH2YEHt2PbrVK61W3jh8tbiaXdywiBA/Mn9K5854JAJ/wBmmkE9AefajlKUTZPiHaAPJklVeAzvzj04qKXXVkEm22UK5yoLH5fxrL8oZ+Yt+FNMADEqRiqsh2iXHvnlQAKu4fxdzVWV3ZS0pzznFPUBTnjP6U1huGeetCVgGrhh16+uRikXH93HOMlutOZQT6AdjSyZyqcEDng0AQvkHduyucCnLzxx+fApXbLYI+UU3BC5B69/SmMVSyyB0J+XoRxXo3w81xJL+GxuILd4bjKvCY8hm9eO/ArzdVZeM5Hauh8CQzS+KrFLcqJWkwCeg9/elJXJmtD2fxh4J0+OwS4021azliO5lWQOjr34PT8K4u8v9O1DU7VbqRol2CORYEAJx6kH6c17nHpMkeliKeT7VdbPmeToTj09K8L8b6Wmm6nIRbiA53bU+VB6d6x6kNG14rsbLT/FvwettOcvbLrDbWJ3Hm6hJ5+pNeN3t3NDql2VkJzOzNk5ycnmvV9WvhqGufBacQpCTqhHlqMAYu4hnH4V5Fq4/wCJpd8Y/fP/AOhGoorVL1/9KO5K8NfL8jvtI8floLKO5YQ3SHY85UMCM8MR1/AeldRpupWN6BFPPCbi5k/dMrY80YySRkY+nf8An4gqnsKkV5VKkO4K9CCeK3dNdDndBdD6Fs0aC2Se0aS5sZfmRDHtkH5nKj2q5H5cgIuHjniyTE5PK8dD6H3qt8JL23v/AAXZR61qDI0l1IrXMhLMiqOOhyw6Dnpmu8mi8GWuySa8vr+QjaGt0VI+vcN0+v5VlazMlA8/u7JZd89tK3noAXKty/8AsE9xyeRTtLk/0owadA3muoJjRi7MDySM5Ofw4/l18XiPw5ZXjjTPDEQccGa6dp1IB7DOOvbPamX3j/xBarL/AGXBbwWyfejtbYRkD1Gfzo0Fyrucrrnwhv8AxQGm0/SZ7S7GNkkieWrDH8W7GfqM12XhSwh8F6Tp2m+NbX4b2FtHCsMk6XGy6mdRgMVKfO5wCx3ZJye+BxR8X63e3cYvby/1CJgwK+YY3UjrhOA35VseGvFOn6awS10eR9XDl4b26iJNuCCPkRhgNy3I65wc1V7mkZpaHq9zovgy101dQu7IWNsFwrSCWFj7CNsNn/gPvXm2r39gLqSTw1G6KAWgaVwTkDlT32ntjNePfEeHxfHrg1u+1a81Qj5o7tWwYl9Ni8IPYALVDw94/ube4UX6RHcRunRACPcgdfwxQ03qhySa909m0DxU+qJpFzf+Za/ejmilypRuihs9cnp65/LPt/EFtJrd94YRszu7SNIBsO08kfXHTHtSpAb6C3uopk1G3lIYZkBWQdeM/wBf0qLxHqPhjRtRh1TVomj1FFIhzAxb6ccfjmkjJXeh1t9pGnvZWtnDGhNugRPMXJIGMAk/TrVK/DWtqY87Y532ZyR5ZPf8fX/GsL/hO9FvovtdvBfRvj5Ue2k2uR1AIBFcvdfES2/sy5vhDNPqkmTGuxjHbDoAxOAenYdaGm+hXodoskYjglRWSSFdqNknP1J9e/8AWsbUPF+nWWuWcN/PsYk+aUO7YT0z2981wNn418Vas6W2jW6PdH7y2tt5jNnuQcgfWrtz8IfiDJdC6bQnEzkMoNzCcnr/AHsfhVKm+o+Tueq3Gp6dYaSHeWKAfxO7Avgcgn0z1zUFnqkd4DcaZIrb1I4O7J7enrXAx/D34lyySSX2ivcALjyp5ojv7cYbtTLjwV8RRbNbQeH57TbwVgnjUcjGMbunajkYmjsvDPjiaS6NvqRS1uVclYoxnywB/Ec4zW1dSWk9rJdzZtZwfNLr8u4HknnjHrmuG8FfDfx5aXEkqeG7ZWkjCCa/uUIVh/Fhcnr/APrrvNN+EepateLJ471p7iLd/wAg6xUxx/Qt1I6eh460ODHY8w1PXda8a+JLa28JW81+bNeXKCNGJ6M3QADnGTzzXq2kfDSBpba/8aXs2rXGQFtpH22sTeyfxfjwfSvStA8LWPh+wSy0izgtLY8tGg2knsxPc1ZnsmdXRpk/d9CGA4qlFIfKZ6xqyqCqqo+VSnAI9MDp+FUJbeSJDtbezcgjjGP171ry28ki7DLExzw27GKgSFxJhXhK4xliT+OKBnmvjHwW2o3EmteGLyTRtWaMrM6cQ3RAwBInQtzgNjvznAx4LrFiJtFkdmm8u1uBDcsU2Gzc8BXi5wCRjcDyfevrmexhLmR5HuCO0abVFcT8StBn1DSrybSvL+2SRbZrdlVkvI1OfLdSMbhztbqDjBHNLbYXmfMvjOaGb4ceFfKVhImoagkuRwWEVngj227fxzXA16T8SNIXSPBHhoRyrJDd6hf3UYHJjVorMBCe5G3BrzaqpfDp3f5mjOp+FeP+Fn+D89P7Ys//AEeldvm5u9NjtZUFxGgDy/usEcdGA9/XuPU1xHwr4+J/hDPT+2LP/wBHpXpVrZC78mKOcqSqlkZPLJPcY57kdT6+lKfxGVTZHN/C/TbXUddvoLuztruMWrHbPGGUfMvPqD7jmt34dX97D4q1Ow095rnQYjKq/vPMjgAJ8sqTkc9MD7wOeduRQ+D+m6fqHiHUY9UtoblY7cskUsSyDdvXkZHXt+Na/hu5lsPiZc6DpE9xd+HUeUNbu5eOABSW2k/dAkO3P8XAOSRQ9WypdSnH4ulPh+90NribeJmJTaVH3sHjrn2zXq/wF/sK6gnh0+8a9kRE+2R7JAqs5bHDqAc7W6Z6V4DfsLXx9qAlAVDfyDMnA2mTIJ6cYwa9f/ZGX/T/ABQ5ZUVVs+SMjrPTSFyJam3+zHqMsnhDW7vU7wmOGdWeadyQiCMEkknAAAJJrvbz4h+Gf+Eaj8RNfXA0dpTAl01jcbC4yDgbd2MgjdjGQRnPFeL/AAQ+w3fwu8Y6dfXVzZxTrta6WImKFTEfmZsgYG35gSOOpGa1tHsb7V/g1pvhC3sBG80hY6vNcotr5JnadZUTPmksCoCtGp+YklcUkraFytfU9N13XdKg0NdW1G7l0+yMm0NcW0kMrOSflETKJC3BONuSAT05qDRfEVpc61d6XHco+pWYXzYJUZXRWUFSQQMjBHTpkA4Nea/G0J4cPw6aKa4ubXS5P3s7L5nmmLyNrOAQCxCuQMjOW5HNb/hbS7afxsviaXWBcXt7E6JFbIqRSwqFBbqSVB2fNnG7aM8gUupDPXra5dTyCjYPCuST9DWT4o8KaX4kVZbpRaXyDC3UXyvn0cdx165qCTVoEuFjMiMpwGYMQV/IelaX9oWwyYZkkbthhTuG55VIfFHw7vCzgXOjyNl0DboXGOvPKHOeOlcj42+H0PiMPrXgSFXZxvu9PYqrRt32diOvf6V9FRTwXts9vOitbniQy4weO3/1q4qfwpc+GL+TVPCUhmi+8+ntn5sf3Wz6H8aVraoVmj5IuLZ7eV45o3hnU7WjkXayn3B6Uxmwctj6V9YeI/DOh/EuzMt0r2OqwjBlihw8Z9HXuM+/0rxDxl8KPEXh5mmjt/7QsskCa0VnOPVlxkfrVXC/c85IyvJG3OelNEuCy9j6ipjAu9kO4MDg8Y2n0oks3jHzcg09B3RHkMeD+AokdmxkYIGAcYqNhsbJ5/HpT1Y7eCCfaiwxAW3bTy3fFNGdwIp2MjJY5+lRu5BwowOufWmFhWcE9FBFDYLjPX0HemLGXAIOOat29rLM3yjkcc0bDdkQAEt8ox9a9Y+DGl21jrC6zqyOwjQm3ihBkkyf4ig56fzNc94X8HT6jIJJ43CA/IfLI3Nk+3tXvmhafBocUcem24F864kcoECA9SSOaiUuhk5c2xPceL9NgRjdXDREn/VlcSLk4+71rxvV77+3/FkkMUryWrHzFOzO0Ad+46nivU/EMltPbFb60tL1lPAkjA5z2JBrM0Hw9aie8uraxA+Ty3MaYCg9R7/hWd9QfY4jVbaWy1/4Mw3EfluNWZ8ezXkRH6GvItVx/ad1ggjzX5HQ8mvdPiDLHL8Q/hH5QAVNVWPG3A4uYR0+ua8J1H/kIXHAH7xun1qKC1+//wBKO6Pw/d+R9Kfshsmsaf4j03Vbezu7KwFs1uk1tGxj81py/wA23JyVXgk4xxirPwWvj4+8R+JtA8WaFpOraVaB3jupLCFHtmL7Fj+RF5K7iG4YbDzyMU/2Lf8AW+M+cfJY/wA7mtH4FeMta8W+KvEPhPxA0N3ogtZpB5cKwGLEqJsDRBeGDt1+bjr1rob95JeZnbRv0K8XgtU1C80Xwla/brWwlY7TOgYKWbGCxG7GME/TJ5zTtL8Ha3e3M5sLJBJbTGOTZJENjjqrru+oyMg4zXefDnw9p/hj4gavpuiyyPY29t5axO+8w8xMEDdeA+OecAZ9a3Ph9C8fiLxc7Fikl9wSMAEPJwP0P41CjfcwdNN3Mb4V+XqOhamLuyt1EQBRGVX2FlbOGxyCa8+j8H6nqNpLNaMy29ufnaVxHGuegDsQD2/r1rvfgzcJPo2vOoBjBXDAcHCt9OnTFJ4fvre9+GUumXJS1MTCMS3L7Y5Tv8wAP/eAB/IHPPC6a9h8t0kef674E1i20tb26s9sUK7o5vtMRKgnr8rEkZI5GaXQvDPiO6treW4tGLzRM1u0ksavMAMkqhYMR0PA711fjjV9NvtF8O6LasuoRW7xm5vYeViQDaQre4Pt0Fb/AMTdVi8La/o2vSaZc3awRvDFJHcLHEjOdu1hsJyQ/HI6e1FkxezR5bZXKYkCedG4YqSuQd4zkEH7uDxg9PauT8WeBdP1h5Ly1uVsr9zlwVJR265YDlSfUVf8UahO3jzWpp7F9FkuZFl+ytiQByilixAAySSxxg5ODzWha37TKomRrhskAdwAOD9PTvSu1qjP4XozyJP+Ej8CX6SPHJFC7cbsvb3H4jhunY5HtXf6R430bxPpcmkeIVeNJnUmKWTOD2Mbn0PZj9M10yt5ipaNHFd2sgxcW8yhlc4xgoeAwPf9K848TfDeSNGudAMk2clrOQfOvPARs/P9CAenU1SalvoacylufTnwg1LyNOGg3hhka2GLe5XAE6Hpx1DDofccV6O1vGcZVM5/uivi74XfECbRtWttL8RCcRRSeUkrZWSBs42uDyR29Rj8vq3RPF+m6jtjWeN8cM2QNv1FaRlbRlR00Zurawwu0kESRMBg4UAN+VSEbuOAT0VuVJ9qkSRXVTHIrDjlcdKcSASOc/jV7lJFWSHClPmbHO0nnPsarJlnO5ZDJ78H8K0DnBHUE9+aZdRB4vmDEjkMPvClYLFOOQheX3MDjLNjPp9DUdzNJwCWH+zu5qSaM+URsyAAPMT+oqp8ucAjaPmyDwfx7UhMjDsqEuWC9SQQcj3qIyxFwSjO+COmMf41K6BgiHBznryPpUMqyExiMKuDgtngUhFc4EbsNj5OScYFU7pWB/dt8x5XPFWhFIo2srA8+wIOaimUAp8pJ6HI7+1IRWJaNGB3hevA/pUMmE+8D07dKmvEjMscgRQ4Xb0G5f8AOB+QrI1zUY9N026kkIG1CeenvUtpaiPm349Wi2elaOsaNHFJqupSopbIAZbU8egzk4968br1z40XUV74X8NXVvMJUmvtRbcGJ5xbcc+nSvI6MP8AB83+bNGdT8K/+Sn+D/8AsMWf/o9K9TtIZPEEbSSRyGVgFxGhQt+XIFeMeFtW/sHxPpGsCHzzp95Dd+Vu2+Z5bhtucHGcYzg16tpHxm0fS52mt/CNy0rdWl1fdn3/ANT1omnzXSuRKPMtz0jTPh9o9lZxpLpFtl0KudzbjnqCc5x7VbPhzT9FiddJjFkj4LmGMZbHQE4ycZPX1rgJ/wBoS1mbLeE5x7Lqox194KrSfHexkJLeFbo5GMHVVwPp/o9S+d9H+H+YvZ+ZteLfB1jqEL6orRTX4BlklY7QyKOOOhxgDJ7V6X8Bf+Ean8K+bo1rFZXkyhLgLI2+QqTgsQc8ZOPTccY5rwjUvi9pN/pd9Yt4b1SCO8GJHg1iNXx3GTbHg9D7Gszwh8SNI8J3v2jSdJ8QAfxRSa1CUb6gWgprnXQcYW3Z9X6h4R0zRvCOv2vhzQ7Yy3tnLE1jG7Qx3RKsNhIIxkEjIIIzwR1ryez+D3g2Wzimj1Dxt54ABzproVfjnZ9nyBn/AGsf7Xesxf2oBtUSeEpZMf3tVHP5Q04/tQQldv8AwhhXPUrqYB/9E1Tu+n5FJWVkz07wx4OW8+Gul6X48torzU/LY3PmOX2NubZhh/y0VGClwc5B5PU5Vr4c0vwHeNDpGn/Z7a6YNJM5YnjoCzEtjGeM4HPHNcJH+03Ckok/4ROckcANqgYf+iakf9pmwuZT9q8JTmJuGH9oK2Bn08ods0nfohcjZ7hBN5kMTbIm3HKtEow1TzSIsYMsUa9mBQHI+hrwG3/aK0i3j2Q+Fr0DP/P8nT2/d8U//ho3STgN4av8ehvUP/slLmfZj9m/I98jurdIvkKK+ewG0fhVyC9ScFVkQAjr0x78V87yftC6A5Cnw3qAQ4LkXEeSe/G36VBN8dfC8kiyJoWswyDPzx3EeevoRjsKnnfZ/cP2b8vvPftS07dMb21do7xP4hgCTn7p9a57XvFs+nWT3UKTpNHlZogw/Mdu9eWQftB+H4kx/Zeu5z182Ln9Bj8KyPFnxg8H+JRF9p0rxDbvHjDW80SlunXOQenp+VJzfRMXs30t95meLPE2o69qM8tz5r2vJWMKEGM98AZ+p9KwUsZrizM8gAhztChD8uOOvYD3rVk8eeBmYeXaeKIR3Eb23tzyvPT9fpUc3jbwJMu1rXxSuM4YSW+cflS9o/5X9xHspeX3owNQ0mS2L7UaWFcZkQEqCR396x2tmyWi4xySD/Su3/4TPwJ5QTyvFwwc432x3fXioG8T/DqSRHks/FfynorW4DfXpVKq+z+4pU5r/h0cYLe4cDHPvirNjo9zcTeWsLvJ6KOfyrrT4n+Gz7i9n4s3HphrfAHpUv8AwmfgIQiOKPxbAvU+WLXP59aftfJ/cwcJ+X3ozoPCs0LRNcgRCQYVSct07gdMd/SvSvBfgVrhPMlmh8mP74RgCx/2ic/5/CuT0v4g+AdPk82Kz8TGY9WZYM9D6MM9e9dJD8b/AAfGhAsPEPHQBIAP/Qqn2jfR/cyfYye/5o9TsLe10uBIbeJTMBgPj7g9RVgwIB87sTjiRj9/8K8ug+PHg6FyRp3iBs9zHD/8XT5Pj74SkZSdP18AD7ojh/8Ai6Obyf3Feza/4c7XU9HfVbd4f3sMbHEZzg/iPSumstLt9M0dbaOVxsQKw67vevLbf9obwdESf7I13d/C2yIkH1+/UrftHeFWjIbTdeLEHJMcJ/8AalPmS6P7mHsnf/glD4mQiD4k/CVAwcf2svzDv/pMNeA35/06fnP7xuc5716L41+Kei65438EarZWWopY6DdpcT+cE82QCZHIUBsdE7kcnt1rlp08FzzySHxLrS723YOhocZ9/tXNKmnGza7/AJnQmrNen5Fzwf8AEbxP4PtJLbw3qENhHLjzGSxt2eTBJG52jLNjc2Mk4zgYq7Y/Fnxjp8d2mm6pb2IvGL3Bs9NtLdpWPVi0cQO7/azn3rCWHwWVyfE2tA/3f7CTP/pVUn2bwTz/AMVXrHT/AKAK/wDyTW3Mnvf7mGn9WOi+Ffj3UPDXiKS5a/n3XLlpHc+Z5jsfmL7slsnknrnnrzXuMHxD1/z1nhvImS5wQsEKFQcnkjnnnnuce1fNkdv4K3D/AIqrWE4JydBX/wCSa6PQvFHhfSgiN4k1a5iXPyPoagDr0/0k9c1lLur/AImU4y3i/wAj32HXpIrZotK1GHw7d3DkzNb2UU6TN/tbhn9eOntXQ+ELi40/wSItObTfE0huZJfLULbhCzFugDdycEDjp2r5/t/iD4Kt0ULqWrkBWVgNMQZ9MfvuP/1fWnf8LD8GC5SQalqpjjJ2xnTAR0x/z27/AIVKk072f3MlRl2/FHufim+tLvwhO2qaPZaRrJdDawxSCR2YHJJAAOMZHzDHf0ri9b+I3ia28Kzvpeopvj2xbvs6ySwnA5Bbg9uoP+HDH4j+BwPlv9YAbJIXTkyDn/rr75/Cop/iD4DaUyLdas0hAGX05WVV7gDzhzx1pXk9Wn+IOM+n5oZDqNwkdsdUkN5LOrM06uJtx67nPUN1z9K03judKkh1GQi90krt2C2dJoX6ZyR8y59a5aDxd4T0/VmutL1/WoUf7ytpKv27N9oH06GtSf4l+HJVlR9f19wzZTdpqkKOmCPtHPqOmKd32/Az9lJ/0v8AM3bbVbCVmbzL20kL5Ex5DewB6DP86tJeWt3dqsTMoYkkrlgceh6Z5571yVn498HQGNm1XWnk/i/4labc8jODP1wfU9B3qxJ8RPBZiZZb3VpTuyMaWi8en+upfJ/cHspf00aeueF9M8QTyTSWzrICRJcWjAOp7EqR859RnNZun3OseEryFdTuFNkz+Xb6sgynGcRy9x+PQ9MjJA3xK8JLDFHbaprsaKPmU6ZGwY9eP3/B4FQN8QvB8yOtzf6pLHKpWaI6Sm2Xp94Gcg9OvWmm9mh8kv6aPa/BXxBJeaG5gZZEG4tAdwI68jo2R0K//r9T0bXbLVo0eznikyMttbp+HaviGz8QeEtN1E3Gk+IdetoA2Y7eXSEk8rPXDC5HH4enU81o6t458MX2lmzTWdZhaTmSYaOhJ9hi5GB7ZNWpSjt+pok1ufcIZThgw2/UYpHcAlQy7j2zX53uPBrtvfxDrDMeudBjJ/8ASutjRPE2laBcxvo3jfxPZ+Wcr5OjoEzz1T7Xg/iO9Xzvt+Zdl3PvGdd3GdsvYg8H61mXQ2sBgq7dxyHr5s0T9oG2sgq6rrWo6mu3Bb+w44nb6n7UR37AV08P7SvhFYgssGsucAnFnGMe3+to9pfo/uE4+Z7LHmOYGdNuwdvT29KV5IHcvJclAOik85+v4V4sP2kvBShgbPX2JGM/Zov/AI7ULftGeDPNDC01wgDp9ki9P+utHP8A1Zk8rPahIZA43gsTyu7p6VT1EB5EAJaXrxwRXkEn7Rfgoqdtlrnmc/P9li/l5tc/rHx18PXIb+zLjW7KVvvSvpsUpP4faFqXLyf3Bys9Y8Q+JNM0C2a51G4SNVAOC/JzxwO5zivnvxn45ufGN0YYC1ppyNucqfmI/wA9q5jVtb8PavdedqPifxHONxO19GjIXPXH+l8VH/aHgxdqpquviNTkA6PDn8/tVJa6y/ITVtiz8Rlt1+Hfg02kexXu9QL5GCzYthu/ID8q80rufHviPSdV8PaDpmkS385sJrqWSW7tUgz5vlbQqrI/Tyz1I7Vw1XRTUde7/MbCiiitRBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the placental \"bulge\", loss of the continuity of the uterine wall, and the dary, intraplacental bands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Resnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38441=[""].join("\n");
var outline_f37_34_38441=null;
var title_f37_34_38442="Treatment of hemophilia";
var content_f37_34_38442=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hemophilia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38442/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38442/contributors\">",
"     W Keith Hoots, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38442/contributors\">",
"     Amy D Shapiro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38442/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38442/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/34/38442/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/34/38442/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/34/38442/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemophilic conditions are a group of related inherited bleeding disorders and include abnormalities of coagulation factors as well as platelet function; the most common of these disorders is von Willebrand disease. However, when the term \"hemophilia\" is used, it most often refers to one of the following two disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Factor VIII deficiency (hemophilia A)",
"     </li>",
"     <li>",
"      Factor IX deficiency (hemophilia B, Christmas disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of these two conditions will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The clinical manifestations and diagnosis of hemophilia A and B and the development of inhibitors to factors VIII and IX are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1322?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hemophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23967232\">",
"    <span class=\"h1\">",
"     PREVENTIVE AND COMPREHENSIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of patients with hemophilia is complex and requires the provision of preventive care, the use of replacement therapy with coagulation factors during acute bleeding episodes as well as for prophylaxis, and the treatment of the complications of the disease and the complications of anti-hemophilic therapy.",
"   </p>",
"   <p>",
"    Patients with hemophilia should receive integrated care as soon as the diagnosis is made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/3\">",
"     3",
"    </a>",
"    ]. Most children with severe disease present with bleeding episodes within the first two years of life, although a few do not bleed before the age of four [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23967282\">",
"    <span class=\"h2\">",
"     Circumcision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 percent of undiagnosed hemophilics bleed in association with circumcision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/6\">",
"     6",
"    </a>",
"    ]. For this reason, male infants born to known or suspected carrier mothers should not be circumcised until hemophilia has been excluded. Assays for the appropriate coagulation factors can be performed on cord blood; if cord blood is not available, a sample can be obtained by venipuncture from a superficial limb vein. Femoral, arterial, and jugular sites should be avoided.",
"   </p>",
"   <p>",
"    Whether hemophilic children should be circumcised is controversial and an important social problem for these families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The use of fibrin glue is safe, lessens the need for factor substitution after circumcision, and markedly reduces the high cost of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25094?source=see_link\">",
"     \"Fibrin sealant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Routine immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine immunizations, such as diphtheria-tetanus-pertussis or measles-mumps-rubella, which are ordinarily given intramuscularly, may instead be given in the deep subcutaneous tissue in patients with hemophilia. The smallest gauge needle should be used, and pressure and ice applied to the site for three to five minutes post injection. Intramuscular injections should be",
"    <strong>",
"     avoided",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     Hepatitis B vaccine",
"    </a>",
"    should be given to all infants with hemophilia as soon after birth as possible, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    is given after the age of one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The live oral polio attenuated vaccine, which is no longer licensed in the United States, is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in an infant when there is an immunocompromised household member. In these instances, the inactivated polio vaccine is utilized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dental care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental care is essential for individuals with congenital bleeding disorders. Early infant dental intervention is recommended to teach proper tooth brushing and ensure adequate household water fluoridation. The teeth should be cleaned routinely, and anticipated problem areas for causing bleeding should be discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Counseling and education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic and psychosocial counseling, as well as education about the disease, is important for the family with a newborn with hemophilia, especially for the approximately 30 percent for whom no previous family experience with the disease exists. Normal socialization and development is encouraged, and experienced personnel should discuss what minimum limitations are reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Exercise and athletic participation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An appropriate exercise regimen should be encouraged as a daily routine. This is especially important because children with hemophilia are particularly vulnerable to loss of physical conditioning and becoming overweight or obese as a result of restrictions on their activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The role of an exercise program for the child and adult following episodes of bleeding is best discussed before the child has a joint bleed.",
"   </p>",
"   <p>",
"    While there are presently no controlled studies that examine long-term effects of participation in formal exercise regimens and athletics by hemophilia patients of any disease severity, the implementation of primary prophylaxis throughout the developed world has clearly had a substantial impact on increasing such participation. Both the World Federation of Haemophilia Working Group on Physical Therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/13\">",
"     13",
"    </a>",
"    ] and the National Hemophilia Foundation Physical Therapy Committee [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/14\">",
"     14",
"    </a>",
"    ] have developed patient educational materials that quantify some of the musculoskeletal benefits and risks of organized and individual physical exercise. As always, however, careful consultation between the patient (and the parents for minor children) and the staff at a local Hemophilia Treatment Center offers the best avenue for defining individual regimens.",
"   </p>",
"   <p>",
"    The effect of impact level of athletic participation on joint outcomes was studied in school-age boys with severe hemophilia A or B who were receiving factor prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/11\">",
"     11",
"    </a>",
"    ]. Of the 37 boys in the study, 73 and 27 percent participated in high-impact or exclusively low-impact activities, respectively. In logistic regression analyses with adjustment for prophylaxis frequency, the level of athletic participation was not a significant prognostic factor for joint hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Comprehensive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Designated hemophilia treatment centers have been established in the United States and many other countries to provide multidisciplinary care of hemophilia and related disorders. The multidisciplinary team provides optimal chronic disease management and lowers associated morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/15\">",
"     15",
"    </a>",
"    ]. The listing of such centers in the United States is available on the",
"    <a class=\"external\" href=\"https://www2a.cdc.gov/ncbddd/htcweb/Main.asp\">",
"     CDC website",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/16\">",
"     16",
"    </a>",
"    ], and a worldwide center listing is available through the",
"    <a class=\"external\" href=\"file://www.wfh.org/en/page.aspx?pid=1264\">",
"     Global Hemophilia Treatment Centre Directory",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    These comprehensive hemophilia centers provide voluntary testing for blood-borne viral infections, counseling of seropositive patients, and access to appropriate care and therapy. Risk reduction counseling and ongoing education of patients and families are essential elements of comprehensive care. The centers coordinate home therapy and preventive services, and work closely with hemophilia consumer organizations.",
"   </p>",
"   <p>",
"    Further information about hemophilia care, hemophilia centers, and HIV risk reduction and counseling is available through the National Hemophilia Foundation (800-424-2634,",
"    <a class=\"external\" href=\"file://www.hemophilia.org/\">",
"     www.hemophilia.org",
"    </a>",
"    ) or from the local comprehensive hemophilia treatment center and Hemophilia Foundation chapter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     REPLACEMENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clotting factor concentrates are given to prevent bleeding and to",
"    <span class=\"nowrap\">",
"     limit/resolve",
"    </span>",
"    existing hemorrhage. Dosing is reasonably standard, but the length of therapy, choice of product, and the use of primary and secondary prophylaxis require expert intervention. Both factor VIII and IX concentrates are administered intravenously. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Choice of product'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment of patients with inhibitors requires considerable expertise. Significant advances have been made in treatment of active bleeding and inhibitor eradication via immune tolerance induction. These advances have led to improved outcomes among patients with hemophilia A and inhibitors against factor VIII. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Factor VIII products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor VIII products are used to treat hemophilia A (ie, factor VIII deficiency). Factor VIII products can be derived from processed human plasma, or produced from cell lines engineered to express large amounts of factor VIII (ie, recombinant). Both are given intravenously. The plasma-derived products are stratified based upon purity, and the recombinant products are characterized by their generation; both of these measures reflect decreasing exposure to human or animal proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Although solvent-detergent-treated fresh frozen plasma is now safe from the viewpoint of viral transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/19\">",
"     19",
"    </a>",
"    ], its main use now is in situations and countries in which appropriate concentrates are unavailable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Plasma-derived concentrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercial fractionation of cryoprecipitate yielded the first generation of lyophilized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/12/198?source=see_link\">",
"     factor VIII concentrates",
"    </a>",
"    . This resulted in an approximately 100-fold increase in the concentration of factor VIII over that in plasma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical use of plasma components\", section on 'Cryoprecipitate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current production of plasma-derived clotting factor concentrates requires a large starting pool of carefully screened donor plasma that is processed to produce a clotting factor concentrate that is as pure as practical. Affinity chromatography using monoclonal antibodies currently provides very pure plasma-derived products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/17\">",
"     17",
"    </a>",
"    ]. Viral inactivation procedures (pasteurization, solvent-detergent treatment, chemical disruption with sodium thiocyanate, or ultrafiltration) are effective against HIV and hepatitis viruses. The products are characterized by their purity, which reflects the amount of contaminating protein:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Intermediate purity",
"      </strong>",
"      concentrates typically contain 6 to 10",
"      <span class=\"nowrap\">",
"       units/mg",
"      </span>",
"      protein.",
"     </li>",
"     <li>",
"      <strong>",
"       High purity",
"      </strong>",
"      products are those with at least 50",
"      <span class=\"nowrap\">",
"       units/mg",
"      </span>",
"      protein (range 50 to 150",
"      <span class=\"nowrap\">",
"       units/mg",
"      </span>",
"      protein), excluding albumin used for stabilization.",
"     </li>",
"     <li>",
"      <strong>",
"       Ultrahigh purity",
"      </strong>",
"      products are the monoclonal antibody affinity-purified plasma-derived factor concentrates and the recombinant products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. The specific activity of the monoclonal preparations (prior to the addition of human serum albumin) is 3000 units of factor VIII per mg protein. This concentration is essentially identical to the purity of the licensed recombinant products, which should provide the means for the ultimate production of pure and safe products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Humate P, one of the intermediate purity products containing both factor VIII and von Willebrand factor, is mainly used for the treatment of von Willebrand disease. It is not a preferred agent for the treatment of patients with hemophilia A who do not have inhibitors.",
"   </p>",
"   <p>",
"    Although solvent-detergent-treated fresh frozen plasma is now safe from the viewpoint of viral transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/19\">",
"     19",
"    </a>",
"    ], its main use now is in situations and countries in which appropriate concentrates are unavailable. The doses of plasma required to raise factor VIII to therapeutic levels are prohibitively high, potentially leading to circulatory overload (eg, the patient&rsquo;s plasma volume would have to be doubled in order to achieve a factor VIII level of 50 percent in a severe hemophiliac).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Recombinant human factor VIII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collaborative clinical trials have demonstrated excellent efficacy with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/1/23574?source=see_link\">",
"     recombinant human factor VIII",
"    </a>",
"    concentrates produced by two companies, Baxter-Hyland-Immuno (Recombinate) and Aventis Bayer (Kogenate) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/17,18,20,21\">",
"     17,18,20,21",
"    </a>",
"    ]. In one multicenter trial, for example, 92 percent of bleeding episodes responded as expected to treatment with Recombinate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808111\">",
"    <span class=\"h4\">",
"     First generation recombinant factor VIII",
"    </span>",
"    &nbsp;&mdash;&nbsp;These recombinant factor VIII products (eg, Recombinate) are purified from the cell culture of transfected hamster-derived cell lines and require no further viral attenuation. The addition of human serum albumin for stabilization constitutes the sole possible source for human viral contamination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/22\">",
"     22",
"    </a>",
"    ], although a theoretical risk for other non-human, mammalian viruses or other infective species remains. Safety trials to date reveal no evidence for viral transmission, excellent recovery and half-life values, and infrequent development of antibodies to the trace quantities of heterologous proteins present in the preparation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808118\">",
"    <span class=\"h4\">",
"     Second generation recombinant factor VIII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-generation recombinant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/12/198?source=see_link\">",
"     factor VIII concentrates",
"    </a>",
"    are without added albumin (Kogenate-FS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/24\">",
"     24",
"    </a>",
"    ]), including a mutated protein lacking the B domain (B-domain deleted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/1/23574?source=see_link\">",
"     recombinant human factor VIII",
"    </a>",
"    , BDDrFVIII, r-VIII SQ, ReFacto) in an albumin-free concentrate that is stabilized with sucrose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The portion of factor VIII coded for by the B domain of the gene is not required for clotting activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/25,27\">",
"     25,27",
"    </a>",
"    ]; furthermore, its deletion confers greater stability on the resultant smaller factor VIII molecule, eliminating the requirement for stabilization with human serum albumin. These products may provide a higher level of confidence against any future microbiologic contamination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808125\">",
"    <span class=\"h4\">",
"     Third generation recombinant factor VIII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presently, the only available third-generation recombinant products (ie, no added human or animal proteins in the manufacturing process or final preparation) are Advate and Xyntha [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In one study, the mean half-life of Advate in individuals with hemophilia A &ge;10 years of age was 12 hours, with a significant degree of individual variation (range: 6.7 to 25 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808132\">",
"    <span class=\"h4\">",
"     Inhibitor development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitor development in previously untransfused patients has averaged approximately 25 to 30 percent for the Recombinate and ReFacto products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/20,31\">",
"     20,31",
"    </a>",
"    ]. In the Recombinate study noted above, for example, the probability of developing an inhibitor in patients with severe hemophilia A was 12, 27, and 38 percent after 8, 10, and 25 exposure days, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/20\">",
"     20",
"    </a>",
"    ]. Many of the inhibitors in these patients are transient or responsive to immune tolerance induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/20,31,32\">",
"     20,31,32",
"    </a>",
"    ]. An initial concern that inhibitor formation might be higher in patients treated with ultrapure preparations has not proven to be correct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100234435\">",
"    <span class=\"h4\">",
"     Longer half-life products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor VIII preparations with longer half lives are desired, as they would decrease the frequency of dosing interval for factor VIII. Two strategies under study for the extension of factor VIII activity are fusion to an immunoglobulin Fc domain and reconstitution with pegylated liposomes.",
"   </p>",
"   <p>",
"    A recombinant product composed of factor VIII fused with a monomeric human immunoglobulin (IgG1) Fc domain (rFVIIIFc), has been created [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/35\">",
"     35",
"    </a>",
"    ]. This product binds to the neonatal Fc receptor (FcRn) present on many adult cells via its Fc domain, and this binding protects rVIIIFc from degradation, extending the half-life of factor VIII 1.5- to 2-fold.",
"   </p>",
"   <p>",
"    In an open label study, 16 patients with severe hemophilia A tolerated rFVIIIFc well and did not develop antibodies or inhibitors to the fusion protein during 28 days of observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/36\">",
"     36",
"    </a>",
"    ]. Compared with recombinant factor VIII (rFVIII) lacking the Fc fusion, rFVIIIFc had a longer therapeutic duration as judged by several pharmacokinetic parameters. As an example, at the 65 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    dose, the half-life of rVIII was 11 hours, compared with 18.8 hours for the rFVIIIFc, a 1.7-fold improvement.",
"   </p>",
"   <p>",
"    Early preclinical models revealed that reconstitution of factor VIII with pegylated liposomes prolonged factor VIII half-life, and also increased protection from bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/37\">",
"     37",
"    </a>",
"    ]. However, despite the fact that in blinded, controlled, crossover studies in adults with severe hemophilia A, use of this liposomal factor VIII preparation significantly increased the mean number of days without bleeds in comparison with similar doses of factor VIII given without liposomes, the pharmacokinetic curves of this agent were superimposable on native FVIII; therefore, this early product attempting to prolong FVIII in-vivo half-life was not pursued. Additional products using pegylation to prolong the half-life are under investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, further product development has resulted in testing of liposomal carriers, including a preparation consisting of high purity plasma-derived factor VIII reconstituted with a liposomal diluent immediately prior to infusion that is currently undergoing testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/41\">",
"     41",
"    </a>",
"    ]. A factor VIII molecule produced by engineering surface-exposed cysteines on the factor VIII molecule that could be conjugated with PEG has demonstrated full in vitro coagulation activity, improved pharmacokinetics, and prolonged efficacy in hemophilic mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/38\">",
"     38",
"    </a>",
"    ]. Other modified factor VIII and IX molecules with improved potency, stability, and circulating half-life are in development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/35,36,42,43\">",
"     35,36,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22197866\">",
"    <span class=\"h4\">",
"     Investigational strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potentially exciting advance is the development of a novel antibody designed to simultaneously bind to factors IXa and X, bringing these two molecules together and essentially substituting for the cofactor role of factor VIII in activating factor X [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/44\">",
"     44",
"    </a>",
"    ]. This approach has not yet reached clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Choice of product",
"    </span>",
"    &nbsp;&mdash;&nbsp;As all of the available factor VIII products are able to achieve satisfactory hemostasis when bleeding needs to be controlled or prevented, the choice of product is usually based upon safety, purity, and cost, as well as the risk of occurrence of inhibitory antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/45\">",
"     45",
"    </a>",
"    ]. There is a marked increase in the average wholesale price between cryoprecipitate and recombinant concentrates, with the unit price increasing in proportion to the final product purity.",
"   </p>",
"   <p>",
"    While plasma-derived products have been free of viral transmission for many years, there remain concerns that must be specifically understood by patients and caregivers of a potential risk of transmission of blood borne diseases. While recombinant products are the preferred treatment, there remain patients for whom plasma-derived products are preferred or appropriate based upon a variety of issues pertinent to the patient in question.",
"   </p>",
"   <p>",
"    Purity and viral safety have become issues of utmost importance to patients and their clinicians given the history of blood borne viral infections transmitted to hemophilics. As noted above, ultrapure products stabilize the CD4 cell count in HIV-infected hemophilics and are the preferred preparation in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/46\">",
"     46",
"    </a>",
"    ]. In some countries in which safety is the primary concern and economics are not limiting, it is recommended that previously untreated and minimally treated patients only receive ultrapure if not genetically engineered products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Factor IX products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor IX products are used to treat hemophilia B (ie, factor IX deficiency). The initial production of factor IX concentrate in the 1970s and 1980s resulted in copurification of all the molecularly similar vitamin K-dependent factors (II, VII, IX and X); the final product was called prothrombin complex concentrate (PCC). Copurification also resulted in inadvertent activation of these proteases to their active enzyme (eg, factor VII converted to factor VIIa), which contributed to a thrombogenic risk associated with PCC use (eg, myocardial infarction, disseminated intravascular coagulation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32039?source=see_link&amp;anchor=H14#H14\">",
"     \"Plasma derivatives and recombinant DNA-produced coagulation factors\", section on 'Prothrombin complex concentrates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of the increased risk of thrombosis and the advent of highly purified products, PCCs are no longer the preparation of choice for patients with hemophilia B. A product either purified from human plasma or derived from cultured cells engineered to express large amounts of factor IX (ie, recombinant factor IX) is preferred. These preparations are obligatory when high-dose recurrent infusion therapy is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/17,48-50\">",
"     17,48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Purified factor IX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromatographic partitioning and monoclonal antibody affinity purification have been used to purify factor IX from human plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/48\">",
"     48",
"    </a>",
"    ]. Both of these products are further subjected to viral inactivation processes, such as solvent-detergent, thiocyanate, and ultrafiltration. The product produced by chromatographic partitioning contains minor residual plasma proteins, whereas the monoclonal product is free of other plasma proteins. Viral attenuation to remove HIV and hepatitis is effective for both processes. However, studies using surrogate viruses may imply greater safety from hepatitis C or similar viruses with the monoclonal factor IX concentrate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Recombinant factor IX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant factor IX has been genetically engineered by insertion of the human factor IX gene into a Chinese hamster ovary cell line. It has been proven to be safe and effective in the treatment of patients with previously treated and previously untreated hemophilia B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/50-52\">",
"     50-52",
"    </a>",
"    ], with a half-life of 16 to 17 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/49,53\">",
"     49,53",
"    </a>",
"    ]. The product has no added albumin, giving it a theoretical advantage over plasma-derived concentrates. The volume of distribution of recombinant FIX is larger than that for plasma-derived FIX, with a more pronounced increase in infants and children. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Dosing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7515472\">",
"    <span class=\"h4\">",
"     Longer half-life products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor IX products with longer half lives are desired, as they would prolong the required dosing interval. One strategy for increasing the half-life of factor IX is a recombinant form of factor IX fused to a monomeric human immunoglobulin Fc domain (rFIXFc) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/54\">",
"     54",
"    </a>",
"    ]. This product binds to the neonatal Fc receptor (FcRn) present on many adult cells via its Fc domain, and this binding protects rFIXc from degradation, extending its half-life by three- to fivefold. In an open label study of 15 patients with severe hemophilia B who received rFIXFc, there were no major drug-related toxicities, and no inhibitor formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/55\">",
"     55",
"    </a>",
"    ]. Pharmacokinetic modeling from this study suggested that the half-life was approximately threefold longer than that reported for recombinant factor IX (rFIX) lacking the Fc fusion. In contrast to the twice weekly dosing currently recommended for rFIX, the longer half-life of rFIXFc may allow for a dosing interval of weekly to every other week.",
"   </p>",
"   <p>",
"    Additional studies are investigating the use of a new recombinant factor IX concentrate and other recombinant, longer half-life factor IX products, such as pegylated factor IX or factor IX fused with albumin (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT00956345\">",
"     ClinicalTrials.gov",
"    </a>",
"    , search for &ldquo;factor IX&rdquo;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/55-60\">",
"     55-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early treatment of bleeding episodes with appropriate coagulation factor dosing decreases the duration of required therapy and the predisposition to re-bleeding, and improves the quality of life. It is critical to verify whether the patient has hemophilia A (factor VIII deficiency) or hemophilia B (factor IX deficiency) so the correct product is administered.",
"   </p>",
"   <p>",
"    One international unit of clotting factor is defined as that amount present in 1 mL of pooled normal plasma. Thus, on average, a normal individual with a plasma volume of 3000 mL would have 3000 international units of each clotting factor in his or her circulation. Provided all of the infused dose of the clotting factor is delivered to the plasma, a dose of 3000 international units of factor VIII would be required to raise the plasma level to normal (ie, 100 percent = 1 international",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    in a patient with baseline levels of less than 1 percent of the normal concentration of factor VIII.",
"   </p>",
"   <p>",
"    In practice, however, the number of units required depends upon body weight (kg), the volume of distribution, and the desired factor level. The volume of distribution for factor VIII is approximately 0.5 (ie, half the plasma volume); in comparison,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/20/34118?source=see_link\">",
"     recombinant human factor IX",
"    </a>",
"    (ie, monoclonal factor IX) has a volume of distribution that is approximately 1.0 to 1.2, which is larger than the value of 1.0 for the native protein. The difference in volume of distribution is primarily caused by a difference in charge conferred by decreased or absent phosphorylation and sulfation at two sites compared with the plasma species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Desired factor levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The desired factor level is a function of severity and location of the bleeding episode.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early joint or muscle bleeding episodes are treated to achieve factor levels of 30 to 40 percent. The usual hemarthrosis typically responds to a single injection if treated early.",
"     </li>",
"     <li>",
"      Patients with more severe muscle hematomas and those undergoing dental surgery are usually treated to achieve factor levels of 50 percent. Oral antifibrinolytic therapy is used to reduce the use of concentrates in patients undergoing dental procedures or those with oral mucous membrane bleeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/61\">",
"       61",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      also can be used in combination with antifibrinolytic agents to raise plasma concentrations of von Willebrand factor and factor VIII in patients with mild hemophilia (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Therapies other than factor replacement'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/62-64\">",
"       62-64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe or potentially serious episodes such as intracranial or intraabdominal hemorrhage or bleeding in areas such as the face, neck, and hip require correction to 80 to 100 percent for longer periods of time, usually until the hemorrhage has resolved [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most orthopedic surgery can be managed with initial levels of 80 to 100 percent followed in a few days by minimum levels of at least 30 percent; an exception occurs at times of wound or joint manipulation when a level of at least 50 percent is necessary.",
"     </li>",
"     <li>",
"      To achieve hemostasis for major surgical procedures, an initial level of 60 to 100 percent is achieved. This level is followed by a prophylactic level of 30 to 50 percent until the wound is healed, typically 10 to 14 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factor levels should be checked to ensure the effectiveness of the calculated dose.",
"   </p>",
"   <p>",
"    The half-life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/1/23574?source=see_link\">",
"     recombinant human factor VIII",
"    </a>",
"    is approximately 8 to 12 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/66\">",
"     66",
"    </a>",
"    ]. For this reason, doses are repeated every 12 hours or longer based upon the expected or measured trough level of factor VIII and the severity of the bleeding episode or required procedure.",
"   </p>",
"   <p>",
"    Recombinant factor IX has a half-life of about 16 to 17 hours, the same as the native protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/53\">",
"     53",
"    </a>",
"    ]. Because of its longer half-life than factor VIII, doses of factor IX are repeated on an 18- to 24-hour basis, and factor IX levels are checked near the end of that period.",
"   </p>",
"   <p>",
"    As an alternative to intravenous dosing at intervals based on the half-life, factor concentrates also can be given by continuous infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. A continuous infusion of factor VIII concentrate at a dose of 2 to 4",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour will often maintain the level initially achieved by bolus infusion. This method offers the advantage of consistent levels, less frequent monitoring, and decreased factor utilization. A similar effect has been noted with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8151?source=see_link\">",
"     factor IX concentrates",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/70\">",
"     70",
"    </a>",
"    ]. Patients undergoing major surgery or those with major hemorrhage at risk of re-bleed may benefit from such continuous therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Dose calculation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Factor VIII replacement",
"      </strong>",
"      &mdash; As noted above, it has been found that, on average, intravenous administration of factor VIII at a dose of 0.5 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      of body weight will increase circulating factor VIII levels by approximately 1 international",
"      <span class=\"nowrap\">",
"       units/dL",
"      </span>",
"      (ie, 1 percent). Although dosing should be individualized for each patient and for each product employed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/71\">",
"       71",
"      </a>",
"      ], one can estimate the dose required to raise the factor VIII concentration by a specified amount according to the following formula:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Dose of Factor VIII (international units) = Weight (kg) x (Desired percent increase) x 0.5",
"   </p>",
"   <p>",
"    As an example, to increase the factor VIII level by 30 percent (eg, from zero to 30 percent or from 10 percent to 40 percent) in a patient weighing 50 kg, the required intravenous dose of factor VIII is 750 international units (ie, 50 x 30 x 0.5). To increase the factor VIII level to 100 percent in a 50 kg individual with a factor VIII level of zero, the dose is 50 x 100 x 0.5, or 2500 international units. Doses are repeated every 12 hours or longer based on the expected or measured trough level of factor VIII and the severity of the bleeding episode or required procedure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Factor IX replacement",
"      </strong>",
"      &mdash; Intravenous administration of 1 to 1.2 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      of body weight of factor IX will increase circulating factor IX levels by 1 percent. Although dosing should be individualized for each patient and differs for each preparation used, one can estimate the dose required to raise the factor IX concentration by a specified amount according to the following formula:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; Dose of Factor IX (international units) = Weight (kg) x (Desired percent increase) x F",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; (F = 1.0 for AlphaNine and Mononine; F= 1.2 for BeneFix in adults and 1.4 in children)",
"   </p>",
"   <p>",
"    As an example, to increase the factor IX level by 80 percent (eg, from zero to 80 percent or from 20 percent to 100 percent) in an adult patient weighing 70 kg, the required intravenous dose is 5600 international units for AlphaNine or Mononine (ie, 70 x 80 x 1) or 6720 international units when using BeneFix (ie, 70 x 80 x 1.2). Doses are given at 18- to 24-hour intervals, with monitoring of factor IX levels before the next dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prophylactic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regular administration of replacement therapy with the aim of reducing spontaneous bleeding is a logical approach to the treatment of severe hemophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/72\">",
"     72",
"    </a>",
"    ]. The goal of such an approach is to maintain the factor VIII or IX level above 1 percent, which should convert the patient from a severe to a moderate phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. This level can be achieved by factor concentrate administration two to three times per week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1322?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of hemophilia\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several retrospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/75,76,78,79\">",
"     75,76,78,79",
"    </a>",
"    ] and two randomized studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/80,81\">",
"     80,81",
"    </a>",
"    ] have amply demonstrated that primary prophylaxis starting during the early years of life can markedly reduce the risk of subsequent arthropathy when compared with on-demand treatment. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first randomized trial studied the incidence of bone or cartilage damage in MRI-defined pristine index joints (ankles, knees, elbows) in 65 hemophilic boys less than 30 months of age who were randomly assigned to receive either high intensity episodic (on demand) or prophylactic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/81\">",
"       81",
"      </a>",
"      ]. At six years of age, normal index-joint structure was found on MRI in 55 versus 93 percent of those receiving episodic or prophylactic therapy, respectively (relative risk 6.1; 95% CI 1.5-24).",
"     </li>",
"     <li>",
"      The second randomized trial compared the efficacy of prophylaxis versus episodic therapy in 45 children (median age four years, range: one to seven) with negative clinical-radiologic joint score at entry and at least one bleed during the previous six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/80\">",
"       80",
"      </a>",
"      ]. Over a 10-year time period, children on prophylaxis had fewer hemarthroses than those on episodic therapy (0.20 versus 0.52",
"      <span class=\"nowrap\">",
"       events/patient",
"      </span>",
"      per month, respectively). Children with no radiologic signs of arthropathy who were started on prophylaxis at &le;36 months had the lowest rate of hemarthrosis (0.12 joint",
"      <span class=\"nowrap\">",
"       bleeds/patient",
"      </span>",
"      per month).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prophylactic therapy, rather than on demand therapy, has been used extensively in parts of Europe, particularly in Sweden, and has been accepted by the Medical and Scientific Advisory Council of the National Hemophilia Foundation and the Pediatric Working Party of the United Kingdom Haemophilia Doctors&rsquo; Organisation as the optimal treatment modality for patients with severe hemophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/82-84\">",
"     82-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential negative impacts from the use of primary prophylaxis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Potential increase in the cost of therapy",
"     </li>",
"     <li>",
"      Side effects associated with the presence of central venous lines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/85,86\">",
"       85,86",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reluctance of parents to commit to multiple weekly injections",
"     </li>",
"     <li>",
"      Unnecessary treatment for a subset of patients that might have fewer musculoskeletal complications with on-demand therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these objections can be dealt with by starting therapy after the age of three when central venous lines may not be uniformly required and the bleeding pattern of the patient is more apparent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/87\">",
"     87",
"    </a>",
"    ]. Patients started on prophylactic therapy at age three have had fewer hemarthroses and a lower risk of radiologic changes than those for whom a similar approach was started at a later age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/76,80\">",
"     76,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another option is to withhold prophylaxis until it is clear that the patient has frequent bleeding episodes. Data from the Orthopaedic Outcome Study Group have shown that prolonged secondary prophylaxis significantly reduces the rate at which joints deteriorate on physical and radiologic examination, and results in significantly fewer days lost from work or school and fewer days spent in the hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term observations in a group of 76 patients with severe hemophilia provide insight into this issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/88\">",
"     88",
"    </a>",
"    ]. Patients who started prophylaxis soon after their first joint bleed showed little arthropathy in adulthood, whereas the longer the start of prophylaxis was postponed, the higher was the risk of developing arthropathy. Since the median age at first joint bleed was 2.2 years, this suggests that the best policy is to start prophylaxis at an early age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/87\">",
"     87",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    after a limited number of joint bleeds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These issues were addressed in a randomized trial in 65 boys younger than 30 months of age with severe hemophilia A (factor VIII level &le;2",
"    <span class=\"nowrap\">",
"     units/dL),",
"    </span>",
"    two or fewer hemorrhages into each index joint, and normal baseline joint imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/81\">",
"     81",
"    </a>",
"    ]. The patients were randomly assigned to receive either prophylactic administration of 25 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    of factor VIII (Kogenate or Kogenate FS) every other day, or episodic (on-demand) therapy (40 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    of factor VIII at the time of joint hemorrhage, 20 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    24 and 72 hours after the first dose, and every other day until joint pain and impairment of mobility had completely resolved).",
"   </p>",
"   <p>",
"    After a mean period of 49 months, the following results were obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in the prophylactic treatment arm had a significantly higher rate of normal MRI studies in all six index joints (93 versus 55 percent).",
"     </li>",
"     <li>",
"      Compared with prophylactic therapy, episodic therapy was associated with a significantly higher rate of damage to one or more joints (relative risk 6.1, 95% CI 1.5-24).",
"     </li>",
"     <li>",
"      By the age of six years, children in the prophylactic and episodic treatment groups were receiving 6000 versus 2500 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per year of factor VIII, respectively. At a cost of",
"      <span class=\"nowrap\">",
"       $1/unit",
"      </span>",
"      of recombinant factor VIII, the cost of prophylaxis or episodic therapy for a 50 kg child was estimated by the authors as $300,000 versus $125,000 per year, respectively.",
"     </li>",
"     <li>",
"      High titers of factor VIII inhibitors developed in two boys who received prophylaxis, while life-threatening hemorrhage occurred in three boys in the episodic treatment group. Hospitalizations and infections associated with the use of central venous catheters were similar between the two treatment groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once prophylaxis is started, it is not clear when it should be replaced with on-demand treatment. This issue was approached in a study of 80 Danish and Dutch patients with severe hemophilia in which 35 percent discontinued prophylactic therapy at a median age of 21.5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/90\">",
"     90",
"    </a>",
"    ]. Median annual clotting factor use decreased by 39 and 68 percent for Danish and Dutch patients discontinuing prophylaxis, respectively, who suffered three more joint bleeds per year compared with those continuing on prophylaxis. At a median follow-up of 3.6 years since the change in treatment, the radiologic joint status was similar between both groups. Outcome in patients with a history of more intensive therapy during their early years tended to be superior to that of the entire cohort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Secondary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is less information on the value of secondary prophylaxis (ie, prophylaxis in patients who already have had some degree of hemophilic arthropathy) in adult patients. This issue was studied in a multicenter, open-label, prospective trial in 20 male subjects 30 to 45 years of age with severe hemophilia and an average of two relevant bleeds per month. All patients received on-demand sucrose-formulated recombinant factor VIII (Kogenate FS) as their sole factor VIII treatment for six months and were then switched to receive seven months of prophylaxis with the same agent at a stable dose of 20 to 40 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    three times per week. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/91\">",
"     91",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the on-demand treatment (months one through six), the median number of joint bleeds was 15 (range: 11 to 26), of which 13.5 (range: 7 to 29) were spontaneous.",
"     </li>",
"     <li>",
"      During the prophylactic treatment period (months 7 through 13), the median numbers of joint and spontaneous bleeds were both zero (range: zero to three). Mean factor VIII trough levels 48 or 72 hours after the last prophylactic infusion were 7.3 and 4.1 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both treatment regimens were safe and well tolerated; no inhibitor development was noted during either treatment period. Neither quality of life nor pharmacoeconomic variables were significantly affected by the two treatment strategies. Longer-term follow-up in a larger series of patients will be required to determine whether this reduction in hemarthroses translates into improved or stabilized joint function, improved ability to participate in work,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     THERAPIES OTHER THAN FACTOR REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two major therapeutic options for patients with hemophilia, in addition to factor replacement, are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    and antifibrinolytic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Desmopressin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild hemophilia A can often be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP), a synthetic analogue of vasopressin (antidiuretic hormone) that lacks pressor activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/62,64,92-96\">",
"     62,64,92-96",
"    </a>",
"    ]. In such patients, desmopressin increases circulating factor VIII levels two to four times above baseline, via release from endothelial storage sites, and as much as four to six times above baseline in those who begin with factor VIII levels greater than 9 percent of normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/92,96\">",
"     92,96",
"    </a>",
"    ]. In another report, factor VIII levels adequate for hemostasis were attained in 82 percent of patients with mild hemophilia or hemophilia A carriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, dDAVP is the treatment of choice for mild to moderate bleeding in most individuals with mild hemophilia A, similar to certain types of patients with von Willebrand disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21866?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of von Willebrand disease\", section on 'Desmopressin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808179\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    can be administered intravenously, by subcutaneous injection, or by intranasal spray. When given intravenously for prophylaxis before invasive procedures or for acute bleeding episodes, a dose of 0.3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    (maximum 20 mcg) is diluted in 50 mL of normal saline and infused over 20 to 30 minutes; the same dose is given with subcutaneous therapy with no single injection exceeding a dose of 1.5 mL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/97\">",
"     97",
"    </a>",
"    ]. An increase in factor VIII levels is expected to occur at approximately 30 to 60 minutes after the infusion, and the response persists for 6 to 12 hours. A repeat dose may be given at 12 hours, and subsequent doses are often switched to once daily dosing.",
"   </p>",
"   <p>",
"    The response to 300 mcg of intranasal spray (150",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    is approximately equivalent to that seen with an intravenous dose of 0.2",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/98\">",
"     98",
"    </a>",
"    ]. The usual dose is one puff (150 mcg) in patients weighing &lt;50 kg and two puffs in patients weighing &gt;50 kg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808186\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    include vasodilatation that causes facial flushing, headache (which can often be controlled by decreasing the rate of infusion), and occasional tingling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/99\">",
"     99",
"    </a>",
"    ]. Both hypotension and hypertension have been reported but are not common and usually are mild. Tachyphylaxis occurs after repeated administration because of depletion of endothelial stores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. Thus, the response should be monitored in individuals who require repeated dosing (eg, daily or more often).",
"   </p>",
"   <p>",
"    Another problem is that the persistent antidiuretic activity can lead to water retention and serious degrees of hyponatremia. As a result, doses often are limited to once daily after the first day, water intake is restricted, and the serum sodium concentration is monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Antifibrinolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     Tranexamic acid",
"    </a>",
"    and epsilon",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    (EACA) inhibit fibrinolysis by inhibiting plasminogen activation in the fibrin clot, thereby enhancing clot stability. They are useful therapeutic adjuncts to stabilize clots in areas of increased fibrinolysis, such as the oral cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/61,101\">",
"     61,101",
"    </a>",
"    ], and in patients with episodes of epistaxis and menorrhagia that have been difficult to control.",
"   </p>",
"   <p>",
"    The usual dose of tranexamic acids is 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose every six to eight hours, whereas the usual dose of EACA is 75 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose every six hours (maximum single dose 3 to 4 g). Both drugs can be administered orally or intravenously. When given orally, they must be given three or four times over a 24-hour period because of their short half-lives.",
"   </p>",
"   <p>",
"    Treatment with antifibrinolytic agents may be required for 7 to 14 days after initial infusion therapy, depending upon the amount of tissue injury. In patients with hemophilia B, a purified factor IX preparation should be used when antifibrinolytic therapy is given to avoid the additive thrombotic risks of these drugs with prothrombin complex concentrates (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Factor IX products'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other adjunctive therapies include the use of microfibrillar collagen, especially for bleeding in the oral cavity, and fibrin glue, which, as noted above, has been used for bleeding following circumcision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25094?source=see_link\">",
"     \"Fibrin sealant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1532414\">",
"    <span class=\"h2\">",
"     Aspirin and non-steroidal anti-inflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    and other nonsteroidal anti-inflammatory drugs are",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in patients with hemophilia. Pain should be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , propoxyphene, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ACUTE THERAPY ACCORDING TO SITE OF BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute therapy varies in part with the site of bleeding. Treatment of such episodes may also require pain management, less often the use of glucocorticoids, and surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Hemarthrosis of peripheral joints",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808214\">",
"    <span class=\"h3\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hemarthroses of peripheral joints (knees, elbows, ankles) often can be treated at home, and home infusion training should begin as soon as possible after diagnosis to permit the benefits of early factor replacement for acute bleeding episodes. At the first indication of bleeding, the patient or parent should infuse clotting factor at a dose that achieves a factor level of 40 to 50 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5800?source=see_link&amp;anchor=H20#H20\">",
"     \"Hemarthrosis\", section on 'Coagulopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a joint undergoes repeated hemorrhage, it is called a",
"    <strong>",
"     target joint",
"    </strong>",
"    . A short course of glucocorticoids can be used to reduce the pain and swelling associated with synovial inflammation in a target joint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/102\">",
"     102",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    or its equivalent is given for a three- to five-day period at a dose of up to 60 to 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three days and 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for two days. Joint aspiration is used infrequently to remove blood and relieve pain. Clotting factors should be raised to at least 50 percent of normal before aspiration.",
"   </p>",
"   <p>",
"    Enforced rest and splinting are used early. They should be followed by a program of active range of motion and strengthening exercises when acute symptoms have resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808221\">",
"    <span class=\"h3\">",
"     Subsequent treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to these acute approaches to a target joint, the patient should be placed on short-term prophylaxis with factor administration three to four times per week for several weeks to months. As mentioned above, such an approach can reduce the rate at which joints deteriorate on physical and radiologic examination and result in significantly fewer days lost from work or school or spent in a hospital (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Prophylactic therapy'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits of secondary prophylaxis are related to promotion of recovery in the affected joint and interruption of established bleeding patterns. Prevention of recurrent bleeding in target joints often requires a higher trough level of the coagulation factor and more frequent dosing compared with primary prophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808228\">",
"    <span class=\"h3\">",
"     Massive target joint bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncontrolled massive target joint bleeding, either spontaneous or following joint replacement, has, in one small series, been controlled through selective angiographic embolization of the affected blood vessel(s) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/103,104\">",
"     103,104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Hemarthrosis of the hip and iliopsoas bleeds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hip joint or acetabular hemorrhages may result in increased intra-articular pressure and osteonecrosis (aseptic necrosis) of the femoral head [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/105\">",
"     105",
"    </a>",
"    ]. Twice-daily infusion therapy designed to sustain a factor level above a minimum of 20 percent for at least three days should be given, along with enforced bed rest.",
"   </p>",
"   <p>",
"    Hip hemarthrosis may be difficult to differentiate from an iliopsoas bleed, but the following observations may be helpful in distinguishing one from the other:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An iliopsoas bleed limits primary hip extension, whereas hemarthrosis makes any motion of the hip excruciatingly painful.",
"     </li>",
"     <li>",
"      An iliopsoas bleed may lead to decreased sensation over the ipsilateral thigh because of compression of the sacral plexus root of the femoral nerve.",
"     </li>",
"     <li>",
"      Ultrasonography may demonstrate a hematoma in the iliopsoas region.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of the two conditions is similar. Both benefit from physical therapy, although rehabilitation from the hip hemarthrosis is more protracted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Closed compartment muscle and soft tissue hemorrhages, often in the upper arm, forearm, wrist, volar hand, and anterior or posterior tibial compartment, may result in impingement on the neurovascular bundle. Swelling and pain precede tingling, numbness, and loss of distal arterial pulses. Surgical decompression is undertaken only if medical therapy fails to forestall progression, and in consultation with a comprehensive hemophilia treatment center. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Severe hemorrhage and head trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acutely hemorrhaging hemophilic patient should be transported, if possible, to an emergency center that stocks appropriate replacement products. For life-threatening bleeding, the factor level should be maintained at levels &gt;50 percent of normal. All head injuries must be considered nontrivial unless proved otherwise by observation and",
"    <span class=\"nowrap\">",
"     CT/MRI",
"    </span>",
"    imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/65,106\">",
"     65,106",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Dose calculation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Late bleeding after head trauma can occur up to three to four weeks following the event. For this reason, patients with head and neck injuries should be infused with replacement factor",
"    <strong>",
"     immediately",
"    </strong>",
"    unless the injury is clearly insignificant. Nonhospitalized patients and their families should be instructed about the neurologic signs and symptoms of central nervous system bleeding so that repeat infusion, clinical and radiological assessment, and hospitalization occur at the earliest manifestation of bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     LONG-TERM COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major long-term complications of hemophilia are chronic hemarthrosis with pain and joint destruction and infections transmitted by clotting factor concentrates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Chronic hemarthrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many options are available for the treatment of synovitis to prevent recurrent bleeding and further joint destruction when conservative therapy fails [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. As mentioned previously, short-term prophylaxis three to four times per week for several weeks to months in patients with target joints can slow the rate of joint deterioration (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Prophylactic therapy'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808266\">",
"    <span class=\"h3\">",
"     Synovectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovectomy is a possible treatment modality for selected patients. Synovectomy can be achieved through an open procedure, arthroscopically, or by injection of a radioactive material into the joint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/109\">",
"     109",
"    </a>",
"    ]. Radioactive synovectomy is indicated in patients with inhibitors to the clotting factor, advanced HIV infection or hepatitis, or multiple joint involvement. One study of synovectomy in 13 knees in 11 patients (eight open, five arthroscopic) showed a reduction in recurrent hemarthroses at an average follow-up of two and eight years for the arthroscopic and open groups, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/110\">",
"     110",
"    </a>",
"    ]. Although several different radioisotope-colloid complexes have been used for radioactive synovectomy, the United States Food and Drug Administration has approved chromic phosphate (",
"    <sup>",
"     32",
"    </sup>",
"    P) for use. The recommendations of a group of hematologists with expertise in the management of hemophilic synoviorthesis, orthopedists, and specialists in nuclear medicine included a protocol for use of",
"    <sup>",
"     32",
"    </sup>",
"    P synovectomy in patients with hemophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/111\">",
"     111",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28565?source=see_link&amp;anchor=H4#H4\">",
"     \"Synovectomy for inflammatory arthritis of the knee\", section on 'Synovectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The greatest risk associated with these procedures is decreased range of motion, an important issue in the young child who cannot cooperate with a program of physical therapy. In the above study, arthroscopic synovectomy generally increased and open synovectomy generally reduced or did not affect the range of motion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/110\">",
"     110",
"    </a>",
"    ]. The rate of roentgenographic progression of disease decreased, but it did not stop after synovectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808273\">",
"    <span class=\"h3\">",
"     Surgical approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic arthropathy and contractures often are treated surgically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/112\">",
"     112",
"    </a>",
"    ]. Common procedures include total joint replacement arthroplasty in the knee and hip [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/113-116\">",
"     113-116",
"    </a>",
"    ], ankle fusion, and synovectomy and excision arthroplasty of the elbow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/117\">",
"     117",
"    </a>",
"    ]. Data from Italian hemophilia centers and a systematic literature review indicate that the proportion of hemophilia A patients who had undergone arthroplasties was higher than that of patients with hemophilia B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study evaluated the effects of total knee arthroplasty in 11 patients (13 knees) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/113\">",
"     113",
"    </a>",
"    ]. Arthroplasty produced clinical and functional improvement with a reduction in the burden of disease to levels similar to those of patients with osteoarthritis undergoing hip arthroplasty. Functional ability did not reach normal levels because of residual symptoms and impairment of other joints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808280\">",
"    <span class=\"h3\">",
"     Weight loss and nutritional intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-sectional data collected from 4343 hemophilic males aged 2 to 19 years who received care at 136 United States hemophilia treatment centers identified the following risk factors significantly associated with joint range of motion (ROM) limitation: older age, nonwhite race, and increased body mass index (BMI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BMI, a potentially modifiable risk factor, was strongly associated with ROM loss across all severity levels, but especially among those with mild hemophilia. Accordingly, we recommend weight",
"    <span class=\"nowrap\">",
"     loss/nutritional",
"    </span>",
"    intervention for those with BMI above",
"    <span class=\"nowrap\">",
"     age/sex",
"    </span>",
"    norms, along with ambulation and exercise as tolerated in order to reduce long-term joint complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Hepatitis C virus, HIV, and end stage liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma-derived concentrate therapy in the 1970s and 1980s was associated with serious viral complications. Many patients became infected with hepatitis C virus (HCV), and HIV infection occurred in up to 65 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/120\">",
"     120",
"    </a>",
"    ]. The continued high prevalence of anti-HCV in this population resulted from past exposure, and new HCV cases related to factor administration are exceedingly rare to nonexistent with current preparations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1322?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of hemophilia\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The current use of donor-screening; virucidal techniques (eg, solvent-detergent treatment, pasteurization); the insistence on safety testing when the product is first used; and the advent of recombinant products have led to a generation of products with extremely low risk of viral transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/17-19,121,122\">",
"     17-19,121,122",
"    </a>",
"    ]. Despite the marked reduction in risk, hepatitis A and hepatitis B vaccination is recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38247?source=see_link\">",
"     \"Pathogen inactivation of blood products\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4\">",
"     'Routine immunizations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Each nonrecombinant clotting factor concentrate currently produced in the United States is made from a donor pool screened for HIV, hepatitis B, and hepatitis C, which, in conjunction with viral inactivation procedures, has eliminated HIV transmission and greatly reduced transmissible hepatitis viruses. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=see_link\">",
"       \"Laboratory testing of donated blood\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parvovirus B19, a nonlipid envelope virus, is an exception to elimination by dry, wet, and steam-heated methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/123\">",
"     123",
"    </a>",
"    ]. Parvovirus has been transmitted to patients with hemophilia in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/12/198?source=see_link\">",
"     factor VIII concentrates",
"    </a>",
"    and has even caused mild hypoplastic anemia in a solvent-detergent-treated concentrate recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major concerns with chronic HCV infection are progressive hepatic injury, which is more pronounced in patients co-infected with HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/125,126\">",
"     125,126",
"    </a>",
"    ], and, in patients who progress to cirrhosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a long-term study of 1816 HCV-seropositive hemophilic patients at 16 treatment centers, the following major findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/120\">",
"     120",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cumulative 16-year incidence of end-stage liver disease (ESLD) for HIV-negative HCV-positive subjects was 2.6 percent; it was 14.0 percent for those who were positive for both HIV and HCV (relative risk (RR) 7.9, 95% CI: 4.2-15).",
"     </li>",
"     <li>",
"      For subjects positive for both HIV and HCV, additional risk factors for development of ESLD included hepatitis B virus surface antigenemia (RR 8.1), a CD4+ count",
"      <span class=\"nowrap\">",
"       &lt;200/microL",
"      </span>",
"      (RR 2.1), and increasing age (RR 1.04 per year of age).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The standard therapy for chronic hepatitis caused by HCV is interferon alfa, usually along with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . The optimal approach to the treatment of chronic HCV in patients with hemophilia is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/129\">",
"     129",
"    </a>",
"    ]. In a controlled trial of patients infected with HCV alone, those treated with interferon alfa had a higher rate of sustained normalization of serum ALT and clearance of serum HCV RNA (13 versus zero percent in patients receiving no treatment) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/130\">",
"     130",
"    </a>",
"    ]. This response rate is similar to that seen in patients with chronic HCV who do not have hemophilia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35768?source=see_link\">",
"     \"Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    increases the sustained response rate to 30 to 40 percent in patients without hemophilia. In trials of patients with hemophilia co-infected with HIV and HCV and being treated with highly active antiretroviral therapy, combination therapy appeared to have similar efficacy and toxicity to that observed in non-HIV infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28184?source=see_link\">",
"     \"Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on these observations and our own experience, our overall approach in individuals with hemophilia who are HCV infected is to make decisions about whether to treat the HCV using criteria that have been established for the general population. Hemophilia is not a contraindication to HCV treatment, and treatment of HCV may ultimately improve thrombocytopenia, which may not be as well tolerated in individuals with hemophilia. However, prophylactic platelet transfusions may be necessary in those who become thrombocytopenic while on HCV therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38841?source=see_link\">",
"     \"Patient selection for antiviral therapy for chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808287\">",
"    <span class=\"h3\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-HIV infected patients who progress to cirrhosis can be treated with liver transplantation, which also will cure the hemophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. One report described the outcome in 26 hemophiliac patients treated with orthotopic liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/133\">",
"     133",
"    </a>",
"    ]. The patients had a variety of underlying disorders, including cirrhosis secondary to hepatitis B and C, hepatocellular carcinoma with cirrhosis, and biliary atresia. The 24 survivors achieved long-term correction of factor VIII or IX deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Quality of life issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the above long-term complications (eg, repeated bleeding episodes, chronic hemarthroses, transfusion-related infection, and other side effects of treatment such as the development of inhibitors), the quality of life (QOL) of patients with severe hemophilia is reduced as are self-esteem and social interactions.",
"   </p>",
"   <p>",
"    As an example, health-related quality of life (HR-QOL) issues were studied in 721 participants in the Hemophilia in the Netherlands 5 study and compared with that of the general population. Patients were divided into two groups, namely those from 16 to 30 years of age after prophylaxis was introduced, and those from 31 to 64 years of age, before its introduction. Findings from this study included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/135\">",
"     135",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occupational disability was present in 36 percent of severe hemophilia patients between the ages of 31 and 64 and in 5 percent of those ages 16 to 30, compared with 9 percent in the general population.",
"     </li>",
"     <li>",
"      While the HR-QOL of patients with severe hemophilia between the ages of 31 and 64 was lower than that of the general population, these differences were least pronounced for patients between the ages of 16 and 30.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest a benefit in HR-QOL resulting from the use of prophylactic therapy. Efforts are underway to study these issues in greater depth and to find additional ways to improve QOL in patients with severe hemophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/136-139\">",
"     136-139",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Prophylactic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Treatment of age-related comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the improved lifespan of persons with hemophilia, a growing number are developing age-related co-morbidities (eg, cardiovascular disease, renal disease, malignancy). Of interest, while the overall incidence of malignancy in individuals with hemophilia appears to be lower than that of the general population, hepatocellular carcinoma is common in those infected with HCV, and non-Hodgkin lymphoma in those infected with HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal management of these complications will be an increasing challenge to clinicians caring for these patients, as their treatment (eg, use of antiplatelet agents, anticoagulants, myelosuppressive agents) are expected to interfere with hemostasis and require more intensive replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/141-144\">",
"     141-144",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study of 58 hemophilia patients &ge;35 years of age attending a comprehensive hemophilia center indicated the following prevalence of cardiovascular risk factors: hypertension (65.5 percent), obesity (19.6 percent), smoking (12.5 percent), and diabetes mellitus (10.3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/145\">",
"       145",
"      </a>",
"      ]. Eight of the 58 patients (14 percent) experienced a cardiovascular event (eg, coronary heart disease, stroke). Five of these eight patients were talking low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      at the time of the event.",
"     </li>",
"     <li>",
"      In a cross-sectional study of 185 patients with hemophilia &ge;35 years of age cared for at a single hemophilia center, the lifetime prevalence of a cardiovascular disease (CVD) event was 19.5 percent, with an overall mortality of 5.4 percent from CVD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/146\">",
"       146",
"      </a>",
"      ]. Compared with US non-Hispanic white males, those with hemophilia had approximately twice the prevalence of coronary artery disease, stroke, and myocardial infarction. Both hypertension and smoking were significantly associated with CVD events, with odds ratios of 4.9 and 6.3, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data are insufficient to make hemophilia-specific recommendations for cardiovascular management. However, there is a clear need for cardiovascular risk screening in these patients, along with appropriate blood pressure control, cholesterol management, and smoking cessation programs as hemophilia patients age and develop these age-related comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     GENE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of approaches are possible in attempting to employ gene therapy for the hemophilias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/147-151\">",
"     147-151",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ex vivo gene therapy in which cells from the intended recipients are explanted, genetically modified to secrete factor VIII or IX, and reimplanted into the donor.",
"     </li>",
"     <li>",
"      In vivo injection of factor VIII or IX encoding vectors into the recipient. Vectors incorporating factor VIIa, a protein to which factor VIII-deficient and factor IX-deficient subjects have immunologic tolerance, have also been employed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/152,153\">",
"       152,153",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nonautologous therapy in which universal cell lines are enclosed in immunoprotective devices before implantation into the recipient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goal of gene therapy does not have to be restoration of normal factor levels; conversion from a severe (eg, factor VIII or factor IX levels &lt;1 percent) to a mild phenotype (eg, factor VIII or factor IX levels &gt;5 percent) would be sufficient to produce dramatic improvement. However, issues of sustained levels of factor delivery, neutralizing antibody response, T cell response to the viral insertion vector, safety, and cost remain to be resolved for all of these approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/154-161\">",
"     154-161",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early studies in patients with hemophilia A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/162,163\">",
"     162,163",
"    </a>",
"    ] and B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/160,164-166\">",
"     160,164-166",
"    </a>",
"    ] have been reported.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In studies using gene transfer techniques in patients with hemophilia A, detectable levels of factor VIII were present in 8 of 12 patients post-treatment; levels above 1 percent were seen in eight patients, with transient clinical improvement lasting approximately 10 to 12 months in those achieving the highest factor VIII levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/162,163\">",
"       162,163",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A single dose of an adenovirus-associated virus (AAV) vector expressing a human factor IX transgene was injected intravenously in six patients with severe hemophilia B (factor IX levels &lt;1 percent of normal) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/34/38442/abstract/166\">",
"       166",
"      </a>",
"      ]. Subjects were followed for 6 to 16 months post-injection. The following results were obtained:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      AAV-mediated expression of factor IX at 2 to 11 percent was observed in all six participants. Four discontinued factor IX prophylaxis and remained free of spontaneous hemorrhage during the observation period, while the interval between prophylactic injections was increased in the remaining two.",
"     </li>",
"     <li>",
"      The two participants receiving the highest dose of vector had transient asymptomatic elevations of serum aminotransferase levels. Each received a short course of glucocorticoid therapy, which rapidly normalized aminotransferase levels and maintained factor IX levels in the range of 3 to 11 percent of normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/24/29058?source=see_link\">",
"       \"Patient information: Hemophilia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6808294\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with inherited factor VIII deficiency (Hemophilia A) or factor IX deficiency (Hemophilia B) require life-long integrated care, preferably through a comprehensive hemophilia treatment center, as soon as the diagnosis is made. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1322?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical manifestations and diagnosis of hemophilia\", section on 'Diagnosis and detection of carriers'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H23967232\">",
"       'Preventive and comprehensive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Where available and when cost is not an issue, we recommend the use of a monoclonal antibody-purified or recombinant factor product for the treatment or prevention of bleeding in patients with hemophilia over the use of fresh frozen plasma, cryoprecipitate, or prothrombin complex concentrates (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the dosing of factor replacement in an emergency trauma situation, it is critical to determine if the patient has hemophilia A (factor VIII deficiency) or hemophilia B (factor IX deficiency) and to give the correct product. To raise factor VIII levels from zero to 100 percent, administer 50 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      approximately every 12 hours (based on trough levels). To raise factor IX levels from zero to 100 percent, administer 100 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      approximately every 18 to 24 hours (based on trough levels). For events with less severe bleeding risk than trauma, lower doses may be used. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Dose calculation'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Factor replacement dosing depends upon the indication (eg, type of bleeding, surgical intervention), the product employed, the weight of the patient, and whether treatment is prophylactic or &ldquo;on demand.&rdquo; (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Dosing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Prophylactic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend the use of prophylactic treatment over &ldquo;on demand&rdquo; treatment for the prevention of significant side effects of repeated bleeding episodes (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Prophylactic therapy can be started after the age of three when central venous lines may not be uniformly required or withheld until it is clear that the patient has frequent bleeding episodes.",
"     </li>",
"     <li>",
"      For mild to moderate bleeding in patients with mild hemophilia A (ie, factor VIII levels &gt;5 percent of normal) we suggest the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      over factor VIII-containing products (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Desmopressin'",
"      </a>",
"      above.) Factor VIII-containing products should be employed for those with hemophilia A not meeting these criteria.",
"     </li>",
"     <li>",
"      Antifibrinolytic therapy is a useful adjunct for stabilizing clots in areas of increased fibrinolysis (eg, oral cavity, nasal bleeding, menorrhagia). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Antifibrinolytic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-term complications of the hemophilias include joint destruction with the possible need for synovectomy or joint replacement, infections transmitted by clotting factor concentrates with or without attendant liver disease, quality of life issues, and the treatment of comorbidities in the aging hemophilic patient. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Long-term complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of inhibitors to factors VIII and IX is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link\">",
"       \"Factor VIII and factor IX inhibitors in patients with hemophilia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/1\">",
"      Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/2\">",
"      Ljung RC, Knobe K. How to manage invasive procedures in children with haemophilia. Br J Haematol 2012; 157:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/3\">",
"      Bolton-Maggs PH. Optimal haemophilia care versus the reality. Br J Haematol 2006; 132:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/4\">",
"      Ljung R, Petrini P, Nilsson IM. Diagnostic symptoms of severe and moderate haemophilia A and B. A survey of 140 cases. Acta Paediatr Scand 1990; 79:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/5\">",
"      Pollmann H, Richter H, Ringkamp H, J&uuml;rgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 158 Suppl 3:S166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/6\">",
"      Koch JA. Haemophilia in the newborn. A case report and literature review. S Afr Med J 1978; 53:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/7\">",
"      Kavakli K, Kurug&ouml;l Z, G&ouml;ksen D, Nisli G. Should hemophiliac patients be circumcised? Pediatr Hematol Oncol 2000; 17:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/8\">",
"      Rosner F. Hemophilia in the Talmud and rabbinic writings. Ann Intern Med 1969; 70:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/9\">",
"      Martinowitz U, Varon D, Jonas P, et al. Circumcision in hemophilia: the use of fibrin glue for local hemostasis. J Urol 1992; 148:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/10\">",
"      Jones P. Management of haemophilia. Arch Dis Child 1984; 59:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/11\">",
"      Ross C, Goldenberg NA, Hund D, Manco-Johnson MJ. Athletic participation in severe hemophilia: bleeding and joint outcomes in children on prophylaxis. Pediatrics 2009; 124:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/12\">",
"      Gomis M, Querol F, Gallach JE, et al. Exercise and sport in the treatment of haemophilic patients: a systematic review. Haemophilia 2009; 15:43.",
"     </a>",
"    </li>",
"    <li>",
"     Search for Publications, General Guides, and article \"Exercises for people with hemophilia.\" www.wfh.org (Accessed on December 22, 2009).",
"    </li>",
"    <li>",
"     Search on \"Exercise\" and \"Sports participation.\" www.hemophilia.org (Accessed on December 22, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/15\">",
"      Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000; 96:437.",
"     </a>",
"    </li>",
"    <li>",
"     www2a.cdc.gov/ncbddd/htcweb/index.asp (Accessed on September 02, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/17\">",
"      Mannucci PM. The choice of plasma-derived clotting factor concentrates. Baillieres Clin Haematol 1996; 9:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/18\">",
"      Lusher JM. Recombinant clotting factor concentrates. Baillieres Clin Haematol 1996; 9:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/19\">",
"      Klein HG, Dodd RY, Dzik WH, et al. Current status of solvent/detergent-treated frozen plasma. Transfusion 1998; 38:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/20\">",
"      Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/21\">",
"      Seremetis S, Lusher JM, Abildgaard CF, et al. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group. Haemophilia 1999; 5:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/22\">",
"      Azzi A, De Santis R, Morfini M, et al. TT virus contaminates first-generation recombinant factor VIII concentrates. Blood 2001; 98:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/23\">",
"      Ingerslev J, Christiansen K, Ravn HB, et al. Antibodies to heterologous proteins in hemophilia A patients receiving recombinant factor VIII (Recombinate). Thromb Haemost 2002; 87:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/24\">",
"      Abshire TC, Brackmann HH, Scharrer I, et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. Thromb Haemost 2000; 83:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/25\">",
"      Berntorp E. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost 1997; 78:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/26\">",
"      Sandberg H, Almstedt A, Brandt J, et al. Structural and functional characterization of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/27\">",
"      Fijnvandraat K, Berntorp E, ten Cate JW, et al. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 1997; 77:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/28\">",
"      Charlebois TS, O'connell BD, Adamson SR, et al. Viral safety of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/29\">",
"      N&eacute;grier C, Shapiro A, Berntorp E, et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients. Thromb Haemost 2008; 100:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/30\">",
"      Blanchette VS, Shapiro AD, Liesner RJ, et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/31\">",
"      Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/32\">",
"      Batlle J, Lopez MF, Brackmann HH, et al. Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors. Haemophilia 1999; 5:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/33\">",
"      Scharrer I, Neutzling O. Incidence of inhibitors in haemophiliacs. A review of the literature. Blood Coagul Fibrinolysis 1993; 4:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/34\">",
"      Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/35\">",
"      Dumont JA, Liu T, Low SC, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood 2012; 119:3024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/36\">",
"      Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119:3031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/37\">",
"      Baru M, Carmel-Goren L, Barenholz Y, et al. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 2005; 93:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/38\">",
"      Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/39\">",
"      Saenko EL, Pipe SW. Strategies towards a longer acting factor VIII. Haemophilia 2006; 12 Suppl 3:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/40\">",
"      Agers&oslash; H, Stennicke HR, Pelzer H, et al. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. Haemophilia 2012; 18:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/41\">",
"      Spira J, Plyushch O, Andreeva T, et al. Safety and efficacy of a long-acting liposomal formulation of plasma-derived factor VIII in haemophilia A patients. Br J Haematol 2012; 158:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/42\">",
"      Schaub RG. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem Pharmacol 2011; 82:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/43\">",
"      Lindhout T, Iqbal U, Willis LM, et al. Site-specific enzymatic polysialylation of therapeutic proteins using bacterial enzymes. Proc Natl Acad Sci U S A 2011; 108:7397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/44\">",
"      Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/45\">",
"      Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood 2012; 119:4108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/46\">",
"      Seremetis SV, Aledort LM, Bergman GE, et al. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Lancet 1993; 342:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/47\">",
"      White GC 2nd, Roberts HR, Kingdon HS, Lundblad RL. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood 1977; 49:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/48\">",
"      Kim HC, McMillan CW, White GC, et al. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/49\">",
"      Roberts HR, Eberst ME. Current management of hemophilia B. Hematol Oncol Clin North Am 1993; 7:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/50\">",
"      White G, Shapiro A, Ragni M, et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/51\">",
"      Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98:3600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/52\">",
"      Shapiro AD, Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/53\">",
"      Poon MC, Aledort LM, Anderle K, et al. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. Transfusion 1995; 35:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/54\">",
"      Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/55\">",
"      Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/56\">",
"      Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118:2695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/57\">",
"      Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/58\">",
"      Allegrante JP, Michela JL. Impact of a school-based workplace health promotion program on morale of inner-city teachers. J Sch Health 1990; 60:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/59\">",
"      Collins PW, M&oslash;ss J, Knobe K, et al. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/60\">",
"      &Oslash;stergaard H, Bjelke JR, Hansen L, et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/61\">",
"      Djulbegovic B, Marasa M, Pesto A, et al. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. Am J Hematol 1996; 51:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/62\">",
"      Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1991; 114:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/63\">",
"      Saulnier J, Marey A, Horellou MH, et al. Evaluation of desmopressin for dental extractions in patients with hemostatic disorders. Oral Surg Oral Med Oral Pathol 1994; 77:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/64\">",
"      Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost 2010; 8:421.",
"     </a>",
"    </li>",
"    <li>",
"     Hoots WK. Emergency management in hemophilia. In: Textbook of Hemophilia, 2nd ed, Lee CA, Berntorp EE, Hoots WK (Eds), Wiley-Blackwell, Oxford, UK 2010. p.394.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/66\">",
"      Lee CA, Owens D, Bray G, et al. Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. Thromb Haemost 1999; 82:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/67\">",
"      Schulman S, Varon D, Keller N, et al. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost 1994; 72:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/68\">",
"      Martinowitz UP, Schulman S. Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B. Acta Haematol 1995; 94 Suppl 1:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/69\">",
"      Hay CR, Doughty HI, Savidge GF. Continuous infusion of factor VIII for surgery and major bleeding. Blood Coagul Fibrinolysis 1996; 7 Suppl 1:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/70\">",
"      Schulman S, Wallensten R, White B, Smith OP. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery. Haemophilia 1999; 5:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/71\">",
"      Henrard S, Speybroeck N, Hermans C. Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A. J Thromb Haemost 2011; 9:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/72\">",
"      Srivastava A. Dose and response in haemophilia--optimization of factor replacement therapy. Br J Haematol 2004; 127:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/73\">",
"      Ljung RC. Prophylactic treatment in Sweden--overtreatment or optimal model? Haemophilia 1998; 4:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/74\">",
"      Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/75\">",
"      L&ouml;fqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients--a long-term follow-up. J Intern Med 1997; 241:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/76\">",
"      Petrini P, Lindvall N, Egberg N, Blomb&auml;ck M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991; 13:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/77\">",
"      Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/78\">",
"      Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/79\">",
"      van den Berg HM, Fischer K, Mauser-Bunschoten EP, et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/80\">",
"      Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/81\">",
"      Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/82\">",
"      Lusher JM. Prophylaxis in children with hemophilia: is it the optimal treatment? Thromb Haemost 1997; 78:726.",
"     </a>",
"    </li>",
"    <li>",
"     Hemophilia Information Exchange: Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. Med Bulletin #197, March 11,1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/84\">",
"      Richards M, Williams M, Chalmers E, et al. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/85\">",
"      Journeycake JM, Quinn CT, Miller KL, et al. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/86\">",
"      Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol 2007; 138:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/87\">",
"      Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/88\">",
"      Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/89\">",
"      Kreuz W, Escuriola-Ettingshausen C, Funk M, et al. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience. Haemophilia 1998; 4:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/90\">",
"      van Dijk K, Fischer K, van der Bom JG, et al. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/91\">",
"      Collins P, Faradji A, Morfini M, et al. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/92\">",
"      Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977; 1:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/93\">",
"      Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada. CMAJ 1995; 153:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/94\">",
"      Revel-Vilk S, Blanchette VS, Sparling C, et al. DDAVP challenge tests in boys with mild/moderate haemophilia A. Br J Haematol 2002; 117:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/95\">",
"      Nolan B, White B, Smith J, et al. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol 2000; 109:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/96\">",
"      Castaman G, Mancuso ME, Giacomelli SH, et al. Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A. J Thromb Haemost 2009; 7:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/97\">",
"      Sutor AH. DDAVP is not a panacea for children with bleeding disorders. Br J Haematol 2000; 108:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/98\">",
"      Lethagen S, Harris AS, Sj&ouml;rin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987; 58:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/99\">",
"      Dunn AL, Powers JR, Ribeiro MJ, et al. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/100\">",
"      Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/101\">",
"      Stajci Z. The combined local/systemic use of antifibrinolytics in hemophiliacs undergoing dental extractions. Int J Oral Surg 1985; 14:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/102\">",
"      Kisker CT, Burke C. Double-blind studies on the use of steroids in the treatment of acute hemarthrosis in patients with hemophilia. N Engl J Med 1970; 282:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/103\">",
"      Saris DB, van Rinsum AC, Dhert WJ, et al. Periarticular aneurysm formation in haemophilia. Lancet 1997; 349:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/104\">",
"      Mauser-Bunschoten EP, Zijl JA, Mali W, et al. Successful treatment of severe bleeding in hemophilic target joints by selective angiographic embolization. Blood 2005; 105:2654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/105\">",
"      Paton RW, Evans DI. Silent avascular necrosis of the femoral head in haemophilia. J Bone Joint Surg Br 1988; 70:737.",
"     </a>",
"    </li>",
"    <li>",
"     Gilchrist GS, Piepgras DG, Roskos RR. Neurologic Complications in Hemophilia. In: Hemophilia in the Child and Adult, Hilgartner MW, Pochedly C (Eds), Raven Press, New York 1989. p.45.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/107\">",
"      Raffini L, Manno C. Modern management of haemophilic arthropathy. Br J Haematol 2007; 136:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/108\">",
"      Jansen NW, Roosendaal G, Lafeber FP. Understanding haemophilic arthropathy: an exploration of current open issues. Br J Haematol 2008; 143:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/109\">",
"      Siegel ME, Siegel HJ, Luck JV Jr. Radiosynovectomy's clinical applications and cost effectiveness: a review. Semin Nucl Med 1997; 27:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/110\">",
"      Triantafyllou SJ, Hanks GA, Handal JA, Greer RB 3rd. Open and arthroscopic synovectomy in hemophilic arthropathy of the knee. Clin Orthop Relat Res 1992; :196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/111\">",
"      Dunn AL, Busch MT, Wyly JB, Abshire TC. Radionuclide synovectomy for hemophilic arthropathy: a comprehensive review of safety and efficacy and recommendation for a standardized treatment protocol. Thromb Haemost 2002; 87:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/112\">",
"      Rodriguez-Merchan EC. Therapeutic options in the management of articular contractures in haemophiliacs. Haemophilia 1999; 5 Suppl 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/113\">",
"      Schick M, Stucki G, Rodriguez M, et al. Haemophilic; arthropathy: assessment of quality of life after total knee arthroplasty. Clin Rheumatol 1999; 18:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/114\">",
"      Nelson IW, Sivamurugan S, Latham PD, et al. Total hip arthroplasty for hemophilic arthropathy. Clin Orthop Relat Res 1992; :210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/115\">",
"      Luck JV Jr, Kasper CK. Surgical management of advanced hemophilic arthropathy. An overview of 20 years' experience. Clin Orthop Relat Res 1989; :60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/116\">",
"      Solimeno LP, Mancuso ME, Pasta G, et al. Factors influencing the long-term outcome of primary total knee replacement in haemophiliacs: a review of 116 procedures at a single institution. Br J Haematol 2009; 145:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/117\">",
"      Rodriguez-Merchan EC. Orthopaedic surgery in persons with haemophilia. Thromb Haemost 2003; 89:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/118\">",
"      Tagariello G, Iorio A, Santagostino E, et al. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009; 114:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/119\">",
"      Soucie JM, Cianfrini C, Janco RL, et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103:2467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/120\">",
"      Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/121\">",
"      Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992; 79:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/122\">",
"      Lee CA. Transfusion-transmitted disease. Baillieres Clin Haematol 1996; 9:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/123\">",
"      Santagostino E, Mannucci PM, Gringeri A, et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion 1997; 37:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/124\">",
"      Morfini M, Longo G, Rossi Ferrini P, et al. Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: the role of human B19 parvovirus. Am J Hematol 1992; 39:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/125\">",
"      Eyster ME, Diamondstone LS, Lien JM, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/126\">",
"      Lesens O, Desch&ecirc;nes M, Steben M, et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 179:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/127\">",
"      Tradati F, Colombo M, Mannucci PM, et al. A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. Blood 1998; 91:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/128\">",
"      Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997; 350:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/129\">",
"      Fried MW. Management of hepatitis C in the hemophilia patient. Am J Med 1999; 107:85S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/130\">",
"      Rumi MG, Santagostino E, Morfini M, et al. A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers. Blood 1997; 89:3529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/131\">",
"      Sauleda S, Esteban JI, Altisent C, et al. Impact of interferon plus ribavirin combination treatment on HIV infection in hemophiliacs with chronic hepatitis C and under HAART (abstract). Hepatology 1999; 30:194A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/132\">",
"      Mancuso ME, Rumi MG, Aghemo A, et al. Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy. J Thromb Haemost 2009; 7:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/133\">",
"      Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/134\">",
"      Wilde J, Teixeira P, Bramhall SR, et al. Liver transplantation in haemophilia. Br J Haematol 2002; 117:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/135\">",
"      Plug I, Peters M, Mauser-Bunschoten EP, et al. Social participation of patients with hemophilia in the Netherlands. Blood 2008; 111:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/136\">",
"      Bradley CS, Bullinger M, McCusker PJ, et al. Comparing two measures of quality of life for children with haemophilia: the CHO-KLAT and the Haemo-QoL. Haemophilia 2006; 12:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/137\">",
"      du Treil S, Rice J, Leissinger CA. Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population. Haemophilia 2007; 13:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/138\">",
"      Pollak E, M&uuml;hlan H, VON Mackensen S, et al. The Haemo-QoL Index: developing a short measure for health-related quality of life assessment in children and adolescents with haemophilia. Haemophilia 2006; 12:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/139\">",
"      van der Net J, Vos RC, Engelbert RH, et al. Physical fitness, functional ability and quality of life in children with severe haemophilia: a pilot study. Haemophilia 2006; 12:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/140\">",
"      Tagliaferri A, Di Perna C, Santoro C, et al. Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers. J Thromb Haemost 2012; 10:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/141\">",
"      Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009; 114:5256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/142\">",
"      Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol 2010; 148:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/143\">",
"      Coppola A, Tagliaferri A, Franchini M. The management of cardiovascular diseases in patients with hemophilia. Semin Thromb Hemost 2010; 36:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/144\">",
"      Schutgens RE, Tuinenburg A, Roosendaal G, et al. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia 2009; 15:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/145\">",
"      Lim MY, Pruthi RK. Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients. Blood Coagul Fibrinolysis 2011; 22:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/146\">",
"      Sharathkumar AA, Soucie JM, Trawinski B, et al. Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia 2011; 17:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/147\">",
"      Pierce GF, Lillicrap D, Pipe SW, Vandendriessche T. Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. J Thromb Haemost 2007; 5:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/148\">",
"      Follenzi A, Benten D, Novikoff P, et al. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest 2008; 118:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/149\">",
"      Nienhuis AW. Development of gene therapy for blood disorders. Blood 2008; 111:4431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/150\">",
"      Kasuda S, Kubo A, Sakurai Y, et al. Establishment of embryonic stem cells secreting human factor VIII for cell-based treatment of hemophilia A. J Thromb Haemost 2008; 6:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/151\">",
"      Kren BT, Unger GM, Sjeklocha L, et al. Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest 2009; 119:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/152\">",
"      Aljamali MN, Margaritis P, Schlachterman A, et al. Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest 2008; 118:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/153\">",
"      Margaritis P, Roy E, Aljamali MN, et al. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood 2009; 113:3682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/154\">",
"      Jiang H, Lillicrap D, Patarroyo-White S, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 2006; 108:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/155\">",
"      Waddington SN, Nivsarkar MS, Mistry AR, et al. Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood 2004; 104:2714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/156\">",
"      Ohlfest JR, Frandsen JL, Fritz S, et al. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood 2005; 105:2691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/157\">",
"      Ide LM, Gangadharan B, Chiang KY, et al. Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. Blood 2007; 110:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/158\">",
"      Brown BD, Cantore A, Annoni A, et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 2007; 110:4144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/159\">",
"      Murphy SL, High KA. Gene therapy for haemophilia. Br J Haematol 2008; 140:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/160\">",
"      Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/161\">",
"      Scott DW, Lozier JN. Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation. Br J Haematol 2012; 156:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/162\">",
"      Roth DA, Tawa NE Jr, O'Brien JM, et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; 344:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/163\">",
"      Powell JS, Ragni MV, White GC 2nd, et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003; 102:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/164\">",
"      Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/165\">",
"      Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101:2963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/34/38442/abstract/166\">",
"      Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365:2357.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1314 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38442=[""].join("\n");
var outline_f37_34_38442=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6808294\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23967232\">",
"      PREVENTIVE AND COMPREHENSIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23967282\">",
"      Circumcision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Routine immunizations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dental care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Counseling and education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Exercise and athletic participation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Comprehensive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      REPLACEMENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Factor VIII products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Plasma-derived concentrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Recombinant human factor VIII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6808111\">",
"      First generation recombinant factor VIII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6808118\">",
"      Second generation recombinant factor VIII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6808125\">",
"      Third generation recombinant factor VIII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6808132\">",
"      Inhibitor development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H100234435\">",
"      Longer half-life products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22197866\">",
"      Investigational strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Choice of product",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Factor IX products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Purified factor IX",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Recombinant factor IX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7515472\">",
"      Longer half-life products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Desired factor levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Dose calculation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prophylactic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Secondary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      THERAPIES OTHER THAN FACTOR REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Desmopressin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6808179\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6808186\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Antifibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1532414\">",
"      Aspirin and non-steroidal anti-inflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ACUTE THERAPY ACCORDING TO SITE OF BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Hemarthrosis of peripheral joints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6808214\">",
"      - Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6808221\">",
"      - Subsequent treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6808228\">",
"      - Massive target joint bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Hemarthrosis of the hip and iliopsoas bleeds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Severe hemorrhage and head trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      LONG-TERM COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Chronic hemarthrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6808266\">",
"      - Synovectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6808273\">",
"      - Surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6808280\">",
"      - Weight loss and nutritional intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Hepatitis C virus, HIV, and end stage liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6808287\">",
"      - Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Quality of life issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Treatment of age-related comorbidities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      GENE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6808294\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1322?source=related_link\">",
"      Clinical manifestations and diagnosis of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=related_link\">",
"      Factor VIII and factor IX inhibitors in patients with hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5800?source=related_link\">",
"      Hemarthrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28184?source=related_link\">",
"      Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35768?source=related_link\">",
"      Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38247?source=related_link\">",
"      Pathogen inactivation of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/24/29058?source=related_link\">",
"      Patient information: Hemophilia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38841?source=related_link\">",
"      Patient selection for antiviral therapy for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32039?source=related_link\">",
"      Plasma derivatives and recombinant DNA-produced coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28565?source=related_link\">",
"      Synovectomy for inflammatory arthritis of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_34_38443="Appr treat dys";
var content_f37_34_38443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Multidisciplinary approach to the treatment of dyspnea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minimize production of symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise training (lower- or upper-limb endurance training, neuroelectrical muscle stimulation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathing techniques (pursed-lips breathing, diaphragmatic breathing)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maximize nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supplemental oxygen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diminish perception of symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fan blowing cool air on face",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distraction strategies (imagery, cognitive-behavioral therapy, acupuncture, music, guided imagery)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stimulation of respiratory afferent nerves (chest wall vibration)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharmacotherapy (opioids)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Reduce the impact of symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Energy conservation (advance activity planning, attention to posture and ergonomics)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Accommodation strategies (change in living arrangement, altered activities, frequent rests)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modify the experience of the symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Action plan for exacerbations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Address patient's interpretation of symptom meaning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If present, treat associated mood/anxiety disorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38443=[""].join("\n");
var outline_f37_34_38443=null;
var title_f37_34_38444="Airway complications";
var content_f37_34_38444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of airway complications after lung transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        1. Stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Anastomotic bronchial stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Stenosis &lt;50 percent of bronchial diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Stenosis &gt;50 percent of bronchial diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Segmental non-anastomotic bronchial stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Stenosis &lt;50 percent of bronchial diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Stenosis &gt;50 percent of bronchial diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Vanishing Bronchus Intermedius Syndrome (VBIS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        2. Necrosis &amp; dehiscence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Grade I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        No slough or necrosis reported. Anastomosis healing well.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Grade II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Any necrotic mucosal slough reported, but no bronchial wall necrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Grade III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Bronchial wall necrosis within 2 cm of anastomosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Grade IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Extensive bronchial wall necrosis extending &gt;2 cm from anastomosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        3. Exophytic granulation tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Granulation tissue with &lt;50 percent diameter narrowing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Granulation tissue with &gt;50 percent diameter narrowing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        4. Malacia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Diffuse tracheo-bronchial malacia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Anastomotic malacia (1 cm proximal or distal)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        5. Fistulae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Broncho-pleural fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Broncho-mediastinal fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Broncho-vascular fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        6. Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Anastomotic infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Non-anastomotic infections (tracheitis, bronchitis, etc)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission of the American Thoracic Society. Copyright &copy; 2009. Santacruz JF, Mehta AC. Airway complications and management after lung transplantation: ischemia, dehiscence, and stenosis. Proc Am Thorac Soc 2009; 6:79. Official Journal of the American Thoracic Society. Diane Gern, Publisher.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38444=[""].join("\n");
var outline_f37_34_38444=null;
var title_f37_34_38445="Causes of cardiogenic shock in children";
var content_f37_34_38445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of cardiogenic shock in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemopericardium with tamponade",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Blunt cardiac injury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Myocardial contusion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Traumatic aneurysm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Traumatic septal defect",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Chamber rupture",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Valvular rupture",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tension pneumothorax",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tension pneumopericardium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Congenital heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Critical aortic stenosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Critical coarctation of the aorta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mitral stenosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mitral atresia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Interrupted aortic arch",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypoplastic left heart",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary hypotension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Severe heart failure secondary to congenital heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postoperative cardiac surgery",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Dysrhythmias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Supraventricular tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ventricular tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atrioventricular block",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Junctional ectopic tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bradycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Drug toxicity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            b-blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Barbiturates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chemotherapeutic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Calcium channel blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Radiation",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Metabolic derangements",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperkalemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypocalcemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital organic acidemias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Late septic shock",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypoxic or anoxic/ischemic injury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypothermia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Viral myocarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cardiomyopathies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dilated cardiomyopathies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Infiltrative cardiomyopathies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mucopoylsaccharidoses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Glycogen storage diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Ischemic heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anomalous left coronary artery",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kawasaki disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocardial infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Thyrotoxicosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Pheochromocytoma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Witte MK, Hill JH, Blumer JL. Adv Pediatr 1987; 34:139.",
"      </li>",
"      <li>",
"       Perkin RM, Levin DL. Shock. In: Essentials of Pediatric Intensive Care, Levin DL, Morriss FC (Eds), Quality Medical Pub, St. Louis, MO 1990. p.78.",
"      </li>",
"      <li>",
"       Tobias JD. Shock in children: The first 60 minutes. Pediatr Ann 1996; 25:330.",
"      </li>",
"      <li>",
"       Bengur AR, Meliones JN. Cardiogenic shock. New Horiz 1998; 6:139.",
"      </li>",
"      <li>",
"       Bell LM. Shock. In: Textbook of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2000. p.47.",
"      </li>",
"      <li>",
"       Williams TM. Indiana Med 1988; 81:18.",
"      </li>",
"      <li>",
"       Hazinski MF, Barkin RM. Shock. In: Pediatric Emergency Medicine: Concepts and Clinical Practice, Barkin RM (Ed), Mosby-Yearbook Inc, St. Louis, MO 1997. p.118.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38445=[""].join("\n");
var outline_f37_34_38445=null;
var title_f37_34_38446="Salmonella Shigella agar";
var content_f37_34_38446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Salmonella-Shigella agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Salmonella-Shigella agar is another selective and differential medium for stool culture. Like MacConkey, this medium inhibits the growth of gram-positive bacteria and differentiates lactose-positive from lactose-negative, gram-negative rods. In addition, growth of E. coli is suppressed, and production of hydrogen sulfide can be detected when black-centered colonies are produced.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38446=[""].join("\n");
var outline_f37_34_38446=null;
var title_f37_34_38447="Hormonal changes during adrenarche";
var content_f37_34_38447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Hormonal changes during adrenarche",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 358px; background-image: url(data:image/gif;base64,R0lGODlh7AFmAcQAAP///wAAACBzOeduNN3d3Ve23e7u7iIiIoiIiJmZmREREWZmZjMzM0RERHd3d1VVVaqqqhoXG8zMzLu7u39/fz8/PxYmGoyLjaKiogAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADsAWYBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChNAGkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6kdAGiw8QtwnPHxcrLIslxzszRodBv1NLXm9ZtzqpN3ZjfmeFu2mzcJuVEAQXs7emPAQPy8++QAQL4+fVl+2fnJf1+rGvHLqCiePPkGVx0Lx++hWAgivlHQmILAgEIqBhI0KKMAwl2gKSCMOHCCR5f/2DUqCLBAZIOH8ZAicIlyWAV0ZlAYAoBjZUbCRbcWYoBSxwjXyQ9sXSEgQAKDJBA2YAEgQalFhxAhXHCiABeU5SkhwJr2KkpXQBt+dKEgwA+SZglsaDUA56nFiCoKmLvxpgCtM0tQfOETZsnnkZFy1fEBAakDiDYeqrr17PNcH7VWcIvAJ4/MwYVSs1zgwc6mrJQTYI1AgYKQo5YAFkqAAMK+D5mCfayb7EJFZ7AyMCBicJC1qZAXCJ3WxHEjYtoYBQAgQeyPX9urP1EQ4fWoh/Xdvh5Z9iyRdAOYBtlXO29m52NvxlZToA7+SJADaDUAQkASABZAAt8lpV1ooklVP8BpfFlE0gPZPRWAAwASNtW1SU10gEDOqgAVCEtoBdcpSCAEikMSMUaAwg40BgACjz2nnkVzWfjRsENYM1eECgwAl4fAuCSBAQagFUADRiA0ZFx+QfgkEUe2cCSpDQZ2ZM0AtDjU2fx6CMAKB1FgnZkvogOYDs20OOPpASJWHn9lWICiy6SECOL0xXo3Y3y4WdfffeNaYp0s6H2QIES8AddABIo592CDd7GQIEHNACgZ3XSptGkAGgYUqXWxTbBARptSZtsrEnWaXoiEEmAqyKs+ZoIDxAK0HynYIZOjtbgqQAEYPYGgTAJKBBXA3GxiJFxCbBHF2rFHlsVAUYFwKz/s4UKmeWhAHArgq/AznoCmaeYCRCaJ4AbrFfDaisCnMyR4CqsWvoo7q8o0IeKrml1QRGgP/JFgKoOfIjkZwro5diRYDmKDqREkZLkqtOZ8pKI777kKcUAiIhXKQRgLEJSIZfI8Qh1AoBnt8ZhBGCt+fLZn64A8WoCkVItgJpnNDGXF1BAFSyxu30uqlHQBlcV723CLoZzxzszgEKZAf8VEzVP67ydY8S2BW+WAKS8Mswuwwjsnr/N7Kcc/2bWWWMeH+CVZxIs0MABuPHXcIL5Qvx2CUk1YGvHes66cVK1ijubnhw/UB2yJ4sQW18vPdXTZ2CrXbTm+dpcwoRtGsBz/9dfnW00ggRMNrfSz9EHdEaqb730ZCNMDjpUBoQ5Lne8Ww2eW6ZENTrRX58wOeZMX94A47emTZ/bbAcKcF98SSCZA1IbwEBVDYSE0lPANjuBwwD5PaaZSSGgwJMFaq29T8UJObmqEsSIUkgCEj7CyvFb71NTWxIBl5hjEwLkRiq72Zy+aFYRz7UmPSDpkYVIN50UfQYBryMA9iTFuhE0YFrVOpqEsrc9ou0vLmGrylJGwoAKWQc71KtaDMWCLsBBMAES7JgwekQAI73EJgEkQRAH+BwgWmuGnFvg2p4hPeixqRQtg4wCSvgxn+DFLOSriPlkOIKl1AUqPllA0rhGof/5Gew9Bmsf45oFlwl8iAGqakqE8gI5AfZGAgxbgG2UuDnvONAxixFBplBEQesciQHjE81KqAWVEjKHkUjKICOn2MEREAkVGAhkCm/zxQA8AEBbQ2J3znQ1wmhykBQ6hpR+WLkBkWCOprAbCrkkpAGpSoEycyIc2tYfb2yRBiLrw1iEo4nv6IOJf9JlL5nAEXfgIJh8GKaOslHDamhGmf2qQTOHAo4/XsKYMtnlNZfZRCRsk0Hi8KYlwBkYZEbvK6nwRjzBMU9x1JMc48SGPsWRz336kxLZ3EJA/0nQPQw0CwctqELrkNAr/OKhEI2oRCdK0Ypa9KIYnehCN8rRjnr/9KMgDalIR0rSkpr0pChNqUpXytKWuvSlMI2pTGdK05raNBoXuKkOMtoKdPB0FT796T2bIdShxqmop0hBBPKF1KT6s6EzoAZUZSDVKFQVCld9QjmW6h2r/nOqMciqE8TqDc5o1axjVWq+vPpUtpZzCWRlJlrLukS6noCrc5VrW7GaV7j2VQlx9Wtd9XrXtfJ1rwI8wJdUdgoDwBIuAQpeSD5GCqkkYEAKw2YKKPsAlnxIKsOS2mOlpqUqrUCsWAHlgEohOlM8wACXbJNsrtImFF6WFJkNLAmkOILHSueSxhkWagxGisGV0xm0hYpGPsSfCEmNs7A1hZpM8MUDOMA2/+Q0AV4HW4JOZidpGoktiCx3OcPuMxkTWiybRBsAYGEFAkSSGpHsdUQ2Teyy08tuZ47YI7zByFmh7VZ7SzDHzOX3GMMiBSjXayDj8MQB8Y2sjwyg2JdBlif3Ja1uW1UK2UQoXAeLrQSE+1/sisWsFMYXBIar4Es+94gPjjAjMfMWn1xlwVs17wmwYuMk8QQ19cNbhOe7P0ad9qvNUe/IjPzhsMElwih5sa22IqYDb7a+NS5xadlrutsoYIoDPvESI7TgJV+Kv56EMoWERKBFaYxvVk7BWyBD2iYzdgJEwhCJP8uCrDaLef9VwAMe8MYGl/aTay7tiyIkOBPrlwTbff+rmwGXoLokQM2kZWyZu4pYySn5Lc0dMGQkIF4LUjZFUNGxMtkknQf/1xTshaKB7uLJjaCVzCQAdV+OWBcElFoqWZYce1Kd13RsxXpMDvOHiXQoJNWauGHmdKCCXTsSkUjKOvR1oiNsScpQ6Cg5lrYJSOwUYjf410Xe9F+ZAY0vkwA3CmAJLEcS3/lqxNVdlFCb4jwuLEOWzwG285JLocliv9LIAvwySyjrk3orl816wsibNbjvR5eDjbK286iZTWFSsNjR4oYeTwD92QP8Z80Mjyxpyf1uF0F21SKIdH4tGQAaUVk9Abg0heyd7iMDImUVO1jQGyOlG7RbvREilMD/VW4gbNvXAIrhN1GCqwD/AnzNAkdJWyKEQoP3FuECJhS+Ofzi7FVYwFZEEtSJvWEeS1jAIK4Ks0v7bGzZem0pBtaKtcz0sTN9xq+Mi6VnHnNVl8DtV2ktkKse3bL3/O40ONHQAFB0LmBE6JiDuqomo3kr4o3CXacqyi6HEk0unduQGZEppDKZA2l2aq61zdVjjaKkx6rmYr5Pgj0eLE36HfVtTq6xfuRtPel2vraBTAIeG5e5C5jFsjY8co8Ub75H+PfS3fR+aitpAMgc5rPpcF/Ay3TG6mnUPo88NDgPei9o5y59MdR75B9/G4AVBhs257r1z13A7v8I4fZ/RpAS/8hBK/Pnfo2RFPilgFLDgPbnVoSXBPkHgAJYBBM4gGoVcoQ1A5KXIbKBX12gHQ44gh+YaSJAAaxQgeqggkNwgRbIgkLggiuIAt/3aIJVEatAASigPajhgCHYGPAXNvQnhN0SFw6gKH0Gg0Eggy2ohEDAhDHohAKRgVLoA1BYNUF4hAhIfJ2Xee3HfrdkDFXYA1f4hGPIA2U4hf0ngVS4hvzXfdRlY3gChqF3BZdnWpQ3eXmIeZXnAmlohWe4A39IhoG4U4WYAwHohhSoiCRQLLw3dIcwiGh4iDggiYJIiUaHiQ9Ig4Z3gxHIT4z4gqE4g3C4iKWIgaPYhJyogZ4Ifv+geIqiCIuk+ImmSIuoKIuqWFis6H+pOAmWaIi9uISaqE3DOArFGFVtiItRGIyR8IuIeIyix4xqqIzCKI2AuIrQGFbZGAjOWInb+ALdmInWSIjjOInYWI6XiI6GgIKm8I1+6I5iqI7PKI/eSI/iqIvwmIQAYQo6yAnhuInUaIb2CJC2GIsFOYslUIP3B475GE0NCXkHmYsRuYwBOY0TWY34OJDEqJGF8I8bWZHXCJLkKJLmSJLpmJEmCYwpeRAPmXsXKZArWY8xeY8vaZEJ2Ym8OJOR2JLSB4GuWIs/eYs1GZLahZNsyJGE4JFigQrH5ZM2mJNDOZJRWZJFuYtHqZP/hqCU+VJKUmdXU3mSX6mSYTmPKDmWMmmWMQB1IIdPSOkdXPl6Z9WW2iiX+MeTVqmQTrmQJWAA2FMUdXgG7CgndFkRb2lxeXmYh4WVxniOiomM+1gK/QgE6oMiLXQl4jSYX1GYWhmNjcmZaEmQQWmQN2mVb/iZKvAUkoFdGjRFl9mZpHRMXbmBoYmQT3mVprmYZTmbEqmbN2AAejQcgLYGm/ma4QSXaYWZ8eiadYmc+pibtVmavCkJw3kuvxObrficQImdQhmdMFmVdul1TLAyrXmbW1mdxumV3GmT2ima60mbI4CXiUmeLvAUxmUO+QhOvKSXySmfc6mcDMmc6eed/wAKkempA/T5Tv6ZmeZpmPFZoFLpoFQJoWA5mt85WPrpFGq5dvUpnPepmRXalA3anrspohQpoAm6nxIKA7cTfeOZon7ooQPqki56ljNKkzUKmpBmlNBJojewosXVBoEJDMyJnyAalyfanPy5nEcaoBQao9LHj0KQoRnqA2opBdNJmAt6pe/opBp4oUzKo93ZpEd6T1pqR6mwoTLAl6slnugJpqMAo0tKoG5KlDf6kUn6n855oURqnT9AXqeApjAwmRRSmTWnbjuqp3B6p1sapzI6pw/qqBGao6SJholap6fpmymieV1GA6iJAKpZMCYIlZZanrB5nrIJqROKqmI5qv+eKaaK2gyVqqoxAEf7Yy5p+psmEDLHOaax6qVy6quNCqw9GaLvqaOUmqUtyWhHiHlMYCQowhJ92IcoKqvG0KuIaaSviqSs2p8mmq17aqoscDcepIcrMDAEZ6g5wKYpQBvfsjOft3nv+pfDqg7WGqLC2qXXuqvduq3UWaoM+gIF0xZ0OJ8tgkFAcKAsoDVhUyBBuB9FWH+L6q31iq38iqfZ+qX3um7wSa/I2ouTQTsP+xlI+AQIuwLakzATQ4LvEqq/OoATq68VG7ExO60Zu4Yb24IvuwJuRACI4YPriq45IKUlqwJ+8bEcs4AlWAJBypRDmrOnWrNFCrPUaqOS2qH/HYuDqhCZoeIVPZu0KWA509UDPlpfKxAjGROyWpiFI9uyFui01wm1fGqbM6utVeuGRgWObnsCkgcyarsCEiA0qbkDYwuotTodVTGwAyuzU3taeSu3i2unc4uxTlmspLlNHvGt//oCiJG4LPAaULEAQJuWQusCAvKskHi6iouoV3uxbEuxj4ubrNuolLt/lqtNjbsczyGtLbBiElNlaSq0aymqr0uqxZm5bQq34Cq8yFubN/swHWG7qxu5J/C3+FIDfjoo9uqy0Tu8rcq93Cq9wTq5hVe5pAG9/lqmLBC886kKhMueqnu+Hxq3h5qvbTq7dlu+b7q9wiqlBoqpankA/5v6ttoLv1wKnlK7vOj7pfYLh7WbvwTMqCuaMDpAq99iq477vsWbwK17wPR7qgv8iQ0cVbf7A2MrrzGgrIyWvW2rvx0swCrsuh/siiFMVSPsA9gDdURSLCw7A+baJqEbBEtrtQ8cu/PKwS8stTH8nDMMT07VrxkcVKSgtUDQQouCPTs8A6LjAAZ7xDFYw+7bwsorvt6no0vcDMFhDZirwQImODxGxdbUtCzMxU8Lxo6bxOlQxv1xxm4Zx0dgQP5BLSbsAqDrUEL8xAVsoXQ8v8Q6vrSLvzVjEns8xOBrABBQsBCgvi8AtgHsuhjcTvKbnQgcv8lbx4x8v8+7K5BMnP+ePMpAUBdegRvBOQPUW3OeaqWFvMrGO8dy7MIwXMoM7MgNlMpOjMtq7MYqc8U04LkJ88NfvMKS7L1KSsT4usvCa8ej4UyoTBaqnJ9JQMGdgsw1wLuRZMQc+8yhfMhRe7xi3Lzlc8qPrM3DzM1IgGEuF8g2QL2bDMoDbMiMWsTqTM2kPMbk687BDM9Yas5JoD1Fgcm/W6W3kQRBDMcIDdCKzMnrTMbA/BV6vM3HBaVEkMW1LLinIMHkrE1MG8/prMsWTdHZac0KQtAaLcwHzc/SPKUijQr2PKL9Mkxo7MW0ec79PM29LNCNDNNmLNMKOtFHgGwsigM3HF06XNKjsNH/KP3J2wnNFgu+/uzBvgzCGX3UBp3UNA2+DPOjE0xay2LMvKxNVD3TxCzKubzW/zzU7KxFRp3HSA2rfGwE1NFDUMcDytrG4PzTldjWYv3W6GzVzbzSdI3Rd83TkTzWWD1un/fXO+DHkQHIUh1Vhq3XSr3Zcq3SSNzVMvzVeB3Wni3ZwFo/2LsDIM3QV73Tnd0fPq3TiazPi0zUpozN70xMVc3KP1DWZNu/ls3YbJ3XtL3XMXjScR3GLH3VLt03jz3badySfe3QOsDUZg3aYUXdtW10342R0mzA9UvaSmzakM3Ris0DEFDZsA0Dwt2+PxDRKZnev93cVhjeYTrZNHvR/wPN2wXt226dnx4tBCsq3y5wN3793oRtdN6t3Euo3+oJ1ONts44N4DGN2sn92UVw4DvQ3jZt3FON3NUt0ap927Ht30WN4WAt4Ictz0jAvzfd1KI94hpe4rwK4aG949Vs3neM3g/O4Wbg4SLO2SQu4SKs485d5NcZ3Y8y3Ueu5FSKqyWgq0Eb4tyNf0F+4s7M5Uy+5KOt278M5TeO5GlKy5/Kmk1QuvERreRKt7Id5UL+hGYeqRSu1Xd54dzU29Ok3sA9FQNSHXtowWNiMC1kS8x8mlRuFbFsFQpgK4gbr1mtqvY94ClN51Je0Vm+o07uvCx+2i6e2oiNiy0iKQ4m6f8m25eNlNPpi+YjsJqDrYWBV38Nu7bh6+By7uU4m+m4/eUBXddfAeS5PuovOTDAUuuZzOAuIKiHbpkqAEeWqbK1NOlxXua8Loh1nqp3zt902+nt/OmV/uKXrgJbwR8+uwRq2ibqigLWpR4NmLTnDgBL28RhGe6iDuO7PudgPtdhDuzNIOzWbs45uIN4Eu/NquyUFxc00bd9m7qFPez43sXXvtib3tI+fs17HuB9ft9p6BcNHwaToREPcLiSzrlw/vABr+sSr+8XjOLs6e12De5bTuy6CX8D43ldeKmjCwVzJOhuzqwnj+spT/PcjuMVPu4tn9v+3h8AH+obrvJEazD/iqK7JnC9NL4NhWjvT0/0nRzxNf71TX7xLy3zEI/0PWD12/3G9T3zXo/pLK/p/F7eYu7VZO70Rh+5wIvwOi/jvg6ObG/2x/r2vV7x0C320k32Q9/2RaD3p8m+z91nf7/elZjtq8rtkqv0eo5O2Wz3lC8DrReGNoD2ww323V32kg/eE9/gfW/xc1/adb/xln76OUBZOXflO68E9F3vkf/nO9X5NGr5Gyz3S4/HWn/3RxXFREAdEgBbJbQDCaD8DMAqpK/lps/7iOj7VLvt2w7zwf76PZ36O8Ap7u78rHUaj39au4/fZIj9OKr9Kr7bGZ/hnA/+OlAXtRIhjT4DLcQT/2oKAoA4kqV5oukYmKz6isEwz24ZCHluA3wMA4E4nYDn6wWTStLxuHyimtCpyimKRKuF7dYpow28xCKzRZ0aDoH1wXAuMRyQgOHBeOORN/yXJiYameXBDOkE7g2eSSVSLTJCWQFgnUT2cHVRgoVRjh2WPcIYIDgguCUuKDQEPAQggD45Nmr+GX7avjJ13v7gKsX2EgoCC6VMClNeFnjNcgLu6g2TICgQqFInGjCsBTCYRlcdT/XVNNeuhPcW7jxXfvM+uyPCx5+jGMsjXy6D0a7Xz/di8EBCgAMKFjASRcobPXTthDBroesfRWDqyFSE1hDfu43sPKIbcQ+gJX2Z+P+V89dxZbQ4CVo5uDMIwQMIILNwhBTxxkSWDwdd9JTR4y+QRYkWwxkl2T4/KTH6bPjggCoIMRM5YINAws2Pb8Ztkugs4888Qb121cgSaU62J0YOXcH0pFOx5qLSm1MQAAOEiSYsUNPKI4Vta0IuAdsPqtrGuM6STYs37dGNkeCulWuyxc5cY30apvDNKgECDrgyIoBAjQPJlX11XtGzcVk+s1/Twx1Pt7vLSvNxaUrOrkra8UwZSJ6cEQRVbGxSRgwbJXHGvIHelp5b+27uvZNS0rL5RuwY2du+MhDAQVbDrQdlVfBgguTJsqjz/Gz8G2T7N69HA+AwvoWXQgBzcYb/n2d37ReNeuwZtl4iCZRSX2RfldfDeSQx0l+DXQlokXf8gafdgeMxkaGHIb6BnHIM5ZFAAwxIwEACro34gmJPCZUZKCvmOGCQIqLXEIEmIkiegrLpxyIeCPgFAHsTbmNAAw/gWGQSO1bXo2OvAKlld2J+RyaJ9vzWQpIpLmlek0PiYUBMyi0gUx4MMIAAHVdFZ6aOKm4Y14+B+ridn0IeSuRbad6w5gqAvpnoG3pF2EAiccxRh53/wUnXcPkx6KQ4hH5pZKdgnvpjiVqeGJynYYFanKhTULrNAajlgYoqrLjSJ4cQtalhpL9iN6yghhIbYKqPHMmqozFAGuqyUIiy/4Byj2SzTTeERTgttMGGmaxtxhY6priKHmuuCZiVWpKrCdYVq3UthBYNAdClN0qFWZ4bRbSyerslqbWhW26Z/T62KkmtYgLvpwsCLOmTdGD74rX8pgtsvBDPK/Go5LarrsFnIowqmgUuheKj4A7cEAHUXNxihNu8B2LAXMrrJcGKtIzxyMp6rOrJSKr87cZMShs0Fe3RHOfMa9TMqdIrH+1m0iVD0rOvGZPMNdCLogxcw0pWLezVXmMVYdRUWByzzVMb/TDSEWMNi9Zv191hwGYpfCzDyry6mM5JJCBYA6Y4Z2kQFluYzs3/dpy3L3dLLTlQe/PRd6F/Cwcrx4MHsf+AKy+7slpyB/QKw2oFpS5ZAweMkHjsaygexKxslh0u2l9RbhTmX/2uiObtch44j2gp0cCND/RKExB6GnajZA4oADsApqdRehvZb/k4yyDv3Ejvbu3uONyXD+1s0T1ADroSEvR6gPQJbJrCjBIYUGPtN622mgjMi8B5ALwelkhQmKcd5nw4+xzyLDI+ywSvEREUx/AqUTyHeW5ukVsBAgMgGhMQIEryEwH9gNCXEdSJEaNgjxyAMAFqFE4EIwRACWdYQtt5L3cPHBT46nM7vZ2Pb+lb2LPY972z/UwEE9jfAB1QwBcsYBVODECUJuYeGLyMPjEEgA3v0MXuKbB9DUz/xw6RVb6EBTFzQ/RbEReoQfeprg3S2B7qgJAGW8HoDA1IxQEcMEMVTGBmBGgilggJRsu50Wp0O+PHkBiygzFSaJYTItiI9i6yyU2RG0yic9ggAtktTl95PEMc/DclwlkPe3VUZet0lMNMmm2RSeRdD332yK7N0nyVVN8lcQdL3eUyThAgAAAMAIFRTqEvc6hT/V6wRQCAEpq088UrM6hJODqwllsLpskmqcZdEnF9iYzlJm/JiCjSxwAHwUobBLM28nETk9YkJzbJqE28RZJZE4REBcXTS6r9soyvwNMICIoNAJimlb4L4xFlac5xOTJ83cwnEL0JvDVuro1ivFA8/xhgPS42s0VuqxxF4zZPYD6UlhH14T5h0dLE9NNAGm1oOSV6Bj01wAGqUCgVJCAYqNnSpr48qUATgVKhVrSk6LOo8DBKvJnq8J7fyNYatjWITgJ1IwfcRjUFN8bHFBWXKdWlUim5LkYxAaoBBV+9HCRKRsyIACNdKCI36h97rjSoLE3jRcHJRnHa9UONo9X2lqNXDNG0nmCVKl3L+k3H9vWsYVMTYBP71cG+TwFX3OZYjdely/Iwr5xFqlFfSk2nWlCtRGUsZpOntsMqIrA/nBxrIcjXpjJVgqj159iG6lWOtvYJcZ0rPDuLwd/edbGixWc89Xlb3fo1o5WN6nLdsf9C9uALDxAoLDJNxVDqOpS0Aqutd3NLweeeN7pPne5aqxsN6DUNPq8dLR9ka1oGApekzU3qfku7W5myd7XuHcYeX+dH6eWBaVllrnHliVzB4jW8ezUvP9FbYfWmNsAPnu0TSgm7Uw5COcecsFLHedTehPVrkMXtiqErWUv2FqACljA9lElFg+ZhGtUIwDW02q3vtpfGAUoxoijsUgsfGcO8Bdxxj0eWtgLDj3eU0CAEQhCDVLGx/TUieGuKYvKacctmFfNjS8CuDP/TpBu+7wmSIwHRMcIlMAlpeUtsXyR/Nr9abrBzjQzT/6YszVwOspfp4dPN5mEqVeETg8VrYiL/q1TIjSYxmSNrZrRqRtCPBvMrsErlPOgFdiekL2K7rFgwQZqslWbxql186ck2SsNOTi4whmvYRJDGNLjSL59lvGY85wy0Ye61f/18WiUDWNN3NvYJtvui4PKX2IOecaGHzGlItjq9Ldb2q2HMZAfPGsLDkIBm4zsTFraQ1LG1rJ6VK2lei3fM0pa3SDAdA9X+mtkm8PQ7qQDfBcO7vuymdWjfved4l3neCa83rNMq6zwTHBe27i4UCtzHPwa81IQ+dcGrPWnYMpjh3u5cvrf9AmcTlwoellK/o7HVBNZ14OJG9bXFinBLKxznIudljNUc7iZAuRcK/jQebMxMkItj/9km/zmbiQHsQy79z8gOdM+nXfJsv2DoLYeClN2JdJ3InMNPY/rTcVh2p+sb7S/m+bd9S/a0l4BxebDYm3lq24XNzLPBbndilI71JEf92IGHerfZTvK3D77NIhix0562dRIUjnaIm+YnKW/2cCo77F1F/N+lnni1d17whcd81Tc9YGDo2BrElJnjgQBn0l2Pjto7nd1hjebS+13apjd4cW/O6pz/fuekb7uvOT9WnZIgmi+wckHWGae2URwFygPAAAXYvCcGw/B6x2/EbZd737sa+OEHP7dJcOYlHx7iMz8BASzPShM64CWjoPMTFLLr98Vvfl7UP+HXm3lTC5v3af/e2WUf3LkSAR7g1IkN8fmc+rEIAtRO9WFfCihaAFgF/SmBOm0DgiVBCI3AF33R5f3V/21cAGpMCfJdnYVe/5Hfha3d8KXf3nWfCUDgB/IfDIQaX2TZFOjJA6ACBp7AEpGAIRmSAXUQblwQuDng5i0hAoKDExpI0xXgC44g7g0gE3TQB5VADcrQDeKgA5TGaSRYABBTFEXfHDHE+72fCEoXCVIbx23J91Ga+JVfCwLe6FHE0+Cb8e0MF1JfrzhREFxXur1BViSHIZ5h5dmKItaO8k1hG1ohAKZgHF7h5z0iHbrgCrKh+f2GDySh2zVhv/jhGr7AvxHd0rSeui1gDHL/3/pRoiTOoM3NoR16Hh52hCfuYSiiTfttQ684ov3w0YGN4cw8Hrb5XySiYCz+SSVqIuhh4h0+Yy1yYtjg4sPJoCsOFCl8WDEmAfTNIvpt3xuZICEww9OkGhoZ4BOmYxQCmlp8YvHpYjOSgNHhGLTh3O0xoNXxocA5hSee40TJYwJaokDaokZUo6s8jRzSQ9cBnD2OHzg2WTzqXjleI4fJGy2KXjRmpPDlYawhpBJWpBSSgBsklENeJESCZCuKHUWqpEiq40C+ZEDG5DQew0Figicq5FR5o0neI0qCYkgC2Sb4Y82pmEyy4zra2/lVRPHgJDNq5EgiEDfyZAm8HBLm/yJQxlw/YiVMHiVXMoqj5Z00cuQteuRNgps5stU2aCEoqEcqTmUmHmM+7p7HJR1KDOXpqeBTbqKjZQhB0iQ+2CTgNKVWtiQCQl8ivuVX+iQ8buWW7chd8t7deaXt8SMs+eVYGmRZCuZZNqZejuQo3F9iQiM+sqI4TqIAEqZpKmORTaZDVOY8XeYVdKJmssBgkgNk0iUwaOAacKBoSiNphuM1jeMypqZwnqYxYiQLvmb4NMstBGZtcmZhGmAP/qBv1uFiNmBn8qVdauc3fh0W/lhKbiJm9ghTRqdqYiMjZEUZUox1/iZ26qNEbmdx0tNwsqZRKmayISNsziR57oJ5uv8dbsLhIyAiIrpnRgJnRHanxgnlgqpixlGdXPZlf8omNdKmO7IkelpkEAxdQx5oV0KihDrlfN6mg37cg16ogvaffy7lXNhmg0rnQHboKX5ofkZoaRrnahpIhuaoK44dQHrmJSaoeDoji64EgBafgNrn3LVNjaJAVY5ccNbncZIjd8ZoiHpBWCKod96olMamJMymw31kgGpn0DmphVilNV7pRFqphkapiu7lY1TAnM6pBb0pkV6ikbqji55nj27omaJjFYooLKZnldLniennoFrmTNqhJzIqfI7TlyrlkfIpma5pcgLq7w3pT14qLMwMj05pxL1jdionQNqp9sFpkVb/aE1e6ItCZ6dmanClqRteXWe5qjuW0ajG55aa6qMmKo7m6aoCZqv2aagWaqxKJpZKKaKK3mOaKGXR6mgGKvHcKaeOp7A6J7FaqptCIbI646YyJqw2K6gy6yp6qa9K0uZUa7hyUHiWyqTuqUncqpJSqbcOG7iSKrcizLw+a4riqV82Kqusa776aUxRqrwWa7na63dm2n7WKnMmbK5eJXgaxpI2K7qaa6oaa3N2pJia5bYWbLcurBFWLKriqcKCnrOKa8ae7D+mLMZCq8Man54+J4a2achSrAeNLISyrLXi7Bnx68rGrKK+ocUS3qnC4LKSCs1qa5L26872HqTm5NGS/6vEqqm+Lp2jgmhcAitKMa3HbibIbqxLQq2N9iy7/mwwBS3WKqvGouxSqavJ+uzYtmPNrm3aBmnZbi2+7qrQ3kDe3S3dJq3buuwjBoAFIC7iwqGuzqWXfG3Dhq3T+q3e3qvUjmjOrkGlSi7bcq3xoCVeWtrbQm7XLi22duzo2uyhFi7lJp/lfSvmMuWn2uXM3I3dRiyYMW7VEiXsTpbo3pu8yi6hcixZgu2rbi7eEswvli0pCul/aq7P0at92K7Y+q67yGz0+ijg/m23YG8s6CHCBijtgszj/u6YHq/gog3z6q0ElurBmi/0muj0nm/1xm6E6O5yfe/76mP3smrxpv9uia4p+Vpv5MLv5KIA+7IuF3lh87Yo+M5v7TZtAXOuEczM8+5v/EbwBa+s/Eow3gowknYw+iZRCLIuCYtAVbprDBzhCrNwC7vwC8NwDMvwDNNwDdvwDePwDVdQDucwvSDQWiowCQGhtxZh+UUtw+Ylpr6uLekprylBEVOu+oplsuYtzB4cl4ac6eJnwyWBFJet8m4kFSsxA6PoEXNWE+/ZEoBxAgcftoxkHv1pCjDErdXrGcwxHLPZHbvmMOhxkcArLvQxUrIxGxpAaRhyacBIIR+yIaPAAiAYAjTTLyjyIifyIjPyCTjyCEDyHo/AJB9yJVvy6plAJgdQJIeDJxv/MihbciM/silzBCojctyFsiiXAClfjysrYDGFsiovMitrMi4P8mD5wE8ZxkeJQBQ9DS2LQAghgCH7ESfL0NMYMwAgsyCBkOg48zQLFjEvIglUc4QoM0Jhcxhq8y9wsyd5MwKFMzNnMzRzkTTXsjpfczOTs3T88TnvRTon8zy3s8gGM0HCslzJciibwEtEiAL0pmAFNC8fckHPDEK780IP9CqXgEEbBkTnhA9I9EjOskMfdEJL8i5PdC9X9EODtMGKwEZ3ckeX9EeT7T8HawIswEzD2Qm8GU1bCwjFXypT5gnINE3b3U3TdB6ZRgLwtDuPwE/PdFDjdE6XQFEfdUaj/4BS17QJCPVME/VOxzJSkxBOMzVOZ7VRb7UfYxpVf/VQ67RYC/RLw3R/QkAqHIRAtJl8UNHrwMgs43FbvPUe1ckEpjRdL4BdP7VIS7UJ7HVc+3UxAbZgkwBec/Vh9/Vcs0Jgy1FjE/ZXQbZcm4A6TTZjj4Bjk3XDZXZic3ZdV/ZnX3ZrtnXDLcADxNAEhFThtJ9cHQAt8+LM7OBRtPZrx3Ztk2Ea2DYC5XZI7DbswLZP+zZtB/fTDHdbFDcAHHdBJzdwN7Zwc/VzR3dFT3dtVzdz2zNaYXdvzzZ1f7Z1+/NqE/cCzPZsS3cQYxxCpXZyzfR6k2F7j9B7g/ZXzTcZsv+3drt3b+Z3u+13adS3f983gMe3uA14f0Me7Bz4YFtyXufyMas3fxd4g/83hFMyW6N3SGwyAzTAjNi0AhhAYDxAj430Wn/Vh4d4SJFbiR/AiYezLn8yV7O4iFs1iZs4inN0jRf2Ft4BiON4Cbz4js84Kkv4UNy4i+t4jPP4Svs4QPxxKfNFi484jMt4m234eXd4XJAke4TmMgfQAoQ5NUdIc8/Dl4sh+415mX8zFXF1MSEUmKPA6kGJm595nKt5mds5mTdynv943M35moNQm/+5YaA5FWbGnte5oWMyoAtyl8ODTI/Ai9d5Q2u5IU9foCd1lFg6+2H6Zh/ypn8VpYv/wKeDUKiPNKm3m6kDAKpr+IzTeGmwenK5Oqxb9iWLuqafdDt2eqWT+KXr+qr3uqTvmWqod2nMwYyzgmHIOuQBM0sguyEv+wk0+zY8e1JHe2NMu7Jf+BCCMwzc0Bh1+718+whc+xpkuxAjdblXuwmk+7n79LajsbvLO/WFuzPRu7Fj221vgwL021tPgKr3eGmkEKf7+xoAfLMpwMAPe8GH0Lb7QMLzWMA3PMFDucFL/FM/tMU7fGmggCcffANR/MIb9sU/fMZH/HdPVsl7PMan9CGPvGob+xEQQAKA4ViXwHa53kXTB6cjFM5H9c5r86P/+8+Tu9DrPAnwPAx8c8O3/7vSqzjR9/zRR33OTz3TF/0o+zzLo8PNYz0yNT0UdT2XS7oTNIcKKPIBDFPKx/zQt1vay3FpsD3Mz3rWJ5fchzzdtz3IZ/rS5/3+7Hrdu/3dj9JR6H2mE77f7zrgvytaJf7g972se/Lh83saj73RWzNcov3WH7M8c36zeb6Z73PoG/bovzm2X+fpq0Dqq7sRa7FjZD7Xlz40Xr5YFdPiM/TDp8EB+P7v1xHQ537f7z7jpzTwA79CHUUaEH+K8z7y/77yhwTzw31AK3PvQ7/0twX1L731xx30+772T/jwVz9LdzL4B3+k87sTWDQ6mwAYLvM7JYCMuPb85wlXt38+v///6pkGCADimCTNUyYMMo5BK74wkAS2fcyiQ4iEMyudUquZrHVs1W6BnI7nA8KEqFIRlozpljfnDAr4BU1VFQurE0XSWREXlwaLp2TiGZnO6/f8vv8PGCgI0OZDcEhgoDOhoAhgoDChc5AwgtBglKmDeOgIw+gIKTlDaYmJhjrDmbjYKCI6WSlyqYm3yenZAvoaGWta65K2mjuy+9hLKgtAmzqzplMYhtsaigxTOntqO8jd7f0N3hf92GNA7OYFgA3TILWcrtUMY1B+TpO+3tJuCU8IPF9vCz5l+twh6NdmHL1H9hIM1LFvFsJ/LRaaE9gi34iI7yiOeObxVcAgD2f/cDwYMpzKlSxb+tOxQEEAAggYtOoRxpouBQ0WPFBwJ5i8ETFn1rzpQ2cxnj6BUoxWlKbNGYxwElAqglHPn0HjbYMR9ShVBVaxAtDatOvLry3CTv1ENukouFudDv3IJo1bpDnn7qyrdpzLwYQL5yl0cMJMCTN1/FwQ80EemgscQMDJdm2LxIsbz3gceTKCypef6uBMgDHmFqAVSBY22vJqr0JhoFbtWAFk16JJz9ZMm5/i1J5htH69KXbpu2ryzrhdnLXu0LB9pzSMPbvLQpAJzPT+WwQEyBD2GIDw013t9UQXgAefZvyC8nrOpzc9o/v36C3k089jnwLqBQecCPod/8LfCP6Zh56A+IHl3n7hAbBgfQ0OWCBe0MAUIYITVgjghddpR2KJ3CDWAHgO6WDAAfZ84oBMD/jFXoaXqNjPIy7yMUGMAcy44V03zrTiDC2+qIuPQD64WYpE5ngkj0rSSCCKOLK44x49ykhlhs0FaZuTBBQ5T5Z6bPljl4KZyGabexTSYgM/2jVPXHk45BoEGtUI5wFycsWinWng+YCeBGXW5590ViSoQHnuWSWWiqp1zIToPHoon5LOSSkklt6DqXM6gHRXnJwG+imhhorqZquuHpaGAbF1KcIDPCCSn4ASqJNppCzOmoetnOTqwK6QFhiNrJXRCoCwuIKlK6+sEv/4CrBpOHsIscb2imys1jp2a7bQFistmM5MO4KyDjCL7W8xkXvsmq/Oa+I4EyQAwYveMcGfrA0owIAC3CaUx735CsNvv5cALDC69uKrb8Kz+cvwwCkZHDG/Ey8csMXMnQUxwhrPw3HD5sJAambFhLyJxCT/2zG69M7MZiEEBHzAAWZJM6y3ATdAJcGq4KwzratYKuvPQXt0swI573w0gDXxtPRdTT9t9CpSK83kCFcXLYzWPlOdUso1hkE01GL/yvXHNL9tWCEONOAIAq7MIAFkeiMpggQIBObR3HXfDUPeei/ANwB+A36X4LMQ3oLhe++xeNc70P24PZJDlnjlQ8n/jfkykI+wOeKU/122zI6Lrvnhpuvhucpwz06Y3At4nSAkDwSwQANmBiI0DA7c7kPurvHue+KwNk58GMbv3vvvgATfwvC4/6Y78tL/Qf0I1heP/fHRKy/zl4E3D1+d0Cd/Iu3uY5cFPXoiAsFbShwAXouf6tG9/PgfUj+B5A9/7ZOH/+hnPxLgbyb6KyBbDgjABKJjgPtb3gMJML8ICpCBBBzEOMwWHAhiUIL3oKAD34dClmThAAlrAkZKcSw+dI+FCcvRimDILRn+g4b8smEOcHjC4PCQCT6UVgzftMMWFhGIHswDCIEzxC68sBJH5F8Kr7iS+B2NFXhrxAIO8JMK/zoMIEfTnBfB2Kjp/YMeZdSBBM4YxiACh43DcCMc08i9NW7RjAb4YhybmIYnarGNXewjGsV4MiwqUhDRqOMmZrGAXcmxkdN45DIi2Y3uea2SqoCkJAEpO0d28pKfZGRIRAkDnIymlMBzYvlQ2QJVYlKOi6ylOLbQw8n0DJRne4MLw/YsXlLLlzkyRDBNeRdi6vKYrUxmLoEpLmG2QJC4JOIyo4lMW2rzlrc4xPc+MzJpUtKbzTNOOLN5Np79oJysOWczQ4mIb5qTCYi0nDHXeS13qjGQr4wnO0ewO3rScpsElV0sR0ehSOwSndRKJUIhoFBm7tOgXntoRLH5znQe9P8cEJ3AQjPa0I3OoKMfnei5EqkKi3pUonksqEtPiYgEPLSYDPUSJ2TKUZqC1KYxnalKNHlPnI5UpyZt6E19Go4P9vMQQoWBnn760qj2kgmLyshlWOoHoL6hqiM4wFUxWtQMbZVS6vhqPe051jR4taQtVVlaJ2HWTLoSpW8lRVwHKlVbNrIECMiYQMUpDL769QZnRVRgE9BXkf21pntF7GBtUFhNbUKwiiUsXqk5WcdWFrJ4zesibZa2rLE1q0wLLTTB2tazfU1to+WmylYrWqy6VrWm7aZsdchPlML2tJHVqGcVCbrBvWghj5Br40Jnt+HihHxj/AJyESqSVxhXZav/S26sljvds1UXuuSQ7mVV91zleleav62l7a53Gpkk4I3Mtec302cb9bJ3kk9AX4JEF4D1che31LVveOyW3/kC9gv+TW+A94vE3J4Pvc+RL4KtWF6CFkIC/8Pg/wqngFVV0YJnozD9Lhy5DDORsW6scAYxrOEcJlhlHgYgiEknYiqqGMIsNvGL+xbjctVUQx5psYUx+sYUdzbCKCyELy2rQCPOmMPDbGF0bihj+gbByauBso53amQq30/JUp6ClpM84p3y2JktrPIPo0xeIl9xnGvLSiMocRVWptaoW4RLixIQ5y6nss47uXOeB6wKPi/FzwqQM2mZs8XZgALOhf4u/0rV+dFF47nRaVZzkQE0ks/8jDd6BghDrrVp5JD4up92TKizG1KLvOgBp+50RTJtnFZXGrMsgjVrZL1jS18aJjKRCpZABGhoGYWELQL2qHM17F+TxxtABcBejOTVZaPaS88uk7HFbD7mVLsi0Z4Ps3Vt3tMcYDi4qVNv7Qmd8J37c+Imt/HWbdjnjLsz6k6qR9JtJDzOWmb4Nre9wQ1cDr3nvu2aNnc6BF/WhGvdQD1QwgG6cIMLXELgai1/z+Zwgkfc0R7JeHgKPmSA08xKT2qZPudsIzGRKZYuC7YprqSKlh+7STBPpcyxfBqV52hfi8U2AGhN85LH/OSHFnkKE/91KtuituhnMxWglM5wjzidq/dc+mypNXWyRs3VOpoUb6c9ZpVl/eshN/q8kvWtwjRbXczKYkjYnp21p712b5/7YJT6aLjDz+xH1wEEtCHunAk+Z+1l90gBL+/BC77w8XYq4m2j+MVz/e96OEjkt8d0alE+D5aPPOM1CnQFPX4zl8f81fkOt0I8NQ8SQKzA+Gr6i2tep623WwoO8nlfOZX2rr997Fd8ttWnofavR+zvaRx83tse9rn30s9lJnw39p75ZUe9m/r01Ybgo+3Ix/paO4GRrnKfyRkqNiK0n5HxN9fa5w+/CMbNdfODnyTp53ipvs/FKWy/+tavWTWlOBb/y2UyM0cCzwQXArhk66cEBrgTCMh1yhSAvJCAiZRl1hSBxzCBqUNXDLgUDlhp/ecqbfADDSAB7ZcbkMEAx0d+Ijg3JTh/nzEdKdh8mjSCLph/xhGDKqiAUUCCJgiDKKiDFKgKLeiDOAiEMzhXFFGDRSgdR8h/IEgibcAAJ0BpeiAfieVqU/gThuZUkIGFLgcAWliFeXCFzdctMCCGXNgfXmiGmpSGfFCGYJdtmfGGexCHTwiFcWdnzjZ6rCdxfcaHgKCGsgccu9A7gviHgxaIfzCIwBcchtiHwyeHz3cykIiIeJiHcaN/6NAHfhMwSCgPRbJyrDc1oMgWokhUfVOK/52Gip24ii7XinzgiQ9GfmHHHrF4Op+IiZlId/dzCAfxghVxCQEAFG34Dw7xi/9jD/5CjF9IgMhIE8r4K3JSjIk4QdEYjOkyjNXIiv8DjDeojdTojD4XetD4jcu4jeMYVrx4fV5WQ/MAM3+Tio4IHEf2S+kSjyjxbaGoRPAIMPL4Dd1jj/BgAPk4j91Xj/1YEQYZkEnIj++4kP+oj5PIjiUigoSEOwyQL6NIgJCWjd6hkQbAkTi3Z7AEkht5kCsYaCYZACE5kmF1kSzpkilZPpSohBhZPDPZkBX5KvKSBj2iMym4kxR1Jg4QlDQphIMAlACDlPbUB0splPtIlAVjlP9MOZQnNSJUeZRXyZNt4pNn8hMHgCEo95UFE5ZjmXnO5wcTcJbWqJRtyXWAwJZOg5anZ4shtZZw+YFduXfgYB+m6Ft/8JdxGQiDCYaDYJgdiZjoAZgoU5OAkJg+x5d9eXZZqR3N5n9uY5GWqYcKpplROJntSC+YWS+cSZmBCZqfeZkOOZWrGZqZWZmq2ZmtOZuo6Zq0eZqO+Wiw+ZqpGZu4qYmymZtquZnCGZyj8pjF2Zu+2ZOmeZy2WZt4qZzQOZx3SZzMuZzV6ZXOqXbc2YvA2Z3GGZ7IuZulmZ232Zzi+Z3U+ZzSiZ3XiZ666Z13d57x2SqkOZ3uaZ9l2Z7wGZ2M05Sc71mf2+FkBWqgB4qgRoCgC8qgB6qgDQqhEZoQEkqhC/qgFYqhLcSaLpChHcovAwqiIRqaFyCiJWqiJ4qiKaqiK8qiLeqiLwqjMSqjM0qjNWqjN4qjOaqjO8qjPeqjPwqkQSqkQ0qkRWqkR4qkSaqkS8qkTeqkTwqlUSqlU0qlVWqlV4qlWcoSIQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changing pattern of adrenal steroidogenic response to adrenocorticotropic hormone with maturation. Shown are plasma steroid levels before (basal, 8:00 AM after dexamethasone 1 mg/m",
"    <sup>",
"     2",
"    </sup>",
"    given eight hours before) and the rise (&Delta;) 30 min after cosyntropin (ACTH) administration (10 mcg/m",
"    <sup>",
"     2",
"    </sup>",
"    ) in healthy prepubertal children, children with premature adrenarche, and follicular phase adult women. Note that 17-hydroxypregnenolone (17PREG) and dehydroepiandrosterone (DHEA) responses of children with premature adrenarche are intermediate between prepubertal and adult responses.",
"    <div class=\"footnotes\">",
"     Prepubertal: prepubertal norms (mean DHEAS 11 mcg/dL); Adrenarchal: premature adrenarche (mean DHEAS 105 mcg/dL); Adult: follicular phase norms (mean DHEAS 208 mcg/dL); 17PROG: 17-hydroxyprogesterone; ADNE: androstenedione; CMPD S: compound S (11-deoxycortisol); DHEAS: dehydroepiandrosterone sulfate.",
"    </div>",
"    <div class=\"reference\">",
"     From: Rosenfield RL, Cooke DW, Radovick S. Puberty and its disorders in the female. In: Pediatric Endocrinology, 3rd Edition, Sperling M (Ed). Elsevier, Philadelphia, 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_34_38447=[""].join("\n");
var outline_f37_34_38447=null;
